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In the modern-day healthcare landscape, innovative drug manufacturing and distribution 
systems have become increasingly prevalent, especially in resource limited settings (RLS). 
One such innovative system is the Medicines Patent Pool (MPP), which seeks to increase the 
availability and affordability of treatments for HIV, TB, and Hepatitis C by making available 
specific patents to generic pharmaceutical manufacturers. However, the implementation of the 
MPP has led to the emergence of certain challenges with respect to inadequacies in drug 
manufacturing and distribution, which affect the pharmaceutical value chain and drug safety 
monitoring (Burrone, 2016). The context within which the MPP was launched thus call for 
effective drug safety monitoring and pharmacovigilance (PV) systems. PV is the science and 
application of the detection, assessment, and monitoring of adverse drug reactions (ADRs) in 
response to drugs, with the objective of minimising drugs risks through the effective and 
efficient reporting of ADRs (WHO, 2002b). 
This research inquiry is thus aimed at addressing the lack of an effective PV system in the 
environments covered by the MPP; such a system must also consider the context of RLS and 
the disease burden of HIV, TB and Hepatitis C (which are referred to as the MPP drug 
provision systems) by proposing a decision support tool that facilitates the development of 
context-specific PV systems. A system engineering approach was thus followed to 
contextualise and address the development of said tool. 
Initially, systematic literature reviews were conducted to develop a challenges landscape 
pertaining to four niche factors, namely, (i) traditional PV systems, (ii) the MPP, (iii) HIV, 
TB, and Hepatitis C, and (iv) RLS within the context of the pharmaceutical value chain. This 
challenges landscape was developed to gain a systems perspective understanding of the 
various challenges that a context-specific PV system would have to address. 
Building on the insights gained from this challenges landscape, a requirement specification 
was developed for a context-specific PV system within the context of the MPP drug provision 
systems. Additional systematic literature reviews focused on the four factors listed above, 
within the context of identifying the requirements that these factors call for in a drug safety 
monitoring system. Furthermore, a verification process was conducted with subject matter 
experts (SMEs) to evaluate the identified requirements. Building on these findings, a 
requirement specification was drafted to guide the development of a decision support tool. 
In order to address the requirement specification, possible intervention strategies were 
identified. The identified intervention strategies were then synthesised to develop components 
for an alternative, context-specific PV system. Based on these findings, a decision support tool 
that would facilitate the development of a context-specific PV systems was developed. This 
decision support tool is refered to as the Customised Vigilance System Implementation Tool 
(CVSIT). Through validation processes it was found that the CVSIT is a robust, adaptable tool, 
that provides a customized strategy based on a specific projects profile. It was validated by 
means of (i) a case study and (ii) semi-structured interviews with SMEs to evaluate the 





In die moderne gesondheidsorglandskap het innoverende medisynevervaardigings- en 
verspreidingstelsels al hoe meer algemeen geword, veral hulpbronbeperkte omgewings. Een 
so 'n innoverende stelsel is die Medicine Patent Pool (MPP); die MPP het die doel om die 
beskikbaarheid en bekostigbaarheid van behandeling vir MIV, TB, en Hepatitis C te verbeter 
deur patente aan generiese farmaseutiese vervaardigers vry te stel. Maar, die implementering 
van die MPP bring sekere uitdagings met betrekking tot die gebreke in die vervaardiging en 
verspreiding van geneesmiddels na vore wat die farmaseutiese waardeketting en die 
monitering van medisyneveiligheid beïnvloed (Burrone, 2016). Die konteks waarin die MPP 
van stapel gestuur word, vereis doeltreffende monitering en geneesmiddelbewaking stelsel. 
Geneesmiddelbewaking is die wetenskap en toepassing van die opsporing, evaluering en 
monitering van nadelige reaksies op medikasie, met die doel om die risiko's van medisyne tot 
die minimum te beperk deur die effektiewe en doeltreffende rapportering van nadelige reaksies 
op medikasie (World Health Organization, 2002). 
Hierdie navorsingsondersoek is daarop gemik om die gebrek aan 'n effektiewe PV-stelsel in 
die omgewings van die MPP, wat die konteks van hulpbronbeperkte omgewings en die 
siektelas van HIV, TB en Hepatitis C, aan te spreek deur die onwikkeling van ‘n besluitsteun 
hulpmiddel wat die ontwikkeling van ‘n effektiewe geneesmiddelbewaking stelsel fasiliteer. 
'n Stelselingenieurswese benadering is gevolg om die probleem te kontekstualiseer en aan te 
spreek. 
Aanvanklik is sistematiese literatuuroorsigte gedoen om 'n uitdagingslandskap te ontwikkel 
rakende die faktore van (i) tradisionele geneesmiddelbewaking-stelsels, (ii) die MPP, (iii) 
HIV, TB, en Hepatitis C, en (iv) hulpbronbeperkte omgewings binne die konteks van die 
farmaseutiese waardeketting. Hierdie uitdagingslandskap is ontwikkel om 'n oorsiggewende 
perspektief te verkry van die verskillende uitdagings wat 'n besluitsteun hulpmiddel in ag moet 
neem. 
Aan die hand van die insigte wat uit die uitdagingslandskap verkry is, is 'n vereiste-spesifikasie 
ontwikkel vir die besluitsteun hulpmiddel wat die ontwikkeling van ‘n effektiewe 
geneesmiddelbewaking stelsel in diekonteks van die MPP-medisyneverskaffingstelsels 
fasiliteer. Bykomende sistematiese literatuuroorsigte rakende die faktore van (i) tradisionele 
PV-stelsels, (ii) die MPP, (iii) HIV, TB, en Hepatitis C, en (iv) hulpbronbeperkte omgewings 
is ondersoek om vereistes te indentifiseer wat hierdie faktore vereis van ‘n 
geneesmiddelbewaking-stelsels. Verder is 'n verifikasieproses met vakkundiges uitgevoer om 
die geïdentifiseerde vereistes te evalueer.  
Ten einde die vereiste-spesifikasie aan te spreek, is moontlike intervensiestrategieë 
geïdentifiseer. Intervensiestrategieë is daarna gesintetiseer om komponente vir die besluitsteun 
hulpmiddel te ontwikkel. Gegewe hierdie bevindinge, is ‘n besluitsteun hulpmiddel ontwikkel 
wat die ontwikkeling van ‘n effektiewe geneesmiddelbewaking stelsel fasiliteer. Die  
besluitsteun hulpmiddel word genoem die Customised Vigilance System Implementation Tool 
(CVSIT). Deur ‘n validasieproses is bevind dat die CVSIT 'n aanpasbare instrument is, 
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aangesien dit 'n unieke strategie ontwikkel gebaseer op 'n spesifieke projek se profiel. Die 
CVSIT is gavalideer deur (i) die toepassing van 'n gevallestudie en (ii) semi-gestruktureerde 
onderhoude met vakkundiges te voer om die toepasbaarheid en bruikbaarheid van die 
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Chapter 1: Introduction 
In this chapter an overview of the research inquiry is provided. It begins with an introduction 
to the background of the research, followed by the research problem statement, aim, and 
objectives. Then the scope and limitations of this study are presented. The research strategy, 
which includes the methodology and validation approaches are subsequently discussed, as well 
as the expected outcome of the study and an outline of the thesis structure. 
 BACKGROUND 
Pharmacovigilance (PV) is a form of drug safety monitoring that is defined as the science and 
application of the detection, assessment and monitoring of adverse drug reactions (ADRs) after 
drugs have been licenced for use (WHO, 2002b). The key objective of a PV system is to 
effectively and efficiently report and monitor ADRs in an attempt to minimise risks In 
addition, the identification and evaluation of previously un- or underreported ADRs is also a 
vital part of such a PV system (Metha et al., 2017). 
In the modern-day healthcare landscape, there has been a significant shift in the healthcare 
trends around the world that calls for innovative drug manufacturing, distribution and 
surveillance monitoring. According to Rohrbach (2017), due to the growing demand for 
healthcare, combined with the shift in focus from treatment to prevention, pharmaceutical 
companies are under pressure from governments and consumers to reduce prices and improve 
the value of therapies. Other stakeholders, such as the World Health Organisation (WHO), are 
also contributing to this pressure (Rohrbach, 2017). Furthermore, it is perceived that the 
epidemic of communicable diseases in resource limited countries further contributes to the 
pressure pharmaceutical manufacturing companies are experiencing from stakeholders to 
ensure an affordable drug supply. These factors, in combination with strict drug patent laws, 
are challenging affordable drug supplies in these countries (Modell, 2003). 
In order to address the unavailability of drugs with reference to certain populations, the 
UNITAID Medicine Patent Pool (MPP)1 was established in 2010 to improve access to 
treatment of Human Immunodeficiency Virus (HIV), Tuberculosis (TB), and Hepatitis C by 
allowing access to specific drug patents (Medicines Patent Pool, 2010). The aim of the MPP 
is to increase the rate of manufacturing and decrease the prices of specific drugs, i.e. drugs 
related to HIV, TB and Hepatitis C, in an attempt to increase the availability of these drugs to 
those who are affected (Perry, 2012).   
The fact that numerous manufacturers could be utilised through the MPP to produce drugs 
intensifies the need to monitor drug quality and the consistency of quality across 
manufacturers, and thus highlights the need for effective drug safety monitoring, by means of 
PV systems, within this context. Furthermore, research has shown that certain challenges arise 
as a result of the implementation of the MPP, often with respect to drug manufacturing and 
                                                 
 
1 MPP is an initiative that allows any manufacturer to access the available patents and to manufacture drugs, thereby 




distribution systems in these developing countries, which affects the pharmaceutical value 
chain and drug monitoring (Burrone, 2016). These challenges are attributed to inadequate local 
drug manufacturing and distribution systems, which often face the additional challenge of 
limited resources (Burrone, 2016). 
In literature it has been argued that there are challenges in the PV system of developing 
countries that necessitate a change in the system (Metha et al., 2017).  In a study done by Allen 
(2014) the development of context-specific adverse drug monitoring and reporting guidelines 
and/or tools were highlighted in order to improve the effectiveness of ADR detecting, and 
monitoring within niche environments (Mehta, Allen, et al., 2014). Thus, the need for context-
specific considerations within PV systems have been highlighted, however the necessary tool 
and guidelines to facilitate such a system is found to be lacking (Mehta, Allen, et al., 2014; 
Wilbur, 2018; Justo et al., 2019).  
Furthermore, contributing challenges have been identified when addressing PV in the context 
of (i) innovative drug manufacturing and distribution – such as the MPP, (ii) diseases burden 
associated with the MPP, and (iii) resource limited settings (RLS). This reaffirms that a 
proposed context-specific PV system should incorporate these factors by considering MPP 
drug provision systems a phrase referring to drug systems that consist of different practices in 
a pharmaceutical value chain, such as drug manufacturing, distribution, and quality monitoring 
within the context of the MPP, and by considering the environment of RLS. 
The outline provided above highlights the need for alternative context-specific PV systems 
that take into consideration the context of MPP drug provision systems, as well as the entire 
pharmaceutical value chain.  
 PROBLEM STATEMENT, AIM AND OBJECTIVES 
In this section the problem identified in the real-world situation is expressed, as well as the 
aim and the objectives of the research inquiry. 
 Problem statement  
Innovative modes of drug manufacturing and provision practices, such as the MPP, are 
emerging globally, especially in RLS. Challenges experienced as a result of these emerging 
practices highlight (i) the inadequacy or lack of existing PV systems to support the unique PV 
needs that such systems require, and (ii) the need to enable such settings to develop and deploy 
PV systems effectively and efficiently in order to support the drug provision and supply in 
such environments. 
Thus, the problem that this research seeks to solve is the lack of a context-specific PV system 
that would address the needs called for by MPP drug provision systems when considering the 
effective and efficient reporting and monitoring of ADRs.  
 Research aim and objectives 
The aim of this research inquiry is to contribute towards effective and efficient reporting and 
monitoring of ADRs, by developing a decision support tool that facilitates the development of 




 Five research objectives (RO), and a number of sub-research objectives, that support the 
above stated aim have been developed. The research- and sub-research objectives include:  
RO1 Review the literature pertaining to the factors of (i) traditional PV systems, (ii) the 
MPP, (iii) the specific disease considered by the MPP (HIV, TB and Hepatitis C), and 
(d) RLS, in order to contextualise the research problem under consideration, namely, 
the fact that traditional PV systems are inadequate in supporting the unique needs and 
challenges brought on by these factors. 
RO2 Develop a challenges landscape related to the factors of (i) traditional PV systems, (ii) 
the MPP, (iii) HIV, TB and Hepatitis C, and (d) RLS in order to gain an understanding 
of what challenges any alternative, context-specific PV system will have to address. 
The sub-objectives related to this RO2 include: 
RO2.1 Conduct systematic literature reviews to identify the challenges associated 
with each of the factors as stated above; 
RO2.2 Identify and define possible relationships between the identified challenges 
and the pharmaceutical value chain; 
RO2.3 Synthesise the challenges and the identified relationships to develop a 
challenges landscape that will support the development of a proposed 
alternative, context-specific PV system.  
RO3 Develop a requirements specification that will guide the development of a decision 
support tool, drawing on the findings from RO1 and RO2. The sub-objectives related 
to this RO3 include: 
RO3.1 Conduct systematic literature reviews pertaining to (i) traditional PV 
systems, (ii) the MPP, (iii) HIV, TB and Hepatitis C, and (d) RLS, to identify 
any additional requirements that these factors would call for; 
RO3.2 Consider the developed challenges landscape as described in RO2, with 
respect to the identified requirements specification; as per RO3.1, to 
determine if additional requirements should be considered;  
RO3.3 Synthesise the requirements identified in RO3.1 and RO3.2 to develop a 
combined requirements specification that will guide the development of a 
decision support tool; and  
RO3.4 Conduct a verification process to authenticate the developed requirements 
specification as stated in RO3.3.  
RO4 Develop a decision support tool that facilitates the development of a context-specific 
PV systems within the context of the MPP. The sub-objectives related to this RO4 
include: 
RO4.1 Identify possible intervention strategies that would address the requirements 




RO4.2 Synthesise the intervention strategies identified in RO4.1 to develop the 
foundational features of the decision support tool; 
RO4.3 Develop the detailed decision support tool; and 
RO4.4 Validate the developed decision support tool to evaluate the applicability and 
practicability of the developed tool. 
 SCOPE AND LIMITATIONS 
This study is limited to a particular ‘niche’ environment, as it developed for the context of 
MPP drug provision systems and thus specifically focusses on the contexts related to PV and 
the MPP; and, this includes RLS and specific disease burdens addressed by the MPP, namely 
HIV, TB and Hepatitis C. 
This research study thus will consider the MPP drug provision system and the challenges that 
are often associated with it. These challenges are mostly attributed to inadequate drug 
manufacturing and distribution systems. Once the challenges have been identified, it will be 
determined how these challenges affect the pharmaceutical value chain and subsequently the 
drug monitoring process. Similarly, challenges associated with the contexts of RLS and 
specific disease burdens addressed by the MPP, namely HIV, TB and Hepatitis C, will be 
identified and evaluated to determine how these challenges in-turn affect drug safety 
monitoring. The research also considers the challenges associated with traditional PV systems, 
as any proposed PV system should ideally address such challenges, or at least not amplify 
them. Once the challenges have been identified and the relevant literature has been reviewed, 
a requirements specification is developed that guides the development of a decision support 
tool that facilitates the development of context-specific PV systems within the context the 
MPP.  
 RESEARCH STRATEGY  
This section will provide an overview of the research strategy and the verification and 
validation approaches that were followed. Furthermore, the description of the research 
products considered in this research inquiry is also provided. 
 Research methodology 
In order to address the research aim - to contribute towards effective and efficient reporting 
and monitoring of ADRs, by developing a decision support tool that facilitates the 
development of context-specific PV systems within the context the MPP - a systematic 
research approach is required that allows for a structured approach to deal with complexity 
and the interrelatedness of components, in order to develop an appropriate solution for the 
complex context of PV. Thus, for this research inquiry a systems engineering approach was 
adopted as overarching research approach.  
Systems engineering is defined as an interdisciplinary approach that facilitates with 
transforming of operational needs into system-level solutions that satisfies customers’ 
expectations (Blanchard and Fabrycky, 1998; United States Government, 2001; International 




a comprehensive, iterative problem-solving technique that is used to translate needs and 
requirements into a system solution (United States Government, 2001).  
The system engineering approach consists of four phases, namely: (i) input identification, (ii) 
requirement analysis, (iii) functional analysis, and (iv) design synthesis (United States 
Government, 2001). Each of these phases has its own subsections, which is provided below, 
and an illustrative outline of this approach is depicted in Figure 1.1. 
 Input identification 
The input identification phase entails identifying and giving context to the factors that 
influence the context of this research, i.e. the environment of the MPP drug provision system. 
Given the context of this dissertation, i.e. the MPP, a comprehensive input identification 
investigation was not required, as the context is clearly defined, and the following factors were 
taken into account during the development of the decision support tool that facilitates the 
development of context-specific PV systems. These factors include: (i) traditional PV systems, 
(ii) the MPP, (iii) HIV, TB and Hepatitis C, and (iv) RLS. For the purpose of this research 
inquiry, these factors are referred to as the niche factors. During the input identification 
process, literature was consulted to contextualise these factors. Furthermore, to ensure that the 
proposed solution effectively addresses these factors, the challenges faced when addressing 
each of these niche factors in the context of drug safety monitoring was identified and 
evaluated. Subsequently, the identified challenges were synthesised to develop a challenges 
landscape pertaining to the context of MPP drug provision systems. 
  Requirement analysis  
In accordance with the systems engineering process, once the inputs, i.e. niche factors and 
relevant challenges, had been identified, the requirements that will guide the development of 
the decision support tool could be specified. For this specific research inquiry, the requirement 
analysis phase entailed determining what requirements each of the niche factors would 
respectively call for in a context-specific PV system. These requirements were identified and 
determined by consulting the literature and the challenges landscape that was developed during 
the input identification phase. A requirements specification was thus developed for each of the 
four niche factors, and to evaluate the significance of these requirement sets, a verification 
process was conducted with a number of subject matter experts (SMEs). The verified 
requirements specification was used to guide the development of the decision support tool.  
 Functional analysis 
The functional analysis phase entailed identifying intervention strategies that would best 
address the requirements specification developed during the requirement analysis phase. These 
strategies were identified by consulting the literature, referring to the requirements 
specification developed during the requirement analysis phase, observing real-world 
phenomena, and conducting interviews with SMEs. The identified intervention strategies were 
synthesised to develop an index that outlines the foundational features of the decision support 
tool. 
 Design synthesis 
The final phase in the systems engineering approach is divided into two subphases namely 




outlines the foundational features  by developing a decision support tool that facilitates the 
development of context-specific PV systems within the context the MPP. This tool, referred 
to as the Customised Vigilance System Implementation Tool (CVSIT), is a decision support 
tool, that aims to facilitate the assessment of the profile of the drug provision project with 
regard to context of the project, the target patients group, the human resources availability, and 
the technology availability. And to then subsequently provide the user with a customised 
implementation strategy that outlines the required system components and interventions 
options to support an effective PV system within the context of the MPP. During sub-phase B, 
a validation process was conducted to evaluate the applicability and practicability of the 
developed tool, which is discussed in more detail in Section 1.4.2. 
 
 Verification and validation approach 
According to the IEEE-STD-610 Glossary of Software Engineering Terminology (1990), 
verification is the process of evaluating a system or component during a phase of development 
to determine if the system or component satisfies the conditions as stated during the initiation 
of said phase; whereas validation is the process of evaluation a product during the end phase 
of development to determine if the expectations and aims of the product is met (IEEE 
Standards Board, 1990). 
As this research study is largely based on literature, verification and validation plays a 
significant role in applying the knowledge to real-world situations and gaining insights from 
subject matter experts’ perspective. Thus, a verification and a validation process were 
conducted to evaluate research findings and outcomes at different phases of the research.  
The verification process was conducted during Chapter 4, as shown in Error! Not a valid 
bookmark self-reference., and entailed contacting SMEs to evaluate the requirement 
specification. The validation process was performed during the final phase of the systems 
engineering approach, i.e. the design synthesis phase, and was aimed at evaluating the decision 
support tool that was developed to assist with the effective and efficient reporting of ADRs in 
the environment of MPP drug provision systems. The validation process is documented in 
Chapter 7. 




 As mentioned, the verification process was performed with the aim of evaluating the 
developed requirement specification for a context-specific PV system. During the verification 
process, SMEs from different fields within the healthcare environment, i.e. pharmaceutical 
industry, PV industry, and academia, were consulted. The verification process involved 
contacting SMEs and providing the necessary documentation, i.e. pre-read2 documents and 
questionnaires related to the developed requirements specifications, upon which they were 
required to provide feedback in the form of completion of the questionnaire. The aim of the 
verification was to evaluate the applicability of the identified requirements when considering 
the development of a decision support tool that facilitates the development of a context-
specific PV system within the context of the MPP, and identify possible, additional 
requirements to take into consideration.  
The validation process sought to evaluate the developed operational, decision support tool 
using two methods of validation, (i) conducting a case study, and (ii) conducting semi-
structured interviews with SMEs. The first validation method is a retrospective case study in 
the field of drug safety monitoring to illustrate the operation of the tool. The aim of the case 
study was to evaluate whether the findings/ output of the tool corresponds with a real-world 
case study. The second method entailed conducting semi-structured interviews with SMEs. 
Similar to the previous method the aim was to evaluate the applicability and practicability of 
the tool, and furthermore to identify any possible weakness or refinements that should be 
made.  
 Research product terminology 
The aim of this research inquiry  is to contribute towards effective and efficient reporting and 
monitoring of ADRs, by developing a decision support tool that facilitates the development of 
context-specific PV systems within the context the MPP; however, to gain an understanding 
of the different possible research products that will be developed during this dissertation, the 
various research products and related findings are summarised in Table 1.1. 
Table 1.1: Defined research products 
Research product Variations of research product References 
Decision support system 
A decision support system is an information system (i.e. 
an organisational system designed for the collection, 
storage and distribution of data in a computer-based 
format) that assists with the decision-making process for 
business or organisational activities. 
(Keen, 1980) 
Tool 
A tool is an instrument that is aimed at achieving a 
specified objective, through considering predefined 
inputs and providing a specified deliverable.  
(Stinson, 2017; 
Hedreen, 2019) 
Decision support tool 
A decision support tool is a variation of a tool that 
incorporates techniques in order to assist with a decision-




An index serves as a representation /overview of various 
components that attribute to or should be taken into 
account when addressing a specific product / system. 
(Collins, 2012) 
                                                 
 
2 A pre-read document in the context of this research inquiry provides the validator with the required background information 
related to the specific component or system being evaluated. Thus, the pre-read document for the verification process provided 
information on the developed requirement specification and the pre-read documented used during the validation process provided 





A landscape is a concept that considers the environment, 
and the attributes and characteristics of said environment 
(Turner, Gardner 
and O’Neill, 2015) 
Considering these research products, it is envisaged that this research inquiry would focus on 
the development of a decision support tool, using complementary research products such as a 
landscapes and indexes.  
 THESIS OUTLINE 
This thesis consists of eight chapters, and the respective chapters are outlined below.  
Chapter 1: Introduction 
In the first chapter, the background of the dissertation as well as the aims and objective for the 
research are described. Furthermore, an overview is given of the research approach and the 
validation process employed in this study.  
Chapter 2: Niche factor contextualisation: Traditional pharmacovigilance systems  
In this this chapter the input identification phase of the systems engineering approach is 
conducted by contextualising the first niche factor, i.e. traditional PV systems. This entails 
providing background information on the history of PV and the traditional PV process. In 
addition to the contextualisation of this factor, the challenges associated with traditional PV 
systems are identified through a systematic literature review. The identified challenges are 
investigated and synthesised to subsequently develop a PV challenges landscape. This chapter 
contributes towards RO1 and RO2.  
Chapter 3: Niche factor contextualisation: Medicines Patent Pool, HIV, TB and Hepatitis C 
and resource limited settings 
In this chapter, the input identification phase is continued by addressing the additional niche 
factors, namely, (i) MPP, (ii) the specific diseases  , and (iii) RLS. Literature reviews 
pertaining to these three factors are conducted to provide context to MPP drug provision 
systems. As was the case in Chapter 2, a systematic literature review is conducted to identify 
challenges associated with these three factors in the context of a PV system, which is then 
synthesised to develop a challenges landscape related to MPP, specific disease and RLS. This 
challenges landscape is then combined with the challenges landscape developed in Chapter 2, 
in order to gain a comprehensive understanding of the challenges associated with the MPP 
drug provision systems, and this also contributes towards RO1 and RO2. 
Chapter 4: Requirements specification development 
In this chapter, RO3 is addressed by conducting the second phase in the systems engineering 
approach, namely, a requirement analysis, in order to identify the requirements each of the 
niche factors call for in a context-specific PV system. The requirements are identified by using 
the literature, consulting SMEs and incorporating the challenges landscape developed in the 
previous chapter.  
Chapter 5: Vigilance System Component-Intervention Index development 
Chapter 5 focuses on the third phase in the systems engineering approach, namely, the 
functional analysis. The focus here is on identifying intervention strategies that address the 




these findings that outlines the foundational features of the decision support tool. This chapter 
contributes towards RO4. 
Chapter 6: Decision support tool development 
This chapter further contributes towards RO4, as the focus is on developing the decision 
support tool that builds on the index developed during the functional analysis phase in Chapter 
5. In this chapter sub-phase, A of the design synthesis phase of the systems engineering 
approach is conducted, which involves taking into consideration all the information obtained 
in the previous chapters to develop the decision support tool that facilitates the development 
of context-specific PV systems within the context the MPP. 
Chapter 7: Validation process 
In this chapter, sub-phase B of the design synthesis phase is completed, which is concerned 
with the validation of the developed decision support tool. The background, method and 
findings of the validation process of the developed tool are presented and discussed. The 
validation process entailed conducting a case study as well as semi-structured interviews with 
SMEs to evaluate the applicability and practicability of the developed tool. The results of the 
validation process are discussed, along with any changes and/ or refinements that were 
identifies and/or proposed during the validation process. RO4.4 is addressed in this chapter. 
Chapter 8: Conclusions and future work 
In this chapter, an overview of the research is provided as well as an evaluation of the research 
objectives. Furthermore, recommendations for future research is made. Chapter 8 concludes 
the research inquiry. 
 RESEARCH OUTPUT 
The research outputs that were produced during research study are outlined below. 
Journal article 
 A journal article, titled “Developing a challenges landscape relating to drug safety, provision 
and distribution in resource-limited settings for the case of HIV/AIDS”, was published in the 
South African Journal of Industrial Engineering (SAJIE) 2018, Volume 29, Issue 3. This 
article was produced from form the research documented in Chapter 3. Authors: Biancé 
Huysamen, Imke H. de Kock, and Louzanne Bam. The published article can be seen in 
Appendix A, Section A1. 
International conference article 
An international conference article titled, “The case for a niche pharmacovigilance system 
relating to drug provision and distribution in resource limited settings”, was accepted for 
publication in the Proceedings of the 25th ICE/IEEE International Technology Management 
Conference; 17th – 19th of June 2019, Sophia Antipolis, Nice, France. © 2019 IEEE. Authors: 
Biancé Huysamen, Imke H. de Kock, and Louzanne Bam. See Appendix A, Section A2.  
 CHAPTER 1 CONCLUSION 
This chapter gives a concise background of the challenges associated with the inadequacy or 




context of the MPP. The research aim and objectives for this research inquiry as well as the 
research strategy that will be followed to address the stated objectives are presented. The 
following chapter concerned with the input identification phase of the systems engineering 
approach, and the contextualisation the first niche factor, i.e. traditional PV systems, is thus 





Chapter 2: Niche factor contextualisation: 
Traditional pharmacovigilance 
systems 
In this chapter, the processes related to the first phase of the systems engineering approach, 
namely, the input identification phase, are discussed with the goal of contextualising and 
investigating the first niche factor, traditional PV systems. In this chapter, traditional PV 
systems will be discussed with regard to the history and the processes relating to PV systems. 
Thereafter, the challenges associated with traditional PV systems will be investigated, 
discussed, and analysed in order to develop a challenges landscape pertaining to traditional 
PV systems that take into consideration the relationships between the identified challenges and 
the pharmaceutical value chain.  
This phase of the research, and how it relates to the rest of the dissertation is shown in Figure 
2.1. 
 
 PROBLEM CONTEXTULISATION AND NICHE FACTORS 
The input identification phase entails contextualising the research problem by identifying and 
investigating factors that have to be taken into account when addressing the research problem 
and the environment under consideration during the investigation; for the purpose of this 
research, this is the environment of the MPP drug provision system (United States 
Government, 2001). These factors have to be addressed when developing a decision support 
tool that facilitates the development of a context-specific PV system 3(United States 
Government, 2001).  
                                                 
 
3 For the purpose of this research inquiry a context-specific PV system is considered within the context of the MPP. 




For the purpose of this research study, in-depth input investigation is not required as the 
environment under consideration during this study, i.e. MPP drug provision systems, 
constitutes that niche, context-specific factors would have to be taken into account. Thus, the 
process of identifying these factors were conspicuous, as these factors are distinctive to the 
environment of MPP drug provision systems. When considering this environment, it is evident 
that the following factors, (i) the MPP, (ii) HIV, TB and Hepatitis C, and (iii) RLS, are 
addressed when investigating the research problem. When considering the MPP drug provision 
systems, which refers to different practices in a pharmaceutical value chain within the context 
of the MPP and RLS, it is required that the context of the innovative drug provision systems, 
such as the MPP, are addressed as well as that the factor of RLS is considered. As stated in 
Section 1.1. through the MPP, numerous pharmaceutical manufacturing companies are 
provided the opportunity to manufacture drugs which established the need for effective drug 
safety monitoring systems in these environments, which are often associated with the 
challenges of having limited resource available (Burrone, 2016). Furthermore, when 
considering the MPP it is required that the disease burden addressed by the MPP is taken into 
consideration. Thus, it is required that a context-specific PV system for the environment of 
MPP drug provision systems, accounts for these diseases namely, HIV, TB and Hepatitis C. 
These diseases need to be addressed in isolation from the MPP as they could attribute to 
additional consideration that have to be taken into account when developing the proposed PV 
system.  
As, the aim of this research inquiry is to develop a decision support tool that facilitates the 
development of context-specific PV systems, it is inevitable that the traditional PV systems 
also be considered as a factor during this dissertation. It is envisaged that the proposed context-
specific PV system would be focused on rather transforming the traditional PV systems instead 
of transitioning to an innovative, new system. Thus, it is required that during this research 
inquiry the factor of traditional PV systems is contextualised and incorporated into the 
development of the proposed PV system.    
Thus, due to the context of this research inquiry it is evident that there are four niche factors, 
(i) traditional PV systems, (ii) the MPP, (iii) the MPP disease burden namely, HIV, TB, and 
Hepatitis C, and (iv) RLS, that haven to be taken into consideration during the development 
of a decision support tool . Furthermore, it is relevant that when considering these factors, 
traditional PV systems, is firstly investigated as the aim of this study is foremost to consider a 
context-specific PV system, and thus the context of this factor firstly needs to be 
comprehended before considering the environmental context-specific factors. The niche 
factors, (i) MPP, (ii) HIV, TB and Hepatitis C, and (iii) RLS, are associated with the 
environment of the MPP drug provision system within which the context-specific PV system 
would have to function and thus the deduction can be made these three factors have to be taken 
into consideration within the context of the traditional PV systems. 
However, to ensure that a context-specific PV system adequately address these niche factors, 
the challenges associate when considering each niche factor would have to be addressed in 
order to ensure that said system does not contribute to these challenges but possible assist in 
alleviating the challenges. Thus, during this research inquiry, systematic literature reviews 
pertaining to (i) traditional PV systems, (ii) the MPP, (iii) HIV, TB and Hepatitis C, and (iv) 
RLS, would have to be conducted in order to identify the challenges associated with these 




perspective understanding of the challenges to address within the context of this research, i.e. 
MPP drug provision systems, a challenges landscape, pertaining to all the niche factors should 
be considered. 
In this chapter the focus would be on contextualising the factor of traditional PV systems as it 
is imperative that the concept of PV and the process associated with this system is firstly 
investigated, as stated above. Thus, in the following section a background overview of PV 
systems will be provided after which the challenges associated with traditional PV systems 
will be investigated. Furthermore, these identified challenges will be synthesised in order to 
develop a challenges landscape pertaining to the challenges associated with traditional PV 
systems. This challenges landscape will form part of the development of the overarching 
challenges landscape which considers all the niche factors.  
In the following chapter, a similar approach as discussed above will be conducted but 
considering the context of, (i) the MPP, (ii) HIV, TB and Hepatitis C, and (iii) RLS. The 
challenges landscape related to these factors will then be synthesis with the challenges 
landscape pertaining to traditional PV systems, developed during this chapter, to ultimately 
develop a challenges landscape for the context of MPP drug provision systems.  
 PHARMACOVIGILANCE SYSTEMS 
As mentioned in Section 1.1 the WHO defines PV as “the science and activities relating to the 
detection, assessment, understanding and prevention of adverse effects or any other drug-
related problem” (WHO, 2015). 
In this section, the history of PV is discussed as well as the process followed by a traditional 
PV system, when adverse effects or reactions to drugs are detected.  
 History of pharmacovigilance 
PV started in 1961 after the Thalidomide disaster, when a large number of babies were born 
with phocomelia, a defect that caused their limbs to be deformed. Doctors and experts from 
across the world collaborated to investigate the cause of this defect and concluded that it was 
due to the off-label prescription of a mild sleeping pill, Thalidomide. This drug had been 
prescribed for the off-label use of morning sickness in pregnant women, although the effects 
of the drug on pregnant women were never verified in clinical trials (Schulz, 2001; Fintel, 
Samaras and Carias, 2009). Thalidomide was only taken off the market in 1962, by which time 
over 10 000 incidents of Thalidomide related disabilities had been reported (Fintel, Samaras 
and Carias, 2009). The Thalidomide disaster caused a shift in the healthcare industry and made 
the world aware that effective drug safety monitoring was essential in the healthcare system. 
According to the WHO, for a PV system to work effectively, it requires data collection from 
health practitioners, systematic monitoring and analysis of input data, especially in the case of 
new drugs that are rolled out (WHO, 2002b).  
PV is aimed at improving patient safety with regard to medication but also contributes to 
monitoring and assessing different drug reactions and drug quality. Furthermore, to ensure 
effective monitoring, PV should be a continuous process throughout the pre- and post-
authorization phases of a drug (WHO, 2002c). Although it is required for all drugs to go 
through a clinical trial, it is often the case that very little is known about the quality and safety 




a 95% surety level, 30 000 patients would have to take part in a clinical trial (British Medical 
Association, 2006). When a new drug is rolled out, an effective PV system is thus of paramount 
importance, as all possible ADRs should be reported and investigated to insure the rapid 
detection of drug risks. Furthermore, PV systems must continuously be able to change and 
adapt in response to certain requirements within a setting (WHO, 2002c). 
However, there are still many challenges with regard to drug monitoring, especially in 
developing countries (WHO, 2002c). From a study done on PV systems in South Africa, 
Uganda and India (2015), it was found that there are still barriers to be overcome, such as 
limited funding and a lack of training programs pertaining to PV for healthcare practitioners 
(HCP). Furthermore, with regard to the PV system in South Africa it was seen that, although 
legal requirements are in place, there is still a lack of effectively monitoring drug reactions to 
minimize risk factors (WHO, 2002c; Kadam et al., 2015). The challenges associated with PV 
systems are discussed in detail in Section 2.3. 
 Pharmacovigilance process 
The traditional PV system follows a process where ADR data is collected and analysed to 
determine if or what necessary drug safety interventions have to be taken when a drug is 
considered to be harmful (Meyboom et al., 2002; Lindquist, 2004; Waller and Harrison-
Woolrych, 2017). According to An Introduction to Pharmacovigilance (Waller and Harrison-
Woolrych, 2017), a PV system must follow four essential steps: the process starts with the 
detection of possible hazards (i.e. ADRs) through (i) signal detection, followed by (ii) 
evaluation and investigation, then (iii) taking the required action, before (iv) considering 
possible methods of communication (Waller and Harrison-Woolrych, 2017). These steps are 
discussed in more detail in the following sections.  
 Signal detection 
Signal detection refers to the detection and reporting processes of ADRs. In the context of 
spontaneous reporting4, a signal, which is defined by the WHO as information that has been 
reported about a possible unknown relationship between a drug and an ADR, needs to be 
generated by a series of reported cases, where the number of reported cases depends on the 
scarcity of the reported ADR (Waller and Harrison-Woolrych, 2017). A single case is usually 
not sufficient; only in very specific instances is one reported case of ADRs considered 
sufficient, for example, when a case of anaphylaxis5 is reported (Waller and Harrison-
Woolrych, 2017). And thus, the strength of an effective PV system lies in the consideration of 
a series of reported cases, which is often lacking and/or challenging due to significant under-
reporting. Since there are other methods of detection, a signal can also be defined as 
information that is obtained from various sources, including experiments and observations 
(Meyboom et al., 2002; Waller and Harrison-Woolrych, 2017). Although passive reporting is 
often more common, the process of signal detection should ideally be an active process 
(Pohlman et al., 2017; Waller and Harrison-Woolrych, 2017).  
                                                 
 
4According to the Uppsala Monitoring Centre spontaneous reporting refers to the voluntary process where patients 
or healthcare professionals report a suspected harm to their local or national PV centres.  
5 Anaphylaxis is a severe allergic reaction that occurs within seconds of contact with the substance and can lead to 




 Evaluation and investigation 
Two formal methods are used to evaluate the signals, namely, triage and impact analysis. 
Triage is most widely used by the WHO and entails the quick analysis of the most important 
features of a case, such as the seriousness and outcomes, in order to decide on the urgency of 
the case; impact analysis, in contrast, is a more quantitative method, which involves 
calculating two scores, viz., the evidence score and the public health score, to determine the 
overall priority of a case (Lindquist, 2007; Waller and Harrison-Woolrych, 2017). 
When evaluating a signal, there are four key aspects to consider. Firstly the causality (in other 
words, does the balance of information support cause and effect), the frequency (in other 
words, how often is the effect or harm occurring), then the clinical implications (i.e., if the 
ADR is not serious, are there other effects that do call for further investigation) and lastly, 
preventability (i.e., are there any possibilities of preventing ADRs from arising) (Waller and 
Harrison-Woolrych, 2017).  
The outcomes of such signal evaluation are often that further investigation is required; 
however, if the evidence supports the fact that immediate action is required urgently, 
confirmation is not necessary (Lindquist, 2004; Waller and Harrison-Woolrych, 2017). If no 
immediate action is required, signals are investigated further to obtain more information 
related to the drug and the suspected ADR (Waller and Harrison-Woolrych, 2017).  
 Taking action 
The taking action step of a PV systems is a three-fold approach, which entails (i) considering 
possible options, (ii) deciding on and selecting the most appropriate option, and (iii) 
implementing the selected option (Waller and Harrison-Woolrych, 2017). When considering 
the possible options, both the user and the drug characteristics need to be evaluated and, based 
on these characteristics, different potential options can be identified. If these recommended 
options are not sufficient, more comprehensive and often system-level actions, such as 
regulatory actions or removing the drug from the market, are considered (Lindquist, 2004; 
Waller and Harrison-Woolrych, 2017). Then, during the decision-making approach, the first 
step is to compile a document containing all the relevant information, often referred to as a 
benefit-risk report, which is used by both companies and regulatory bodies to determine the 
most suitable option to implement. Lastly, during the implementation step, the final option is 
executed; this may involve market authorization or product information changes, or the 
removal of the drug from the market entirely (Waller and Harrison-Woolrych, 2017). An 
important consideration during the implementation step is the urgency of communicating the 
information regarding the selected option to the different HCP and patients, especially in the 
case of life-treating ADRs (Lindquist, 2004; Waller and Harrison-Woolrych, 2017).  
 Communication 
Communication within the context of the PV process refers to the sharing of information 
related to the actions that have to be taken when an ADR is reported or when a drug is being 
investigated (Waller and Harrison-Woolrych, 2017). According to Waller and Harrison-
Woolrych (2017), communication is seen as the most important step of the PV process; and 
yet, it has proven to be very challenging within the PV context, especially if information needs 
to be distributed quickly to the involved stakeholders, i.e. PV centres, HCP, pharmaceutical 




communicating information regarding drug safety, it is important to ensure that information is 
accurate, balanced, and transparent, meaning that there is clarity when discussing possible 
hazards (Waller and Harrison-Woolrych, 2017). Furthermore, the information should also be 
understandable, ideally communicated in layman’s terms, and targeted towards the intended 
audience group (Waller and Harrison-Woolrych, 2017).  
 CHALLENGES ASSOCIATED WITH TRADITIONAL PV SYSTEMS 
As stated in Section 2.1, a context-specific PV system needs to not only address the niche 
factors, but should consider and address the challenges associated with or brought about by 
the four identified niche factors, i.e., (i) traditional PV systems, (ii) MPP, (iii) HIV, TB and 
Hepatitis C, and (iv) RLS. The key reasoning supporting this statement is that a context-
specific PV system is specifically aimed at addressing the environment of MPP drug provision 
systems, where these niche factors are integrated and where they require unique 
considerations, should ideally alleviate the known challenges in a traditional PV system, or at 
the very least not perpetuate such challenges. 
Thus, the challenges associated with traditional PV systems will be identified and investigated 
in this section. The approach taken to identify these challenges will be discussed first, followed 
by an overview of these challenges and the challenges landscape related to traditional PV 
systems that is developed.  
 Systematic literature review approach 
Due to the vast amount of literature available with regard to PV and drug surveillance 
monitoring, a systematic literature study was conducted to identify the literature most relevant 
to this study, i.e. literature pertaining specifically to challenges associated with traditional PV 
systems. The primary search protocol was conducted in the academic database, Scopus6, as 
this is considered the largest and most comprehensive database to consult when using 
keywords in a search protocol; in addition, the database PubMed7 was consulted for 
serendipitous findings. For this systematic review, three expanded search term sets were 
developed to ensure that the most relevant articles would be included. The search terms that 
were used were within the context of challenges associated with PV systems and are shown in 
Table 2.1. 
Table 2.1: List of search terms used for the systematic literature review pertaining to the PV 
challenges landscape 




(“drug monitoring” OR 
pharmacovigilance) W/58 (challenges*9 
OR weakness* OR concern* OR 
issues*) 
580 420 
                                                 
 
6 Scopus is the largest database of peer reviewed literature with the format of abstract and citation 
(https://www.elsevier.com/solutions/scopus) (Scopus, 2019) 
7 PubMed is a database for biomedical literature: https://www.ncbi.nlm.nih.gov/pubmed/ 
8 Within the context of Scopus, the term W/5 refers to, within 5 words of each other 
9 Within the context of Scopus, the * replaces multiple characters in a term, for example behav* finds behave, behaviour, 





(“drug monitoring” OR 
pharmacovigilance) AND challenges* 
90 84 
(“drug monitoring” OR 
pharmacovigilance) AND “developing 
countries” AND challenges* 
34 32 
A total of 704 articles were identified after the search process, however to ensure that only the 
most relevant articles were included, certain additional criteria were considered; i.e. 
documents were limited to documents conducted in English and published between the years 
2000 and 2017 were included to insure consistence of the systematic review. After these 
criteria points were applied, 536 articles were still under consideration and these articles’ 
abstract were screened for relevance with regard to traditional PV systems. Subsequently 73 
articles remained which were then reviewed and to ensure that the most relevant articles were 
included and thus documents that did not consider challenges associated with PV systems were 
removed. After the completion of this process 33 documents from Scopus and an additional 2 
documents from PubMed, were reviewed to identify the challenges found in traditional PV 
systems. Figure 2.2 provides an overview of the process that was followed during the 





Figure 2.2: Systematic literature review process pertaining to PV challenges 
 Challenges associated with traditional pharmacovigilance systems  
During the systematic review, 20 challenges associated with traditional PV systems were 
identified. These identified challenges are discussed individually in the following section. The 
20 challenges include: 
i. Absence of a PV curriculum; 
ii. Consumers;  
iii. Confidentiality and ethics; 



































vi. Government and regulatory bodies; 
vii. Inadequate quality of data; 
viii. Incorporation of paediatrics & pregnancy; 
ix. Lack of effective communication channels;  
x. Lack of PV education within the healthcare environment; 
xi. Lack of Knowledge, Attitude and Practices; 
xii. Lack of training; 
xiii. Limited finances; 
xiv. Limited resources; 
xv. Pharmacists; 
xvi. Pharmaceutical companies; 
xvii. Stakeholders involvement; 
xviii. Traditional medicines; and 
xix. Under-reporting of ADR. 
 Absence of a pharmacovigilance curriculum 
Studies have shown that students studying BPharm and PharmD have insufficient knowledge 
of PV and how to report ADRs, and that there is a need to incorporate these processes into the 
curriculum of these healthcare studies (Farha et al., 2015). Since pharmacists need to be able 
to correctly identify ADRs and to report them, as they are often the first line of contact, it is 
necessary for pharmacy students to be trained in these aspects. Furthermore, incorporating PV 
subjects into the curriculum of medical students will enhance their KAP, which will advance 
the healthcare delivery system for the future (Aylin Arici et al., 2015; Abubakar and Haque, 
2016). The improvements to the curriculum can be achieved through various applications such 
as implementing ADR reporting training into undergraduate programs or institute internships 
and post-graduate training programs (Umair Khan et al., 2015; Abubakar and Haque, 2016).  
The PV curriculum can be seen as a subset of PV education, which has also been identified as 
a challenge, see Section 2.3.13; the literature pertaining to PV education highlights the lack of 
implementation of a PV curriculum (Lamprecht, Bam and De Kock, 2017). 
 Absence of a pharmacovigilance culture 
A PV system is built on a culture of drug safety, in which the importance of identifying, 
reporting, and monitoring ADRs is integrated within the healthcare system (Lamprecht, Bam 
and De Kock, 2017). However, according to the literature, there is a need to address the lack 
of such a culture in traditional PV systems, which will require the improvement of 
misconception and general understanding related to PV systems (Vallano et al., 2010; 
Lamprecht, Bam and De Kock, 2017). It has been stated that integrating education on PV into 
the healthcare system is necessary to build a culture of PV (Lamprecht, Bam and De Kock, 
2017). Similarly, by improving the culture and raising awareness on the importance of PV, it 




responsibility with respect to ADR reporting (Dal Pan, 2014; Matos, Hunsel and Joaquim, 
2015).  
 Consumers  
In a PV environment, consumers have to be aware of the importance of ADR reporting; 
however, studies looking at consumers’ KAP with regard to PV show that this has not yet been 
achieved and that more efforts should be made to engage the public (Thomas and Zachariah, 
2017). Furthermore, communication between consumers and HCP are vital, as HCP are 
responsible for informing consumers on both ADR and PV (Lumpkin, 2000).  
 Confidentiality and ethics 
In the modern-day healthcare landscape, where the use of electronic databases and technology 
is a growing reality, confidentiality in the healthcare environment poses a bigger challenge 
than ever before (Tobaiqy et al., 2010; Thomas and Zachariah, 2017). A lack of confidentiality 
assurance has resulted in consumers being reluctant or fearful of reporting ADRs because they 
are afraid that their privacy will be compromised if they admit to taking certain medication – 
specifically in the case of HIV, TB and Hepatitis C (Thomas and Zachariah, 2017). 
Furthermore healthcare professionals are concerned that reporting ADRs will negatively affect 
their medical reputation, and subsequently a patients’ confidence in the healthcare system, but 
not reporting ADRs and denying that ADRs occur, on the part of HCP –will also most likely 
further reduce faith in the healthcare system because it is failing patients (Ronald H.B. 
Meyboom, 2002; Isah et al., 2012). 
 Detection of adverse drug reactions 
The identification of ADRs together with the detection of the relation between ADRs and drug 
exposure are a significant challenge faced in PV (Talisuna, Staedke and D’Alessandro, 2006; 
Isah et al., 2012; Pillay et al., 2017). The lack of ADR detection is often attributed to the lack 
of KAP and education in PV (Ronald H.B. Meyboom, 2002). According to a study by 
Abubakar and Haque (2016) this challenge has given rise to new methods of screening reports 
in order to identify signals, such as automated programs to screen large electronic databases 
(Abubakar and Haque, 2016).  
 Doctors 
Doctors play a vital role in the PV system, as they are often the first point of contact for the 
reporting of ADRs and thus should be able to easily identify, manage and report ADRs; it is 
evident from the literature, however, that one of the main shortcomings of ADR surveillance 
is poor education of health professionals, including doctors, with regard to PV (Nilseng et al., 
2014; Abubakar and Haque, 2016). According to the literature, the curriculum of students in 
pharmaceutical studies needs to include PV (Dikshit, 2010; Brickel et al., 2017).  
 Governments and regulatory bodies  
Governments have a key role to play in developing and supporting PV systems, and require 
support through collaborations with safety and regulatory departments (Palaian, 2017; Thomas 
and Zachariah, 2017). The government plays a vital role with regard to drug registration, drug 
bans, labelling, usages, and restrictions (Thomas and Zachariah, 2017). However, the KAP, 




affecting the PV culture (Olsson et al., 2010). The lack of government involvement in PV also 
negatively affects other areas, such as poor financial support, which has a vital impact in RLS 
(Lindquist, 2004; Olsson et al., 2010; Miller, Nwokike and Stergachis, 2012; Olivera et al., 
2014). 
 Inadequate quality of data 
The impact of incomplete and inadequate quality reports is identified as a pressing concern 
within PV systems (Lindquist, 2004; Dal Pan, 2014; Kheloufi et al., 2017). In order for a PV 
system to be effective in all the different stages from retrieval of ADRs to analysis and 
decision-making, methods should be put in place to ensure that the highest quality of data is 
received (Kheloufi et al., 2017). Furthermore, it is often also the case that reports are of poor 
quality, especially in the case of consumer reports, due to a lack of education with regard to 
PV and ADRs (Dal Pan, 2014). Reports that are of insufficient quality and provide no useful 
information, or more specifically, information that would be useful to the context of drug 
safety monitoring, places a further burden on RLS, as resources need to be diverted from 
important activities to assist with the addressing of these reports (Lester, 2009; Tobaiqy et al., 
2010; Isah et al., 2012).  
 Incorporation of paediatrics and pregnancy  
These specific groups of users require specialized needs in a drug monitoring system, which 
has proven to be challenging in a PV system (Lester, 2009). Studies have shown that there is 
insufficient information on medicine safety with regard to pregnancies, and thus more 
attention should be paid to ADR reporting among pregnant women, with specific attention 
being paid to the fetus (Lester, 2009; Tobaiqy et al., 2010; Isah et al., 2012). Furthermore in 
the field of paediatrics, more focus should be placed on PV too, as children are classified as a 
high risk group (Tobaiqy et al., 2010). Consequently, according to Dikshit (2010) it has proven 
challenging for parents to gain confidence in the healthcare system with regard to paediatric 
PV, as children are more likely to react negatively to drugs (Dikshit, 2010). 
 Lack of effective communication channels  
Communication between different stakeholders such as healthcare professionals, consumers 
and other stakeholders is very important in a PV system, which must ensure that accurate 
information is provided to the different parties (Bahri, 2010; Mehta, Dheda, Steel, M. 
Blockman, et al., 2014). Thus good platforms for communication should be in place in order 
for healthcare professionals to communicate both with consumers and the government 
(Thomas and Zachariah, 2017). However, according to Olsson (2010), it has been found that 
this is often lacking in PV systems, which leads to poor consumer-provider communication 
that is further worsened by a lack of resources (Olsson et al., 2010). 
 Lack of pharmacovigilance education within the healthcare environment 
The concept of education in a PV system comprises several different aspects, such as training 
programs, knowledge of different stakeholders, and culture of ADR reporting (Lumpkin, 2000; 
Farha et al., 2015; Kheloufi et al., 2017). Furthermore studies have also indicated that students 
studying medicine, both pharmacists and doctors, have insufficient knowledge on PV and the 
importance thereof, and that a change in the curriculum of the students is needed in order to 




of education regarding PV and the PV system also leads to other challenges, such as the 
identification and reporting of ADRs, communication between different stakeholders and the 
under-reporting of ADRs (Sevene et al., 2008; Vallano et al., 2010; Abubakar and Haque, 
2016). The challenge of improving PV education is a pressing matter, and studies have been 
conducted on methods on how to address this problem. Both pharmacists and students in the 
medicine field acknowledge the importance of ADR reporting and agree that training 
programs, feedback sessions, the implementation of a focal person and continuous PV 
education should be integrated into the healthcare system, although this still has not been 
incorporated effectively (Thomas and Zachariah, 2017).  
 Lack of Knowledge, Attitude and Practice  
KAP refers to the knowledge, attitude and practices associated with PV, where knowledge 
refers to the true understanding of a topic, attitude is how an individual’s actions or behaviours 
are influenced through their beliefs, and practice comprises the actions of an individual, which 
in this case refers to a HCPs actions in observing, reporting and assessing ADRs (Vallano et 
al., 2010; Thomas and Zachariah, 2017). From the literature, it is evident that there is a lack 
of awareness about this system in the PV community, as most healthcare professionals have 
inadequate knowledge of ADRs and do not always have a positive attitude towards the 
reporting thereof, largely because reporting ADRs is voluntary (Prabhakar and Edwards, 
2010). However, improving KAP may also address other challenges, such as under-reporting, 
as the participants, whether HCP or consumers, will likely have an improved understanding of 
the reasons for reporting ADRs and the importance of this process (Olsson et al., 2010; Vallano 
et al., 2010; Abubakar and Haque, 2016). 
 Lack of training  
The lack of effective training programs for healthcare professions, which includes the lack of 
PV training in the curriculum of students, is closely related to PV education (Olsson et al., 
2010; Abubakar and Haque, 2016). A study by Farha (2015) shows that students comprehend 
the importance of PV practices and agree that PV training should be integrated into the 
curriculum, although this is found to still be challenging (Farha et al., 2015). Moreover, 
students should be trained how to effectively recognize, avoid and report ADRs, as this will 
reduce under-reporting (Isah et al., 2012; Abubakar and Haque, 2016). The implementation of 
training in the curriculum will also alleviate the challenge of KAP (Olsson et al., 2010; Isah 
et al., 2012; Skalli and Soulaymani Bencheikh, 2015).  
 Limited finances  
Limited finances in the field of PV has been shown to pose a major challenge, especially in 
developing countries, where basic PV needs are often not being met (Simooya, 2005; Olsson 
et al., 2010). In a study conducted by Skalli and Soulaymani Bencheikh (2015) it was found 
that poor funding to PV in the healthcare system can be attributed to stakeholders not 
comprehending the importance of a PV system and thus not allocating resources to it (Skalli 
and Soulaymani Bencheikh, 2015). Such a lack of finances does not only directly affect the 
PV programs of a country but also the PV training programs (Talisuna, Staedke and 




 Limited resources  
For a PV system to work effectively, resources, such as people, time and money, are required, 
but in the traditional PV system, little attention has been paid to such resources (Talisuna, 
Staedke and D’Alessandro, 2006; Mudzviti et al., 2012; Dal Pan, 2014). A lack of resources 
further makes it difficult to identify and ascertain the seriousness of ADRs, as the available 
resources often lack PV education (Mudzviti et al., 2012).  
 Pharmacists  
As pharmacist are often the first line of contact for reporting ADRs, they have a vital role to 
play in PV; however, there are issues that prevent them from assisting in this process. In most 
developing countries, there is a lack of qualified personnel, which results in under-reporting 
and low quality standards of reporting (Dikshit, 2010; Nilseng et al., 2014; Olivera et al., 
2014). Furthermore, the lack of a culture of drug safety reporting has created an environment 
where HCP, such as pharmacists are not aware of the importance of PV and thus often do not 
receive the necessary education on how to identify and report ADRs (Dikshit, 2010; Olivera 
et al., 2014).  
 Pharmaceutical companies 
A challenge that often arises when considering PV is the extent of involvement from the 
private sector and pharmaceutical companies (Jeetu and Anusha, 2010; Isah et al., 2012; Dal 
Pan, 2014). Pharmaceutical companies are under pressure to ensure that the quality of their 
products is up to standard with regulations, and thus have been encouraged to improve 
collaboration with the PV system (Jeetu and Anusha, 2010). However, it has been found that 
generic pharmaceutical companies do not always recognize or accept their responsibility in 
continuous drug safety monitoring (Baroutsou, 2009; Dal Pan, 2014).  
 Stakeholder involvement 
PV is a collaborative endeavour that involves multiple stakeholders from different fields. The 
involvement of the HCP raises challenges that need to be considered (Dikshit, 2010; Dal Pan, 
2014). Furthermore, the involvement and role of the government as stakeholder also needs to 
be considered, as the government has a key role to play with regard to ensuring that the PV 
programs are sustainable and achievable (Palaian, 2017; Thomas and Zachariah, 2017). The 
extent and nature of the involvement of the private sector, in the form of pharmaceutical 
companies, also raises challenges for PV systems that need to be overcome (Skalli and 
Soulaymani Bencheikh, 2015).  
 Traditional medicine  
With the growing use of herbal and/or traditional medicines, especially in developing countries 
(Isah et al., 2012; Skalli and Soulaymani Bencheikh, 2015), challenges regarding PV and the 
need for monitoring of these products are increasing, and call for the adaptation of PV systems 
(Skalli and Soulaymani Bencheikh, 2015). Studies have shown that, as with all medicines, 
traditional medicine too may cause ADRs to appear, often due to incorrect dosages, herb-drug 
interactions, contamination and mistaken use (Skalli and Soulaymani Bencheikh, 2015). To 
improve traditional medicine drug monitoring, educational campaigns and training programs 




 Under-reporting of adverse drug reactions 
Under-reporting of ADRs by HCP and consumers is one of the most challenging issues in PV 
(Tobaiqy et al., 2010; Isah et al., 2012; Matos, Hunsel and Joaquim, 2015; Abubakar and 
Haque, 2016). According to a study done by Matos (2015), there are several factors regarding 
knowledge and attitude that affect under-reporting, such as complacency, diffidence, 
ignorance, insecurity and indifference (Isah et al., 2012). Other challenges include a lack of 
knowledge on reporting requirements, an inability to identify ADRs, and insufficient ADR 
reporting forms and methods (Isah et al., 2012; Dal Pan, 2014). Although it is important to 
educate health professionals on the importance of ADR reporting, it is just as important to 
ensure that patients comprehend that consumer reporting is also a vital part of PV (Vallano et 
al., 2010; Lamprecht, Bam and De Kock, 2017).  
 OVERVIEW OF CHALLENGES LANDSCAPE RELATED TO 
TRADITIONAL PV SYSTEMS 
From the identification, and contextualisation of the challenges related to traditional PV 
systems, as discussed in Section 2.3, it is deduced that certain challenges are inter-related and 
furthermore impact the PV process at (possible) different stages. Thus, in order to gain a more 
holistic view of the challenges identified with regard to traditional PV systems, a challenges 
landscape is developed, showing the different impacts of and relationships between the 
challenges, if any exists, as well as where these challenges affect the different stages of a PV 
system. This challenges landscape pertaining to traditional PV systems will form part of the 
larger challenges landscape by considering the entirety of the MPP drug provision system, 
which is developed during the later phase of this dissertation.  
In this section the landscape development methodology is discussed after which a relationship 
diagram pertaining to the identified challenges will be developed to assist with synthesising 
these challenges to create a landscape. 
 Challenges landscape development methodology 
During the process of developing the challenges landscape in the context of traditional PV 
systems, a relationship diagram is firstly developed in order to determine if any relationships 
exist between the different identified challenges. These relationships are deduced from the 
insights gained in the discussion of the challenges as discussed in Section 2.3. Furthermore, 
based on the discussion of the different challenges it was deduced that these challenges affect 
the PV process, as discussed in Section 2.2.2 at different stages, and thus these impacts were 
also considered during the development of the challenges landscape.  
The relationship diagram is the used to gain insights on the possible relations between the 
challenges and deductions are made with respect to challenges that can be grouped together 
based on overarching characteristics, i.e. shared attributes. Building on these insights with 
respect to the grouped challenges, a challenges landscape pertaining to traditional PV systems 
is created. In the following sub-sections, the relationship diagram and challenges landscape 




 Relationship diagram 
Once the challenges related to traditional PV had been identified and discussed the interactions 
and relationships between the identified challenges could be investigated. These relationships 
refer to, but are not limited to, the impact that these challenges have on one another, i.e. with 
one challenge contributing to, aggravating, or alleviating another challenge. Furthermore, a 
relationship between two challenges could also indicate a resemblance between the relevant 
characteristics and thus lead to the possible grouping of challenges together. The relationship 
diagram for the PV challenges landscape is provided in Figure 2.3 below. 
 
 Challenges landscape  
Once the different relationships were derived, the challenges were grouped together based on 
overarching characteristics, i.e. shared attributes; in this way, three overarching groups of 
challenges were identified, namely: (i) education, (ii) stakeholders, and (iii) reporting 
inefficiencies. The challenges associated with education were attributed to a lack of education 
relating to PV within the healthcare system, the challenges related to stakeholders refer to the 
different stakeholders’ involvement within the PV system and their specific roles, and the 
reporting inefficiencies were seen as challenges that are directly caused by inadequacies in the 
reporting process. Furthermore, from the discussion of the challenges and the developed 
relationship diagram, it was found that the PV culture posed an overarching challenge that 
directly affected education, stakeholders and inadequacies in the PV process, thus indirectly 
affecting those challenges within these groups (see Figure 2.4).  
 























































































































































































Stakeholders X X X X X X
Education X X X X
Under-reporting X X X X
KAP X X X X X X
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The challenges landscape related to traditional PV systems was developed based on the 
groupings of the challenges within the context of PV culture within the context of the different 
PV process as discussed above. The challenges landscape related to traditional PV systems is 
illustrated in Figure 2.5 while the typology and the groupings are summarised in Table 2.2. In 
Table 2.2, the code number, as indicated in Figure 2.5, along with the challenges group, the 
different challenges, are provided. Furthermore, the discussion of the typology, in terms of 















































 Table 2.2: PV challenges landscape discussion 
 


















As previously mentioned from the literature review, it could be deduced that the over-arching challenge with regard to PV was the culture associated 
with PV and the PV process. It was determined that this culture affects all the other identified challenges, either directly or indirectly. The effects of the 
PV culture directly implicate the stakeholders, education and the reporting system. For example, creating a culture focused on the importance of PV 
will positively influence stakeholder involvement, leading to increased reporting of ADRs and improvement in the education of PV throughout the 













Education is one of the main challenges that affects different stages of the PV system; there are many different challenges that are caused by a lack of 
PV education, such as detection of ADRs, under-reporting and inadequate quality of reports (Prabhakar and Edwards, 2010). PV education is mainly 
related to KAP, training programs and student healthcare curriculums, which are often found to be lacking, thus causing further challenges. For 
example, a low KAP often leads to under-reporting of ADRs, since most stakeholders do not comprehend the importance of PV (Isah et al., 2012; 
Abubakar and Haque, 2016). This issue of KAP can be addressed by implementing training programs and improving the curriculum of students in 
healthcare (Baroutsou, 2009; Dal Pan, 2014). Without effective training programs and relevant subjects within study fields, education with regard to 

















As mentioned, PV is a collaborative undertaking that actively involves all stakeholders, such as the government and the pharmaceutical and health 
industry professionals, but a lack of involvement by these stakeholders has been found, leading to further implications and challenges that affect the PV 
system negatively (Sabblah et al., 2015; Thomas and Zachariah, 2017) 







As mentioned, the government has a vital role to play in the PV process with regard to decision making and 
implementation of the actions taken, and then communicating these decisions to those involved. Furthermore, it has 
been found that the lack of government involvement is associated with a lack of finances and low resources being 
allocated to PV, which again relates back to the lack of KAP in respect of PV within the political environment 
(Mudzviti et al., 2012; Skalli and Soulaymani Bencheikh, 2015). Such a lack of resources creates further challenges, 
such as effectively identifying ADRs, whereas the lack of finances also implicates PV education, such as training 






























The involvement of pharmaceutical companies is often a challenge in itself, as there is commonly a conflict of interest 
between healthcare delivery systems and the pharmaceutical industry, which affects PV. Furthermore, pharmaceutical 
companies are mostly involved during the decision making and implementation step of the PV process, as they are 
directly involved with the manufacturing of the drugs that are being investigated (Mudzviti et al., 2012).  
C3.3 Pharmacists  
As pharmacists are often the first line of contact, they are mostly involved during the signal detection step, with regard 
to identifying and reporting ADRs (Mudzviti et al., 2012; Nilseng et al., 2014). However, due to the lack of a PV 
culture and education in relation to PV, pharmacists are often not able to correctly identify ADRs, leading to under-
reporting and low-quality reports (Farha et al., 2015). Improvements in the curriculum will positively affect 
pharmacists’ abilities in this regard (Abubakar and Haque, 2016; Thomas and Zachariah, 2017). 
C3.4 Doctors 
Doctors are mostly involved during the detection and reporting of ADRs; however, this has proven to be challenging, 
and under-reporting has been associated with doctors’ lack of involvement. This is often due to the poor PV education 
in the healthcare system, and the ethical issues that doctors have with regard to reporting and their busy schedules 
(Nilseng et al., 2014; Abubakar and Haque, 2016). However, improvements in the curriculum could overcome these 







In the PV process, consumers are mostly involved with the reporting of ADRs and symptoms to either doctors or 
pharmacists; however, due to a lack of KAP, consumers often do not understand the importance of PV. Furthermore, 
certain specialized groups, namely pregnant women and users of traditional medicine create further challenges. The 
main challenges in these cases are the lack of education with regard to PV, which is often associated with an absence 
of PV in training program, curriculum or public awareness (Thomas and Zachariah, 2017). A lack of paediatric 
monitoring has also often been associated with ethical and confidentiality issues that parents have with the reporting 
process. Moreover, a lack of communication between consumers and HCP is one of the leading challenges with PV 


















& ethics, under 
reporting, 
quality of data 
In the process of reporting, it has been found that many challenges can be inter-related, such as detection of ADRs, ethics, quality of data and under-
reporting, which has been found to be one of the biggest challenges faced in PV. Under-reporting further relates to challenges, such as detection of 
ADRs and a lack of knowledge with regard to reporting requirements (Dal Pan, 2014; Thomas and Zachariah, 2017). The inadequate quality of the data 
is often attributed to the lack of resources, whereas ethical issues are related to the involvement of certain stakeholders, such as doctors (Isah et al., 
2012; Dal Pan, 2014; Kheloufi et al., 2017). However, most of these challenges can be attributed to the lack of PV related education within the 





 CHAPTER 2 CONCLUSION 
In this chapter, the input identification phase was executed, with the aim of contextualising the 
first niche factor, viz., traditional PV systems, which needs to be taken into account when 
developing a decision support tool that facilitates the development of context-specific PV 
systems within the environment of MPP drug provision systems.  
In addition to the contextualisation of traditional PV systems, challenges associated with this 
factor were also identified and investigated, and a challenges landscape related to traditional 
PV systems was developed in order to gain a systems perspective understanding of these 
challenges and the impact that they have on the PV process.  
In the following chapter, the input identification process will be continued, but the focus will 
be placed on the contextualisation of the other identified niche factors, (i) MPP, (ii) HIV, TB 
and Hepatitis C, and (iii) RLS. Furthermore, challenges associated with these factors will also 
be investigated, as was the case in this chapter, and the developed PV challenges landscape 
will be amended to include the additional challenges. In this way, a challenges landscape for 






Chapter 3: Niche factor contextualisation: 
Medicine Patent Pool, HIV, TB 
and Hepatitis C, and resource 
limited settings 
In this chapter, the input identification phase of the systems engineering approach will be 
continued by focusing on the environmental context of MPP drug provision systems. The same 
approach that was used in Chapter 2, viz. to contextualise the first niche factor, namely, (i) 
traditional PV systems, will be followed in this chapter, but with regard to the three other 
identified niche factors, (ii) the MPP, (iii) HIV, TB and Hepatitis C, and (iv) RLS.  
When considering the aim of this research inquiry of developing a decision support tool that 
facilitates the development of context-specific PV in particular for the environment of MPP 
drug provision systems, it is necessary to consider the factors that could influence such a 
proposed system. However, as stated in Section 2.1 given the context of this dissertation, an 
in-depth input identification process is not required; it has already been established that the 
environment under consideration, i.e., MPP drug provision systems, comprises four niche 
factors as stated above. Furthermore, to ensure that the proposed context-specific PV system 
adequately addresses all of these factors, it is necessary to identify any challenges associated 
with them.  
In Chapter 2, the first niche factor, traditional PV systems, and challenges associated with this 
factor, was investigated and discussed in order to gain a systems level understanding of PV. 
In this chapter the other three niche factors will be contextualised, after which a systematic 
literature review will be conducted to identify any challenges related to these factors within 
the context of PV. This will lead to the development of a challenges landscape. Moreover, in 
order to gain a systems level perspective of all the challenges related to the context of this 
dissertation, the challenges landscape developed in Chapter 2 and in the current chapter will 
be synthesised to form a single challenges landscape. This phase of the research is illustrated 
in Figure 3.1.   
It should be noted that a substantial portion of this chapter has been published as a journal 







Figure 3.1: Systems engineering approach: Input identification related to MPP, HIV, TB and 
Hepatitis C, and RLS 
 NICHE FACTOR CONTEXTUALISATION 
When considering a context-specific PV system within the context of MPP, there are four 
niche factors that need to be considered, namely: (i) traditional PV systems (which was 
discussed in Chapter 2), (ii) the MPP, (iii) the disease burden addressed by the MPP (HIV, TB 
and Hepatitis C), and (iv) RLS. This section looks at the context of the latter three niche factors 
within PV systems.  
 The Medicine Patent Pool 
In developing countries, it was found that patients were often not receiving treatment for 
certain disease, such as HIV and TB, due to the high costs of the patent system, which gave 
some companies a monopoly over a certain drug (Modell, 2003). Thus, in 2010, the MPP was 
established by UNITAID to increase access to specific communicable disease treatments, 
namely HIV, Hepatitis C and TB, in low- and middle-income countries by sharing 
technologies and patents (Modell, 2003). A patent pool is defined as a collaboration between 
patent holders and other third parties, where licences are offered for usage in exchange for a 
price or royalties. The implementation of a medicines patent pool allows drugs to be produced 
and distributed to a broader population, at a faster rate and at a more affordable price (Modell, 
2003; UNITAID, 2010; Medicine Patent Pool, 2011; Perry, 2012). The WHO assists the MPP 
by prioritising the required medicines, while patent holders voluntarily agree to license their 
medicines to the MPP, who in turn agree to licence manufacturing rights to generic 
pharmaceutical companies.  
The implementation of the MPP has numerous advantages, such as facilitating competition, 
increasing low-cost manufacturing and encouraging research and development (R&D) (Perry, 
2012). Moreover, it encourages competition, as multiple drug manufacturing companies can 
access the same patents. As competition increases, it may decrease drug prices, leading to 
more affordable drugs being available (Modell, 2003). Through the MPP, numerous 
pharmaceutical manufacturing companies are also able to approach the patent pool to negotiate 
licensing agreements to create generic versions of these drugs (Modell, 2003; UNITAID, 





the drugs are easily accessible and can thus be used to develop new fixed-dosage combinations 
in order to create appropriate formulations to meet the specific needs of the patients, as the 
drugs are often not adapted for usage in developing countries (Burrone, 2016). 
However, there are also certain challenges, such as inadequate generic pharmaceutical 
manufacturing and distribution systems, a lack of R&D, sub-standard medicines, and other 
regulatory challenges of providing access to medicine through the MPP (T’Hoen et al., 2011; 
Taylor et al., 2011) .The challenges associated with the MPP within the context of PV are 
discussed in detail in Section 3.2 below. The patents, which are accessible through the MPP, 
are made available at no cost, to any generic pharmaceutical manufacturing company in low- 
and middle-income countries that wishes to make use of it (T’Hoen et al., 2011; Taylor et al., 
2011). Although such generic pharmaceutical manufacturers do need to meet certain quality 
standards, it is often challenging to monitor and enforce these standards of quality. This is why 
effective drug safety monitoring systems must be considered and implemented. From research, 
it is evident that, that the drug manufacturing and distribution systems, which are made 
possible through the MPP, result in numerous challenges, such as counterfeit, or substandard 
drugs, which reaffirms the need for effective drug safety monitoring systems (Medicines 
Patent Pool, 2010b, 2010a).  
 Medicine Patent Pool related disease burden: HIV, TB and Hepatis C 
The MPP makes available patents for certain drugs to increase access to and facilitate the 
development of treatments related to HIV, TB and Hepatitis C, as these communicable 
diseases are highly prevalent in environments targeted by the MPP, i.e. developing countries, 
and as they are often the biggest contributor to the high burden of diseases (WHO, 2019d). 
The three communicable diseases addressed by the MPP, are discussed in more detail in the 
following subsections. 
  HIV/AIDS 
HIV is an immunodeficiency virus that weakens a person’s immune system and increases 
susceptibility to other infections and diseases. The most advanced stage of HIV is AIDS; it 
can take up to 15 years to develop this, depending on the specific individual. The virus is 
transmitted through bodily fluids (WHO, 2019d).  
HIV/AIDS is a global public health issue, which has caused more than 32 million deaths to 
date. In 2018, 770 000 had died from AIDS whilst approximately 37.9 million people are still 
living with the disease. Furthermore, according to the WHO, the African region accounted for 
almost two thirds of the 1.7 million newly infected HIV patients of 2018 (WHO, 2019d). 
Although access to treatment for HIV infected patients has been improving, 48% of these 
patients in low-and-middle income countries do not have access to antiretroviral treatment 
(ART) (Medicines Patent Pool, 2010a). 
These statistics indicate that HIV is still seen as a prevailing diseases  in developing countries, 
which reaffirms the need for innovative drug manufacturing platforms such as the MPP. ART 
is used to treat HIV-infected patients, by supressing the replication of the HIV virus, which 
thus prevents the weakening of the infected patient’s immune system. The MPP attempts to 





manufacturing companies access to patents for the following ARTs (Medicines Patent Pool, 
2010a; Angamo et al., 2016; Tetteh et al., 2016)  
i. Atazanavir;  
ii. Bictegravir;  
iii. Cobicistat;  
iv. Dolutegravir;  
v. Elvitegravir;  
vi. Emtricitabine;  
vii. Lopinavir, Ritonavir;  
viii. Patents related to Darunavir; 
ix. Solid drug nanoparticle technology; 
x. Tenofovir Alafenamide;  
xi. Tenofovir Disoproxil Fumarate; and  
xii. Valganciclovir. 
Apart from these ARTs, the MPP also allows access to the following four paediatric related 
ARTs: 
i. Abacavir;  
ii. Dolutegravir (paediatric specific); 
iii. Lopinavir, Ritonavir (paediatric specific); and 
iv. Raltegravir.  
Within the context of drug safety monitoring, there are HIV related challenges, such as the 
high occurrence of ADRs, that have to be addressed and taken into account when considering 
a context-specific PV system (WHO, 2018c). Section 3.2 provides a more detailed explanation 
of these challenges.  
  TB 
Tuberculosis is an airborne bacterial disease that affects the lungs and can thus rapidly be 
spread if infected patients are not treated timeously and effectively |(WHO, 2018c). An 
infected patient could also have latent TB, which is referred to when the patient does not 
exhibit symptoms of the disease and cannot transmit it; however, in the case of activated TB, 
an infected patient could infect up to 10 – 15 people through close contact in the time span of 
one year (WHO, 2018c). Furthermore in the case that a patient has a compromised immune 
systems, i.e. such as the case for HIV patients, said patient is at a higher risk of falling ill with 
TB and developing co-infections, which are often more challenging to address and treat 
(Medicines Patent Pool, 2019).  
Like HIV, TB is prevalent in developing countries. Thus, the MPP seeks to improve access to 





Pfizer10. Sutezoid is an investigational TB drug that, when accessed through the MPP, can be 
studied further to improve the potential impact with respect to new TB regimes (Chen et al., 
2015; Winston and Underwood, 2015; Masuka et al., 2018). 
As is the case with HIV, effective PV system are required which consider the manufacturing 
of TB drug treatments, and thus challenges associated with this disease should also be taken 
into account when addressing a context-specific PV system (WHO, 2019c). 
  Hepatitis C 
Hepatitis C is a blood-borne viral disease that ranges in severity from mild disease to a fatal, 
lifelong disease which can lead to severe complications, such as liver cancer (WHO, 2019c). 
The Hepatitis virus is carried through the blood and is most commonly transmitted through the 
sharing of injectable materials, transfusion of unscreened blood, or sexual practices that lead 
to blood exposure. However, is can also be transmitted from mother to child during pregnancy 
or through sexual intercourse. Research done by the WHO indicates that Hepatitis C mostly 
affects the Eastern Mediterranean region (i.e. Afghanistan, Egypt, Iraq, Qatar, and Saudi 
Arabia to name a few), an area in which drug manufacturers also have access to the MPP 
(WHO, 2019c). In 2016, 399 000 people died from Hepatitis C globally, although the use of 
antiretroviral medication is claimed to cure more than 95% of the infected patients. However, 
access to diagnosis and treatment is very low, especially in developing countries (WHO, 
2019c). In 2017, of the 71 million Hepatitis C patients, only 19% knew their diagnosis and of 
that group only 38% were being treated most likely due to a lack of access to treatment (WHO, 
2019c). Clearly, such challenges need to be addressed in order to ensure that the Sustainable 
Development Agenda11 2030 target for Hepatitis C treatment is met, which is aimed at 
reducing viral hepatitis infections with 90% and deaths by 65% by 2030 (Medicines Patent 
Pool, 2010a). 
Through the MPP, access to the following three Hepatitis C related drugs is made available to 
generic pharmaceutical manufacturing companies (Fitzgibbon and Wallis, 2014; Geiling et al., 
2014). These three drugs are: 
i. Daclatasvir; 
ii. Glecaprevir/Pibrentasvir; and 
iii. Ravidasvir. 
As is the case with the previously discussed diseases, HIV and TB, Hepatitis C must also be 
taken into account when developing a decision support tool that facilitates the development of 
context-specific PV systems for the context of the MPP.  
 Resource limited settings  
The MPP is implemented in developing countries that are often faced with the challenge of 
having limited resources available, which may lead to additional challenges within the context 
of PV systems. RLS, also referred to as resource-poor or resource-constrained settings, are 
                                                 
 
10 One of the largest US pharmaceutical companies. 
11 This agenda was adopted in 2015 by all United Nations Members States as a plan for peace and prosperity related 





defined as environments where the capability to provide care to life-treating illnesses is limited 
to the provision of basic resources, i.e. financial, academic, and human (Sevene et al., 2008; 
Geiling et al., 2014). These RLS are often characterised by having limited access to medical 
equipment and supplies, inadequate infrastructures with limited access to maintenance, a 
limited number of trained HCP to meet the need of the population, or insufficient capacity to 
deal with a high disease burden (Kinfu, Poz and Evans, 2009).  
A study of healthcare workers in sub-Saharan Africa indicated that the number of healthcare 
workers available was not sufficient for meeting the patients’ needs (Mohr, 2006). This is 
confirmed by studies done by the WHO, which have further found an uneven distribution of 
healthcare workers globally, with countries that have the highest need of patient care also 
having the lowest number of HCP (Mohr, 2006). A study conducted by the WHO in (2006) 
states that, although the African region has more than 24% of the global burden of diseases, 
this region only has access to 3% of the world’s HCP (WHO, 2019b).  
Recent statistics from the WHO’s Global Health Observatory data repository12 showed that, 
in 2017, there were only 9.1 medical doctors per 10 000 population in South Africa, in 
comparison to the United Kingdom’s 28 per 10 000. Other developing countries also had very 
low doctor-to-patient ratios, such as Angola (2.1/10 000), Ghana (1.8/10 000), India (7.6/10 
000) (WHO, 2019a).  
Furthermore, this uneven distribution of human resources is not only applicable to medical 
doctors, but also extends to all types of HCP, pharmaceutical personnel and nurses. The Global 
Health Observatory data repository shows that, in 2017, there were only 1.52 pharmacists per 
10 000 population in South Africa, which was more than 6 times lower than the United 
Kingdom, which had 8.8 per 10 000 (Kinfu, Poz and Evans, 2009). Research also indicates 
that the pre-service training of healthcare workers in developing countries is insufficient for 
meeting current and future health needs (Kotagal et al., 2009; Fonjungo et al., 2012). 
Moreover, resource limitations do not only refer to human resources, as mentioned. The 
literature pertaining to healthcare systems in low- and middle-income countries also argues 
that it extends to a lack of finances, which subsequently results in a lack of medical supplies, 
equipment, and infrastructure, including poor access to healthcare (Kotagal et al., 2009; 
Fonjungo et al., 2012). Limited finances also lead to unreliable quality processes, delays in 
treatment, and a lack of information to support clinical decisions (Urmila, Brown and Yajnik, 
2011). In Section 3.2, more detail will be provided on the challenges associated with RLS.  
Furthermore, RLS also considers the lack of academic research with respect to specific niche 
aspects. In RLS environments, academic research is often prioritised to consider the highest 
healthcare related needs within the environment – which is often focused on the treatments of 
the most prevalent illnesses (WHO and The Global Fund, 2010).  
The WHO states that, for a PV system to function effectively, trained staff and a PV system 
(infrastructure) needs to exist (Taylor et al., 2011; Burrone, 2016); in RLS, however, this is 







challenging. Thus, when considering the development of a new PV system within the 
environment of MPP drug provision systems, it is evident that RLS will need to be addressed.  
 CHALLENGES ASSOCIATED WITH THE MEDICINE PATENT POOL, HIV, 
TB, AND HEPATITIS C, AND RESOURCE LIMITED SETTINGS 
As mentioned earlier, the challenges that arise in the manufacturing and distribution of those 
drugs of which patents are made available through the MPP, can be attributed to inadequate 
drug manufacturing and distribution systems (Naicker et al., 2009). These challenges affect 
patient safety and thus need to be addressed to ensure that the necessary monitoring systems 
are in place. The low- and middle income countries that incorporate the MPP also often have 
limited resources, which poses further challenges (WHO, 2002a). 
The aim of this section is to identify the challenges relating to drug manufacturing and 
distribution systems in RLS, especially with regard to HIV, TB and Hepatitis C. These 
challenges are identified through a systematic literature review in order to develop a challenges 
landscape (similar to the PV challenges landscape developed in Chapter 2), which will create 
a systems level perspective with a context-specific understanding of the relevant challenges. 
Thereafter, this challenges landscape will be integrated with the challenges landscape 
developed in Chapter 2 pertaining to traditional PV systems, to develop an overarching 
challenges landscape within the context of MPP drug provision systems. 
In the following section, the approach of the systematic literature review, as well as its findings 
and results, will be presented, together with a discussion of the identified challenges.  
 Systematic literature review approach  
As was the case with the systematic literature review presented in Section 2.3.1, the academic 
database Scopus was consulted to identify literature pertaining to PV systems and drug safety 
monitoring, in order to subsequently identify the challenges associated with (i) the MPP, (ii) 
HIV, TB and Hepatitis C, and (iii) RLS within the context of PV. PubMed was also used for 
informal search methods and serendipitous findings.  
A total of 2307 relevant articles were found via Scopus, using specific key words and phrases 
(shown in Table 3.1). In order to find the most relevant documents, inclusion / exclusion 
criteria were included in the search protocol. Only documents from 2010 – 2017 were 
included, as the MPP was only introduced in 2010. Furthermore, documents that were not 
primarily published in English, and thus translated, and any duplicate documents were 
excluded. Applying this criterion 1302 relevant articles were identified of which the abstracts 
of these documents were reviews with context to (i) drug manufacturing or (ii) distribution 
systems or (iii) RLS or (iv) HIV, TB or Hepatitis C, and irrelevant articles were removed. The 
remaining articles, a total of 107, were then reviewed with respect to challenges within the 
context of (i) drug manufacturing or (ii) distribution systems or (iii) RLS or (iv) HIV, TB or 
Hepatitis C, of which only 57 relevant articles were found. An additional 7 articles were found 
using serendipitous search methods in PubMed. A total of 64 articles were then reviewed in 






Table 3.1: List of search terms used for MPP, RLS and specific diseases in the systematic literature 
review 








“Drug Manufacturing” 480 257 
“Drug Manufacturing” AND Challenges 45 31 
“Drug Manufacturing” AND HIV 4 1 
“Drug Manufacturing” AND “Developing Countries” 16 8 
“Drug Manufacturing” AND Challenges AND “Developing Countries” 3 1 
“Drug Manufacturing” AND Quality 188 102 
“Drug Distributions” AND Challenges AND HIV 232 147 
“Drug Distributions” AND Challenges AND “Developing Countries” 14 7 
“Drug Resistance” AND HIV AND “Developing Countries” 352 189 
“Counterfeit drugs” AND “Developing Countries” 126 84 
“Resource Limited Settings” AND Challenges AND HIV 337 257 
“Resource Limited Settings” AND Challenges AND “Developing 
countries” 
144 123 
“Patient safety” AND HIV AND “Developing Countries” 24 17 
“Drug Packaging” AND Challenges AND HIV 10 5 
“Drug Packaging” AND Challenges AND “Developing Countries” 9 8 
“Adverse Drug Reactions” AND “Drug Manufacturing” 58 29 
“Adverse Drug Reactions” AND HIV AND “Developing countries” 84 64 
“Drug Manufacturing*” AND Tuberculosis 5 5 
“Drug Manufacturing” AND “Hepatitis C” 1 0 
“Drug Manufacturing*” AND Tuberculosis AND Challenges 1 1 
“Drug Manufacturing” AND “Hepatitis C” AND Challenges 0 0 
“Drug Distributions*” AND Tuberculosis AND Challenges 15 12 
“Drug Distributions*” AND “Hepatitis C” AND Challenges 8 5 
“Resource Limited Settings” AND Challenges AND Tuberculosis 97 58 
“Resource Limited Settings” AND Challenges AND “Hepatitis C” 18 15 
“Patient safety” AND Tuberculosis AND “Developing Countries” 17 10 








Figure 3.2: Systematic literature review process pertaining to (i) the MPP, (ii) HIV, TB and Hepatitis 
C, (iii) RLS challenges within context of a PV system 
 Results of systematic literature review 
During the systematic literature review, the following 22 challenges relating to either or a 
combination of (i) the MPP, (ii) HIV, TB and Hepatitis C, and (iii) RLS within the context of 
PV systems were identified as: 
i. Adverse drug reactions; 
ii. Co-infections; 
iii. Counterfeit drugs; 
iv. Diagnostic testing; 



































vi. Drug adherence; 
vii. Drug dosages; 
viii. Drug-drug interactions; 
ix. Drug quality; 
x. Drug resistance; 
xi. Drug shortages; 
xii. Drug stock-outs; 
xiii. Drug supply system; 
xiv. Laboratories; 
xv. Lack of awareness & knowledge; 
xvi. Lack of reporting; 
xvii. Late initiation;  
xviii. Mislabelling of drugs; 
xix. Record keeping; 
xx. Specialised drugs; 
xxi. Substandard drugs; and 
xxii. Traditional medicines. 
For a more detailed overview of the occurrence of these challenges in the documents, refer to 
Appendix B.  
Within the context of this research inquiry, these challenges refer to concepts of concern that 
negatively impact the healthcare environment, especially relating to patient safety, and they 
are associated with one or more or a combination of the niche factors, (i) the MPP, (ii) HIV, 
TB and Hepatitis C, and (iii) RLS. As this research study investigates a context-specific PV 
system, these challenges must be considered within the context of PV and drug safety 
monitoring. These identified challenges are not necessarily directly related to PV systems, but 
they could, within the context of MPP drug provision systems, have an impact on drug safety 
monitoring and PV. 
Furthermore, when considering the challenges listed above, and the challenges pertaining to 
traditional PV systems (see Chapter 2), it can be seen that similar challenges relate to both 
these instances. For example, ADR detection, which is associated with traditional PV systems, 
is similar in nature to the challenges Adverse drug reactions, listed above as (i), and the PV 
culture that is identified as a challenge within the context of traditional PV systems, see Section 
2.3.4, is similar to a lack of awareness and knowledge, listed as (xv).  
The 22 factors that were identified in the systematic review have an impact on the 






 Adverse drug reactions  
According to the WHO, an ADR is defined as “any response to a drug which is noxious and 
unintended, and which occurs at doses normally used in man for prophylaxis, diagnosis, or 
therapy of disease, or for the modification of physiological function” (Angamo et al., 2016; 
Tetteh et al., 2016). ADRs were found to pose a challenge in traditional PV systems (see 
Section 2.3.7); however it is also related to the MPP and RLS, as it has been found that 
inadequate drug manufacturing in RLS contributes to an increase in ADRs (Angamo et al., 
2016; Tetteh et al., 2016). 
ADRs can moreover affect the treatment process and have a negative impact on a patient’s 
quality of life, especially for HIV infected patients on ART (Manickum and Suleman, 2012; 
Masenyetse, Manda and Mwambi, 2015; Syed et al., 2015; Angamo et al., 2016; Mouton et 
al., 2016; Tetteh et al., 2016). Serious ADRs often causes patients to stop taking drugs, leading 
to a failure of drug adherence or treatment; it can also lead to patients being readmitted to 
hospital, thus placing an extra burden on the healthcare system, especially in the case of RLS 
(Manickum and Suleman, 2012; Angamo et al., 2016; Tetteh et al., 2016). It has also been 
determined that many reported ADRs are in fact preventable, which justifies the need for 
improving PV systems. Furthermore, through the MPP, multiple drug manufacturers are able 
to produce generic drugs and new fixed-dosage combinations, making it critical that ADRs are 
monitored carefully (Cox, 2001).  
 Co-infections 
Co-infections are defined as simultaneous infection by multiple pathogenic species 
(Easterbrook, Sands and Harmanci, 2012). In the context of this research inquiry and in the 
relevant literature, co-infections are frequently documented in HIV, TB and Hepatitis C (e.g. 
between HIV and Hepatitis C, or between HIV and TB), especially in RLS (Miyano et al., 
2013; Marais and Schaaf, 2019). 
It is also found that poor communication in the healthcare system leads to problems in 
referrals, monitoring and understanding of co-infections, thus increasing the disease burden of 
HIV, TB and Hepatitis C (Venkatesh et al., 2011). Furthermore, the late initiation of 
treatments, especially in the case of co-infection, is often due to limitations in the diagnostic 
or screening process, with respect to HCP inadequately identifying and assessing the diseases 
(WHO, 2018b).  
 Counterfeit drugs 
According to the WHO, counterfeit or falsified drugs are described as: “medical products that 
deliberately/fraudulently misrepresent their identity, composition or source” (Johnston and 
Holt, 2013). The WHO also state that counterfeit drugs can be branded or generic drugs 
containing the incorrect ingredients, no correct ingredients at all, or inadequate amounts of 
active ingredients, or they may be falsely packaged (Maponga et al., 2007). When patients 
receive and take counterfeit drugs, their health may be compromised, or they may be put at 
risk to develop ADR or drug resistance (Maponga et al., 2007; Nsimba, 2009; Miller, Nwokike 
and Stergachis, 2012; Djobet et al., 2017). Counterfeit drugs are often a concern in areas where 
there is a shortage of drugs or where unregistered drug manufacturing and distribution systems 





 Diagnostic testing 
With certain diseases, such as the three under consideration in this research study, diagnostic 
testing forms an integral part of diagnosing and monitoring the illness (Dominique et al., 2015; 
Purohit et al., 2015; Easterbrook et al., 2017). However, it has been found that, in RLS, the 
infrastructure for diagnostic testing is not up to standard, i.e. accuracy, accessibility and cost-
efficiency, which subsequently affects the prevention and monitoring systems related to these 
diseases (Purohit et al., 2015). A delay in correct diagnosis can further increase the 
transmission of the disease in the community (Sands and Hons, 2012). Furthermore, the 
challenge of co-infections, for instance between HIV and TB, or HIV and Hepatitis C, and 
their diagnostic testing and identification, should also be considered when setting up testing 
facilities (Muhamadi, Nsabagasani and Nazarius, 2010; Bezabhe et al., 2014; Busza et al., 
2018).  
 Dissatisfaction with healthcare system 
The support, integrity and confidentiality of the HCP have a significant impact on the efficacy 
of treatment; it has been found that HIV patients’ distrust or dissatisfaction with the healthcare 
system can lead to challenges, such as the late initiation of treatment or a failure in drug 
adherence, which often results in drug resistance or treatment failure (Houston, 2002). Thus 
the compassion and support of HCP are important to ensure that patients follow through with 
treatment (Bezabhe et al., 2014). 
 Drug adherence 
Drug adherence is when patients follow the recommendations made regarding the dosage, 
timing and frequency of medication in order for treatment to be effective (Bezabhe et al., 
2014). With regard to HIV, for example, a 95% of drug adherence is required in order to ensure 
that patients do not develop resistance or treatment failure (Oguntibeju, 2012; Syed et al., 
2015; Tetteh et al., 2016). From the literature consulted it is evident that non-adherence in 
treatment is often attributed to the occurrence of ADRs (Maponga et al., 2007; Bezabhe et al., 
2014; Syed et al., 2015). In developing countries, other aspects that contribute to non-
adherence are dissatisfaction with the healthcare system, perceived stigmas, lack of proximity 
to clinics, limited social support, poor record keeping, poor attitude of healthcare workers and 
certain personal factors (Haberer et al., 2017). A study by Fontanarosa and Christiansen (2007) 
does, however, indicate that adherence can be improved with peer counselling and education 
(Fontanarosa and Christiansen, 2007).  
  Drug dosages 
According to the American Medical Association, a dosage is defined as the prescribed 
administration of the amount, number and frequency of a specific drug over a period of time 
(Arnum, 2013). When considering drug safety monitoring within the context of the quality of 
a drug, ensuring that patients receive the correct dosages is imperative (Phelps and 
Rakhmanina, 2011). According to the literature, ensuring that patients receive the correct 
dosages is challenging, especially when considering paediatrics. Taking an incorrect dosage 
of a drug can lead to there being an inadequate number of drugs to fight the virus (Phelps and 





subsequently results in unproportioned dosages of the drug being administered. Furthermore, 
it cannot be assumed that the ingredients are evenly distributed throughout a tablet, and thus 
pill splitting is not recommended (U.S. Department of Health and Human Services, 2019).  
Consequently, when considering the MPP, and the opportunity to conduct R&D with respect 
to the development of context-specific drugs, i.e. paediatrics drugs, drug dosages need to be 
taken into account to ensure that quality of drugs within these settings. 
 Drug-drug interactions 
Drug-drug interactions are defined as changes in the effect of the drug when it is taken in 
combination with another drug, which often result in the development of ADRs (Chen et al., 
2015; Winston and Underwood, 2015; Masuka et al., 2018). The literature reviewed shows 
that drug-drug interactions are a frequent occurrence brought on by co-infections related to the 
diseases being investigated herein (Maponga et al., 2007). 
Drug-drug interactions can lead to other challenges, such as poor drug adherence or ADR 
(Prueksaritanont et al., 2013), and can reduce the effectiveness of a drug. Furthermore, drug-
drug interactions have been found to be a leading cause of drugs being withdrawn from the 
market (Houston, 2002; Stevens et al., 2014; Djobet et al., 2017). 
 Drug quality  
Ensuring that the drugs that patients take are safe and effective is one of the priorities of the 
pharmaceutical industry with respect to PV systems, and it needs to be addressed continuously 
throughout the pharmaceutical value chain, from drug manufacturing, to distribution and 
patient monitoring (Kremzner, 2016). There are many different factors, such as a lack of good 
manufacturing practices (GMP), a lack of effective quality monitoring and the existence of 
poor drug plant characteristics that may contribute to the manufacturing of low quality drugs 
(Houston, 2002; Stevens et al., 2014; Djobet et al., 2017). It has been found that, in RLS in 
particular, the quality of drugs is often inconsistent and thus highlights the need for the 
implementation of effective quality control, especially where generic drug manufacturers are 
part of the pharmaceutical supply chain within the context of the MPP (Miller, Nwokike and 
Stergachis, 2012). Generic drug manufacturing and the production of fixed-dosage 
combinations challenge the existing drug quality management system (Maponga et al., 2007; 
Keiser, 2010). 
 Drug resistance 
Drug resistance is when the response to a drug in a susceptible population decreases 
significantly (Houston, 2002; Bertagnolio et al., 2018; Wallis et al., 2018). According to 
studies done by the WHO, it was found that treatment failure is often attributed to drug 
resistance; for example, in 2010, the prevalence of HIV drug resistance for patients starting 
treatment was rated at 6.8% and these patients were found most likely to fail their treatment 
(Easterbrook, Sands and Harmanci, 2012). Furthermore, it has also been documented that, due 
to co-infections, cross-resistance between drugs used for the treatment related to HIV, TB and 





 Drug shortages 
A drug shortage is defined by the WHO as the insufficient supply of medication or health 
products to meet the public and patients’ needs (Wechsler, 2016). Drug shortages are often 
associated with smaller generic companies with little redundant capacity, which poses 
complications in situations with production problems (Jaskot et al., 2011). Furthermore in 
literature it is argued that if possible drug suppliers were investigated and approved at a faster 
rate, it may lead to the mitigation of drug shortages (Wechsler, 2016; WHO, 2016).  
 Drug stock-outs 
According to the WHO, a drug stock-out is defined as the absence of a medication that has 
been identified as essential at the point of service delivery (Pasquet et al., 2010; Nilseng et al., 
2014). Drug stock-outs are often the result of poor infrastructure and insufficient human 
resources (Tassie, Bertagnolio and Souteyrand, 2011; Fokam et al., 2013; MSF et al., 2016). 
It has been reported that one third of countries globally struggle with drug stock-outs, which 
increases the risk of treatment failure and drug adherence (Tassie, Bertagnolio and Souteyrand, 
2011). In order to insure that stock-outs do not occur, it is critical that planning and rational 
forecasting processes are in place (Maponga et al., 2007; Nsimba, 2009). 
 Drug supply system  
In developing countries, drug supply has often been a challenge, especially when considering 
the particular diseases within the context of this research inquiry, i.e. (i) HIV, (ii) TB and (iii) 
Hepatitis C. The treatment of these diseases requires a strict regime, in order to be effective 
(Maponga et al., 2007; Steyn et al., 2008). Furthermore, when limited amounts of drugs are 
available, ethical issues often arise with regard to how the medication should be prioritised for 
different patients (Nsimba, 2009; Nilseng et al., 2014). Delays in drug delivery in RLS are 
often affected by poor infrastructure, such as poor roads, and financial burdens, such as a lack 
of funding for fuel (Steyn et al., 2008). Challenges posed by a poor drug supply relate to all 
aspects of the supply chain, from ordering systems and storage of drugs to their distribution. 
According to the literature, ineffective drug supplies, which often result in drug shortages or 
stock-outs, are attributed to ineffective communication between national authorities, such as 
provincial districts, and healthcare provision facilities, or between the patients and the 
provision facilities (Easterbrook et al., 2017).  
 Laboratories 
When considering RLS and the three diseases focused on in this research, one of the challenges 
is the limited number of laboratories and testing infrastructures (Dominique et al., 2015). 
Furthermore, laboratory systems are often faced with challenges with regard to quality control, 
connectivity and record keeping, which further influence diagnostic testing (Dominique et al., 
2015). The quality of the testing may also affected by challenges, such as regular stock-outs, 
untrained staff and ineffective equipment (Fitzgibbon and Wallis, 2014). Laboratories often 
lack well-written standard operation procedures and good clinical laboratory practices (Purohit 
et al., 2015). In a healthcare setting, especially when considering RLS in which there is a high 
burden of diseases, it is important for HCP to have the right knowledge on how to perform 





pressure placed on laboratories by having HCP perform diagnostic testing ) (Easterbrook et 
al., 2017; Marais and Schaaf, 2019). 
 Lack of awareness & knowledge 
A particular challenge faced within the healthcare landscape is the lack of knowledge and 
awareness of the disease burden with respect to three prevalent diseases examined in this 
research. This lack of awareness entails a lack of understanding of these disease as well as a 
lack of knowledge of possible treatments (Easterbrook et al., 2017). This aggravates other 
challenges, such as the lack of effective diagnostic testing or poor patient adherence to 
treatment (Easterbrook, Sands and Harmanci, 2012). Furthermore, there may also be a lack of 
effective drug safety reporting, which is important in a PV culture (see Section 2.3.4). 
(Ampadu et al., 2016). 
 Lack of reporting 
The lack of ADR reporting is a challenge that has already been identified in Chapter 2 with 
reference to traditional PV systems; however the situation may be worse in RLS (Ampadu et 
al., 2016).  
According to the literature, limited healthcare resources contribute to a lack of reporting of 
(Olsson et al., 2010; Tassie, Bertagnolio and Souteyrand, 2011; Angamo et al., 2016). In most 
low- and middle income countries, there is also inadequate legislation regarding the mandatory 
reporting of ADRs by HCP (Angamo et al., 2016). Furthermore it has been found that under-
reporting of ADRs in RLS is often caused by inadequate education of HCP relating to the 
identification and reporting of ADRs (Ford, Calmy and Mills, 2011). 
 Late initiation 
The need to ensure that patients start treatment during the early phases of the disease is just as 
important as ensuring patients receive treatment (Muhamadi, Nsabagasani and Nazarius, 
2010). It has however been found that, in RLS, treatment programs related to HIV, TB and 
Hepatitis C are not initiated early enough, often due to a lack of effective diagnostics 
(Muhamadi, Nsabagasani and Nazarius, 2010; Dominique et al., 2015; Purohit et al., 2015; 
Easterbrook et al., 2017). This is often caused by inadequate healthcare infrastructures, i.e. 
limited human resources, delay in diagnostics, or socio-economic factors, such as 
misconceptions about the treatment (Arnum, 2013). Furthermore, these socio-economic 
factors are closely related to the factor of dissatisfaction with the health system (see Section 
3.2.7). 
 Mislabelling of drugs  
Mislabelling of drugs can have severe impacts on a patient’s safety and health but not only in 
the context of PV systems, but generally (Arnum, 2013). In RLS contexts, in particular, 
mislabelling of drugs are more prevailing (WHO, 2007a; Djobet et al., 2017). According to 
the WHO, drug labels need to contain the name and amount of the active ingredients, the batch 
number of the manufacturer, the expiry date, the name and the address of the manufacturer; 
moreover, any required storage and usage directions must be clearly indicated (World Health 





 Record keeping 
Patient health records are essential to HCP, as they contain vital patient information, such as 
unique patient identifiers and medical histories. Health records track a patient’s health 
information to facilitate follow-up and to keep track of the treatment process and outcomes 
(Olsson et al., 2010; Fokam et al., 2013). However, in RLS, effective record keeping is often 
lacking or absent (Bezabhe et al., 2014). Patients’ records are often lost, resulting in patients 
having to repeat certain medical procedures unnecessarily (Phelps and Rakhmanina, 2011; 
Dahinten et al., 2016).  
 Specialised drugs 
In developing countries, which are often associated with having limited resources, the 
development of context-specific drugs with respect to population groups or disease burdens 
are becoming prevalent. Furthermore, these drugs are often have associated with low-quality 
control systems and thus require even more effective drug safety monitoring (Dahinten et al., 
2016).  
Two examples of this are the prevailing use of traditional medicines and the use of paediatric 
drugs to treat HIV (Phelps and Rakhmanina, 2011; Dubrocq, Rakhmanina and Phelps, 2017). 
The need for paediatric drugs is much higher in low-middle income countries, as it has been 
found that, in developed countries, mother-infant transmission has been reduced effectively 
(Phelps and Rakhmanina, 2011). Furthermore, the use of adult ART for children is actually 
ineffective, as children absorb and metabolize drugs differently to adults (Phelps and 
Rakhmanina, 2011; Dubrocq, Rakhmanina and Phelps, 2017). Through the MPP, drug 
manufacturers can develop innovative fixed-dosage combinations specifically for paediatric 
use; however, when developing paediatric drugs, the palatability, taste, size, dosages, 
formulation and ease of handling or administration of the drugs should be considered (WHO, 
2018b).  
 Substandard drugs 
The WHO defines substandard drugs as: “authorized medical products that fail to meet either 
their quality standards or specifications, or both” (Djobet et al., 2017). A drug is regarded as 
a substandard drug if it contains too much or too little active ingredients in comparison to the 
formulation specifications (Johnston and Holt, 2013; Djobet et al., 2017). Substandard drugs 
are often attributed to poor manufacturing and distribution systems with unqualified personnel 
and inadequate control systems (Kisangau et al., 2007; Johnston and Holt, 2013). 
 Traditional medicines 
It has been found that, in RLS in particular, there is an increasing production and usage of 
traditional medicines for the purpose of treating diseases. Traditional medicines are skills and 
practices based on indigenous cultural beliefs and theories, which are used to prevent, 
diagnose, improve and/or treat health related issues (Kisangau et al., 2007; Perampaladas et 
al., 2010). The increase in production of these medicines is, however, resulting in challenges 
with regard to quality control, although intercultural standards are already being developed for 
traditional medicines (Perampaladas et al., 2010; Sahoo and Manchikanti, 2013; Kloos, 2017). 





example, the type and quality of the raw materials used, and the knowledge of the 
manufacturers regarding quality monitoring processes, as well as the lack of general drug 
safety related processes (Kankhar, 2006).  
 Discussion of challenges related to Medicine Patent Pool, HIV, TB and Hepatitis 
C, and resource limited settings  
After contextualising the 22 challenges discussed above it was found that certain relationships 
exist between some of the identified challenges, i.e. the challenges may relate to one another, 
aggravate or even alleviate each other. In order to gain a better understanding of these 
relationships, a challenges landscape was developed (see Section 3.4 below), as had been done 
in Chapter 2 in relation to traditional PV systems. 
However, when considering these challenges, it is clear that they are not only related to the 
PV system but to the broader context of the pharmaceutical value chain. Thus, in order to gain 
a systems perspective understanding of these relationships between the challenges and the 
pharmaceutical value chain, the envisaged challenges landscape will consider the context of 
the entire pharmaceutical value chain and not only the context of drug safety monitoring. 
 PHARMACEUTICAL VALUE CHAIN 
From the literature related to the pharmaceutical landscape, it can be deduced that the 
pharmaceutical value chain has three main components, namely, the manufacturing of the 
drugs, the final product, and the distribution of the drugs or products (European Union, 2013). 
Drug safety monitoring should be included throughout the entire pharmaceutical value chain, 
as it has been seen that innovative modes of drug supply, such as the MPP, not only affect 
manufacturing and distribution but also patient monitoring (Kankhar, 2006; UNITAID, 2010; 
European Union, 2013). Thus, in the context of this dissertation, the pharmaceutical value 
chain is considered to have four phases: (i) supply, (ii) distribution, (iii) final product, and (iv) 
the health system, which refers to patient usage and drug monitoring (Dahinten et al., 2016). 
Within the context of this research inquiry, the drug supply is sub-divided into the process of 
R&D and the process of manufacturing, where R&D relates to any form of investigation 
conducted with regard to drugs, and manufacturing refers to the process of developing these 
drugs. Distribution refers to the processes associated with the transporting of the drugs after 
manufacturing to the required healthcare facility. The third phase, i.e., the final products, refers 
to the actual drug that is accessible at the healthcare facility. The last phase, the healthcare 
system, is subdivided into the processes of patient usage and monitoring. Patient usage refers 
to the process of providing the final product to the patient, while monitoring refers to the drug 
safety monitoring process to ensure patient safety monitoring (Kankhar, 2006; UNITAID, 
2010; European Union, 2013; Dahinten et al., 2016). 
In order to gain a systems perspective understanding of the relationships between the identified 
challenges, as listed in Section 3.2, and the above described pharmaceutical value chain within 
the context of the MPP drug provision systems, a challenges landscape is developed. This is 





 OVERVIEW OF CHALLENGES LANDSCAPE OF MEDICINE PATENT 
POOL, HIV, TB AND HEPATITIS C, AND RESOURCE LIMITED SETTINGS 
As emerged from a discussion of the challenges associated with the traditional PV system in 
Chapter 2, here too it was found that the challenges relating to the niche factors, (i) the MPP, 
(ii) HIV, TB and Hepatitis C, and (iii) RLS do possible relate to one another; furthermore, they 
may also have (possibly different) impacts on the respective stages of the pharmaceutical value 
chain. Thus, an additional challenges landscape is developed to gain a holistic view of these.  
The development methodology of the challenges landscape is discussed in the following sub-
section. The challenges landscape is then discussed from three perspectives below: firstly, the 
relationships between the various challenges are considered and presented in a relationship 
diagram; secondly, the relationship diagram, the pharmaceutical value chain framework and 
the various challenges are amalgamated and presented in a schematic representation of the 
challenges landscape; and, thirdly the schematic representation of the challenges landscape is 
discussed.  
 Challenges landscape development methodology 
A similar approach was followed here as had been used in Chapter 2 to develop the challenges 
landscape related to traditional PV systems. Firstly, based on the discussion of the challenges 
it could be deduced that many of the challenges are inter-related with each other and with the 
different phases of the pharmaceutical value chain. Thus, in order to gain a better 
understanding of these relationships, a relationship diagram was developed, indicating which 
challenges relate to one another.  
Using the insights gained from the development of this relationship diagram, the challenges 
could be grouped together based on shared or similar attributes and according to their impact 
on the pharmaceutical value chain. From this it was deduced that there were three overarching 
groups of challenges with respect to the pharmaceutical value chain: (A1) – inadequate 
manufacturing and distribution systems challenges, (A2) – quality related challenges, and (A3) 
– ineffective drug safety monitoring systems. Within these groups there were subsets, which 
will be discussed in more detail in Section 3.4.3.  
 Relationship diagram  
Figure 3.3 illustrates the respective relationships between the challenges. The relationships are 
based on: (i) challenges that share common attributes or characteristics, and (ii) challenges 
that affect one another by either aggravating or alleviating each other. These relationships and 
correlations were not necessarily explicitly mentioned in the literature but emerged after 
synthesising the information gathered through the systematic literature review. The 
relationships, indicated in Figure 3.3, are grouped in such a manner as to indicate the impact 
that a relationship has on a specific section of the pharmaceutical value chain. In the case 





 Challenges landscape related to the Medicine Patent Pool, HIV, TB and Hepatitis 
C and resource limited settings 
Once the relationships between the different challenges at the irrespective phases of 
pharmaceutical value chain had been established, a graphical synthesis of the challenges 
landscape was developed. This graphical landscape is presented in Figure 3.4. 
As stated, three overarching groups of challenges were identified, namely: (A1) – challenges 
due to inadequate manufacturing and distribution systems, (A2) – challenges due to quality 
issues in drug manufacturing and distribution, and (A3) – challenges related to inadequate 
drug safety monitoring systems. In Figure 3.4 these groups are denoted as A1, A2, and (A3). 
In group (A1), there are five sub-groups: (A1.1) refers to challenges associated with 
specialised drugs; (A1.2) to challenges due to an inadequate drug supply; (A1.3) to challenges 
within the context of drug-drug interactions; (A1.4) to challenges relating to drug resistance, 
and (A1.5) to inadequate laboratory and diagnostics testing. In group (A2), there are two sub-
groups relating to inadequate quality systems: (A2.1) are the challenges relating to drug 
manufacturing, while (A2.2) are the challenges relating to the physical drug or product. (A3) 
did not have any sub-groups, as the related challenges were found to all form part of the 
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Figure 3.4: Challenges landscape related to (i) the MPP, (ii) HIV, TB and Hepatitis C, and (iii) RLS 
Pharmaceutical	value	chain	
Supply Distribution Product Health	system




























































Challenges  Explanation 
A1 
A1.1. 
Specialized drugs, paediatric 
drugs, traditional medicines 
In RLS the development and manufacturing of drugs often requires the creation of drugs for the specific needs of patients, referred 
to as specialized drugs. For this research inquiry, the two cases of specialized drugs are paediatric drugs and traditional medicines 
(Maponga et al., 2007; Phelps and Rakhmanina, 2011). These challenges mostly appear during the phases of drug development and 
manufacturing. Furthermore, traditional medicines often have an impact on drug-drug interactions (Steyn et al., 2008). 
A1.2. 
Drug supply, drug shortages, 
drug stock-outs 
Within the drug distribution side of the value chain, drug supply in the low- and middle-income countries is one of the major 
concerns; it is further affected by the limited resources of these settings. As mentioned, there are many factors that affect drug 
supply, from poor infrastructure to factors in the supply chain, such as ordering systems (Fokam et al., 2013). The problems in drug 
supply lead to drug shortages and drug stock-outs. These in turn lead to difficulties with regard to patient safety, since shortages and 
stock-outs are often the causes of drug resistance in patients and poor adherence (Maponga et al., 2007). 
A1.3. 
Drug-drug interactions, ADR, 
drug adherence 
Of the identified challenges, drug-drug interactions arise in the final product stage of the value chain. Co-infections related to HIV, 
TB and Hepatitis C often require that drugs are taken in combination with other drugs, which can lead to negative drug-drug 
interactions. It has also been identified that traditional medicines, which are often used in RLS, have an effect on drug-drug 
interactions (U.S. Department of Health and Human Services, 2019). Drug-drug interactions often cause serious side-effects and 
ADRs (Bezabhe et al., 2014). ADRs often have an effect on a patient’s treatment process, as serious ADRs can affect a patient’s 
adherence to the treatment, since they often stop taking their medications due to ADRs (Ford, Calmy and Mills, 2011; Fokam et al., 
2013). This inevitably affects not just the patient but the community as a whole. Drug adherence implicates the value chain in both 
the final product stage and the patient usage stage.  
A1.4. Drug resistance 
Drug resistance is one of the challenges associated with the patient’s usage of certain drugs. Many factors can lead to drug resistance 
such as, drug delivery, shortages and stock-outs as well as drug adherence (Muhamadi, Nsabagasani and Nazarius, 2010; Bezabhe et 
al., 2014). Furthermore, drug resistance is also caused by inadequate drug monitoring systems, such as the poor integrity of the 
health system and weak record keeping (Dominique et al., 2015; Purohit et al., 2015; Easterbrook et al., 2017).  
A1.5 Laboratories, diagnostics 
In RLS the challenges of inadequate infrastructures and limited numbers of laboratories result in limited diagnostic testing, which 
further burdens the healthcare system; it can also increase disease transmission (Dominique et al., 2015). Furthermore the quality of 
the testing is also affected by challenges, such as regular stock-outs, untrained staff and ineffective equipment (Stevens et al., 2014; 
Djobet et al., 2017). 
 






























Challenges pertaining to Explanation 
A2 
A2.1 Quality, dosages, labelling 
The quality challenges identified have an impact on the supply side of the value chain. Drug manufacturing companies have to have 
quality systems in place to ensure that the drugs are safe and effective, and that will not harm patients (Phelps and Rakhmanina, 
2011). Insufficient quality systems in drug manufacturing companies manifests in mis-labelling and wrong drug dosages. If drug 
manufacturing companies do not have quality systems in place, drug dosages may be inadequate or incorrect, with ingredients not 
distributed evenly, for instance, and labels being incorrect (WHO, 2007a). This causes problems with regard to patient safety 
(Miller, Nwokike and Stergachis, 2012; Djobet et al., 2017).  
A2.2 
Quality, counterfeit drugs, sub-
standard drugs 
The quality of the final product is affected by ineffective manufacturing and distribution systems (Maponga et al., 2007). It may lead 
to poor-quality, counterfeit or sub-standard drugs. These challenges are mostly brought on by a lack of quality in the drug supply 
process and can seriously affects patient safety. Furthermore, counterfeit drugs often lead to serious ADR or drug resistance 
(Nsimba, 2009; Miller, Nwokike and Stergachis, 2012; Djobet et al., 2017), (Muhamadi, Nsabagasani and Nazarius, 2010).  
A3 
Integrity of the health system, 
record keeping system, late ART 
initiation, poor health systems, 
lack of awareness, lack of 
reporting 
In the final stage of the drug value chain, namely monitoring, many challenges arise, often due to limited resources. The integrity of 
the health care system and the lack of effective record keeping are two of the contributing factors for the late initiation of treatment. 
This can be very detrimental to patient care and often leads to unnecessary deaths. Furthermore, the lack of effective record keeping 
and patient dissatisfaction with the health care systems affects drug adherence, which again leads to drug resistance (Angamo et al., 
2016). The lack of reporting is one of the major challenges in RLS during the monitoring stage of the value phase. Preventable 
ADRs are often under-reported, which leads to further complications, such as a lack of drug adherence and an increase in drug 
resistance (Easterbrook, Sands and Harmanci, 2012). Furthermore the lack of awareness related to the disease, HIV, TB and 






 THE PHARMACEUTICAL VALUE CHAIN CHALLENGES LANDSCAPE 
When considering the challenges landscape developed in this chapter, coupled with the 
challenges landscape related to traditional PV systems that was developed in Chapter 2, it can 
be seen that there are certain correlations and analogies that can be drawn, and thus they can 
be synthesised into an overarching challenges landscape that is applicable for the development 
of a decision support tool within the context of MPP drug provision systems.  
After examining the different challenges created by the four niche factors, in other words, (i) 
traditional PV systems, (ii) the MPP, (iii) HIV, TB and Hepatitis C, and (iv) RLS, it was found 
that certain correlations and relationships exist between them. Thus, in order to gain a holistic 
view, the two challenges landscapes were synthesised together to develop an overarching 
landscape referred to as the “Pharmaceutical Value Chain Challenges Landscape” (PVCCL). 
This challenges landscape covers the entire pharmaceutical value chain from the drug 
manufacturing through the distribution phase to the drug safety monitoring phase (which 
includes the PV related process).  
Given that the PVCCL was developed by merging the two previously developed challenges 
landscapes, the identified relationships and discussions of the groupings in Table 2.2 and Table 
3.2 are still relevant within the context of the PVCCL. Furthermore, it was established that 
certain challenges in both the drug supply system and the PV system affect and relate to one 
another during certain stages of the pharmaceutical value chain. These different relationships 
are illustrated in Figure 3.5. The schematic representation of the PVCCL typology is provided 
in Figure 3.6. The seven identified groups are indicated by means of a colour key. 
This overarching challenges landscape provides a system perspective understanding of the 
relevant challenges that should be taken into account when developing a decision support tool 
that facilitates the development of context-specific PV systems and the identified niche factors. 
In the following chapter the PVCCL will be investigated to determine what requirements need 





































































































































































































































































































































































specialised drugs X X
Paedtric drugs X X X X X X
Traditional medicines X X X X X X X
Supply X X X X X X X X X X
Shortages X X X X X X X X
Stock-outs X X X X X X X X X X
Drug-drug interactions X X X X
ADRS X X X X X X X X X X X X X X X
Co-infections x x X X X X
Drug adherence X X X X X X X X X X
Drug resistance X X X X
Laboratory X X X X X
Diagnostics X X X X X
Quality X X X X X X X X
Dosages X
Labelling X
Counterfeit X X X
Sub-standard
Intergirty of the system X X X X X
Record keeping X X X X
Late initiation X X X
Lack of reporting X X X X X X
Awareness X X X X X X X
X X X X X X X
Education X X X X X X X X X
KAP X X X X X X
Training X X X
Cirriculum X X X
Government X X X X
Limited resources X X X
Lack of finances X X X
Pharmaceutical companies X X X X
Doctors X X X X X X
Pharmacists X X X X X
Consumers X X X X X
Paedtric/pregant X
Traditional medicines
ADR detection X X
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 CHAPTER 3 CONCLUSION 
In this chapter, the input identification phase of the systems engineering approach was 
concluded by contextualising and investigating the three remaining niche factors – in other 
words, the MPP, the MPP disease burden of HIV, TB and Hepatitis C, and RLS – in order to 
identify the challenges associated with these factors within the context of PV. A challenges 
landscape was developed, and then synthesised with the challenges landscape previously 
developed in Chapter 2 in relation to traditional PV systems, in order to develop an overarching 
challenges landscape that covers the entire pharmaceutical value chain - PVCCL.  
In the following chapter, the next phase of the systems engineering approach, the requirement 
analysis, will be executed. During this phase, the PVCCL will be looked at closely in order to 







Chapter 4: Requirement specification 
development 
As previously outlined, this research inquiry follows a systems engineering approach to 
address the lack of an existing PV system that is aligned with and appropriate for MPP drug 
provision systems. The systems engineering approach used herein is a four-phase approach, 
as discussed in Section 1.4. In Chapter 2 and Chapter 3, the input identification phase was 
executed, which entailed contextualising the research problem by addressing the four niche 
factors and identifying the challenges associated with these factors in the context of drug safety 
monitoring. The identified challenges were synthesised to develop a challenges landscape, the 
PVCCL. However, in order to advise on a PV system that will effectively address and alleviate 
these challenges in the context of the MPP drug provision systems, a requirement specification 
for such a system needs to be developed. 
Thus, in this chapter, the requirement specification that will guide the development of a 
decsion support tool, will be be developed. The process of developing said requirements 
specification is firstly discussed, which entails considering the developed PVCCL, and 
conducting systematic literature reviews pertaining to the niche factors. Thereafter, the 
developed set of requirement specifications is discussed, followed by a discussion of the 
verification process executed to confirm whether the developed requirement specifications 
would be satisfactory given the conditions of a context-specific PV system. 
The requirement analysis phase of the research is illustrated in Figure 4.1, as well as how it 
relates to other phases of the research.  
It should be noted that a substantial portion of this chapter has been published as an article in 
the Proceedings of the 25th ICE/IEEE International Technology Management ©IEEE. The 
article can be found in Appendix A, Section A.2. 
 




 REQUIREMENT ANALYSIS PHASE 
As stated, the requirement analysis phase is the second phase in the systems engineering 
approach (United States Government, 2001). This phase entails identifying the functional 
requirements called for by the niche factors in designing a decsion support tool for a context-
specific PV system by addressing the challenges associated with these factors, and defining 
the specific requirements in the context of such a system (United States Government, 2001).  
In this dissertation, a three-step approach was conducted during the requirement analysis in 
order to develop and verify a requirement specification. During the development phase, (i) 
systematic literature reviews were conducted to identify the requirements that would be called 
for by the niche factors in such a system, and (ii) the PVCCL was consulted to identify possible 
additional requirements. Systematic literature reviews were conducted in respect of each of 
the four niche factors, (i) traditional PV systems, (ii) the MPP, (iii) HIV, TB and Hepatitis C, 
and (iv) RLS, in order to identify documented requirements related to PV systems.  
In 2010, the WHO was recruited by the Global Fund13 to develop a minimum set of 
requirements for a functioning PV system, in an attempt to assist countries that were seeking 
to improve their national PV centres (WHO and The Global Fund, 2010). However, these 
requirements were found to be inadequate when considering the context of this research 
inquiry. Thus, it was decided to conduct systematic literature reviews to identify whether there 
were any unique requirements related to the four niche factors that should be taken into 
consideration when developing a a decision support tool that facilitates the development of 
context-specific PV systems.  
Consulting the PVCCL entailed addressing the challenges identified with regard to the four 
niche factors to ensure that the proposed decsion support tool would be able to address, 
alleviate and/or eliminate these challenges. Each of the groups of challenges, as described 
Chapter 3, was examined independently to determine if any additional requirements, which 
had not been identified during the systematic literature reviews, should be taken into account. 
If additional requirements were identified, they were synthesised to form a preliminary 
requirement specification. 
Furthermore, a verification process was conducted to evaluate whether the preliminary 
requirement specification was satisfactory with respect to the conditions, i.e. challenges 
landscape, the niche factors call for in a context-specific PV system. This verification process 
was used to determine whether the identified requirements were acceptable within the context 
of this research inquiry, and to identify possible additional requirements that should be taken 
into account (the verification process is discussed in Section 4.5). After the necessary changes, 
adaptations and recommendations were integrated, a final requirement specification was 
developed, which is discussed in Section 4.6. These specifications will then be used as guiding 
and foundational principles for the development of a decision support tool that would facilitate 
the development of a context-specific PV system, which will be discussed in the following 
chapters. 
                                                 
 
13 The Global Fund is an international organization aimed at ending the disease burden of AIDS, TB and malaria as epidemics 




 CONSULTING THE LITERATURE  
As this dissertation considers a PV systems it is first necessary to identify the requirements 
such a system would have to fulfil. Furthermore, as this research study considers the 
environment of MPP drug provision systems, and consequently the niche factors (i) traditional 
PV systems, (ii) the MPP, (iii) HIV, TB and Hepatitis C, and, (iv) RLS, it is necessary to 
investigate the possible unique requirements these factors call for.  
According to the WHO, (WHO and The Global Fund, 2010), there are five minimum 
requirements for an effective PV system: 
i. A national PV centre with designated staff members and a defined structure;  
ii. A national spontaneous reporting system with ADR reporting forms; 
iii. A system for collecting the ADR reports; 
iv. A PV advisory group that can provide technical assistance; and 
v. A clear communication strategy between the stakeholders involved. 
However, when considering the challenges associated with the niche factors as discussed in 
Chapter 3 in relation to the PVCCL, it can be assumed that the minimum requirements for a 
PV system are inadequate to address the requirements these niche factors would call for in a 
drug safety monitoring system. Thus, systematic literature reviews focused on each of the four 
identified niche factors (see Chapters 2 and 3).  
In the following sub-section, each systematic literature review will be discussed, along with 
the identified requirements.  
 Systematic literature review related to traditional pharmacovigilance system 
requirements 
The aim of this systematic literature review was to gain a better understanding of the PV 
requirements that have been documented in the literature and to identify any potential 
universal requirements relating to traditional PV. As was the case in the previous systematic 
literature reviews presented in Section 2.3.1 and Section 3.4.1, Scopus and PubMed were used 
as primary search databases. Using keywords14 related to PV, as indicated in Table 4.1, a total 
of 293 relevant documents were initially identified. To ensure that the most relevant 
documents were included, inclusion/exclusion criteria were applied, which entailed only 
including documents that were published in English and from 2000 onwards. After these initial 
criteria had been applied, a total of 262 documents remained for consideration; their abstracts 
of the documents were thus screened for relevance with regard to any requirements pertaining 
to traditional PV. Thereafter, 31 documents were found to be relevant; after each of these full 
articles had been reviewed, only 12 were found to be of value to the requirements identified 
in this study. Any duplicate documents found when conducting the search in PubMed were 
excluded, as they had already been included when conducting the search in Scopus. 
                                                 
 
14 It should be noted that, in the search protocol used with Scopus, W/5 (within 5 words) was used as an attempt to ensure that 
the requirements would be related to pharmacovigilance; however in PubMed W/5 is not identified as a search protocol and 




Furthermore, Google Scholar was consulted for serendipitous findings and thus a further three 
articles were included as a result. In the end, therefore, a total of 15 documents were reviewed 
to identify the requirements that are universal to traditional PV systems. 
Table 4.1: List of search terms used to identify traditional PV related requirements 
Search 
base 



















W/5 requirements  




194 176 14 5 
Google 
Scholar  
Serendipitous findings 3 
Total number of documents  293 262 31 15 
 Requirements relating to traditional PV systems identified from the literature 
After these 15 articles had been reviewed, 11 requirements pertaining to traditional PV systems 
were identified; they are described in the following sub-sections. For a detailed overview of 
the occurrence of each of these requirements in the documented literature, refer to Appendix 
B. 
 Pharmacovigilance education as part of the health systems environment 
The literature calls for PV education to form a more vital part of the health system (WHO, 
2002b, 2006b; Hanzl-Dujmović, Sulić-Milišić and Starešinić-Šernhorst, 2007; Khattri et al., 
2012; Zun, 2014; Olsson, Pal and Dodoo, 2015a; Nwaiwu, Oyelade and Eze, 2016; Olivier et 
al., 2016). In a study done by the WHO and the Uppsala Monitoring Centre (UMC), the 
importance of integrating drug safety and PV into the medical health curricula is highlighted, 
as well as the lack of research and postgraduate training in this field. The research argues that, 
if healthcare practitioners were confident in their ability to correctly diagnose, manage and 
prevent ADRs, they would be more likely to report ADRs. Furthermore, when looking at PV 
education, all stakeholders should be actively involved, although the national PV centres and 
other similar establishments should be seen as the primary teaching bases. Also, it is argued 
in the literature that PV education should not be limited to training sessions but should include 
a variety of different methods, such as conferences, educational programmes and scientific 
publications (WHO, 2002b).  
 Clear lines of communication within a pharmacovigilance system 
For a system to work and function effectively, clear lines of communication between all the 
different stakeholders are vital (WHO, 2002b, 2006b; Olsson, Pal and Dodoo, 2015a). Thus, 
in order for the proposed context-specific PV system to operate effectively, clear channels of 
communication would have to be formed between, for example, quality control labs and PV 
centres; government/regulatory bodies and PV centres; healthcare professionals and 
consumers (WHO, 2002b, 2006b; Olsson, Pal and Dodoo, 2015a). A clear communication 
strategy is also one of the WHO’s minimum requirements for a functioning PV system (WHO 




 Patient involvement in the reporting of adverse drug reactions 
In the literature it is argued that a PV system requires the involvement of patients with respect 
to the reporting of ADRs (Pietrek, Coulson and Czarnecki, 2009). Furthermore, patients should 
also receive feedback related to reported ADRs (WHO, 2006b).  
 Database for managing adverse drug reactions reports  
The WHO states that one of the minimum requirements for an effective PV system is that a 
database for the collecting and the managing of ADRs needs to exist (WHO and The Global 
Fund, 2010). Although the success of a PV system requires the reporting of ADRs, its 
effectiveness will rely on the correct management of the data gathered and the quality of the 
databases (WHO, 2006b).  
 Pharmacovigilance centre or reporting system with designated staff  
A well-structured PV system should consider all the stages of the system, from collecting and 
managing ADR reports and clinically evaluating these to taking regulatory action in response 
to reported ADRs and alerting prescribers, manufacturers and the public (WHO, 2006b; 
Pietrek, Coulson and Czarnecki, 2009; WHO and The Global Fund, 2010; Khattri et al., 2012; 
Olsson, Pal and Dodoo, 2015a). Furthermore, a PV system requires designated, qualified staff 
as well as an advisory committee to assist with technical matters (WHO, 2006b; Olsson, Pal 
and Dodoo, 2015a; Nwaiwu, Oyelade and Eze, 2016).  
 Quality management and control systems to be integrated within 
pharmacovigilance 
Quality management and quality control systems need to be integrated into the different steps 
of the PV system, i.e. from signal detection to evaluation and taking action (Olsson, Pal and 
Dodoo, 2015b). Good Pharmacovigilance Practices (GVP) state that quality management 
systems should include (i) clear policies, (ii) standard operating procedures, (iii) working 
instructions, and (iv) job descriptions with regard to drug safety (Pietrek, Coulson and 
Czarnecki, 2009). Furthermore, quality management also entails ensuring that the system is 
regularly reviewed and audited, and that the equipment used is regularly validated (Pietrek, 
Coulson and Czarnecki, 2009). All stakeholders involved with pharmacovigilance need to 
embrace the concept of quality control and to demonstrate collaborative, transparent, proactive 
behaviour with respect to the implementation of quality control (Pietrek, Coulson and 
Czarnecki, 2009; Olsson, Pal and Dodoo, 2015a; Nwaiwu, Oyelade and Eze, 2016).  
 Definition of stakeholders’ roles  
In the literature it is argued that, in order for a PV system to function effectively, all the 
different stakeholders involved, i.e. government, regulatory bodies, national PV centres, HCP, 
pharmaceutical companies and patients, must have clearly defined roles and responsibilities 
of which they are informed (Hanzl-Dujmović, Sulić-Milišić and Starešinić-Šernhorst, 2007; 
Khattri et al., 2012; Nwaiwu, Oyelade and Eze, 2016). Furthermore, the national PV centre or 
other specified regulatory body (i.e. SAPRHA in the case of South Africa) is responsible for 
managing the databases collecting and evaluating the reports, identifying any suspicious 




 Adverese drug reactions reporting forms containing all the relevant information 
For a PV system to operate successfully and effectively, it is vital that ADRs are reported, and 
thus an ADR reporting form has to exist (WHO, 2006b). The report must capture the relevant 
information, i.e. patient information, suspected product or drug information, and a description 
of the ADR; moreover, a degree of standardisation is required (WHO, 2006b). Furthermore, 
if relevant information is omitted or questioned, the system must be able to verify the report 
by contacting the necessary parties (Olivier et al., 2016; Poirot et al., 2016; Nguyen et al., 
2018). 
 Collaboration between clinical trials and pharmacovigilance systems  
The WHO defines a clinical trial as any research study that evaluates the health effects by 
prospectively assigning humans to health-related studies (WHO, 2015c). However, in the 
literature it is argued that there should be collaboration between the clinical trial phase of a 
drug and the PV monitoring system (Zun, 2014; Harugeri, Shastri and Patel, 2017). It is thus 
imperative that, during the clinical trial phase, the planning and operation of the PV system is 
taken into account. This entails considering if additional or more strenuous PV activities would 
need to be included (Iwasaki, Kaneko and Narukawa, 2017). Furthermore, certain 
improvements are needed for the clinical trial and PV databases when addressing the 
timeliness, duplication, coverage and harmonization of the data collection (Harugeri, Shastri 
and Patel, 2017). 
 Context-specific conditions  
Although a PV system requires some form of standardisation with regard to ADR reports, it is 
argued in the literature that context-specific conditions have to be taken into account too (Zun, 
2014; Cheaib, 2016). This entails considering specific populations of patients (such as 
paediatric patients, pregnant patients, elderly patients, and traditional medicine users), as well 
as drugs or treatments for specific disease burdens (i.e. HIV, TB etc.) and specific countries 
when developing a PV system and/or processes (Zun, 2014).  
 Proactive reporting processes 
Spontaneous reporting methods are the most common method used with regard to ADR 
reporting; however, from the literature it is evident that a more proactive approach needs to be 
taken, which entails modernising and customising the entire reporting system (Hanzl-
Dujmović, Sulić-Milišić and Starešinić-Šernhorst, 2007). Furthermore, in order to reduce 
under-reporting, implementing either compulsory reporting or alternatively providing some 
form of compensation may be required (Khattri et al., 2012). 
 Systematic literature review related to Medicine Patent Pool requirements 
This systematic literature review was conducted to identify the possible requirements of the 
MPP within the context of PV systems. As was the case in the previous systematic literature 
reviews, Scopus and PubMed were consulted and search terms related to the context of MPP 
and PV were used; these are summarised in Table 4.2. The search term “MPP or Medicines 
Patent Pool” could not be used directly, as no relevant documents were identified with this 
search term. Thus, as in the systematic literature review conducted in Section 3.4.1, which 




supply” were used instead, as the MPP contributes to the manufacturing and supply of drugs. 
The term “requirements” was not included during the search protocol as had been done in the 
previous review (see Section 4.2.1), because the inclusion of this term limited the initially 
identified documents to five documents. Thus, in an attempt to identify possible additional 
relevant documents, this term was excluded, although it was still considered when the 
documents themselves were closely reviewed.  
By using the search terms listed in Table 4.2, a total of 74 potentially relevant documents were 
identified. Furthermore, to ensure that only the most relevant documents were considered, 
inclusion/exclusion criteria were used, which entailed only including documents that were 
published from 2010 onwards, as the MPP was only established in that year, and thus it would 
not be relevant to search from 2000 onwards, as with the previous search, as well as only 
including documents that were published in English. Once these criteria had been applied, it 
reduced the total number of articles to 37. The abstracts of these remaining documents were 
then reviewed, and any documents that were not specifically relevant to requirements related 
to PV within the context of drug manufacturing or supply (i.e., with regard to the MPP) were 
removed, until 18 relevant documents remained. The last step entailed reviewing the entire 
documents, and any documents that did not contribute to the identification of any requirements 
related to PV within the context of MPP or drug supply or manufacturing, were removed. In 
the end, a total of relevant documents remained, which were then closely reviewed. 
Table 4.2: List of search terms used to identify MPP related requirements  
Search 
base 



















OR “drug supply”) AND 
(pharmacovigilance OR 
(drug safety monitoring))  
54 30 12 6 
PubMed 
(“drug manufacturing” 
OR “drug supply”) AND 
(pharmacovigilance OR 
(drug safety monitoring)) 
27 20 6 0 
Total number of documents 74 37 18 6 
 Requirements relating to Medicine Patent Pool identified from the literature 
After analysing the relevant documents, a total of 4 requirements related to PV within the 
context of the MPP (or subsequently drug manufacturing and supply) was found. Some of 
these were similar in nature to those previously identified in Section 4.2.2. However, where 
this is the case, there are specific considerations that the MPP calls for in the development of 
the requirement specification for that will guide the development of a decision support tool 
that facilitates the development of context-specific PV systems. 
  Education of pharmaceutical companies on pharmacovigilance  
As previosuy stated the system must incorporate PV education. In the context of the MPP, 
however, the PV education should be incorporated into the education of pharmaceutical 




(Vashisth, Singh and Nanda, 2012; Flood et al., 2017). In a study done by Flood (2017) on 
generic pharmaceutical companies, it was found that the pharmaceutical staff had very limited 
or no pharmacy-specific training, which included drug safety monitoring or PV related 
education (Flood et al., 2017). As the MPP is associated with generic drug manufacturing 
companies, it is important to extend PV education into the drug manufacturing and supply 
environments.  
 Definition of stakeholders’ roles with respect to pharmaceutical companies 
When considering the different stakeholders involved with drug safety monitoring, it has been 
found that pharmaceutical companies need to be more actively involved with the PV process 
and reporting of ADRs (Arabia, 2015; Nwaiwu, Oyelade and Eze, 2016; Nguyen et al., 2018). 
Thus, pharmaceutical companies’ roles within the context of PV systems should be clearly 
defined, in order to improve quality control in the PV system (Arabia, 2015; Nwaiwu, Oyelade 
and Eze, 2016; Nguyen et al., 2018).  
 Quality control for substandard or counterfeit drugs 
In the context of the MPP, inadequate quality drugs, i.e. substandard or counterfeit drugs, are 
more prevalent, as stated in Sections 3.2.5 and 3.2.23 (Johnston and Holt, 2013). Thus, PV 
systems must be able to improve quality control for these kinds of drugs. PV systems are thus 
required to have a higher and more sensitive index with respect to inadequate quality drugs 
(i.e. counterfeit or substandard drugs) by having systems in place (i) when reports related to 
ineffective drugs are received, or (ii) when there are presenting circumstances that raise 
suspicions with respect to a reported drug (Khurelbat et al., 2014; Beninger, 2017). 
 Context-specific conditions with respect to traditional medicines 
According to the literature, traditional medicines raise unique issues for a PV system, for 
instance with regard to the occurrence of drug-herb interactions and previously unknown 
ADRs; a PV system within the context of these drugs must be able to address these issues 
effectively (Beninger, 2017). In this research inquiry, it has been found that traditional 
medicines are often associated with the MPP, as indicated in Section 3.2.24 and the PVCCL, 
and thus, when a context-specific PV system is being considered for the MPP, systems must 
be in place to address these unique issues related to traditional medicines.  
 Systematic literature review related to HIV, TB and Hepatitis C requirements 
The focus of the third systematic literature review was to identify requirements related to HIV, 
TB and Hepatitis C within the context of a PV system. As was the case with the previous 
systematic literature review described in Section 4.3.2, the academic databases Scopus and 
PubMed were used as the primary search databases to conduct a similar search protocol to 
identify requirements related to the specific diseases, viz. HIV, TB and Hepatitis C. Table 4.3 
indicates the different search terms used, similar to the previous systematic literature reviews, 
but now within the context of HIV, TB and Hepatitis C. However, it should be noted that, in 
this systematic literature review, the search term ‘characteristics’ was included together with 
‘requirements’, as the initial search protocol, only using ‘requirements’, only identified a 
relatively limited number of documents (i.e., only 23 relevant documents in total). Thus, after 
the search was extended to include the word ‘characteristics’, a total of 107 relevant articles 




Thereafter, to ensure that only the most relevant documents were included in this research, 
inclusion/exclusion criteria were used, which entailed only including documents that were 
published from 2010 onwards, as this was the year in which the MPP was established, as well 
as only including documents that were primarily written in English. After these 
inclusion/exclusion criteria were applied, 96 relevant documents remained; their abstracts 
were reviewed to identify any requirements that these specific diseases, (i) HIV, (ii) TB, and 
(iii) Hepatitis C, would call for in a PV or drug safety monitoring system; this reduced the 
number to 68 relevant documents. The final step of the systematic literature review was to 
review the full remaining documents and remove those documents that were not relevant to 
the specific PV requirements related to (i) HIV, (ii) TB, and (iii) Hepatitis C, and a total of 15 
relevant documents remained. Furthermore, after additional sources, such as Google Scholar, 
were used, five additional documents were included as serendipitous findings. A total of 20 
relevant documents were thus identified and used.  
Table 4.3: List of search terms used to identify HIV, TB and Hepatitis C related requirements 
Search 
base 




















(HIV OR (TB OR tuberculosis) OR 
(Hepatitis C)) AND (requirements* 
OR characteristics*) AND 
(pharmacovigilance OR (drug safety 
monitoring) 
121 54 26 8 
PubMed 
(HIV OR (TB OR tuberculosis) OR 
(Hepatitis C)) AND ((requirements* 
OR characteristics*) AND 
(pharmacovigilance OR (drug safety 
monitoring)) 
73 66 42 7 
Google 
Scholar 
Serendipitous findings 5 
Total number of documents 107 96 68 20 
 Requirements relating to specific diseases, HIV, TB and Hepatitis C identified 
from the literature 
After the relevant documents identified were reviewed a total of nine requirements related to 
HIV, TB, and Hepatitis C were identified with respect to PV systems. It was found that many 
of the requirements identified are similar to those previously identified (see Section 4.2.2), 
however there are unique considerations pertaining to (i) HIV, (ii) TB and (iii) Hepatitis C that 
have to be taken into account. Thus, in the case were a similar requirement is listed, the unique 
aspects which require consideration within the context of these disease are addressed. A 
detailed overview of each of the requirements occurrences within the identified literature can 
be found in Appendix B. 
 Context-specific pharmacovigiance education  
In the literature, it is argued that PV education should be country-specific as well as patient-
specific, by focussing more on the highly prevalent illness that are present in the specific 




Mwambi, 2015; Leufkens et al., 2016; Kigozi et al., 2018). Furthermore, patients should not 
only be educated how to identify and report ADRs, but such education should focus on being 
context-specific with regard to the specific ADRs associated with the prevailing illnesses or 
diseases within a particular environment. According to Masenyetse, Manda and Mwambi 
(2015) it has been advised that incorrect beliefs and perceptions regarding treatments should 
also be addressed by such education (Masenyetse, Manda and Mwambi, 2015;).  
 More active reporting processes 
According to Bailey et al. (2016), when considering HIV, TB and Hepatitis C , a more active 
approach to monitoring and ADR reporting should be adopted (Bailey et al., 2016). Active 
reporting process are required within the context of these disease as the disease are often 
attributed to low treatment adherence, see Section 3.2.8, and thus in an attempt to focus on 
early ADR detection, active reporting processes are advised (Akshaya Srikanth et al., 2012). 
Litrature argues that in addition to spontaneous reporting, other methods and techniques such 
as targeted spontaneous reporting (TSR) and cohort event monitoring (CEM) should be 
considered for PV systems related to these diseases (Masenyetse, Manda and Mwambi, 2015; 
Bailey et al., 2016; Leufkens et al., 2016; McEwen, Vestergaard and Sanburg, 2016; Rachlis 
et al., 2016). 
In a study by Manickum and Suleman (2012) focusing on PV systems related to HIV, it was 
found that enforcing compulsory ADR reporting significantly reduced under-reporting within 
the context of HIV treatments (Manickum and Suleman, 2012). In other HIV related studies, 
it was also found that a lack of incentivising ADR reporting may have contributed to an 
increase in under-reporting. Furthermore, if no form of PV promotion and/or prioritisation is 
incorporated, then other tasks, such as treatment of patients, is prioritised above drug safety 
monitoring and ADR detection (Rachlis et al., 2016).  
 Standardised but context-specific adverse drug reaction reports 
In the literature it is argued that ADR reporting forms should be standardised, but also allow 
for context specificity when considering the environments where TB and HIV are prevalent 
(Avong et al., 2015). This standardisation entails ensuring the consistent use of terminology, 
i.e. adverse reaction vs adverse event (Bailey et al., 2016). Furthermore, when considering 
HIV, TB and Hepatitis C, the reports should be patient- and disease-specific (Masenyetse, 
Manda and Mwambi, 2015; Leufkens et al., 2016).  
 Work organisation structure  
In environments with a higher burden of disease related to (i) HIV, (ii) TB , and (iii) Hepatitis 
C, when addressing the processes of a PV systems, i.e. the collection, analysis, and evaluation 
of ADRs, there are certain factors related to ‘work organisation’15 that could complicate or 
hinder the process, such as poor access to computers, multiple conflicting demands, and poor 
information technology systems design (Bailey et al., 2016). Thus, when designing a PV 
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system in these environments, it is important to consider the work organisational factors, i.e. 
limited access to specific resources.  
 Consideration of vulnerable patients  
When considering HIV, TB and Hepatitis C, certain patients groups that are more susceptible 
to these diseases, and more attention should be placed on such vulnerable patient groups, 
which include (i) older patients, (ii) pregnant patients, (iii) first regime patients, and (iv) 
patients who take multiple different drugs (Staszewski et al., 1999; Eluwa, Badru and 
Akpoigbe, 2012; Masenyetse, Manda and Mwambi, 2015). 
A study conducted by Masenyetse (2015) that considered ADR occurrences in HIV patients 
receiving ART, found that patients older than 38 years had a significantly higher rate of ADR 
occurrence than patients younger than 30 years (Masenyetse, Manda and Mwambi, 2015). 
These results are also supported by other studies (Staszewski et al., 1999; Eluwa, Badru and 
Akpoigbe, 2012). Furthermore, a study by Masenyetse (2015) also established that there is a 
difference in ADR occurrence based on sex, as there is a slightly higher rate of ADR 
occurrence in female patients compared to male patients (Staszewski et al., 1999; Eluwa, 
Badru and Akpoigbe, 2012; Masenyetse, Manda and Mwambi, 2015). In the literature it was 
also found that patients starting their first regime treatments should be monitored more closely 
(Dube et al., 2012; Masenyetse, Manda and Mwambi, 2015; Leufkens et al., 2016). 
 Definition of stakeholders’ roles  
When addressing ADR reporting within the context of HIV, TB and Hepatitis C treatment 
projects, a designated person in charge of PV is required (Rachlis et al., 2016). Furthermore, 
studies also affirm that reporting facilities and PV stakeholders actively need to increase their 
involvement in the reporting process, through prioritising funding and resources (Rachlis et 
al., 2016).  
 Consideration of specialised drugs  
In a study done by Giezen (2010) related to the safety profiles of biologicals, it was established 
that traditional medicines have a different safety profile when compared to other drugs in 
traditional PV databases; however, there is limited data available on the nature of ADR 
reporting in relation to these traditional medicines and thus more careful consideration should 
be paid to the ADR reporting related to these medicines (Giezen et al., 2010). Furthermore, 
the ADRs associated with inactive ingredients and ingredients related to traditional medicines, 
should also be taken into account when developing a PV system in the context of HIV, TB and 
Hepatitis C (WHO, 2002b; Nwaiwu, Oyelade and Eze, 2016).  
 Implementation of quality control systems  
In a PV system, it is vital that regular quality control checks are in place and conducted to 
ensure that all different phases and processes are up to standard (Kimutai et al., 2017). 
Furthermore, the quality control activities are also required to verify the quality of the data as 
well as the consistency, accuracy and completeness of the records (Kimutai et al., 2017). 
Addressing the improvement of quality control systems could also contribute to the early 
detection of sub-standard and counterfeit drugs, which are often associated with HIV and TB 




 Incorporation of public awareness  
When addressing PV systems that are implemented in environments with a higher burden of 
HIV, TB and Hepatitis C, public awareness with respect to PV and ADR reporting should be 
enhanced (Dennison, Wu and Ickes, 2014). Furthermore, targeted interventions specifically 
aimed at the populations where these diseases are more prevalent, such as college students, 
pregnant women, and sex workers, should be implemented to improve awareness (National 
Insitute on Drug Abuse, 2012; Dennison, Wu and Ickes, 2014). In this regard, the vulnerable 
patient groups, identified in Section 4.2.6.5, should also be targeted by these intervention 
strategies.  
 Systematic literature review related to resource limited settings requirements 
As was the case in the previous three systematic literature reviews, Scopus and PubMed were 
consulted as primary databases to identify requirements related to RLS in the context of PV. 
Similar search terms and inclusion/exclusion criteria were applied to identify the most relevant 
documents to review and analyse when considering requirements pertaining to RLS and PV 
systems.  
The search terms used within the context of RLS and PV systems are listed in Table 4.4. The 
term “requirements” was excluded during the search protocol here, although it had been used 
during the previous systematic literature reviews. This is because only a very limited number 
of documents were identified when using this search term (two documents from both databases 
before any criteria had been applied), as had happened during the systematic literature review 
related to the MPP (Section 4.2.3). Thus, in an attempt to enlarge the search protocol, and 
possible identify additional relevant documents, this term was initially excluded but still 
considered during a revision of the documents. Using these search terms, a total of 33 relevant 
articles were identified; thereafter, as with the previous systematic literature reviews, two 
inclusion/exclusion criteria were applied to ensure that only the most relevant documents were 
included for review and analysis. Only documents dated from 2010 onwards were included, 
as the MPP was established in 2010, and only documents published in English were included. 
Once these criteria had been applied, a total of 16 documents were identified from Scopus and 
14 from PubMed. Furthermore, as with the previous systematic reviews, if the same document 
was present in both sets of documents, duplicates were removed. Thereafter, the remaining 
documents’ abstracts were screened to identify requirements in the context of PV systems 
related to RLS. A total 23 relevant documents were identified in this way. The final phase of 
the review was to evaluate the entire document, and 4 documents were found to be relevant. 
In addition, Google Scholar was consulted for serendipitous findings, and a total of eight 










Table 4.4: List of search terms used to identify RLS related requirements 
Search 
base 





















“resource limited settings” AND 
(pharmacovigilance OR “drug 
safety monitoring”) 
18 16 11 4 
PubMed 
“resource limited settings” AND 
(pharmacovigilance OR “drug 
safety monitoring”) 
15 14 12 0 
Google 
Scholar 
Serendipitous findings 8 
Total number of documents 33 30  12 
 Requirements relating to resource limited settings identified from the literature 
The 12 documents identified during the systematic document identification and selection 
process, as outlined above, were reviewed and a total of nine requirements related to RLS 
within the context of PV systems were identified; they are discussed in the following sections. 
As with the requirements relating to HIV, TB, and Hepatitis C, it was found that a number of 
these requirements were similar in nature to those identified in Section 4.2.2 relating to 
traditional PV systems. However, as stated previously with respect to the requirements relating 
to the MPP and (i) HIV, (ii) TB and (iii) Hepatitis C, where similar requirements were 
identified, their unique consideration in respect of RLS is highlighted. 
In Appendix B, a detailed overview is given of the occurrence of each of the requirements 
found in the identified literature. 
 Addressing pharmacovigilance education and capacity building in academia 
In the context of RLS, it has been found that, in the academic fields related to healthcare, i.e., 
in universities’ HCP curriculum, there is a lack of PV education (Olsson, Pal and Dodoo, 
2015b). Limited courses related to PV are offered in RLS, and there is a need to not only 
include PV subjects in undergraduate programs but also to encourage their development in 
postgraduate fields, such as PhDs related to PV (Andreatta et al., 2014; Hagemann et al., 2014; 
Olsson, Pal and Dodoo, 2015a). Furthermore, it has been found that addressing capacity 
building in RLS, through education interventions, may improve oversight of ADR detection 
and medical management related to drug safety monitoring (Godfrey et al., 2014).  
 Adoption of additional reporting and more active reporting processes 
For a PV system to function effectively in the context of RLS, both active and passive 
surveillance methods are required (Mehta, Dheda, Steel, M Blockman, et al., 2014). 
Spontaneous reporting programmes in RLS have been found to provide little support for 
addressing all the needs of health systems, resulting in low reporting rates, which subsequently 
lead to inadequate credible risk profiles being developed (Olsson, Pal and Dodoo, 2015b). 
Thus, additional methods are needed to improve safety profiling (WHO, 2012; Olsson, Pal and 




 Collaboration with clinical trials 
PV systems within the context of RLS require strong collaboration between clinical trials and 
PV systems (Godfrey et al., 2014). Randomized clinical trials in combination with long-term 
follow-up of trial participants can be seen as a great source for ADR reporting. Such a 
collaboration with clinical trial databases can allow for comparisons to be drawn between 
different drugs, toxicity assessments, and the evolution of drug resistance (Godfrey et al., 
2014). One such study that considered the collaboration between these databases was the 
Development of AntiRetroviral Therapy in Africa Trial (Miller, Nwokike and Stergachis, 
2012). Furthermore, Godfrey et al. (2014) states that clinical trial oversight (i.e. monitoring of 
the patients partaking in the clinical trial, and the data gathered), which is an essential aspect 
to ensure the integrity of the data and the protection of the research participants, is a challenge 
faced in many RLS and thus quality management approaches need to be incorporated to 
support the integrity of the data quality and protect participants (Godfrey et al., 2014; Stenning 
et al., 2018). 
 Adoption of effective communication and feedback channels  
PV systems are safety monitoring systems that provide information related to the observation 
of ADRs, the reporting and evaluation of ADRs, and the mediation thereof, to ensure the safety 
of patients (Olsson, Pal and Dodoo, 2015a). Thus, communication and feedback systems 
should be incorporated within PV systems to ensure that patients and other stakeholders, 
including HCP, regulatory bodies and pharmaceutical companies, are informed about actions 
related to ADRs (Olsson, Pal and Dodoo, 2015a). However, in RLS it is often more 
challenging to provide stakeholders effectively with the necessary information and thus PV 
systems in the context of RLS must adopt effective communication and feedback systems 
(Mehta, Dheda, Steel, M Blockman, et al., 2014; Olsson, Pal and Dodoo, 2015a).  
 Adoption of patient involvement during the reporting stage 
PV systems in RLS require communication channels to exist, not only between HCP, 
regulatory authorities, and PV centres but also between these stakeholders and patients 
(Olsson, Pal and Dodoo, 2015a). However, in the literature it is argued that the involvement 
of patients with respect to PV in RLS should extend past the action of communication and 
should include the reporting of ADRs too. In the modern-day landscape, the growing usage of 
technologies has fundamentally changed the methods of reporting ADRs and thus it is 
necessary to incorporate patient self-reporting in order to address the under-reporting of ADRs 
in RLS (Olsson, Pal and Dodoo, 2015a).  
 Existence of a context-specific pharmacovigilance system  
In RLS, there is a need for a context-specific PV system, with the long-term goal of developing 
country- and context-specific PV systems within these RLS environments (Atuah, Doodoo 
and Winstanley, 2007; Caudron et al., 2008; Miller, Nwokike and Stergachis, 2012; Mehta, 
Allen, et al., 2014). Countries should identify the objectives that would address the PV needs 
of the particular environment in which the system will have to function (Mehta, Allen, et al., 
2014). Furthermore, it is argued in the literature that, when considering the development of a 
PV system within the context of RLS, the following aspects should be taken into consideration: 




(iii) the impact of these diseases within the specific context, and (iv) the conditions of the 
environment in which the PV system would have to be implemented (Mehta, Allen, et al., 
2014).  
 Reporting processes in resource limited settings  
In RLS, certain requirements have to be taken into account when considering the process of 
reporting. As the HCP to patient ratio is low in RLS, the time allowed for recording and 
capturing ADRs is often limited (Olsson, Pal and Dodoo, 2015a). Innovative, non-time-
consuming methods of data capturing must thus be explored and adopted (Olsson, Pal and 
Dodoo, 2015a). Furthermore, having limited resources available means that the ADR reporting 
forms within these environments must be transparent, uncomplicated and not time-consuming 
to administer or complete (Atuah, Doodoo and Winstanley, 2007; Olsson, Pal and Dodoo, 
2015a; Ha et al., 2016). The use of standard terminology is also important to improve the 
uniformity of data collection and monitoring (WHO, 2012). In RLS, standard operating 
procedures are necessary in order to assist and improve the review capacity of the health 
system (WHO, 2012; Godfrey et al., 2014; Poirot et al., 2016). The reports must also be 
available in the local languages of the relevant countries or regions (Olsson, Pal and Dodoo, 
2015a).  
 Remuneration for the reporting of adverese drug reactions 
RLS are often associated with under-reporting of ADRs, and thus incentives and remuneration 
should be included to improve reporting in these environments and subsequently improve 
patient relations. These incentives should be directly related to the performance of the HCP 
with regard to PV and ADR reporting (Olsson, Pal and Dodoo, 2015a). 
 Adoption of national strategy with respect to pharmacovigiance  
The countries associated with RLS need to establish national strategies that define the realistic 
objectives related to PV requirements within the context of the specific country (Mehta, Allen, 
et al., 2014). Having national engagement and a national strategy for a PV system would create 
a sense of shared responsibility and ownership of a PV program. These strategies should 
include stakeholders, such as practicing clinicians, nurses, doctors, academics, policy-makers, 
pharmaceutical companies and government agencies/regulatory bodies (Mehta, Allen, et al., 
2014).  
 CONSULTING THE PHARMACEUTICAL VALUE CHAIN CHALLENGES 
LANDSCAPE 
In order to ensure that a proposed a decision support tool that facilitates the development of 
context-specific PV systems allows for the required contextual specificity relating to the MPP 
drug provision systems and the four niche factors, the unique set of challenges posed by these 
factors, as identified in Chapter 2 and Chapter 3, have to be taken into consideration. 
Thus, in order to determine whether the identified requirements are adequate in addressing 
these challenges, a relationship matrix is developed, which indicates which of the identified 
challenges, as depicted in the PVCCL, are addressed. Furthermore, this relationship matrix 




In this section, the relationship matrix as well as the additional requirements posed by the 
challenges that have not been addressed are discussed. 
 Relationship diagram of requirements and pharmaceutical value chain 
challenges landscape  
The requirements identified during the systematic literature review are mapped against the 
different challenges in a relationship matrix, to determine if there are possibe additional 
requirements to consider. This relationship matrix is illustrated in Figure 4.2. If a requirement 
was found to address a challenge, this is indicated using a “X”. If none of the identified 
requirements address a specific challenge, an additional requirement pertaining to the specific 


































































































































































































































































































































































PV1 PV education to form part of the health systems environment  x x x x x x x x x x x x x x x x
PV2 Clear lines of communication within a PV system x x x x x x
PV3 Patient involvement for the reporting of ADRs x x x x x x x x x x
PV4 A database for managing ADR reports needs to exist x x x x
PV5
A PV centre or reporting system with designated staff needs 
to exist
x x x x x x x x x x x
PV6
Quality management and control systems to be integrated 
within the PV system
x x x x x x
PV7 Stakeholders’ roles should be clearly defined x x x x x x x x x x x
PV8
ADR reporting forms have to exist that contain all the 
relevant information
x x x x
PV9
Collaboration should exist between clinical trials and PV 
systems 
x x x x x x x
PV10 Context specific conditions need to be taken into account x x x x x x x
PV11 Incorporating proactive reporting processes x x x x
MPP1
Pharmacovigilance education should entails educating 
pharmaceutical companies 
x x x x x x x x x x
Mpp2




The system should address quality control for substandard or 
counterfeit drugs
x x x x
MPP4
Context specific conditions need to be taken into account 
with respect to traditional medicines.
x x x
D1 PV education should be context specific x x x x x x x x x x x x
D2 More active reporting process x x
D3 Standardised but context specific ADR report x x x x
D4 Work organisation structure should be taken into considered x x x
D5 The system must consider vulnerable patients x x x x x x
D6 Stakeholders’ roles should be defined x x x x x x x x
D7 Specialised drugs should be taken into consideration x x x x x x
D8
Quality control systems within PV system should be 
implemented
x x x x x x
D9 Public awareness should be incorporated into the system x x x x x x x x
RLS1
PV education and capcaity buidlings needs to be addressed 
in academia
x x x x x x x x x x x
RLS2
Additional reporting and more active reporting process need 
to be adopted
x
RLS3 Collaboration with clinical trials x x x x x x x x
RLS4
Effective communication and feedback channels have to be 
adopted
x x x x
RLS5
Patient involvement during the reporting stage should be 
adopted
x x x
RLS6 Context specific PV system need to exist x x x x x x
RLS7
Reporting process should be context specific to the resources 
available 
x x x x
RLS8 Remuneration for the reporting of ADRs x x x x x


































































































































 Additional requirements identified 
The relationship diagram was used to identify possible additional requirements, as the 
following challenges were not addressed: (i) diagnostics, (ii) laboratories, and (iii) labelling. 
Thus, two additional requirement specifications were developed, one pertaining to diagnostics, 
and laboratories (as these two challenges are part of the same challenges group see PVCCL ) 
and one with reference to the challenges related to labelling. Furthermore, as these three 
challenges are considered within the environment of the MPP and thus associated with the 
niche factor of MPP (see Section 3.4), it was decided to include these two requirements in this 
discussion of the MPP related requirements.  
MPP 5: Clear lines of communication have to exist between PV stakeholders, pharmaceutical 
companies, and diagnostic labs. 
When considering the PVCCL, one of the identified challenges was that there is a lack of 
communication between diagnostic testing facilities, laboratories and PV stakeholders, such 
as HCP, regulatory bodies and PV centres. This lack of communication extends further to 
pharmaceutical companies. Thus, it is required that a context-specific PV system has clear 
communication channels between PV stakeholders and diagnostic testing facilities or 
laboratories, as well as with pharmaceutical companies. 
MPP 6: Drug labels must be clear, readable and unambiguous, especially the section on 
adverse drug reactions. 
To overcome the challenge posed by drug labels within the context of inadequate quality, the 
a context-specific PV system should ensure that drug labels contain all the pertinent 
information related to ADRs as well as information related to the pharmaceutical companies 
and to the manufacturing details. Furthermore, there must be systems in place if deficient or 
faulty drug labels are found. 
These two additional requirements, as well as the requirements identified during the systematic 
literature were synthesised to develop a preliminary requirement specification, which will be 
discussed in more detail in the following section. 
 PRELIMINARY REQUIREMENT SPECIFICATION 
From consulting the literature and the PVCCL, a preliminary requirement specification was 
developed that considers the 4 niche factors, namely, (i) traditional PV systems (ii) MPP, (iii) 
HIV, TB and Hepatitis C and (iv) RLS. The preliminary requirement specification has a 
specific set of requirements related to each of the said niche factors, and it is found in 
Appendix C. However, to authenticate the developed requirement specification a verification 
process was conducted, which entailed consulting SMEs from different fields relevant to this 
research inquiry. This approach and the results will be discussed in more detail in the following 
section.  
 VERIFICATION OF REQUIREMENT SPECIFICATION  
During the requirement analysis approach, the PVCCL and the literature were consulted to 




systems that considers the four niche factors. To confirm the credibility and reliability of this 
developed set of requirement specifications, and to identify possible inconsistences or 
shortcomings, a verification process was conducted with SME. 
The verification process was conducted by using a questionnaire, with SMEs from various 
backgrounds within the context of pharmaceutical industry and PV. Four separate verification 
processes were conducted, pertaining to each of the specific niche factors. These processes 
were similar in nature, but the objective of each specific process was to verify the credibility 
of the requirements related to the specific factor under consideration. Each verification process 
consisted of (i) a pre-read document, providing a brief overview of the background of the 
research and a breakdown of the requirements related to the specific niche factor, and (ii) a 
corresponding questionnaire. The questionnaire focused on determining the relevance of the 
specific niche factors’ identified requirements with regard to the development of a PV system. 
Using a seven-point Likert scale, the SMEs were requested to rate each of the identified 
requirements and to make additional comments pertaining to the provided rating. Furthermore, 
they were also given the opportunity to include additional requirements if they believed there 
were gaps in the proposed requirement specification. SMEs from different fields within the 
healthcare landscape, i.e. the pharmaceutical industry, PV and academia, were consulted. Each 
SME was requested to complete the verification of the niche factor related to their specific 
field of expertise. They were granted an opportunity to complete the other verifications, if their 
expertise expanded across those fields. The pre-read documents and questionnaires used 
during this verification process can be found in Appendix D. 
Eight SMEs participated in the verification process; an overview of their qualifications and 
experience can be found in Table 4.5 along with an indication which of the four verifications 
they completed.  













Advisory associate at PricewaterhouseCoopers (PwC), a 
multinational professional services network, from 2018 to the 
present. 
Master’s thesis focussed on a topic within pharmacovigilance 
(Investigated challenges of PV in SSA and how existing 








PhD student at the University of Oxford. Thesis topic within 
the field of pharmacovigilance. 





MB, BS in 
Medicine 
Board member and treasurer of ISoP (International Society of 
Pharmacovigilance) (2016 to the present) 
Principal consultant at the NDA Group AB, a drug 
development consultancy company (2007 to the present) 
The deputy qualified person of PV at Johnson & Johnson (2005 
– 2007). 
The Senior Medical Assessor of the Medical and Healthcare 

























CEO and co-finder of VICORE HEALTH, a medical 
and regulatory affairs partner in Africa (2018 to the 
present). 
Founder of EMHC, an African healthcare and 
pharmaceutical consultancy. 
Area medical director at GlaxoSmithKline (GSK), a 
leading international pharmaceutical company (2015 – 
2018). 
Medical advisor (2010 – 2012) and business director 
(2012 – 2013) at Pfizer, a leading international 








Head of clinical research at University of Cape Town 
(UCT) (2002 to the present). 
Clinical operations manager at i3 Research, a global 
pharmaceutical services company (1998 – 2002)  
Clinical research Associate at Novo Nordisk, a global 
healthcare company focused on treatments related to 
chronic diabetes. (1996 – 1998). 








PhD Eng. candidate 
(Industrial) 
PhD research in Pharmacovigilance at the University of 
Stellenbosch (2017 to the present). 




7 BSc in Biochemistry 
Deputy Qualified Person for Pharmacovigilance at 
Salom Pharmacy Ltd Ghana (2017 to the present). 
Lab officer at Wenchi health centre, a healthcare facility 






Bachelor’s degree in 
applied biology 





PhD research in Pharmacovigilance at the University of 
Sheffield, School of Health and Related Research (2014 
to the present). 
Member of ISOP  
Member of the Clinical Human Factor Group, a charity 
aimed at improving the healthcare environment. 
Member of the Pharmaceutical Information and 
Pharmacovigilance Association. 
Member of Pharmaceutical and Human Factor Group, 




 Verification results 
After the verification processes related to each of the niche factors were completed, the results 
were analysed and evaluated. These results are graphically represented in Figure 4.3, 
indicating how each of the different SME rated the specific requirement with reference to the 
Likert scale. It can be seen that the majority of the SMEs were in agreement that the identified 
requirements, related to each of the niche factors, were mandatory for the development of a 




However, as can be seen too, there were certain requirements where the SMEs were in 
disagreement, and a more detailed description of the results pertaining to these requirements 
(PV7, PV8, PV9, PV10, PV11, RLS8) is provided in the following subsection. 
Furthermore, they were also consulted with respect to the absence of any requirements related 
to the niche factors within the context of drug safety monitoring or PV. However, no additional 
requirements were identified to be include, as the SMEs were satisfied with the identified 
requirements.  
 
Figure 4.3: Results of requirement specification verification  
 Areas for improvement  
As previously mentioned, the results showed that there were six requirements where the 
different SMEs differed with regard to their contribution to the development of developing a 
decision support tool that facilitates the development of context-specific PV systems. Thus, in 
order to get a better understanding of this feedback, these six requirements are discussed in 
detail below. Each of the requirements in question is provided below, along with the SMEs’ 
comments pertaining to the requirement in question. The recommendations made by them 
were taken into consideration and the necessary adjustment, if applicable, were made. These 





PV 7: The stakeholders’ roles need to be clearly defined 
As shown in Figure 4.4, 80% of the SMEs’ strongly agreed that PV7 should be included in the 
requirement specification, although 20% of the SME’s had a neutral view. To gain a better 
understanding of this rating, the SMEs’ comments are summarised in Table 4.6. 
 
Figure 4.4: SME responses with regard to PV7 
Table 4.6: SME comments with regard to PV7  
SME ID no SME rating SME quoted commentary 
4 4 
Clear roles exist. Pharma resources PV extremely well based on my experience. 
Government departments in resource limited settings do not. Some countries in SSA 
have only 1 person working in government to oversee PV for the whole country's 
population. 
1 7 
As simple as this might sound, several stakeholders who participate (or who are 
supposed to) in PV are not entirely aware/sure what their role/responsibilities are. In 
this case, PV is not advocated sufficiently, and as a result is "losing" efficiency and 
effectiveness. However, the current problem is that many healthcare professionals 
are not supporting PV (even if they are instructed to) because their priorities lie 
elsewhere (e.g. attending to patients). It is necessary for a type of "balancing-act" to 
balance their current responsibilities and that of PV. 
2 7 - 
3 7 
Accountability (legal) and responsibility needs to be defined through a hierarchical 
analysis to demonstrate who is legally culpable and where control lies. 
7 7 - 
From the results, it is clear that defining the roles and responsibilities of the different 
stakeholders involved with PV is a valid requirement to ensure the effectiveness of a PV 
system. However, it was highlighted by SME 4 that there is a clear difference between the 
responsibility and accountability aspects of the different stakeholders’ and that this needs to 
be incorporated into the system.  
PV8: ADR reporting forms need to contain all relevant information 
With regard to PV8, there was disagreement between the SMEs on the inclusion of this 
requirement. As depicted in Figure 4.5, 20% of the SMEs strongly disagreed, while 40% had 
a neutral perspective. As with the previous requirement, PV7, their comments are summarised 






Figure 4.5: SME responses with regard to PV8 





SME quoted commentary 
1 1 
No one wants to fill in a long, highly detailed form that contains several pages. 
Especially healthcare professionals who are already under pressure to attend to 
crowds of patients. Rather include minimal information in these reports, and 
follow up where necessary (e.g. when a definitive signal is identified). 
3 4 
ADR forms need to be designed with the reporter in mind. Forms need to be 
designed to encourage collection of all relevant information 
4 4 
Balance between getting people to report vs collecting all possible data fields 
needs to be considered. Some adverse events ask for 12 - 15 pages worth of data 
inputs. Not realistic that busy HCPs will provide this.  
7 7 - 
2 7 - 
After analysing the feedback received from the SMEs with respect to requirement PV8, it can 
be concluded that the ADR report would need to contain the necessary information, i.e. patient 
information, the suspected drug and ADR, but not to request or insist that detailed, irrelevant 
information be captured, as time consuming, tedious documents may contribute to the already 
high burden of HCP, especially in RLS. Furthermore, the report should be specifically 
designed to bear in mind the audience and the context, i.e. vulnerable patients, specific disease 
burden etc. Thus, the wording of PV8 should be adapted to state that the ADR report should 
only require the necessary information to be captured, as stated above, and it should be 
designed by keeping the target audience and environment in mind.  
PV9: Collaborations needs to exist between pharmacovigilance systems and clinical trials 
As indicated in Figure 4.6, 20% of the SME’s were either in neutral agreement or more or less 
in agreement with the inclusion of PV10 in a requirement specification for developing a 
decision support tool that facilitates the development of context-specific PV system. Thus, as 
with the previous requirements, the comments of the SMEs were analysed to gain a better 
understanding for this rating. These direct comments are provided in Table 4.8. 
 




Table 4.8: SME comments with regard to PV10 
 From the results obtained regarding requirement PV10, it seems that this is a valid 
requirement to include, as it builds on GVP (European Medicines Agency, 2017). SME4 stated 
that the links between the clinical trials and PV systems do already exist, although this does 
not diminish the fact that this should not be a requirement for an effective PV system within 
the context of this dissertation.  
PV10: The system must be designed for context-specific conditions 
With respect to PV10, it was found that the majority of the SMEs were in agreement with this 
requirement to some extent (20% more or less agreed, 20% agreed, and 40% strongly agreed); 
20% of the SMEs had a neutral perspective with regard to PV11 (see Figure 4.7). To gain an 
understanding of the ratings with respect to PV11, the commentary made by the SMEs were 
advised and is provided in Table 4.9. 
 
Figure 4.7: SME responses with regard to PV11 
Table 4.9: SME comments with regard to PV11 
SME ID no SME rating SME quoted comment 
4 4 
Whilst this is a pragmatic approach, one needs to guard against lack of 
standardisation. I would argue one should rather push for better resourcing to 
get all national systems harmonised. This will align better to most 
manufacturers that operate on a global level. 
1 5 
In several contexts, a niche PV system would be beneficial and the "answer to 
all the problems". However, building niche systems is very resource intensive, 
and one cannot build several niche systems in different settings. This will 
make the sharing of information and the interaction with other parties 
extremely difficult. Also, since PV is not necessarily a priority in several 
countries, it will be difficult to convince those countries to invest more 
resources in building a new/niche PV system. 





SME quoted comment 
4 4 
I would argue a link already exists. New medicines with safety signals in 
clinical trials (before these medicines are authorised for use) generally require 
additional safety studies and surveillance in countries once the drug is 
registered. New malaria vaccine (RTSS GlaxoSmithKline) very good example 
of this. 
1 5 
It is important for PV systems to interact with clinical trials since this is the time 
when new ADRs will be experienced. However, this link is difficult to achieve 
since the clinical trial market is so heavily governed and monopolised by 
pharma. Since there are several stakeholders who want "a piece of the pie" in 
clinical trials, PV systems will struggle to have a foothold. 
2 7 - 
3 7 This is a legal requirement but also has to adapt to Good Clinical Practice 





… continued from previous page. 
3 6 Overlap with PV 9 
2 7 - 
7 7 - 
Although the SMEs do agree that developing a system that is fit for a specific environment, 
develop a niche system, could be beneficial, the focus should still be on developing a 
standardised national system. Furthermore, from the results it was also concluded that 
requirements PV9 and PV11 correspond and should possibly be combined.  
RLS8: Reporting should be made compulsory or some form of remuneration should be granted 
to healthcare workers when they report adverse drug reactions 
When considering the requirement, RLS8, it is found that the SMEs disagreed with this 
requirement. As shown in Figure 4.8, 25% of the SME’s disagreed with the requirement or 
had a neutral perspective of the requirement, however 25% also agree, and 25% strongly agree. 
As with the previous requirements listed above, to gain an understanding of these ratings, the 
SME commentary was advised and is provided in Table 4.10. 
 
Figure 4.8: SMEs’ responses with regard to RLS8 
Table 4.10: SME comments with regard to RLS8  
SME ID no SME rating SME quoted comment 
8 2 
The quality of reports would be reduced. Compulsion in RLS would also increase 
fear of blame because of medication error and possible litigation consequence. In 
addition, it would be a challenge to determine how much each report should be paid 
for. A system of reward is however important for reporting. This would improve the 
feedback loop. 
5 4 
This could be challenging to sustain and also may influence reports, so would need 
to be carefully investigated before implementation. 
6 6 
I agree that reporting should be made compulsory, however, I do not think that 
healthcare workers should be remunerated for reporting, it should be part of their 
professional responsibility.  
7 7 
When monetary remuneration is given for reporting ADRs, the system may be 
flooded with false reports because people want to make some quick money. 
Reporting must be made compulsory. Reporters should be recognized and given 
non-monetary rewards. 
The findings here suggest that, although compulsory reporting in RLS could contribute do 
additional challenges, such as increasing fear of blame, reporting of ADRs should still be made 
compulsory and be seen as part of HCP’s professional responsibility. However, the suggestion 
of using monetary remuneration should be reconsidered. Remuneration can be an effective 




 Adjustments made to preliminary requirement specification  
After analysing the results of the requirement validation, adjustments were made to the 
preliminary requirement specifications. From the original 39 identified requirements, 8 
requirements were adjusted. A description of these adjustments, each of which is related to a 
specific requirement, is provided below: 
PV1 (PV education should form an integral part of the system) was adapted to include the 
aspect of educating on the importance of PV, as it was brought to our attention that, in order 
to create a culture of PV, the emphasis should be placed on providing an understanding of PV 
and not only on providing education related to the process of PV. 
PV5 (A PV centre with an effective and functioning reporting system needs to exist) was 
adapted to include that the HCP and public should be made aware of existing PV centres. This 
is because HCP are often just not aware of PV centres in their surroundings, which contributes 
to a lack of reporting. 
PV8 (ADR reporting forms need to contain all relevant information) was changed from having 
all the information captured to only capturing the necessary information. It was also changed 
to include that the report needs to be designed for the context of the specific audience group. 
From the verification process, it emerged that requiring the capturing of all information could 
be a tedious process that would place a further burden on the system. Thus, only the necessary 
information should be captured, such as the patient’s personal information, the details of the 
suspected drug and the ADR. 
PV11 (The system must be designed for niche specific conditions). From the verification 
results, it emerged that developing a niche system could be resource intensive and thus lead to 
more challenges within an RLS environment. It was therefore decided that the system should 
rather be required to be agile enough to adapt to different environment settings.  
MPP5 (The stakeholders’ roles need to be clearly defined) was adapted to include that 
patients’ roles and responsibilities need to be communicated to them. 
RLS5 (Adoption of patient involvement during the reporting stage) was adapted to include that 
the system should have supporting structures in place, such as a patient PV education and 
feedback system, in order to facilitate and incorporate ADR reporting by patients. 
RLS6 (The system needs to be region specific and take the specific environments' needs into 
account) was changed from requiring the system to be region/niche specific to rather being 
agile enough to adapt to the different environments. From the validation it was gathered that, 
as stated above in PV9, having a specifically designed system would be more resource 
intensive and thus contradict having the system be able to function effectively within an RLS.  
RLS8 (Reporting should be made compulsory or some form of remuneration should be granted 
to healthcare workers when they report adverse drug reactions) was changed from having the 
system incorporate remuneration to requiring the system to make ADR reporting compulsory. 
The system should require reporting to form part of the HCP corporate responsibility and 




 FINAL SYSTEM REQUIREMENT SPECIFICATION 
The aim of this research inquiry is to consider the development of a decision support tool that 
facilitates the development of context-specific PV systems. 
During this chapter, a three-fold requirement analysis approach was executed to identify the 
unique requirements called for by each of these niche factors in an effective PV system, 
considering the context of the challenges associated with these factors.  
Taking into consideration the findings of this approach, it can be argued that (i) the minimum 
set of requirements for an effective PV system (WHO and The Global Fund, 2010) and the 
requirements associated with traditional PV systems, Section 4.2.2, are not adequate in 
addressing the needs of the MPP drug provision systems, and (ii) the niche factors and 
challenges associated with these factors require unique considerations to be taken into account 
when developing a PV systems within this context. It can thus be affirmed that a context-
specific PV system is required when considering the niche factors within the MPP drug 
provision system.  
Thus, in order to assist with the development of a decision support tool that facilitates the 
development of context-specific PV systems a requirement specification was developed that 
will guide the developmeny the envisage tool, using the insights gained from the systematic 
literature reviews, the PVCCL, and the verification process. The findings from these 
approaches were synthesised to develop the requirement specification, provided in Table 4.11.  
This requirement specification should be considered in its entirety but specifies the 
requirements each of the niche factors call for within a context-specific PV system. The 
requirements are listed as: (i) traditional PV systems (Requirements PV1 – PV11), the MPP 
(Requirements MPP1 – MPP6), RLS (Requirement RLS1 – RLS9) and MPP disease burden, 
HIV, TB and Hepatitis C (D1 – D9). The requirement specification that guides the 
development of a decision support tool for which facilitates the devopmentant of a context-
specific PV system is summarised in Table 4.11 – Table 4.14. Certain requirements have 
additional information to provide clarity. 
Table 4.11: Requirement specification related to PV systems 
PV related requirements 
PV1: Pharmacovigilance education should form an integral part of the system. 
• Pharmacovigilance education needs to be incorporated into the health care system at undergraduate and 
graduate levels of teaching. 
• Qualified personnel have to be in charge of pharmacovigilance within the different sectors. 
• The importance of PV should also be communicated to the different stakeholders to create a culture of PV. 
PV2: Channels of communication have to exist between the different stakeholders involved within the healthcare 
system. 
• Transparency needs to be executed between the different communication channels. 
• Feedback systems need to be in place between the different stakeholders. 
PV3: Patient and public involvement should be adopted within the system. 
PV 4: The system requires an effective database for the collecting and managing of reports. 






… continued from previous page. 
PV5: A PV centre with an effective and functioning reporting system needs to exist. 
• A reporting system with adverse drug reaction reporting forms needs to exist. 
• The pharmacovigilance plan should take into account risk identification during product development and 
risk management. 
• A national pharmacovigilance centre needs to exist with designated staff, roles and well-defined structures. 
• A pharmacovigilance advisory committee needs to exist and assist on technical matters. 
• The HCP and the public need to be made aware of the different PV centres that exist within their areas. 
PV6: The system requires effective quality management and quality control systems. 
• Regular audits and inspections of pharmaceutical companies by healthcare workers need to be implemented. 
• Quality management and control systems need to be implemented. 
PV7: Stakeholders' roles should be clearly defined. 
• All organizations involved with PV need to embrace the concept of quality control and behave in a 
collaborative, transparent proactive way. 
• The difference between the stakeholders’ responsibilities and their accountability needs to be defined.  
PV8: ADR forms need to capture the necessary required information and should be context-specific to the 
audience group. 
• Reports need to capture the minimal required information (patient contact details, ADRs experienced and 
suspected drug used). The report should not be tedious and long. 
• The report needs to be designed by keeping the reporter in mind, and their knowledge and environment. 
PV9: Collaboration between pharmacovigilance systems and clinical trials has to be adopted. 
• In clinical trials, improvements in the mode of safety data collection, timelines, duplication, harmonization, 
and coverage need to be explored. 
PV10: The system needs to be agile and adapt to the specific environments. 
• Specific populations/patients need to be considered when setting up a pharmacovigilance system. 
• It is necessary for traditional medicines to be incorporated into national pharmacovigilance programmes. 
• Generic drugs must be treated as a new released drug and to follow all the necessary safety reporting 
requirements. 
• Special attention needs to be placed on drugs that are suspected for defects. 
PV11: A more proactive reporting process is required. 
• A more proactive approach needs to be taken with regard to reporting. 
• Low-cost reporting solutions at international standards are required. 
• ADR reporting must be compulsory for healthcare professionals. 
Table 4.12: Requirement specification related to MPP 
MPP related requirements 
MPP1: Pharmacovigilance education should entail educating pharmaceutical companies. 
• PV Education should include education on specialised drugs (such as traditional medicines). 
• Drug manufacturing companies should be informed and educated on the importance of PV. 
MPP2: Stakeholders’ roles need to be defined with respect to pharmaceutical companies. 
• Healthcare workers must be able to identify an illness and/or ADRs and report them as soon as possible.  
• Pharmaceutical companies need to play a vital role in the system. 
MPP3: The system should address quality control for substandard or counterfeit drugs. 
• Special attention needs to be paid to quality control monitoring of counterfeit and sub-standard drugs. 
• Special attention needs to be paid to quality control monitoring of specialised drugs, such as traditional 
medicine and paediatrics drugs. 
• Proper quality control should be exercised over ingredients used in traditional medicines. 




… continued from previous page. 
MPP4: Context-specific conditions need to be taken into account with respect to traditional medicines. 
• Special attention needs to be paid to quality control monitoring of specialised drugs such as traditional 
medicine and paediatrics drugs. 
• Generic drugs must be treated as new released drug and to follow all the necessary safety reporting 
requirements. 
MPP5: Communication channels should include/extend to the inclusion of pharmaceutical companies and 
diagnostic/laboratories. 
• Communication channels should exist between quality control labs and PV centres. 
• Communication channels should exist between drug manufacturers and PV centres. 
MPP6: Drug labels must be clear, readable and unambiguous, especially the section on adverse drug reactions. 
• The labels of drug medications, especially the section on ADRs, must be easily visible. 
• Patients and health care professionals must easily be able to identify this section. 
Table 4.13:  Requirement specification related to HIV, TB and Hepatitis C 
HIV, TB and Hepatitis C related requirements 
D1: PV education should be context specific. 
• PV education should be targeted at specific groups of people. Patients should be educated about their specific 
ADRs. 
• In order to improve adherence to treatment (e.g. HIV treatment) basic education and counselling should be 
provided. 
D2: More active monitoring systems and additional methods and techniques have to be incorporated. 
D3: Reports need to be standardised but also be context-specific to the investigated diseases and patient group. 
• Reports need to be patient and illness (treatment) specific. 
• Standardised ADR reporting should be used. Terms/words in reports should be consistent, e.g. adverse reaction 
vs adverse event. 
D4: Work organisation structure should be taken into consideration. 
• The system should take the environment into account (e.g. lack of computers, internet etc.) 
• Reports need to be patient and illness (treatment) specific. 
D5: More care needs to be taken with vulnerable patients.  
• Special care should be taken for specific patients, such as patients who are on a first line regime. 
• More care should be taken when considering ADR reporting of older patients. 
• Patients who are on their first line of treatment should be monitored (to ensure that they do not stop the 
treatment). 
D6: Stakeholders’ roles and responsibilities need to be clearly defined. 
• Patients should be treated professionally but compassionately (e.g., no discrimination against patients with 
certain illnesses). 
• There should be a designated person in charge of PV activities. 
D7: The system should consider specialised drugs, such as traditional medicines. 
• The specific drugs and treatments need to be listed on PV databases. 
• Special care should be taken with regard to traditional monitoring. 
D8: The system requires proper quality management and control systems to be in place. 
• Regular quality control checks to be performed. 
• The system should focus on reporting on the quality of drugs, especially on reporting suspected counterfeit and 
sub-standard drugs. 
D9: Public awareness should form an integral part of the system and should be targeted at specific patient 
populations. 
• Targeted interventions should be aimed at vulnerable patient groups and context-specific audience groups. 




Table 4.14: Requirement specification related to RLS 
RLS related requirements 
RLS1: PV education and capacity building need to be addressed in academia. 
• Pharmacovigilance education should be implemented in academia. This entails the inclusion of pharmacovigilance 
subjects into undergraduate programmes. 
• Capacity building should be integrated in the pharmacovigilance system. 
RLS2: Additional and more active reporting methods are required. 
RLS3: Collaboration between pharmacovigilance systems and clinical trials have to be adopted. 
RLS4: Effective communication and feedback channels have to be adopted. 
RLS5: Patient involvement during the reporting stage should be adopted. 
RLS6: A context-specific PV system needs to exist. 
• The system needs to be region specific and take the specific environments’ needs into account. 
• Specific populations/patients need to be considered when setting up a pharmacovigilance system. 
RLS7: The reporting process should be context-specific to the resources available. 
• Innovative ways are required of capturing data in resource limited settings. 
• The reports should be available in the local languages of the region/country. 
• The ADR reporting process should be easy to complete, non-time consuming and friendly to RLS. 
RLS8: Reporting should be made compulsory and form part of HCP corporate responsibility. 
• Non-monetary forms of remuneration should be considered for compensation. 
RLS9: A national strategy with respect to PV should be adopted 
 CHAPTER 4 CONCLUSION 
In this chapter, the requirement analysis process of the systems engineering approach was 
conducted in order to identify what requirements would be called for by an a context-specific 
PV system for the MPP drug provision systems. It was established that the minimum 
requirements for an effective PV systems were inadequate in addressing the unique challenges 
associated ith the niche factors within the context of PV. Thus a three step-approach was 
conducted to develop a requirement specification that will guide the devlopement of a decision 
support tool that facilitates the development of context-specific PV systems. 
In the following chapter, the next phase of the systems engineering approach, the functional 
analysis, will be conducted; this entails identifying different intervention startegies that will 
address the requirement specification, and guide the development of a decsion support tool 





Chapter 5: Vigilance System Component-
Intervention Index development 
In a systems engineering process, the aim is to contextualise a problem in order to develop a 
solution (United States Government, 2001). Within the context of this research inquiry, the 
particular research problem, namely, the absence of an effective PV system to meet the unique 
needs called for by the MPP drug provision systems, is addressed by proposing a decision 
support tool that facilitates the development of context-specific PV systems.  
At this stage of the research, the first two phases of the system engineering approach, which 
entailed contextualising the research problem and addressing the requirements of a context- 
specific PV systems, have been completed. During the contextualisation of the problem, four 
niche factors were identified: (i) the traditional PV system, (ii) the MPP, (iii) HIV, TB and 
Hepatitis C, and (iv) RLS. Furthermore, to ensure that a proposed decision support tool would 
address and consider the challenges associated with the context of MPP drug provision 
systems, a challenges landscape pertaining to the niche factors and the pharmaceutical value 
chain was developed. This challenges landscape is referred to as the PVCCL and is discussed 
in Chapter 3. The second phase entailed conducting a requirements analysis using insights 
gained from the PVCCL, the literature, and a verification process, which led to the 
development of a requirement specification for said system as discussed in Chapter 4. 
In this chapter, the functional analysis phase of the system engineering approach is conducted; 
this entails addressing the developed requirements specification by identifying intervention 
strategies that can address this set of requirements (United States Government, 2001).  
In this chapter, the approach used to identify the intervention strategies will be discussed, along 
with the process of synthesising the intervention strategies into an index that will guide the 
development of a decision support tool that facilitates the development of context-specific PV 
systems. This phase of the research, and how it relates to the rest of the research study, is 
shown in Figure 5.1. 
 




 FUNCTIONAL ANALYSIS APPROACH 
A functional analysis is a process, where the system is defined in terms of its functions by 
translating the requirements into operational functions (United States Government, 2001). The 
aim of the functional analysis within the context of this research inquiry is thus to identify 
these operational functions, referred to as the intervention strategies, which will address the 
requirement specification, and subsequently form the foundational features of a decision 
support tool. The primary objective of such a system is that it has to operate effectively in the 
context of an MPP drug provision system, with reference to the effective reporting of ADRs. 
The functional analysis is conducted by using the method of triangulation. Triangulation is the 
practice of using multiple sources and approaches to enhance the credibility of the research 
(Hastings, 2012). The triangulation method was conducted using the following approaches to 
identify possible intervention strategies: (i) consulting the literature by considering the 
requirement specifications (see Section 4.6), (ii) using knowledge gained from observations 
and real-world phenomena, (iii) and entering into discussion with SMEs.  
The first approach entailed using insights gained from the literature regarding the requirement 
specification. This involved consulting previously identified literature that was used during 
the development of the requirement specification, Chapter 4, to identify possible intervention 
strategies. During the functional analysis, intervention strategies were identified by 
decomposing the higher level requirements, i.e. the entire developed requirement 
specification, into the lower-level requirements, i.e. each specific requirement called for by 
the factors, requirements (PV1 – PV1), (MPP1 – MPP6), (RLS1 – RLS9), and (D1-D9), refer 
to Table 4.11 - Table 4.15. Each of the lower-level requirements was individually considered 
and possible interventions strategies that would address the requirements in question, were 
identified. Furthermore, additional literature reviews were also conducted to investigate these 
intervention strategies.  
The second approach entailed using knowledge from a systems engineering and PV 
perspective, as well as from observing real world phenomena, to identify possible 
interventions for each of the requirements identified. This entailed addressing each of the 
requirements individually and identifying all possible interventions to address the requirement 
in question, similar to the previous approach.  
The last approach entailed entering into continuous discussions with SMEs in the field of 
pharmacovigilance. Although the SMEs come from different backgrounds, they all have 
knowledge and experience in the field of pharmacovigilance. The first SME has a Bachelor 
Degree in Medicine and has been the director of the International Society of 
Pharmacovigilance (ISoP), and is currently a board member of ISOP the International Society 
of Pharmacovigilance since 2016. The second SME is a PhD candidate from Oxford with an 
MPharm degree, who is one of the coordinators for Global website, organised and funded by 
The Global Health Network16.   
Using this triangulation method, a total of 45 intervention strategies were identified that could 
address the different requirements, as stated in Chapter 4. However, when analysing and 
                                                 
 
16 The Global Health Network is a global platform that encourages research through sharing knowledge and methods (The 




contextualising these intervention strategies, it was ascertained that certain intervention 
strategies were related to one another due to being linked to similar outcomes and/or objectives 
with reference to the requirement specifications. Thus, these intervention strategies could be 
grouped together to  create a structure of overarching components that should be addressed 
when considering the implementation of a context-specific PV system (this is discussed in 
more detail in Section 5.2). Furthermore, from these groupings of the intervention strategies, 
i.e. from the overarching components, an index guide for the implementation of a context-
specific PV system could be derived.  
The process of developing this index guide, along with a discussion of the components and 
intervention strategies will be provided in the following section. 
 VIGILANCE SYSTEM COMPONENT-INTERVENTION INDEX OVERVIEW  
During the functional analysis approach, it was ascertained that an index guide could be 
developed that provides an overview of the various components and respective intervention 
strategies that should be addressed when implementing a context-specific PV system.  
Furthermore, building on the findings it is deduced that a Vigilance System should be proposed 
as a context-specific PV system. A Vigilance System is defined as a context-specific PV 
system for MPP drug provision systems that assists with the effective and efficient reporting 
of ADRs through the development of a decision support tool. Furthermore, the Vigilance 
System address the niche i.e. (i) traditional PV systems, (ii) the MPP, (iii) the HIV, TB and 
Hepatitis C, and (iv) RLS, throughout the entire pharmaceutical value chain. The development 
of a Vigilance System is proposed through the creation of an index guide – the Vigilance 
System Component-Intervention Index - which provides an overview of the various 
components and respective intervention strategies that should be considered for the 
implementation of a Vigilance System. 
In this section, the development of the index with respect to the contextualisation of the 
intervention strategies and the overarching components is considered, by discussing the 
approach and the relationship diagram, which indicates the relations between the different 
intervention strategies and overarching components with respect to the requirement 
specification.  
 Vigilance System Component-Intervention Index development approach 
Using the method of triangulation, 45 intervention strategies were identified. These range from 
solutions that can be implemented in different social and economic environments, i.e. in 
developing or developed countries, in places without a previous infrastructure or high level of 
organisation; they are all aimed at addressing the requirement specifications, as stated in 
Chapter 4. However, after investigating these intervention strategies, it was found that certain 
intervention strategies could be grouped together based on similar outcomes and/or objective. 
Furthermore, when considering these grouped intervention strategies and their similar 
objectives, it was found that they could be synthesised into overarching components that 
should be addressed when implementing a Vigilance System (see relationship diagram in 
Section 5.2.2 for a more detailed discussion on this). Thus, within the context of this research 




identified. These 10 components are referred to as the Vigilance System components and they 
are: 
i. Mode of reporting; 
ii. Reporting process; 
iii. Databases; 




viii. Quality management; 
ix. Responsibility & accountability; and 
x. Novel technologies. 
These 10 Vigilance System components are discussed in more detail in Section 5.3. 
Furthermore, as these Vigilance System components are derived from the groupings of the 
identified intervention strategies, which address the requirement specification, the Vigilance 
System components subsequently also address these requirements too.  
Furthermore, in order to provide a more detailed explanation of the development of these 
Vigilance System components with respect to the grouping and synthesising of the 
intervention strategies, a relationship diagram is developed and discussed in the following 
section.  
  Relationship diagram 
In order to provide more clarity and insight on the development of the 10 Vigilance System 
components, with respect to the grouping of the intervention strategies, a relationship diagram 
is developed. This relationship diagram provides an overview of the different identified 
intervention strategies and which of the requirements, as stated in the Vigilance System 
requirement specification in Chapter 4, the applicable intervention strategy addresses. 
Furthermore, the relationship diagram also gives insight into the development of the Vigilance 
System components, by grouping the intervention strategies based on them achieving similar 
outcomes and/or objectives with reference to the requirement specification. Refer to Figure 
5.2. 
Referring to the relationship diagram when considering the different intervention strategies 
within the context of the specific requirements addressed by said intervention strategy, it 
emerged that certain intervention strategies addressed the same requirements. For example, 
referring to Figure 5.2 , when considering the following intervention strategies: (i) learning 
centres, (ii) patient information cards, (iii) paper-based resources, (iv) PV curriculum, (v) short 
courses, (vi) social media networks and (vii) web-based learning, it was found that all seven 
of these intervention strategies address requirements PV1, MPP1, D1 and RLS1. Thus, 
because these intervention strategies fulfil or share the same outcomes, it was decided to group 
them together in order to develop the component of education (Component 7, Section 5.3.7). 




components, the Vigilance System components, were synthesised. These components are 
indicated using the colour-key as shown in Figure 5.2. Furthermore, when investigating the 
relationships, with respect to the intervention strategies that shared similar outcomes within 
the context of the requirements, it was found that certain requirements addressed multiple 
different requirements and thus can be related to different Vigilance System components. For 
example, when considering the component of web-based learning, it was found that this 
intervention strategy addresses both PV8 and PV7, which are related to the components of 
mode of reporting (orange) (Component 1, Section 5.3.1) as well as to PV1, MPP1, D1, and 
RLS1, which are associated with the component of education (green) (Component 7, Section 
5.3.7). Thus, when investigating the intervention strategies, the following strategies were 
found to be associated with more than cone component: (i) paper-based resources (ii) policy, 
(iii) social networks, and (iv) web-based resources. Moreover, each of these intervention 
strategies is also applicable to the different components within the context of addressing the 
same requirements.  
Based on these findings, and as discussed in Section 5.2.1, an index was developed with the 
aim to guide the implementation of a Vigilance System by providing an overview of the 
various components and associated intervention strategies to be addressed when considering 















































































































































































































































































































































































































PV1 PV education to form part of the health systems environment  X X X X X X
PV2 Clear lines of communication within a PV system X X X X Mode of reporting
PV3 Patient involvement for the reporting of ADRs X X X X X Reporting process
PV4 A database for managing ADR reports needs to exist X X X X Database
PV5
A PV centre or reporting system with designated staff needs to 
exist
X X X X X X X X X Response strategy
PV6
Quality management and control systems to be integrated within 
the PV system
X X X X X X X X Awareness
PV7 Stakeholders’ roles should be clearly defined X X X X X X Communication
PV8
ADR reporting forms have to exist that contain all the relevant 
information
X X X X X X X X X X X X X Education
PV9
Collaboration should exist between clinical trials and PV 
systems 
X X X Quality management
PV10 Context specific conditions need to be taken into account X X X Responsibility & Accountability
PV11 Incorporating proactive reporting processes X X X Novel technologies
MPP 1
Pharmacovigilance education should entails educating 
pharmaceutical companies 
X X X X X
MMP 2
Stakeholders roles need to be defined with respect to 
pharmaceutical companies
X X X X X X X
MMP 3
The system should address quality control for substandard or 
counterfeit drugs
X X X X
MMP 4
Context specific conditions need to be taken into account with 
respect to traditional medicines.
X X X X X X X X
MMP 5
Communication channels should include/ extent to the inclusion 
of pharmaceutical companies and diagnostic/ laboratories
X X X X
MMP 6
Drug labels must be clear, readable, unambiguous especially the 
section on adverse drug reactions.
X X X X
D1 PV education should be context specific X X X X X X X
D2 More active reporting process X X X X X X X X X X X
D3 Standardised but context specific ADR report X X X
D4 Work organisation structure should be taken into considered X X X X X X X X
D5 The system must consider vulnerable patients X X X X
D6 Stakeholders’ roles should be defined X X X X X X X
D7 Specialised drugs should be taken into consideration X X X X
D8
Quality control systems within PV system should be 
implemented
X X X X
D9 Public awareness should be incorporated into the system X X X X
RLS1
PV education and capcaity buidlings needs to be addressed in 
academia
X X X X X X X
RLS2
Additional reporting and more active reporting process need to 
be adopted
X X X X X X
RLS3 Collaboration with clinical trials X X X
RLS4
Effective communication and feedback channels have to be 
adopted
X X X X
RLS5
Patient involvement during the reporting stage should be 
adopted
X X
RLS6 Context specific PV system need to exist X X X X X
RLS7
Reporting process should be context specific to the resources 
available 
X X X X X X X X X X X X X
RLS8 Remuneration for the reporting of ADRs X X X X X

































































































































 Vigilance System Component-Intervention Index  
Vigilance system components and their associated intervention strategies were identified and 
synthesised to develop an index that addresses all the developed requirement specifications, 
and subsequently provides the foundational concepts for the development of a decisions 
support tool that facilitates the development of a Vigilance System. 
However, when considering the Vigilance System components and taking into consideration 
the environment of the MPP drug provision systems, which addresses the niche factors and 
the associated challenges (see Chapters 2 and 3) within the context of the entire pharmaceutical 
value chain, it was found that the different Vigilance System components could be clustered 
into three larger categories, namely: (i) direct components, (ii) supporting components, and 
(iii) additional factors.  
The direct components refer to the components required within a PV system that directly affect 
the reporting, managing and processing of the reported ADRs. These direct components 
consist of: (i) mode of reporting, (ii) reporting process, (iii) database, and (iv) response strategy 
and feedback. The supporting components refer to the components and intervention strategies 
that assist with the effectiveness of the system. The vigilant system components that fall under 
this category are: (i) awareness, (ii) communication, (iii) education, (iv) quality, (v) 
management, and (vi) responsibility and accountability. Lastly, novel technologies are 
grouped under ‘additional factors’, as these do not directly influence the reporting process, nor 
do they support the effectiveness of the system; rather, they provide the system with an agile 
component that focuses on the future of PV systems. 
The Vigilance System components, along with their associated intervention strategies within 
their different groupings, form the basis of the index referred to as the Vigilance System 
Component – Intervention Index (see Figure 5.3). This index thus provides an overview of the 
various components and associated intervention strategies to be addressed in a Vigilance 
System, and will be synthesised to form the foundational concepts of a decision support tool 
for the implementation of said system. 
 In the following section, the Vigilance System Component-Intervention Index will be 
discussed according to the index’s elements i.e. the various Vigilance System components and 
their associated intervention strategies.  
 VIGILANCE SYSTEM COMPONENT-INTERVENTION INDEX ELEMENTS 
As mentioned, the Vigilance System Component-Intervention Index consists of three 
component categories, each with their associated Vigilance System components and 
intervention strategies. In this section, therefore, the various Vigilance System components 






 Component 1: Modes of reporting  
Within the context of this research inquiry, the phrase ‘mode of reporting’ refers to the form 
used for the reporting of ADRs. One of the minimum requirements for a functioning PV 
system, as stated by the WHO, is that the system must have a functioning reporting system 
with a national ADR reporting form (WHO and The Global Fund, 2010). However, there are 
various modes in which such an ADR form can be offered.  
 Interventions identified for Component 1: Modes of reporting  
Four intervention strategies were identified that are associated with this component namely: 
(i) mobile application reporting, (ii) paper-based reporting forms, (iii) text-based monitoring, 
and (iv) web-based reporting. Each of these intervention strategies is discussed in the 
following subsections.  
Mobile application reporting 
With the emerging growth of mobile technologies, new opportunities to improve and address 
problem areas in the healthcare environment are being proposed (Haque et al., 2017), and thus 
the field of mobile Health (mHealth) is rapidly growing. This intervention provides 
alternatives and/or solutions to challenges such as limited resources, uneducated or untrained 
staff and poor health information systems (Aranda-Jan, Mohutsiwa-Dibe and Loukanova, 
2014). Mobile Health refers to the use of mobile communication technologies in healthcare 






































































information, provision of care, and patient observation (Mechael, 2009; Aranda-Jan, 
Mohutsiwa-Dibe and Loukanova, 2014). 
A popular form of mHealth to consider in the context of this research study, is the use of 
mobile applications to report ADRs. In India, the Pharmacovigilance Programme of India 
launched a project that used Android mobile applications to report ADRs (Kuchya et al., 
2016). This method is a paperless, quick and relatively uncomplicated way of reporting and 
managing ADR reports. The app uses simple techniques to prompt the user to enter 
information (reporter information and information on the suspected adverse event); once the 
data is captured, it is sent to the monitoring centre. The reporter also receives verification that 
the report has been received, thus facilitating an effective feedback system. Using built-in 
algorithms, the report is analysed using a causality assessment based on criteria of the WHO; 
in the case of severe adverse events, the report is sent via the right channels to the relevant 
parties to take further action (Kuchya et al., 2016). Mobile application tools in the healthcare 
environment have also been used to address other problem areas, such as TB contact tracing 
in Botswana (Ha et al., 2016).  
When considering the implementation of mHealth within the context of RLS, however, access 
to mobile phones and connectivity needs to be considered, particularly as this study addresses 
the development of a PV system in these environments. Global usage of and access to mobile 
technology is growing around the world, and according to a Gallup World poll done in 2017, 
79% of adults had access to mobile devices even in RLS, thus affirming that this intervention 
strategy can be a viable option (Spotlight, 2017).  
Paper based reporting forms  
This mode of reporting entails using paper-based forms, which require the patient or HCP to 
complete a form and send it to the corresponding authority via post, facsimile (SCOPE and 
MHRA, 2015). Paper-based reports are often found to be one of the most common and easiest 
forms of reporting. The management of these reports, however, does prove a challenge, as the 
management, distribution and extraction of data can be more resource inefficient than using 
information technology communications, such as web-based or mobile-based approaches 
(Almenoff, 2007; SCOPE and MHRA, 2015). 
Text-based monitoring 
Another form of mHealth to consider for ADR reporting is text-based reporting. A study was 
done in Cambodia on the use of a text message-based PV Tools. This pilot project, using 
FrontlineSMS17, which commenced in 2012, was one of the first SMS text-based reporting 
and surveillance systems for ADR detection (Baron et al., 2013). The objective of the project 
was to test if vaccine adverse events could be reported in an effective and timely manner to a 
vaccine centre. The systems run through a software operation that received responses, analyses 
these and provides adequate replies back to the user based on their response. For example, if 
a user reports a severe adverse event (based on a rating of codes), the system prompted a 
message to the user to consult medical assistance as required (Baron et al., 2013). This pilot 
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project, although small and limited, showed very favourable results when considering drug 
safety monitoring in urban and resource limited settings.  
Furthermore, studies also indicate that text messages are more likely to work effectively if 
there is follow-up with the users, the messages are more personally tailored, and the content is 
relevant to the patient (Tomlinson et al., 2013). The use of text message-based surveillance 
can be seen as a possible intervention for the Vigilance System, and using simple software, 
such as FrontlineSMS, can be a very useful tool to address challenges (Baron et al., 2013; 
Tomlinson et al., 2013). 
Web-based reporting  
Web-based reporting is similar in nature to mobile application reporting; in the context of this 
study, it refers to website-based reporting on a desktop, laptop or tablet. Electronic ADR 
reporting forms or online platforms are the most commonly used mode of reporting ADRs in 
both developing and developed countries (Medicines & Healthcare Agency Regulatory 
(MHRA), 2019). Using an online platform is an efficient and cost-effective mode of reporting, 
that does not require an extensive amount of resources. Furthermore, these online platforms 
can be adapted and customised for specific niche environments and cases (Edwards, 2019; 
Medicines & Healthcare Agency Regulatory (MHRA), 2019). 
One such an online reporting platform used in the UK is the Yellow Card scheme18. This 
platform allows HCP and members of the public to report suspected ADRs (Medicines & 
Healthcare Agency Regulatory (MHRA), 2019). It also makes available reporting forms for 
adverse effects related to medical devices, suspected counterfeit medications, and side effects 
related to e-cigarettes.  
 Component 2: Reporting process 
Reporting process in the context of this research inquiry refers to the ADR process associated 
with the capturing of the data, and the processing thereof. The WHO states that one of the 
minimum requirements for a functional PV system is to have a functioning national 
spontaneous reporting system (WHO and The Global Fund, 2010). Thus, one of the basic 
fundamentals of a working PV system is to have an effective system for the reporting of ADRs.  
 Interventions identified for Component 2: Reporting process 
The following nine reporting intervention strategies were identified and will be discussed in 
more detail below: (i) 3-step approach, (ii) black triangle monitoring, (iii) cohort event 
monitoring (CEM), (iv) dedicated PV person/department, (v) patient direct reporting, (vi) 
sentinel surveillance sites, (vii) spontaneous reporting, (viii) targeted spontaneous reporting, 
and (ix) task shifting.  
3-step approach 
The 3-step approach of reporting ADRs and collecting data is found to be very effective in 
RLS, which is defined as having limited numbers of qualified HCP and low levels of PV 
knowledge, as stated in Section 3.2 (Mudzviti et al., 2013). This approach looks at utilising 
different stakeholders for each of the different practices of the reporting process. The first step 
                                                 
 




refers to using any available individuals, no qualification needed, to capture the data by filling 
out a form with the patient. The second step requires a clinically qualified HCP, such as a 
pharmacist or nurse, to collect the data from the various treatment centres, and the third step 
is to then submit the data to the necessary central body, such as the National PV centre or 
WHO (Mudzviti et al., 2013; Edwards, 2019). 
Black triangle monitoring 
Black triangle monitoring was introduced by the EU European Medicines agency, for drugs 
that require additional or more intensive monitoring by regulatory authorities, such as 
SAHPRA (European Medicines Agency, 2013). More intensive monitoring is required for 
these drugs, often because there is less safety information available about them, or because 
these drugs may contain a new active substance, or because the drug may only have been 
approved under exceptional circumstances, or because it is a ‘biological medicine’19. 
Furthermore, black triangle monitoring is also often exercised in cases where the 
manufacturing company is required to perform additional monitoring due to the occurrence of 
a rare side effect that was identified during the clinical trial phase (Martin et al., 1998; Zun, 
2014). Drugs under black triangle monitoring are denoted with a black inverted triangle (▼) 
often with a short explanatory sentence. The black triangle does not mean the drug is unsafe 
for patient usage, but merely highlights that the safety information related to the drug is being 
advised (Martin et al., 1998; European Medicines Agency, 2013). 
Cohort Event Monitoring 
Cohort Event Monitoring (CEM) is an active20 form of PV that is used to monitor ADRs in 
patients who are receiving a specific treatment regime in order to assess causality (Wallberg, 
2009; Pal et al., 2013). CEM involves actively following up with a cohort of patients to register 
all ADRs that occur during and for a period after the patients’ treatment (Wallberg, 2009). 
However, CEM also captures all other medicine-related events, from medication errors, issues 
caused by poor storage conditions, poor quality drugs, counterfeit drugs, and drug interactions, 
and it records all events regardless of their severity. This PV method is specifically applicable 
during the early stages of exposure to a new medicine in the field, as it is a systematic and 
comparable method of monitoring. CEM does not only contribute to risk management of 
drugs, but can also provide insights into utilisation and adoption patterns of drugs. CEM has 
also been effectively implemented in both low- and high-income counties. The WHO has 
developed a detailed handbook that sets out the principles of CEM and its implementation in 
the public health programmes (Pal et al., 2013; WHO, 2015a). 
Designated PV person/department  
This initiative is aimed at introducing a dedicated department to the reporting and other PV 
related processes. In RLS, HCP often have a heavy workload, and thus reporting of ADRs is 
often considered a redundant task (Edwards, 2019; Walker, 2019). A person or a department 
designated to deal with PV may thus be introduced into the healthcare facilities with the sole 
responsibility of addressing all PV related areas, from reporting of ADRs, to the providing of 
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feedback and follow-up with patients (Rachlis et al., 2016; Edwards, 2019). The department 
staff would have to come from a medical background, to assist with the ADR detection, and 
would be required to have or receive PV education with reference to the identification and 
reporting of ADRs (Rachlis et al., 2016; Edwards, 2019). 
Patient direct reporting  
Patient direct reporting (PDR) of ADRs was introduced in Denmark and the Netherlands in 
2003 (Delaney, 2017). To date the most commonly used forms of PDR are by using mobile 
applications, such as the UK’s Yellow Card Scheme, which is originally a paper-based scheme 
that was adapted to an online platform, and that is directly linked to the databases, such as the 
Upsala reporting database Vigibase21, thus providing the public with basic access to the 
database (Anderson et al., 2011; Delaney, 2017). 
Sentinel surveillance sites 
Sentinel surveillance is another active form of reporting that is used when higher quality data 
is required about a specific disease (Management Sciences for Health (MSH), 2010; Olsson et 
al., 2010; Miller, Nwokike and Stergachis, 2012). It operates by selecting specific reporting 
units that have a higher probability of addressing cases about the illness under consideration 
and that have highly qualified and experienced staff (Miller, Nwokike and Stergachis, 2012). 
Whereas passive systems, such as spontaneous reporting, focus on retrieving data from as 
many health care facilities as possible, a sentinel site purposefully only involves a limited, 
specific network of healthcare facilities (Management Sciences for Health (MSH), 2010; 
Olsson et al., 2010). As sentinel sites often do not represent the general population, a limitation 
is that of generalising national disease patterns. However, there are additional advantages to 
the implementation of sentinel sites. More feedback and supervision can be provided, as 
sentinel sites are located in fewer facilities, which again leads to higher quality data being 
obtained. Sentinel sites are often also less expensive to run and maintain when compared to a 
universal reporting system (Management Sciences for Health (MSH), 2010). 
Targeted spontaneous reporting 
Spontaneous reporting is a universally used method that HCP, drug manufacturers, and 
patients use to report ADRs to national PV coordinating centres (Masenyetse, Manda and 
Mwambi, 2015). It provides the highest volume of information at the lowest cost. Spontaneous 
reporting provides early signal detection of a potentially problematic medication, which leads 
to further investigation, regulatory warnings or even product changes. Spontaneous reporting, 
as mentioned, is a passive form of reporting and thus relies on the initiative of the patient to 
report an ADR. Furthermore, as there are no systematic patient follow-ups, clear protocols or 
PV mandates, it is challenging to determine the accurate rates and frequencies of ADRs 
experienced (Pal et al., 2013; Masenyetse, Manda and Mwambi, 2015). Thus, spontaneous 
reporting is more effective when it is combined with additional reporting processes (Pal et al., 
2013).  
                                                 
 





A study by Olsson et al. (2015) found that, in RLS, the patient records are often lost or 
incomplete and thus can often not be used to extract information about a reported ADR at a 
later stage (WHO, 2007b; Olsson, Pal and Dodoo, 2015a; Prasad et al., 2018). This means that 
the reports have to be filled out at the time of the consultation, which creates an additional 
challenge in RLS environments, as the patient to physician ratio is very low (WHO, 2007b; 
Olsson, Pal and Dodoo, 2015a). Thus, tasks such as completing ADR reports and collecting 
data should be ‘task-shifted’ to other HCP, such as nurses or interns (WHO, 2007b; Olsson, 
Pal and Dodoo, 2015a). Nonetheless, the ultimate responsibility and accountability would still 
lie with the physician or the treating HCP (Olsson, Pal and Dodoo, 2015a).  
Targeted spontaneous reporting  
Targeted spontaneous reporting (TSR) was introduced by the WHO in 2010 and builds on the 
principles of spontaneous reporting but applied more actively and within a defined setting (Pal 
et al., 2013; Ndagije, Nambasa and Namagala, 2015; Rachlis et al., 2016; Prasad et al., 2018). 
This method requires HCP to manage a well-defined patient group, i.e. patients who are being 
treated for drug resistant TB, for instance, and to report specific medicine related safety 
concerns. TSR can be customised to either report all suspect ADRs experienced by the group 
or it can focus on specific reactions that are of particular concern, in order to limit the ADRs 
to those that are of more significance (Pal et al., 2013; Ndagije, Nambasa and Namagala, 
2015). This method is used for targeted follow-up of patients with additional complications, 
such as drug resistant TB (Pal et al., 2013; Prasad et al., 2018). The benefit of using TSR 
instead of spontaneous reporting is that the number of patients being managed within the 
cohort will be known and thus the rates of ADRs being reported will be known (Pal et al., 
2013).  
 Component 3: Databases  
One of the fundamental properties of a functioning PV system is to have a national database 
for the collating and managing of the ADR reports (WHO and The Global Fund, 2010). 
 Intervention identified for Component 3: Database 
 Four intervention strategies related to databases were identified, namely: (i) individual 
databases, (ii) outsourcing, (iii) physical storage and (iv) Vigibase.  
Individual database 
When developing a PV system, a unique database can be created for the specific system that 
is being developed, that is solely used to manage the data retrieved by that system and to 
monitor the specific reports gathered (WHO and The Global Fund, 2010; Chakrabarty and 
Thawani, 2011). This database should be classified, safely stored and managed, retrievable 
and retain some degree of confidentiality. The WHO and UMC provide guidelines on how to 
set up commercialised data programmed that can be customised for specific usage 
(Chakrabarty and Thawani, 2011).  
Outsourcing 
Various companies, like PrimeVigilance or Oracle, maintain global ADR databases (Arora, 




processing, analysing and reporting of ADRs and enable clients to view their data in real time 
(Edwards, 2008; Arora, 2012). These companies are often employed by pharmaceutical 
manufacturing companies to manage their own databases of reported ADRs (Edwards, 2008). 
Physical storage  
In the case of paper-based reporting, the forms need to be stored in a safe space once they have 
been uploaded to the specific database, as the reports could contain confidential medical 
information (Almenoff, 2007; SCOPE and MHRA, 2015). The reports need to be disposed of 
in such a manner that the information is completely destroyed, i.e. by burning or shredding the 
documents (Almenoff, 2007; SCOPE and MHRA, 2015). 
VigiBase  
VigiBase22 is a database system used for data management and processing that is operated by 
the UMC on behalf of the WHO (Lindquist, 2008; UMC, 2019b). Its main aim is to collect 
and analyse the ADR reports of all members of the ‘WHO Drug Monitoring Program’23. 
VigiBase compromises medicinal products, the WHO Drug Dictionary, the medical 
terminology classifications, and the case safety reports that are directly reported to VigiBase. 
The ICSR are updated on a continuous basis as they are received from the global National PV 
centres (Lindquist, 2008).  
 Component 4: Response strategy 
Within the context of this research, the response strategy refers to the approach that should be 
taken once an ADR has been reported. This intervention strategy addresses the methods that 
should be implemented to ensure that the stakeholders are informed about the report that has 
been received, the process to follow and in the case of severe or dangerous ADRs, the 
interventions that will follow to improve patient safety. 
 Interventions identified for component 4: Response strategy 
Three interventions were identified related to response strategies. These intervention strategies 
are: (i) App alerts, (ii) feedback, and (iii) policy and guidelines.  
App alerts 
An intervention that can be used to provide rapid information flow regarding serious reported 
cases, is App Alerts. This intervention is aimed at informing HCP, pharmacist and doctors, 
about drugs that are suspected to cause severe drug reactions or to be of sub-standard quality, 
by using a mobile application (Edwards, 2019; Walker, 2019). If a specific action regarding a 
drug needs to be taken, the necessary stakeholders would be alerted via the mobile app. The 
focus of the alert is only to inform an HCP, if immediate action needs to be taken. The app 
alerts should work on a severity scale, i.e. only provide an alert if a drug has had a high volume 
of reports in a specific time frame (Edwards, 2019; Walker, 2019).  
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In any reporting system, it is essential that the stakeholders, including patients, receive 
feedback (WHO, 2006b). This feedback should confirm that the report has been received and, 
if needed, the actions to be taken. In a PV system, it is crucial to give feedback to the reporter 
of the ADR, as under-reporting of ADRs is often associated with a lack of feedback (Anderson 
et al., 2011). As mentioned, at the very least a confirmation of receiving the ADR report is 
required; however, a study on direct reporting by patients found that patients often have a need 
for more information regarding their reported ADR, and not only to receive confirmation 
(Anderson et al., 2011). For example, patients would like to be informed if the report has 
contributed in some way, if more reports were received and, if necessary, what action has been 
taken (WHO, 2006b). The following modes of providing feedback were identified and will be 
discussed below: (i) emails, (ii) mobile platforms, (iii) web-based platforms, and (iv) paper-
based responses.  
The usage of emails and mobile phones is very high globally, and thus these forms of 
technology of providing feedback can be very effective in both developed and developing 
countries (Spotlight, 2017). To ensure that there is continuous communication between the 
reporter and the PV centre regarding further steps to be taken, the reporter should be allowed 
the opportunity to access additional information and be informed about the decision taken with 
regard to the reported suspected drug (Edwards, 2019). Web-based platforms, such as 
VigiAccess24, which allow members of the public access to information about the amount or 
reports received and the list of ADRs reported for every drug, is such an intervention (UMC, 
2019).  
Another mode to consider for providing feedback would be to use paper-based resources, such 
as formal letters or newsletters (Almenoff, 2007; Vermeir et al., 2015). Formal letters can be 
distributed using postal services, whilst newsletters that provide information about the reported 
ADRs can be distributed to healthcare facilities. However, these forms of reporting will be 
more resource intensive and will take longer to reach the recipient.  
Policy and guidelines 
Guidelines need to be created to ensure that there is an effective, feasible response strategy in 
place for when a suspect drug has been identified and needs to undergo further monitoring, or 
when further action needs to be taken, such as removing the drug from the market entirely. 
The guidelines need to be clear about the exact steps that need to be taken by each of the 
stakeholders during the response strategy (U. Mehta et al., 2014; Edwards, 2019). These 
guidelines should stipulate the actions that pharmaceutical manufacturing companies need to 
take when a drug needs to be monitored more carefully or be taken of the market (WHO, 
2002c; Mehta, Allen, et al., 2014). 
 Component 5: Awareness 
Creating a culture of PV and drug safety monitoring is of the utmost importance, as it will 
improve the challenges recognised in the reporting process with regard to ADR detection, 
under-reporting, and the quality of data (Dennison, Wu and Ickes, 2014; Lamprecht, Bam and 
                                                 
 




De Kock, 2017). Thus, improving both the public’s and the HCP’s awareness of the 
importance of PV should form an integral part of a Vigilance System.  
 Interventions identified for component 5: Awareness 
The following five awareness related interventions were identified and will be discussed 
below: (i) campaigns, (ii) collaboration and partnerships, (iii) communities of practice, (iv) 
paper-based resources, and (v) social media platforms. 
Campaigns  
A campaign consists of a series of planned events and activities aimed at achieving a specific 
objective (Steurbaut and Hanssens, 2014; BusinessDictionary, 2019). Campaigns share a 
single message and aim to convey that message to a target audience  (Steurbaut and Hanssens, 
2014). In 2015, the UMC initiated a campaign, Take & Tell25, with the focus of making PV a 
household concept. The Take & Tell campaign was aimed at improving the public’s 
knowledge about PV by informing patients about how to report a possible side-effect (Upsala 
Monitoring Centre, 2019). The objectives of the campaign were thus to create awareness about 
PV, to create open communication between patients and HCP, and to support the active 
reporting of ADRs (Montastruc et al., 2006; Steurbaut and Hanssens, 2014; Upsala Monitoring 
Centre, 2019). 
Collaboration and partnerships 
Collaborating and partnering with existing PV bodies, healthcare facilities and pharmaceutical 
companies can be an effective strategy to engage with people and create awareness about PV 
with different stakeholders. Advocating the importance of PV can be conducted by creating 
and fostering partnerships with different stakeholders. The different pharmaceutical industries, 
pharmaceutical manufacturers and PV bodies could partner with one another to improve 
patient safety and drug safety monitoring (Schito et al., 2015). Partnership policies can be 
created that define the agreement between the partners and stipulate the agreed upon objectives 
the partnership needs to fulfil with regard to improving PV awareness (Schito et al., 2015; 
Edwards, 2019). 
Communities of practice 
Improving the awareness of PV and a PV culture within the public, focusing on patients, can 
be achieved through community involvement projects (Dennison, Wu and Ickes, 2014). This 
can be done by including patients and/or stakeholders into the different phases of the system 
and incorporating effective channels of communication to ensure the patients’ needs can be 
addressed (Edwards, 2019). Furthermore, awareness campaigns focus on conveying a message 
to educate and raise public interest and knowledge about the subject matter, in order to improve 
community involvement (Dennison, Wu and Ickes, 2014). 
Paper-based resources 
Paper-based resources can be effective in creating awareness, considering the context of this 
research (Almenoff, 2007). A study published in the Health Information and Libraries Journal 
found that posters are not only some of the most commonly used forms of proving information 






in the healthcare field, but may also contribute towards altering behaviour and attitudes (Ilic 
and Rowe, 2013). Thus, using paper-based resources to create a culture of PV and ADR 
reporting can be very effective, especially in RLS (Almenoff et al., 2007; Ilic and Rowe, 
2013). Furthermore, the most effective awareness campaigns are aimed at evoking emotions 
in readers, and thus using tactics such as statistics, images and slogans would improve the 
impact of the campaign (Ilic and Rowe, 2013).  
Social media platforms  
As previously mentioned, social media platforms are expanding and are being utilised in many 
different fields for different purposes (Sloane, Osanlou and Lewis, 2015). Social media can 
thus be a vital instrument for improving awareness on PV in the healthcare and public 
environments. Platforms such as YouTube, Twitter, Facebook, and LinkedIn can all be used 
as platforms to create awareness on the importance of ADR reporting and PV (Sloane, Osanlou 
and Lewis, 2015; Edwards, 2019; Walker, 2019). 
 Component 6: Communication 
In a PV system, there are various stakeholders who all play a vital role in the system. However, 
as mentioned, the challenge of not having effective channels of communication often leads to 
further complications, such as a loss of information (Mehta, Dheda, Steel, M. Blockman, et 
al., 2014). Thus, interventions are needed to create, improve, enhance and maintain 
communication channels between the different stakeholders.  
 Interventions identified for component 6: Communication 
Four communication interventions were identified: (i) communication network plans, 
(ii) information communication technologies (ICTs), (iii), guidelines and policies, and (iv) 
paper-based resources. 
Communication network plans 
Ensuring that there is an effective communication network plan, which indicates a flow of 
information between the different stakeholders, is vital to ensure that the different stakeholders 
react appropriately to the emergence of an event, i.e., emerging new safety data regarding 
ADRs (Bahri, 2010). The communication network plan should give an overview of the 
different communication channels that have to exist between the different stakeholders. 
Furthermore, the communication network plan should specify the flow of information and 
communication tool used (Bahri, 2010).  
Information Communication Technologies 
 ICTs are technologies, such as the internet, wireless and cellular networks, that use 
telecommunication to provide access to information (TechTerms, no date; Lu, 2009). 
ICTs can be an effective intervention and communication tool used by different stakeholders 
for different PV objectives, from reporting to providing feedback and ensuring the flow of 
information between the different stakeholders. The literature has furthermore argued that ICT 
has enabled improvements in clinical safety monitoring and PV systems (Lu, 2009). 
Possible ICT tools that can be considered for the purpose of this research study with respect 
to communication purposes are (i) email, (ii) text message applications or short message 




and specifically in PV system, emails have been found to be a very effective form of 
communication in many different fields and environments (Lhotska et al., 2011). In 2019, 
Radicati, a technology market research firm, released statistics about global email usage, 
stating that there are 3.9 billion active email users, which is more than 50% of the entire 
world’s population (The Radicati Group, 2019). Text-message applications are also widely 
used in both developing and developed countries for the purpose of communicating (Aranda-
Jan, Mohutsiwa-Dibe and Loukanova, 2014).  
Guidelines and policies  
Guidelines and policies can be used to improve communication between the different 
stakeholders within the PV system (Bahri, 2010). When considering these policies within the 
context of addressing communication within the proposed Vigilance System, it would be 
required to stipulate and define the different communication channels between the 
stakeholders (WHO, 2004; Bahri, 2010). Furthermore, the policies that address these 
communication channels would also be closely related to the responsibilities of the different 
stakeholders, as the policies would clarify the information flow and communication between 
stakeholders (Mehta, Allen, et al., 2014). 
Paper based resources 
As previously mentioned, in RLS, paper-based forms of communication, and in the 
environment of PV, paper-based reporting of ADRs, have been shown to be very effective 
(Almenoff, 2007). Thus, in environments where electronic forms of communication are not a 
viable option, paper-based communication should be considered instead to ensure the flow of 
information between the different stakeholders (Almenoff, 2007). According to the WHO 
(2004), the following forms of paper based communication resources are used within the 
context of PV: formal letters, patient information leaflets, personal feedback letters to 
reporters, etc. (WHO, 2004).  
 Component 7: Education  
Within the context of this dissertation, when considering the PVCCL it is evident that there is 
a lack of education regarding pharmacovigilance and the ADR reporting system within the 
healthcare setting. This has been more apparent in RLS in healthcare environments (Lumpkin, 
2000; Farha et al., 2015; Kheloufi et al., 2017).  
 Interventions identified for component 7: Education 
The following interventions were identified, and are discussed below: (i) learning centres, (ii) 
paper-based resources, (iii) patient information cards, (iv) PV curriculum, (v) short courses, 
(vi) social media networks, (vii) web-based resources.  
Learning centres 
The focus of learning centres is to create an environment for collaboration, discussion and 
teaching opportunities on an increasingly permanent basis, within the context of a physical 
space, i.e. a PV facility or healthcare facility (WHO, 2012). These learning centres may serve 
as an environment for PV education by providing and facilitating workshops and training 
courses. Furthermore, these learning centres can be aimed at different stakeholders within the 




centres can, for example, host workshops aimed at students in the pharmaceutical and medical 
fields, or conferences for experts in the field of PV, or events for all types of audiences 
(Gerritsen et al., 2011; WHO, 2012). 
Paper based resources 
Paper-based educational resources, such as pamphlets and posters, can be an effective way of 
improving education related to PV, ADRs and drug safety monitoring in RLS (Ilic and Rowe, 
2013). They can be used to provide necessary and important information about what PV is, 
why it is needed and how to go about reporting ADRs (Ilic and Rowe, 2013). These paper-
based educational resources can be aimed at different target groups, but would probably be the 
most effective educational resource for educating patients on PV (Ilic and Rowe, 2013).  
Patient information cards 
Patient information cards are a paper-based method of providing education that are specifically 
aimed at providing the patient with information regarding their specific treatment and possible 
ADRs (Poirot et al., 2016). These cards contain information on the symptoms of the known 
ADRs related to the specific diseases, and how and where to report these ADRs (Poirot et al., 
2016).  
Pharmacovigilance curriculum  
As PV is often seen as having a multi-disciplinary nature, as it considers clinical medicines, 
pharmacoepidemiology, pharmaceutical manufacturing, legal aspects, and molecular 
mechanisms of ADRs, the structure of the PV curriculum may be overwhelming (Hagemann 
et al., 2014; Hartman, Härmark and van Puijenbroek, 2017; Edwards, 2019). Consequently, 
the WHO in collaboration with the International Society of Pharmacovigilance (ISoP) and its 
Education and Training Project group developed the Pharmacovigilance Curriculum, an 
existing PV curriculum that is currently in the process of being rolled out (Hagemann et al., 
2014). The focus of this curriculum is to provide an overview of PV, to provide information 
and teachings on new topics in PV, and to propose a range of tasks for practical training 
(Hagemann et al., 2014).  
The developed Pharmacovigilance Curriculum consists of 15 different theoretical chapters that 
look at the background and history of PV, clinical aspects of ADRs, risks of serious ADRs, 
quality defects, reporting methods, regulatory bodies, and communication (Hagemann et al., 
2014). This curriculum has been developed in such a way that it can be adapted to the specific 
audience, environment and availability of time (Hagemann et al., 2014).  
Short courses  
Short courses are an educational intervention that do not require an extensive amount of time 
and resources that can be used to acquire, update or enhance skills in PV (Dunn and 
Thorogood, 2002). These short courses can be provided on an online platform or in a physical 
space such as at a university or at PV centres (Global Pharmacovigilance, no date; Dunn and 
Thorogood, 2002). The website, Global Pharmacovigilance26, currently offers two free online 
                                                 
 




short courses (e-learning courses), one on collecting ADR reports, and the other on data safety 
monitoring (The Global Health Network, 2019a). 
Social media networks 
As social media networks have expanded significantly and are being used in different domains, 
it should be considered to use social media as an educational platform for PV (Sloane, Osanlou 
and Lewis, 2015). For instance, when considering the different social media platforms and the 
focus of PV education, platforms such as Twitter, Facebook, LinkedIn or YouTube could be 
utilised for PV educational purposes (Edwards and Lindquist, 2011). 
Web based learning 
Web-based learning and PV websites can also be used to improve PV education for different 
audience groups, from HCP to patients. These websites can serve as a platform that links the 
user to e-learning services, articles and reading materials, and to training or workshops being 
held (The Global Health Network, 2019b; Walker, 2019). Furthermore, a website can be used 
as a platform to provide current news and information about pharmacovigilance and drug 
safety monitoring. Websites, such as that of Global Pharmacovigilance, have proven to be a 
great success not only for educational purposes, but also for networking, creating awareness 
and providing information about careers, conferences and events (The Global Health Network, 
2019b). 
 Component 8: Quality Management 
In any system, ensuring that effective quality management is integrated within the different 
processes is of the utmost importance (Olsson, Pal and Dodoo, 2015b). The concept of quality 
management for the purpose of this research inquiry is concerned with the process related to 
the reporting and assessing ADRs, but also considers the integration of quality management 
with the drug manufacturing and distribution systems (Olsson, Pal and Dodoo, 2015b).  
 Interventions identified for component 8: Quality Management 
Four quality management intervention were identified for a proposed Vigilance System 
namely: (i) addressing good manufacturing practices (GMP) and good distribution practices 
(GDP), (ii) audits, (iii) Good Pharmacovigilance Practices (GVP), and (iv) policies and 
guidelines.  
Addressing good manufacturing practices and good distribution practices  
Guidelines for GMP and GDP have been developed by the WHO to ensure consistent quality 
standards are met in all aspects of drug manufacturing, from material sourcing to the final 
product (WHO, 2002b, 2011). These guidelines also consider drug safety monitoring aspects 
(WHO, 2011). Furthermore, the WHO guidelines include guidelines related to complaints, 
product recalls, quality audits, materials, and training, all of which can be improved to 
incorporate PV specific aspects (WHO, 2011). The processes of product recall and complaints 
should be directly linked to PV systems and should stipulate aspects relating to the procedures 
and communication lines (WHO, 2011). Referring to quality audits and materials, these 
guidelines should be linked to PV guidelines with regard to the process that should be followed 
if sub-standard or counterfeit drugs are reported (Pan American Health Organization, 2011; 




including pharmaceutical companies, are also educated on the quality management process 
within the context of a PV system, which should be stipulated in the GMP (WHO, 2011). 
Audits 
Audits play a vital role in ensuring that the quality standards are met; as with any system, the 
PV system also requires regular audits to be conducted (Pietrek, Coulson and Czarnecki, 2009; 
Nwaiwu, Oyelade and Eze, 2016). During a PV audit, a number of investigations are 
conducted to ensure that each process meets the required quality standards. The aim is to use 
evidence to evaluate the PV system and the effectiveness of the system. The audit entails a 
review of the quality management of the collection, processing and management of the data 
systems, within the context of ADR reporting and investigation, and assessing whether the 
database meets the current regulations (Pietrek, Coulson and Czarnecki, 2009; Nwaiwu, 
Oyelade and Eze, 2016). 
Good Pharmacovigilance Practices  
The guidelines for Good Pharmacovigilance Practices (GVP) were published in 2010 by the 
EU and are divided into two main chapters: pharmacovigilance processes and population- and 
product specific considerations (European Medicines Agency, 2017). The guidelines provide 
a comprehensive overview of all the relevant aspects with regard to PV and drug safety in 
general. The guidelines provide best practice information about the collection of the different 
reports, the validation and follow-up of the reports, and the data management process. 
Information of the use of medications during pregnancy and for paediatric and elderly patients 
is also included (Pietrek, Coulson and Czarnecki, 2009; Pan American Health Organization, 
2011; European Medicines Agency, 2017).  
Policies and guidelines 
As previously stated, policies and guidelines are identified as an intervention strategy that 
could address three of the identified v Vigilance System components, i.e. communication, 
responsibility and accountability, and quality management. Within this context of quality 
management, policies and guidelines are aimed at ensuring that the PV processes meet the 
required quality standards to ensure effective and efficient reporting by using 
regulation/legislation of said policies (WHO, 2002b, 2004; European Medicines Agency, 
2017). To ensure that effective quality management is executed within a Vigilance System, a 
document, i.e. a policy, which outlines the standard operating procedures within the context 
of a PV system, i.e. the process related to reporting, collection, management of the ADR 
related data, should be developed (European Medicines Agency, 2017). The policy should thus 
stipulate requirements and recommendations within the context of quality management 
principles that would ensure the effectiveness of the PV process (WHO, 2004). 
 Component 9: Responsibilities and accountability 
Responsibility and accountability are key factors that relate to stakeholder involvement within 
a PV system (Hanzl-Dujmović, Sulić-Milišić and Starešinić-Šernhorst, 2007; Khattri et al., 
2012; Nwaiwu, Oyelade and Eze, 2016). As there are multiple stakeholders involved within 
the PV system, it is vital that each stakeholder understands their specific role (Edwards, 2019). 
Responsibility refers to an individual conducting and taking ownership of a specific task, 




task (Cambridge University Press, 2018, 2018). Thus, it is important to note that there may be 
a difference between the person, department or institution that is accountable or responsible 
for a specific process or activity (Edwards, 2019).  
 Interventions identified for Component 9: Responsibility and accountability 
Three interventions were identified to ensure that the stakeholders are aware of their roles, and 
of their accountability and responsibilities associated with such roles; these intervention 
strategies include: (i) designated PV department/stakeholder, (ii) incentives that contain a sub-
set of four possible intervention strategies, and (iii) policy and guidelines. 
Designated PV department/group 
Having a designated member of staff, or a designated department that specifically takes on the 
role of accountability of ADR reporting within the healthcare facility would not only reduce 
the workload of the HCP but will also address the concept of accountability, as there would 
be a specific group or individual that takes on all aspects of PV (Rachlis et al., 2016; Edwards, 
2019). As this department would be responsible for all PV related functions, the margin of 
error in the reporting process would also be reduced and the process of follow-up on actions 
to be taken with respect to the suspected ADR would be easier (Edwards, 2019; Walker, 2019). 
Furthermore, this concept of designated PV staff members or departments can also be 
introduced to pharmaceutical manufacturing companies to improve the relationships, 
communication, and responsibility of pharmaceutical manufacturing companies with the PV 
centres and healthcare facilities (Rachlis et al., 2016; Edwards, 2019).  
Incentives schemes 
In the healthcare landscape, incentive schemes27 have become an emerging strategy in various 
PV-related fields and are targeted at a range of HCP (Elovainio, 2010; Gerritsen et al., 2011). 
From a study done by the Global Health Workforce Alliance28, there are seven characteristics 
for a good incentive strategy within the healthcare system (Elovainio, 2010). These 
characteristics include that the incentive scheme has clear objectives, that these are realistic 
and deliverable, reflect the need needs of the HCP, are well designed, contextually appropriate, 
fair and transparent, and measurable, and that they include financial and non-financial aspects 
(Elovainio, 2010). There are five types of incentive schemes that have been identified for the 
Vigilance System and they will be discussed in the following sub-sections.  
Incentives schemes 1: Financial incentives 
There are three main categories of financial incentives, namely basic wages and conditions, 
performance-linked payments, and additional financial services (Weller, 2008; Elovainio, 
2010; Gerritsen et al., 2011). The first category ensures that the wages paid are fair when 
compared to similar roles and responsibilities (Weller, 2008). The second category comprises 
additional payments or bonuses linked to performance, which are aimed at promoting a culture 
of ADR reporting within PV systems (Weller, 2008; Gerritsen et al., 2011). The last category, 
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additional financial services, can refer to fellowships or subsides for housing, transport and 
other expenses (Weller, 2008).  
Incentives schemes 2: Career and professional development 
In the literature, it is argued that HCP value lifelong professional development and learning 
(Weller, 2008; Gerritsen et al., 2011). Thus, incentives such as access to education programs 
and training, effective monitoring and supervision can all contribute to a supportive approach 
to continuous development within the context of PV systems (Gerritsen et al., 2011). 
Furthermore, by providing educational opportunities, the professional development of 
stakeholders, such as HCP within the context of ADR reporting, is improved, which further 
enhances their ability to receive financial and other benefits (Weller, 2008).  
Incentives schemes 3: Workload management 
In the healthcare landscape, HCP are often burden by an excessive workloads , which 
subsequently contributes to low motivation, poor performance or ultimately leaving the 
healthcare profession (Weller, 2008; Elovainio, 2010). Many of these factors that contribute 
to excessive workloads are a shortage of workers, uneducated staff, or even just an increased 
demand (Weller, 2008; Elovainio, 2010) Incorporating an incentive of workload management 
alleviates this challenge to some extent (Weller, 2008). Firstly, overtime payments for staff 
could be incorporated as a compensation for working overtime and a motivation for employers 
to improve workload management (Weller, 2008). Secondly, additional leave or time-in-lieu 
could be introduced to prevent burnout (Weller, 2008). Another possible method is to revise 
existing roles and responsibilities to improve workload distribution among staff members. 
Finally, the number of continuous working hours worked by staff members should be regulated 
to ensure patient safety (Weller, 2008; Elovainio, 2010). 
Incentives schemes 4: Positive working environment 
Ensuring a positive working environment29 by creating a positive organisational culture and 
safe working environment is crucial for retaining staff members and improving job satisfaction 
(Weller, 2008; Elovainio, 2010). Factors to consider incorporating when addressing positive 
work environments are: supportive management relations, flexible working hours, and 
systematic communication between management and staff (Weller, 2008; Elovainio, 2010). 
These may enhance the working environment and may also improve staff member morale 
(Weller, 2008).  
Policy and guidelines 
For a system to be effective, it is necessary to have a policy that stipulates a high-level 
statement regarding the responsibilities of the different stakeholders within the context of PV 
systems (Mehta, Allen, et al., 2014). Thus, when considering addressing the component of 
responsibility and accountability within a Vigilance System, a policy should be drafted that 
ensures that the different stakeholders are clear about the different roles, responsibilities and 
required tasks within the PV systems (European Medicines Agency, 2017). Such a policy 
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needs to state the required actions called for by the different stakeholders, from PV regulatory 
bodies to HCP and pharmaceutical manufacturers, and be linked to the different standards, 
procedures and guidelines relating to PV (WHO, 2004; Mehta, Allen, et al., 2014). The WHO 
has in fact set up a policy for PV systems that can be used as a guideline on how to address 
stakeholders’ responsibility and accountability within the context of a policy (Chakrabarty and 
Thawani, 2011). 
 Component 10: Novel technologies 
In the modern-day health landscape, especially given the Fourth Industrial Revolution30, 
artificial intelligence is becoming part of everyday systems and operations (Yoon, 2017). 
Thus, for the Vigilance System to be both agile and robust within this context, novel 
technologies should be investigated and incorporated into the system where appropriate.  
 Intervention identified for component 10: Novel technologies 
The four novel technologies identified as relevant to the context of Vigilance System are: (i) 
blockchain, (ii) datamining, (iii) machine learning and deep learning, and (iv) social media. 
Blockchain 
Blockchain, commonly used in cryptocurrencies, is a form of distributing data, thus allowing 
users to process data through nodes on a network instead of through a central authority 
(IoTCoreSoft, 2018; Price, 2018). Blockchain can be a valuable method of ensuring that data 
is not falsified or manipulated within the context of PV. Blockchain also provides a reliable 
flow of data between the different stakeholders, which assists with PDR  of ADRs (Price, 
2018). Furthermore, the literature also argues that blockchain could be used to improve data 
integrity, which would assist with ensuring quality management of a PV system (Price, 2018). 
Datamining 
Due to the growing development of large electronic health data storage systems and advances 
in technology, the demand for datamining within the healthcare environment has increased 
significantly (Wilson, Thabane and Holbrook, 2004). Datamining, for the purpose of this 
study, refers to the utilisation of statistical techniques within the knowledge discovery process, 
which refers to the extraction process of valid, previously unknown information from large 
databases (Wilson, Thabane and Holbrook, 2004). Using datamining techniques, data related 
to ADRs can be identified from medical databases that can be used to build a big-data 
platform31. Then using this platform and different intelligent data processing techniques 
(keyword auto-mining and image recognition, for instance), an ADR monitoring and filtering 
model can be developed to assist with the identification of suspected ADRs (Wu et al., 2017).  
Machine learning and deep learning 
Machine learning is an application that offers a system the ability to automatically deduce and 
gain insights from past experiences in order to improve a system automatically (Price, 2018; 
Lee and Chen, 2019). Conventional machine learning methods have been used to keep track 
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changing the operations of current work practices by increasing productivity (Yoon, 2017). 
31 Within the context of this research inquiry, a big-data platform is a universal data storage server that be utilized 




of post-marketing drug side effects, however the complex biological and chemical structures 
of drugs often make it more challenging to be detected and thus deep learning methods are 
often preferred for prediction tasks (Lee and Chen, 2019). In a study done by Lee (2019), a 
two-stage framework was developed based on using deep learning methods to predict the 
association between ADRs and drugs; it involved integrating individuals’ biological data into 
a system. This framework can be used to determine the likelihood of an ADR occurring in a 
patient before a new medication is prescribed (Lee and Chen, 2019).  
Social media 
Social media generates large volumes of data that can be utilised for signal and ADR detection, 
and thus assist with the challenge of under-reporting within a PV system (Nikfarjam et al., 
2015; Sloane, Osanlou and Lewis, 2015). The use of social media sites as platforms to facilitate 
discussions of ADRs between patients and HCP have become increasingly predominant 
(Nikfarjam et al., 2015). Furthermore, suspected ADRs can also be identified from social 
media and recorded for data gathering(Nikfarjam et al., 2015; Sloane, Osanlou and Lewis, 
2015). There are however still technical and ethical challenges (i.e. the use of informal 
language on social media platforms, for instance, and considerations of privacy and 
confidentiality) that have to be addressed for this to become a viable intervention |(Nikfarjam 
et al., 2015). Furthermore, effective techniques, such as algorithms that can be used to identify 
ADRs through social media platforms, are still in the process of development (Nikfarjam et 
al., 2015; Sloane, Osanlou and Lewis, 2015).. However, the use of social media brings with it 
the opportunity for early detection and enhancement of patient safety (Sloane, Osanlou and 
Lewis, 2015).  
 CHAPTER 5 CONCLUSION 
In this chapter, the third phase in the systems engineering process, namely the functional 
analysis, was conducted with the aim of identifying intervention strategies that would address 
the requirements specification, which led to the proposition of the Vigilance System - an 
context-specific PV system for MPP drug provision systems aimed to assist with the effective 
and efficient reporting of ADRs within this context. Building on the insights gained form the 
contextualisation of the identified intervention strategies, an index, the Vigilance System 
Component-Intervention Index, was developed to provide an overview of the various 
components and intervention strategies to address when considering the implementation of a 
Vigilance System 
Building on the insights gained from this chapter, in the following chapter the final phase of 
the systems engineering approach will be taken, namely, the design synthesis. The aim of this 
phase is to transform the Vigilance System Component-Intervention Index into an operational 






Chapter 6: Decision support tool 
development 
In this chapter, the final phase of the systems engineering approach, the design synthesis, is 
conducted; the design synthesis entails the development of a functioning product based on the 
findings from the previous phase, in this case, the functional analysis conducted in Chapter 5 
(United States Government, 2001).  In the context of this research study, the design synthesis 
is the development of a decision support tool, by synthesising the findings of the functional 
analysis, i.e. the Vigilance System Component-Intervention Index that was documented in 
Chapter 5. The purpose of the decision support tool is to facilitate the development of an 
implementation strategy for a Vigilance System within the context of the MPP drug provision 
systems that addresses the three specific diseases (i.e. HIV, TB and Hepatitis C), within RLS. 
The design synthesis phase is divided into two sub-phases: sub-phase A relates to the 
development of a decision support tool, and sub-phase B relates to the validation of the 
developed tool. Sub-phase B is presented and discussed in Chapter 7. 
In this chapter, the tool development, the different dimensions of the tool, and the 
implementation of the tool are discussed. Figure 6.1 shows how the design synthesis relates to 
the overarching systems engineering approach that was followed in this research study.  
 
Figure 6.1: Systems engineering approach: Design synthesis: Subphase A  
 DECISION SUPPORT TOOL PURPOSE, DEVELOPMENT APPROACH, 
AND OVERVIEW 
The design synthesis phase is the final phase of the systems engineering approach and draws 
together the findings from the preceding phases, i.e., (i) input identification, (ii) requirement 
analysis, and (iii) functional analysis. The design synthesis phase is the process of defining 
and developing a functioning product that can be implemented to address the research problem 
(United States Government, 2001). During this research inquiry, it was found that PV systems 
in the environment of MPP drug provision systems are not adequately designed to address the 




developing a decision support tool that would assist with the implementation of a, context-
specific PV system (i.e. a Vigilance System) within the context of the MPP. 
In this section, the purpose of the tool, an overview of the tool and the approach used to develop 
said tool will be discussed. 
 Decision support tool purpose 
In order to synthesise the operability of the Vigilance System Component – Intervention 
Index, which provides a overview of the different components that should be addressed when 
implementing a Vigilance System, a decision support tool referred to as the Customised 
Vigilance System Implementation Tool (CVSIT) was developed. The CVSIT is a decision 
support tool that assesses a drug projects’ profile, with respect to the specific drug being 
considered, together with the environment and resource availability, in order to developing a 
customised implementation strategy for a Vigilance System. This customised implementation 
strategy provides an approach of how to address the implementation of a Vigilance System, 
by identifying which of the intervention strategies, as provided for in the Vigilance System 
Component-Intervention Index, are most appropriate to the specific drug provision project 
under consideration. Furthermore, when considering this implementation strategy, it should 
be noted that this approach provides an overview of the intervention strategies most 
appropriate or suitable for a specific project, given the context-specific characteristics of the 
project, and subsequent to the identification of such intervention strategies, should the 
financial, technical and operational feasibility be pursued. 
 Decision support tool development approach 
The CVSIT was developed based on the insights gained form the Vigilance System 
Component-Intervention Index with reference to the 10 Vigilance System components and 
their subsequent intervention strategies. In order for the tool to facilitate the process to 
determine the intervention strategies most appropriate for the specific project under 
consideration, a set of inclusion/exclusion criteria set was established for each of the 
interventions, that stipulate the requirements called for by the specific intervention in order to 
operate effectively within the context of the specific drug provision project, given the 
environment of the MPP drug provision systems. These inclusion/exclusion criteria sets were 
developed based on the findings of the Vigilance System Component-Intervention Index and 
the associated literature. Furthermore, these inclusion/exclusion criteria sets are related to the 
requirements that a specific intervention strategy would call for when considering the 
environment in which the drug provision project would operate, i.e. the available resources, 
the accessible healthcare and reporting facilities, as well as the characteristics of the project, 
i.e. the specific drug being considered and the targeted audience. A detailed explanation of 
these criteria sets for the different intervention strategies can be found in Appendix F, Section 
F.1. 
From the above-mentioned sets of criteria, four project profile dimensions, which facilitate the 
gathering of the respective data that is required to determine which of the intervention 
strategies would be most appropriate for the specific drug provision project under 





 Decision support tool overview 
The CVSIT is a Microsoft Excel32 based tool that consists of four dimensions, i.e. 
Dimension 1– vigilance profile assessment, Dimension 2 – Vigilance System Component-
Intervention Index, Dimension 3 – profile-interventions mapping tool, and Dimension 4 – 
vigilance implementation strategy. These dimensions and how they are combined to form the 
CVSIT are shown in Figure 6.2. Dimension 1 is the input section of the tool and is found at 
the user interface level, as the user is required to provide the input data. Dimensions 2 and 3 
are the background logic level of the tool, and Dimension 4 is the user output level.  
The first dimension is the vigilance profile assessment dimension and is aimed at determining 
and assessing the profile of the project, by collecting the required data with respect to the 
characteristics and environment. There are four domains that have to be considered in order to 
gather all the necessary data to create a vigilance profile, which is the output of Dimension 1, 
for the project under consideration. These four domains were identified by drawing on the 
inclusion/exclusion criteria set of the intervention strategies as discussed in Section 6.1.2. As 
mentioned, this dimension is at the user interface level and thus requires the input from the 
user. The user is required to complete questions related to each of the domains in order to 
gather all the required data. 
The second dimension is the Vigilance System Component-Intervention Index which was 
developed in Chapter 5. This dimension provides the information on the 10 vigilance 
components with their respective implementation strategies.  
The third dimension is the profile-interventions mapping tool dimension. And, in this 
dimension the project’s unique vigilance profile, as developed in Dimension 1, is mapped 
against the Vigilance System Component-Intervention Index to identify which of the 
intervention strategies would be most appropriate or suitable for the drug provision project 
under consideration. This domain is the background logic section of the tool and is not 
accessible by the user. The background logic associated with the Profile-intervention mapping 
tool is discussed in detail in Section 6.2.3. The input to this dimension, as shown in Figure 6.2, 
is the output from the first dimension (i.e. the vigilance profile of the project) and the output 
of the second dimension (i.e. the information related to the vigilance components with their 
respective implementation strategies). The output from this dimension is found in 
Dimension 4.  
The fourth and final dimension, which is the output of Dimension 3, is the vigilance 
implementation strategy, which provides the user with a customised strategy for the 
implementation of a Vigilance System. This provides the user with the identified intervention 
strategies that are most appropriate to the project under consideration, given the context. As 
mentioned above, the financial, technical and operational feasibility of interventions fall 
outside of the scope of the CVSIT. Each of these dimensions of the CVSIT is discussed in 
detail in the following sections. 
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Figure 6.2: Graphical representation of the CVSIT 
 THE CUSTOMISED VIGILANCE SYSTEM IMPLEMENTATION TOOL 
In this section a detailed discussion of each of the dimensions, as briefly discussed in 
Section 6.1, will be provided.  
 Dimension 1: The vigilance profile assessment 
This dimension is aimed at determining the project’s vigilance profile with regard to the 
implementation of a Vigilance System best fit for the specific project. This dimension is 
situated in the user interface and requires the user to answer different questions with respect 
to the four domains, in order for the tool to gain all the required data with respect to the specific 
project, the targeted patient group(s), and the availability of both human and technological 
resources, as depicted in Figure 6.3. These four domains are individually assessed in the Excel 




































































Excel based forms, one for each domain that is developed to capture the necessary information 
from the user to ensure that the implementation strategies that best fit the project can be 
identified in the third dimension. The four respective Excel sheets, corresponding to the four 
domains of the Vigilance profile assessment dimension, are shown in Appendix F, Section 
F.2.1. 
Once the profile data has been captured, a vigilance profile for the respective project is 
developed, which is then transferred to Dimension 3 – the profile-intervention mapping tool. 
An overview of the four domains is given below.  
 
Figure 6.3: Dimension 1 - Vigilance profile assessment 
 Domain 1: Project information 
The project information domain is aimed at capturing data with regard to the focus of the 
project’s aim for the Vigilance System, such as: (i) data on the drugs being considered in the 
project, (ii) considerations in respect of ADRs that have to be monitored and (iii) the healthcare 
facilities being considered for the project. This domain corresponds to the first Excel based 
form of the CVIST, and is found in Appendix F, Section F2.1, Figure F.1. 
 Domain 2: Patient profile 
In this domain, the specific patient audience that may be affected by the drug provision project 
under consideration, is determined and assessed. The specific factors of the patient audience 
that need to be considered when identifying the applicable intervention strategies of the project 
are determined, whether or not the project focuses on a controlled group is considered, the 
education level of the patient audience with regard to drug safety monitoring is evaluated, and 






















reflected on. The Excel based form for the patient profile domain is shown in Appendix F, 
Section F2.1, Figure F.2. 
 Domain 3 : Human resource availability  
In this domain, the extent to which the project has access to human resources, i.e. HCP such 
as doctors, pharmacist or other specific resources, who can assist with ADR reporting are 
considered. It also considers the availability and the education level of the HCP with regard to 
drug safety monitoring. The Excel based form for the human resource availability domain is 
shown in Appendix F, Section F2.1, Figure F.3. 
  Domain 4 : Technological resource availability 
This domain determines the project’s access to different technologies, and thus determines 
whether a project has access to different technologies, such as the internet, handheld devices, 
and/or desktops for the purpose of ADR reporting and monitoring. It also determines the 
capacity of the drug provision project to investigate and adopt novel technologies, such as 
blockchain, datamining, machine learning or social media, to assist with ADR detection. This 
domain is aimed at capturing information to determine if the project will be able to utilise 
technology focused intervention strategies when implementing the Vigilance System. The 
Excel based form for the technological resource availability domain is shown in Appendix F, 
Section F2.1, Figure F.4. 
 Dimension 2: Vigilance System Component–Intervention Index 
The second dimension of the CVSIT tool is the Vigilance System Component-Intervention 
Index, which was developed in Chapter 5. This index provides an overview of the different 
Vigilance System components that have to be addressed when developing a Vigilance System. 
For reference purposes, the key features are reiterated here: Each of the Vigilance System 
components have a subsequent set of intervention strategies that could be implemented to 
address the specific component. The index contains 10 different Vigilance System 
components, which are grouped into three categories, namely: (i) direct components and 
interventions, (ii) supporting components and interventions, and (iii) additional factors. The 
direct components refer to the components that directly affect the ADR reporting process, the 
supporting components refer to those that address the effectiveness of a Vigilance System 
within the context of the profile of the drug provision project, and the additional factors are 
the components that are neither direct nor supporting components but that rather consider the 
drug provision project from a future perspective. The different components are illustrated in 
Figure 6.4. Furthermore, this dimension only includes the inclusion/exclusion criteria for the 
different intervention strategies, as discussed in Section 6.1.2 and found in Appendix F, 
Section F.1. 
Similar to the project vigilance profile, the Vigilance System Component–Intervention Index 
data is transferred to Dimension 3 (i.e. the Excel based form for the third dimension), viz., the 
profile-intervention mapping, where the different intervention strategies are evaluated against 
the project’s vigilance profile to determine which of the intervention strategies are most 
applicable and suitable for the specific project. The Excel based form for the second domain 





 Dimension 3: Profile-intervention mapping tool 
The third dimension of the CVSIT tool, see Figure 6.5, the profile-intervention mapping, is 
the background logic section of the Excel based tool. In this dimension, the output of the first 
dimension, i.e. the project vigilance profile, and the second dimension information, i.e. the 
vigilance components, intervention strategies and respective inclusion/exclusion criteria sets, 
are mapped against each other to determine which of the intervention strategies are most 
appropriate or suitable to the specific drug provision project, based on the information gathered 
with reference to the project’s profile. 
As mentioned, each of the intervention strategies, as shown in the Vigilance System 
Component – Intervention Index, have a specific set of inclusion/exclusion criteria, based on 
the requirements called for by the intervention strategies in order to operate effectively in a 
Vigilance System within the environment of the drug provision project (shown in Appendix 
F). As mentioned, these criteria sets were based on the findings of the Vigilance System 
Component – Intervention Index and the related literature as documented in Chapter 5. These 
sets of criteria, along with the project vigilance profile data, are mapped using Visual Basic of 
Appications (VBA) programming in Excel to determine which of the intervention strategies 
would be the most appropriate or suitable to the specific project. Furthermore, the profile-



























intervention mapping tool also determines if the project’s profile calls for additional aspects 
of ADR reporting to be considered when implementing certain intervention strategies, such as 
the type of information that needs to be captured for the specific project’s ADR report. The 
Excel based form for the 3 dimension is shown in Appendix F, Section F.2.3, while the 
background logic is shown in Section F.3. 
 
Figure 6.5: Dimension 3 - Potential mapping assessor 
 Dimension 4: Vigilance implementation strategy 
The final dimension of the CVSIT tool is the Vigilance implementation strategy dimension, 
see Figure 6.6. This yields the customised vigilance implementation strategy for the specific 
drug provision project under consideration. Its objective is to provide the user with an 
implementation strategy for a Vigilance System, i.e. the different vigilance components, which 
need to be addressed with their respective implementation strategies that are most suitable or 
appropriate for the specific drug provision project. In this dimension of the Excel tool, the best 
suited intervention strategies for each of the vigilance components are provided, with a short 
description of each. However, they still require additional feasibility investigations to ensure 
that they would in fact be the most effective implementation strategy for the specific project 
under consideration. However, this phase lies outside of the scope of the CVSIT. A description 
of the unfavourable intervention strategies is also provided, in case the user would like to 
investigate these intervention strategies as well. Furthermore, the customised vigilance 
implementation strategy also provides the user with additional important information to 
consider, based on the project’s vigilance profile, the ADR reports, the specific patient groups, 
and the education interventions. The Excel based form for the fourth dimension is shown in 



































Figure 6.6: Dimension 4: Vigilance implementation strategy 
 OPERATIONALISATION OF THE CUSTOMISED VIGILANCE SYSTEM 
IMPLEMENTATION TOOL 
In this section, the operationalisation of the CVSIT tool is discussed, i.e. how the different 
dimensions of the tool can or should be implemented, the flow of data and information through 
the CVSIT and between the various dimensions and domains, and the background logic of the 
CVSIT. 
The CVSIT may be used for two distinct, yet related objectives, and can be denoted based on 
the ‘direction’ in which the tool is operationalised – see Figure 6.7. The two different 
operationalisation paths each serve a different outcome or objective with regard to the 
development of a vigilance implementation strategy. The two operationalisation paths are: (i) 
CVSIT Operationalisation Path 1: Project profile to vigilance implementation strategy guide, 
and CVSIT Operationalisation Path 2: Vigilance implementation strategy to project profile 
guide. 
In Path 1, the CVSIT may be used to assess a specific drug provision project’s profile and to 
identify applicable intervention strategies for a Vigilance System related to the project. 
Essentially this is the operationalisation path that is aligned with how the CVSIT is described 
in Section 6.1.3 and Section 6.2 – thus progressing through Dimensions 1 to 4. However, 
during the development of the CVSIT, it became evident that it may also be used in the form 
of an index guide, which provides the user with the considerations that a specific intervention 
strategy calls for, thus operationalising the CVSIT through Dimensions 4 to 1 (see Figure 6.7). 
Path 1 is referred to as the CVSIT project profile to vigilance implementation strategy guide, 
as it provides the user with an implementation strategy for a Vigilance System and, as 
mentioned, because it operationalises the CVSIT from Dimension 1 through to Dimension 4. 
Path 2, the CVSIT vigilance implementation strategy to project profile guide, provides the user 


















audience group, and the accessibility to human and/or technology resources, which each of the 
intervention strategies calls for in a Vigilance System.  
It is thus suggested to use Path 1 when deciding on a customised implementation strategy for 
a Vigilance System by identifying which intervention strategies are most appropriate or 
suitable for the specific drug provision project, based on the profile of the project with respect 
to the specific drug being considered, the environment and the availability of resources.  
It is suggested to use Path 2, in contrast, when a specific intervention strategy should be 
adopted in the implementation strategy for a Vigilance System, by providing the consideration 
that said intervention strategy would call for with respect to the profile of the project, i.e. the 
human resources availability, the technological resources available and the target patient 
group. 
The respective operationalisation paths, their respective purposes, and data flow will be 
discussed in more detail in the following sections. 
 
 Customised Vigilance System Implementation Tool operationalisation path 1: 
Project profile to vigilance implementation strategy guide 
As mentioned, Path 1 of the CVSIT progresses from Dimension 1 through to Dimension 4, 
with the user providing project profile data related to the specific drug provision project, the 
patient group that is being focused on, and the availability of resources. The output of this path 




is a vigilance implementation strategy customised to the profile of the project under 
consideration.  
The process flow associated with Path 1 is illustrated in Figure 6.8. During the vigilance profile 
assessment, the user provides project data related to the project information domain, the patient 
information domain, the human resource availability domain, and the technology resource 
availability domain. The user is requested to answer questions related to these four domains, 
after which this data is captured in the Excel based form (see Appendix F, Section F.2.1) and 
transferred to the profile-intervention mapping tool dimension’s Excel based form. The most 
appropriate or suitable intervention strategies are then indicated to the user in the final 
dimension. A high-level process map was created to represent the flow of the data (see Figure 
6.8), but a more detailed version of the data flow can be found in Appendix F, Section F.3, 
along with the different dimensions of the CVSIT in Appendix F, Section F.2. 
 Customised Vigilance System Implementation Tool operationalisation path 2: 
Vigilance implementation strategy to project profile guide 
Path 2 of the CVSIT moves in the opposite direction, i.e., from the strategy to the specific 
project profile, and is aimed at providing information related to the considerations the 
intervention strategies call for in a Vigilance System. Path 2 allows the user to select specific 
intervention strategies that they may want to implement in a Vigilance System, and Path 2 then 
gives the user the relevant project profile considerations to consider with respect to the 
environment and the availability of resources. This set of considerations that will support the 
implementation of the intervention under consideration can then be compared to the existing 
profile of the drug provision project to identify and highlight any misalignments between the 
existing profile and the required profile based on the intervention’s system considerations. The 
process flow that depicts Path 2 is shown in Figure 6.9. 
Path 2 of CVSIT consists of three index guides: (i) considerations of direct components and 
interventions, (ii) considerations of supporting components and interventions, and (iii) 
considerations of additional factors. Each of these index guides give the user a list of the 
different intervention strategies and the respective considerations that these interventions call 
for in order to be adopted effectively in a Vigilance System. These considerations are directly 
linked to the vigilance profile domains, namely (i) project information, (ii) patient information, 
(iii) human resource availability, and (iv) availability of technology resources.  
It is important to note that these considerations are not an exhaustive set of the considerations 
the intervention strategies need for an effective implementation, but that they are aimed at 
providing guidance with respect to the context of this tool and the four domains, i.e. the details 
of the project, the patient, and the human and technology resources. There may be other 
considerations that fall outside these four domains, such as feasibility, and technical or 
financial considerations.  
The three index guides, shown in Figure 6.10 to Figure 6.12, are subdivided into the three 
categories with respect to the Vigilance System Component – Intervention Index, i.e. the 
direct, supporting and additional factors. The first index guide (considerations of direct 
components and interventions) lists the four direct Vigilance System components, namely, 
(i) the mode of reporting, (ii) the reporting process, (iii) the response strategy, and (iv) the 




intervention strategy calls for in a Vigilance System. The second index guide (considerations 
of supporting components and interventions) has a similar format, but with regard to the 
supporting vigilance components, i.e., (i) awareness, (ii) communication, (iii) education, (iv) 
quality management, and (v) responsibility and accountability. Lastly, the third index guide 



























































































































































































































































































































































































































































































































































































































































Figure 6.12: Index guide for additional factors considerations  
 CHAPTER 6 CONCLUSION 
In this chapter, sub-phase A of the final phase of the systems engineering approach, namely 
the design synthesis, was conducted with the aim of developing a decision support tool, that 
synthesises the operability of the Vigilance System implementation landscape. 
The aim of this tool is to assist drug provision projects in the environment of the MPP drug 
provision systems with the implementation of a Vigilance System that would facilitate the 
effective and efficient reporting of ADRs within this context. CVSIT was developed in order 
to assess a project’s profile with respect to the specific drug being considered, the particular 
environment and the availability of resources, with the aim of customising an implementation 
strategy for a Vigilance System by identifying the intervention strategies most appropriate or 
suitable for the specific project under consideration. In the following chapter, sub-phase B of 
the design synthesis approach will be executed, which is aimed at validating the CVSIT by 







































































Chapter 7: Validation process 
In this chapter, sub-phase B of the design synthesis phase of the systems engineering approach 
is conducted, which entails validating the developed decision support tool, the CVSIT.  
In this research inquiry, the research problem, i.e. the absence of an effective PV system within 
the environment of MPP drug provision systems, was addressed by developing a decision 
support tool that facilitates the process of developing and implementing a context-specific PV 
system that will assists with the effective and efficient reporting of ADRs within the context 
of the MPP drug provision systems, while taking into consideration the niche factors. Such a 
system is thus proposed by developing an index, the Vigilance System Component-
Intervention Index, which provides a guideline for the implementation of a Vigilance System. 
This index creates an outline of the various components that should be addressed in such a 
Vigilance System. Building on this, an operation tool, the CVSIT, was developed during sub-
phase A of the design synthesis that provides a drug provision project within the context of 
the MPP with a customised implementation strategy for a Vigilance System. However, in order 
to authenticate and evaluate whether the tool addresses the research aim, a validation process 
needs to be conducted.  
In sub-phase B, therefore, a twofold validation approach was conducted that entailed 
(i) applying a case study and (ii) conducting semi-structured interviews with SMEs. In this 
chapter background information pertaining to the identified case study as well as the findings 
from the case study are presented, along with the processes, results, and recommendations 
from the semi-structured interviews. Refer to Figure 7.1 for an overview of this process and 
how it relates to the rest of the research inquiry. 
 
 VALIDATION APPROACH OVERVIEW 
According to the IEEE-STD-610 guidelines, a validation process is the process of evaluating 
the developed system, model or component to ensure that the expectations, stated at the 




beginning of the process, are met (IEEE Standards Board, 1990). Thus the final phase of the 
design synthesis phase in the systems engineering approach, is to validate the CVSIT, which 
was developed to assist drug provision projects (for example pilot, roll-out, and/or existing 
drug provision projects) to formulate customised implementation strategies for a Vigilance 
System (refer to Chapter 6), with the aim of improving drug safety reporting and monitoring. 
The focus of the validation is to determine if the CVSIT would be an effective tool to assist 
with the effective and efficient reporting of ADRs within the environment of MPP drug 
provision systems. 
In this section, an overview is presented of the purpose of the validation approach, within the 
context of this research, followed by a discussion of the applied validation methods.  
7.1.1 Validation purposes 
As mentioned, the aim of the validation process within this research context is to determine if 
the CVSIT meets the required expectation, i.e. the research aim – assisting with the efficient 
and effective reporting of ADRs by proposing a context-specific PV system for MPP drug 
provision systems. In order to determine this, there were three purposes for the validation of 
the CVSIT, namely: 
i. Evaluating the applicability of the CVSIT, where applicability refers to the quality 
of the tool being relevant to the context of the MPP drug provision systems 
considering real world situations; 
ii. Evaluating the practicality of the CVSIT, defined as the quality of being suitable 
for a specific objective. Within this dissertation, the practicality of the CVSIT was 
aimed at evaluating the tool in terms of its ease of use and to what extent it was 
intuitive to understand; and 
iii. Evaluating the value of the CVSIT within the context of drug safety monitoring and 
PV systems. Thus, within the context of this dissertation it is to determine if the 
CVSIT is a value-added tool that enhances the current traditional PV system. 
7.1.2 Validation methods approach 
In order to address the validation purposes, as discussed in Section 7.1.1, the validation process 
included two approaches: (i) applying the CVSIT to a case study, and (ii) conducting semi-
structured interviews with SMEs in the fields of pharmaceuticals and PV.  
A retrospective case study was applied with the aim of determining whether the outcomes 
from the CVSIT corresponded to a previously documented case, in order to ascertain whether 
the CVSIT might be an effective tool to use for ADR reporting within the context of MPP drug 
provision systems. Thus, a customised implementation strategy for a Vigilance System, 
developed using the CVSIT, was compared with the actual PV plan executed for the case, and 
the respective outcomes are subsequently compared.  
The second validation process entailed validating the CVSIT by conducting semi-structured 
interviews with SMEs using the case study to illustrate the operability of the tool. SMEs were 
contacted to discuss and assess the applicability, practicality and the value of the CVSIT with 




In this chapter, the approaches, results and inferences drawn from the respective validation 
processes are discussed.  
 VALIDATION PROCESS 1: THE CASE OF BEDAQUILINE  
For this research inquiry a retrospective case study was applied. This is a type of case study in 
which the data is collected after the specific event or activities have occurred, and the final 
outcomes and events are known (Street and Ward, 2012). The main reasoning for conducting 
a retrospective case study is to evaluate whether the CVSIT can effectively develop an 
implementation strategy for a Vigilance System that has been implemented in a real world 
scenario, deducing that the tool would be effective in addressing the implementation of a 
context-specific PV systems that will assist with the effective reporting of ADRs. Furthermore, 
the case study also sought to determine whether the CVSIT would be able to address shortfalls 
or improve the strategy that was developed and implemented during the relevant case.  
The selection of the case is one of the most essential parts of case study research, as the selected 
case should be relevant and provide sufficient information with regard to the research objective 
being investigated (Bleijenbergh, 2012). For the purpose of this research, therefore, the 
objective of the case study was to evaluate whether the CVSIT would be useable tool for ADR 
reporting, i.e., whether the CVSIT would be able to effectively facilitate the process to develop 
an implementation strategy for a Vigilance System that could be implemented in real world 
situations. Furthermore, as this research inquiry considers the context of the MPP drug 
provision system, evaluating the applicability would also look at to what extent the CVSIT 
considers and accommodates the context-specific factors. Thus, to identify an appropriate case 
study, the following selection criteria were developed:  
i. The case had to be retrospective in nature; 
ii. Information related to the drug safety monitoring or PV system implemented for the 
drug provision project had to be available; 
iii. Information on the specific drug provision project (related to the patients and 
resource availability) had to be available; and 
iv. The case should be deemed representative of the context of the MPP drug provision 
system; thus the case should be (i) within an environment where the MPP is active, 
(ii) in the context of RLS, and (iii) considering the disease burden addressed by the 
MPP (i.e. HIV, TB or Hepatitis C). 
Using these criteria as a guideline to identify a case study, it was evident that the roll-out of 
Bedaquiline, a drug used in the treatment of multi-drug resistant TB (MDR-TB) in the context 
of South Africa meets all the identified requirements. The roll-out of Bedaquiline in South 
Africa occurred in 2012, which means that the case could be applied as a retrospective case 
study. Furthermore, the case for the roll-out of Bedaquiline has been thoroughly documented 
in the literature, and information was readily accessible about both the drug safety 
requirements, as stated by the WHO, and about the context-specific information related to the 
project, i.e. where the project was rolled out, what resources were available and what 
additional information on the specific drug existed (Conradie et al., 2014; WHO, 2015b; Jones 
et al., 2019). As the selected case study was conducted in South Africa and regarded as a roll-




given the environment where the MPP was launched, i.e. South Africa (Medicines Patent Pool, 
2010a); in addition, it considers a disease specifically addressed by the MPP, i.e. TB 
(Medicines Patent Pool, 2010a), and it relates to RLS, i.e. South Africa is a country with access 
to limited resources within the healthcare landscape (Mathlathi et al., 2015). 
Furthermore, a multiple organisation approach (Street and Ward, 2012) was used to conduct a 
comparable process to determine the applicability of the CVSIT. This approach is appropriate 
when investigating what the outcomes of different organisations are (in the case of this 
research, it was drug provision projects) when using the same tool (Street and Ward, 2012). 
Thus, for the purpose of this research, two case studies were applied, namely, Case A, which 
considers the cohort launch of Bedaquiline in South Africa, and Case B, which investigates 
the countrywide roll-out of Bedaquiline, also in South Africa. Both cases concerned the 
provision of the drug, Bedaquiline, but did so in different environments with regard to area, 
patients, and resource availability.  
 Background of case studies 
TB treatments were often found to be prolonged and have poor outcomes and thus, in 2012, 
under the provision of accelerated approval by the Food and Drug Administration (FDA) 
Bedaquiline was introduced for multidrug resistant TB (MDR-TB) treatments. Bedaquiline 
was the first new drug to be released in the last 50 years for such TB treatment (Jones et al., 
2019). The WHO recommended the roll-out of Bedaquiline, but advised that PV systems 
needed to be robust to actively monitor Bedaquiline (Jones et al., 2019). Bedaquiline was 
initially released under controlled access to 6 different countries, South Africa being one, in 
2012. This controlled access program was known as the Clinical Access to Bedaquiline 
Programme (BCAP). However, after successful and favourable outcomes, in June of 2018, 
South Africa integrated Bedaquiline into the MDR TB treatment regime (MSF| Doctors 
Without Borders, 2018). Figure 7.2 depicts a timeline for the roll-out of Bedaquiline within 
the South African context. 
For the purpose of this research, it was decided that the CVSIT would be applied to two cases 
for the roll-out of Bedaquiline. The first case, Case A, refers to the BCAP of 2012, while Case 
B refers to the countrywide roll-out of 2018. The reasoning behind this was to identify if and 
how the customised implementation strategy for a Vigilance System as developed using the 
CVSIT, would change when considering the same drug, Bedaquiline, but in different 
environmental conditions, i.e. different target patient groups, facilities, etc.  
In this section, background is provided on the roll-out of Bedaquiline for both cases, followed 
by the actual PV plan developed and implemented for the respective cases, and the outcomes 
from the application of the CVSIT to the respective cases. A comparison is then made between 





Figure 7.2: Timeline for Bedaquiline launch in South Africa  
 Case A: Clinical access to Bedaquiline programme  
In South Africa in 2010, 14 161 case of of multi-drug resistant (MDR) TB were reported, of 
which 10% were cases of extreme drug resistant TB (XDR-TB). However, in 2012, after 
accelerated approval, a new drug, Bedaquiline, was authorised by the US Food and Drug 
Association (FDA) for the treatment of MDR-TB (Conradie et al., 2014).  
Although Bedaquiline was not yet approved by the South African Medical Control Council 
(MCC) at that stage, through an early access program, some patients with little or no other 
treatment options were granted access to Bedaquiline through the drug manufacturers Janssen 
Pharmaceutica (Conradie et al., 2014; MSF| Doctors Without Borders, 2018). Thus, under a 
controlled early access program, referred to as BCAP, a few countries including South Africa 
made available Bedaquiline to selected patients with drug resistant TB, including MDR and 
XDR-TB (Conradie et al., 2014). Selection criteria were used to determine which patients 
would be allowed to participate in the study. The selected patients had to be older than 18, be 
resistant to at least 3 anti-TB drugs and not be pregnant or breastfeeding (Clayden, 2014; 
Ndjeka et al., 2015). In 2013, the program was launched in 5 sites across South Africa, with 
Tshepong hospital in Klerksdorp being the first site; due to favourable outcomes, this was later 
extended to 12 sites (Clayden, 2014; Health-e News, 2018; The Union, 2018). In 2014, the 
MCC approved the nation-wide roll-out of Bedaquiline within the National TB program 
(Clayden, 2014). 
This document has been prepared to serve as a guideline to those reporting ADRs. It represents 
the MCC current thinking on the safety, quality and efficacy of medicines. It is not intended 
as an exclusive approach. The MCC reserves the right to request any additional information 
to establish the safety, quality and efficacy of a medicine and may make amendments in 
keeping with the knowledge that is current at the time of consideration of the safety data.  
In Section 7.2.2.1. the PV plan that was executed for the BCAP will be discussed, after which 
in Section 7.2.2.2. the implementation strategy for a Vigilance System, as developed using the 
CVSIT, will be discussed. Lastly a discussion regarding the findings with respect to Case A 































 Actual PV plan executed for Case A 
Since Bedaquiline was a novel drug being rolled out for the first time, it was of utmost 
importance that effective pharmacovigilance plans and drug safety monitoring systems were 
in place (WHO, 2013; Jones et al., 2019). When Bedaquiline was launched as part of the TB 
treatment plan in the Western Cape, HCPs were encouraged to report all suspected ADRs to 
the Western Cape Pharmacovigilance Programme, a spontaneous reporting system for 
suspected ADRs related to TB and HIV treatments (Mehta, Dheda, Steel, M Blockman, et al., 
2014; Medicines Control Council of South Africa, 2017; Jones et al., 2019). The BCAP 
collected reports on serious ADRs, deaths and/or birth defects. The BCAP is a collaboration 
between the Western Cape Province Department of Health and the University of Cape Town’s 
Division of Clinical Pharmacology (Jones et al., 2019).  
For the BCAP, a structured reporting form was used to obtain the following information 
regarding the patient: age, sex, weight, pregnancy status, HIV status, co-morbidities, and 
medical history (Medicines Control Council of South Africa, 2017; Jones et al., 2019). The 
reports also acquired information on the suspected ADRs, management of the ADR and 
relevant laboratory investigations. The data were then captured, and a pharmacist would 
perform the initial assessment and contact the patient if additional information was required. 
As mentioned, during the first year, HCPs treating drug resistant TB were actively encouraged 
and reminded to report any suspected ADR. The causality assessments of the suspected ADRs 
were monitored by the WHO Uppsala Monitoring Centre (Jones et al., 2019).  
In order to assist countries with the roll out of Bedaquiline, the WHO set up an implementation 
plan, that included guidelines on the implementation of a PV system (WHO, 2013, 2015a). 
These guidelines emphasise the importance of some form of reporting and PV systems, as 
Bedaquiline is a newly released drug and should thus be monitored particularly carefully. 
These guidelines provide a short overview of the three main methods of pharmacovigilance to 
be considered, namely spontaneous reporting33, targeted spontaneous reporting34 and cohort 
event monitoring35 (WHO, 2015b). The guidelines state that, when deciding which method to 
implement, the existing PV systems in the relevant should be considered. However, it also 
states that, when introducing Bedaquiline, a more active approach is advised, such as CEM. 
Moreover, reporting forms should be made available and staff should be trained appropriately 
(WHO, 2013, 2015b). 
In the context of this research study and the CVSIT, however, the WHO implementation plan 
did not consider certain factors, and thus there is a valid case to propose the implementation 
of a Vigilance System by applying the CVSIT. Furthermore, the WHO recommendations do 
not consider the possible different environment capabilities where the projects were launched, 
i.e. the resource availability and capabilities, the patients’ knowledge and the availability of 
facilities, whereas the CVSIT can provide a customised implementation plan for the specific 
project in the specific setting.  
                                                 
 
33 Spontaneous reporting is the most common form which entails having a healthcare practitioner or the patient 
reporting a suspected ADR. This is a passive form of reporting. 
34 Targeted spontaneous reporting is a more active form that monitors a specific set of safety concerns for a 
predefined population. 





  An implementation strategy for Case A using CVSIT  
To complete the vigilance profile assessment (i.e. Dimension 1 of the CVSIT), information 
regarding the project, the patient and resource availability was required. From the background 
information on the BCAP, as defined in Section 7.2.1, the data for the project information and 
the patient information sections could be identified. Considering the Tshepong Hospital as one 
of the first sites, and assuming that the other sites were in similar settings and environments, 
conclusions could be drawn for the profile assessment data regarding the human and 
technological resources. 
In Appendix G, Section G.1, the vigilance profile assessment data for Case A can be found 
along with the resources used, and the Excel based form for the vigilance profile assessment 
can be seen in Appendix G, Section G.2. 
The vigilance implementation strategy for Case A provided multiple intervention strategies 
for each of the vigilance components, except for the component of novel technologies. This is 
because this case does not have the required technical or human resources to implement these 
interventions at the given stage of the project. Furthermore, additional information was 
included regarding certain intervention strategies related to the reporting process, 
communication and education (i.e. that the reporting form should specifically mention 
Bedaquiline, that the HCP should be educated about the context of the drug before considering 
certain reporting processes such as CEM or TSR). The comprehensive / complete customised 
implementation strategy for a Vigilance System for the Case A can be found in Appendix G. 
 Discussion of Case A findings 
When considering the Vigilance System developed with the CVSIT for Case A, a comparison 
can be drawn between the actual PV plan developed and implemented for the BCAP and the 
implementation strategy for a Vigilance System developed by using the CVSIT within the 
context of the BCAP. The intervention strategies for both the actual PV plan that was executed 
and the CVSIT Vigilance System’s implementation strategy is summarised in Table 7.1.  
From these results, it is firstly identified that, for the actual PV plan, the following vigilant 
components, as discussed in Chapter 5, were addressed and intervention strategies for each of 
these components were implemented: (i) modes of reporting, (ii) reporting process, (iii) 
databases, (iv) responsibilities and accountability and (v) education. When comparing these 
five components with the outcomes found using the CVSIT, it was found that the CVSIT 
identified the same intervention strategies as the actual PV plan. This reaffirms that the CVSIT 
is correctly able to analyse the profile of the project and adequately identify intervention 
strategies best suited to the project in a real-life situation. Furthermore, although the CVSIT 
did identify the same intervention strategy for the components of the reporting process as 
actually implemented in the PV system for the BCAP, the CVSIT also identified additional 
interventions that could have been investigated. In the BCAP spontaneous reporting was 
implemented, although the WHO recommended that more active reporting should have been 
considered, such as CEM. The CVSIT implementation strategy indicated that CEM, TSR and 
black triangle reporting could all have been investigated further. 
Moreover, when considering the PV plan that was executed, the following Vigilant System 
components were not directly addressed: (i) response strategies, (ii) awareness, (iii) 




the actual PV plan did consider the Vigilant System components of education, and 
responsibility and accountability, direct intervention strategies were not implemented, as HCP 
were only encouraged to report ADRs, but no clearly defined proposed strategies were 
provided. However, when reviewing the implementation strategy developed by using the 
CVSIT, these Vigilant System components were addressed, and multiple intervention 
strategies were identified for each component. The only vigilant component that delivered no 
intervention strategies was novel technologies, and this is due to the profile of the BCAP 
focusing on the reporting of ADRs and not focusing on the incorporation of expanding 
technologies.  
Table 7.1: Case A: actual PV plan comparison with implementation strategy for Vigilance System  
 Case B: Countrywide roll-out of Bedaquiline 
In 2018 the Department of Health announced that Bedaquiline would be implemented for 
standard MDR TB treatment regimens across South Africa, thus replacing the injectables, 
which were often associated with harsh side effects (Global TB Community Advisory Board, 
2018; SAnews, 2018). The Department of Health made the decision to implement the 
countrywide roll-out, which is wider than recommended by the WHO, in an attempt to improve 
the high TB burden in SA. 
This case differs from Case A, as certain project and patient information changed when 
Bedaquiline was rolled out to the entire country. With Case A there was more control over the 
Case A: BCAP 
Vigilant component Actual PV plan executed 













 Mode of reporting 
Paper-based, Web-based reporting 
forms 
(i) Paper-based, (ii) Web-based 
reporting forms 
Reporting process 
Spontaneous reporting but WHO 
recommended CEM 
(i) Spontaneous reporting, (ii) CEM, 
(iii) TSR,(iv) Black triangle reporting, 
(v) 3-step approach (vi) Task-shifting 
Databases Vigibase (i) Vigibase, (ii) Physical storage 
Response strategy Not addressed 



















Awareness Not addressed 
(i) Paper-based resources, (ii) 
Communities of practices 
Communication Not addressed 
(i) Communication network, (ii) Email, 
(iii) Videoconferences, (iv) Paper-based 
(v) Policy & guidelines 
Education 
No direct interventions implemented 
the WHO only suggest that HCP 
should be educated 
(i) Web-based, (ii) Patient information 









HCP urged to report ADRs 



















patients taking the drug, but in Case B any TB patient could, in theory, access the drug. The 
project was also more focused on the entire culture of reporting. Thus, the CVSIT was used to 
determine a Vigilance System’s implementation strategy for Case B and to explore how the 
CVSIT implementation strategy compares to that of the actual PV plan executed for Case B. 
As with Case A, firstly in Section 7.2.3.1 the PV plan that was executed for the countrywide 
roll-out will be discussed, after which in Section 7.2.3.2 the implementation strategy for a 
Vigilance System using the CVSIT will be discussed, and final concluding remarks will the 
discussed. 
 Actual PV plan developed and implemented in Case B 
For the countrywide roll-out, which took place in June of 2018, a very similar drug safety 
reporting and monitoring system was implemented as had been done with the cohort roll-out 
of Bedaquiline (Case A). As South Africa made use of spontaneous reporting for most of the 
PV systems, this mode of reporting was implemented for this case too (Jaramillo, 2015; 
Medicines Control Council of South Africa, 2017). The WHO, however, still recommended 
active modes of reporting to be implemented (Jaramillo, 2015; Stop TB Partnership and 
Medecins Sans Frontieres (MSF), 2015; MSF| Doctors Without Borders, 2018). Furthermore, 
as with Case A, web-based reporting forms were implemented to report ADRs and Vigibase 
was used to capture and monitor these reported ADRs (Jaramillo, 2015; Stop TB Partnership 
and Medecins Sans Frontieres (MSF), 2015; WHO, 2015b). With regard to this specific 
project, no customised intervention strategies were implemented for a Vigilance System, as 
specified in Chapter 5, with regard to the supporting components, i.e. education, response 
strategies, awareness, and quality management, or the additional factors, i.e. novel 
technologies.  
 Implementation plan using CVSIT in Case B 
In Case B, the CVSIT tool was applied to a countrywide roll-out of Bedaquiline to treat MDR 
TB. As with Case A, information on the project was gathered from the literature to complete 
the Vigilant Assessment section of the CVSIT. This information can be found in Appendix H, 
Section H.1. Although for Case B the same drug, Bedaquiline, was used as in Case A, certain 
project profile changes required the implementation plan to be adapted. These profile changes 
were that for Case B Bedaquiline was being rolled out over the whole country, and thus there 
was not as much control over the patients taking the drug as there had been with Case A. 
Considering the customised implementation strategy for a Vigilance System for Case B, 
multiple intervention strategies were once again identified for the different vigilance 
components. CVSIT Excel document for Case B can be found in Appendix H, Section H.2.  
 Discussion of Case B findings 
When considering Case B, the countrywide roll-out of Bedaquiline, similar inferences were 
made as with Case A. The PV plan for the countrywide roll-out that was actually implemented 
as well as the strategy developed using the CVSIT can be found in Table 7.2. For the actual 
PV plan, once again three of the direct components were addressed, namely modes of 
reporting, reporting process, and databases. As with Case A, the CVSIT identified the same 
intervention strategies for these components as had been executed in the PV pan for the 
countrywide roll-out of Bedaquiline, thus validating that the CVSIT is able to effectively 




Furthermore, as with Case A there were certain vigilant components that were not addressed 
at all in the actual PV plan, but the CVSIT was able to identify multiple intervention strategies 
for these components. 
Table 7.2: Case B actual PV plan comparison with implementation strategy for Vigilance System 
Case B: Countrywide roll-out 

















(i) Paper based, (ii) Web based 
Reporting 
process 
Spontaneous reporting but 
WHO recommended 
CEM 
(i) Spontaneous reporting, (ii) 3-step approach, (iii) 
Task shifting 
Databases Vigibase (i) Vigibase, (ii) Physical storage 
Response 
strategy 


















Awareness Not addressed 
(i) Paper-based resources, (ii) Communities of practices, 
(iii) Collaboration & partnerships 
Communication Not addressed 
(i) Communication network, (ii) Email, 
(iii) Videoconferences, (iv) Paper based, (v) Policy & 
guidelines 
Education Not addressed 
(i) Web-based, (ii) PV curriculum, (iii) Patient 




(i) CVP, (ii) Audits, (iii) Policy & guidelines, 





(i) PV stakeholder policy, (ii) Incentive schemes: 
Financial, career performance, positive working 
















Not addressed No intervention strategies identified 
 Discussion of case studies A and B  
Although both cases considered the same drug, there were profile changes with regard to the 
respective contexts, such as the control over the patients and the areas where the drug were 
being rolled out. Thus, when comparing the CVSIT implementation strategy for Case A and 
Case B, further inferences may be made regarding the customisation of the intervention plans 
in different scenarios. When comparing the two cases (refer to Table 7.3), differences with 
regard to the intervention strategies can be identified; the vigilant components relating to 
(i) the reporting process, (ii) awareness, (iii) education, (iv) quality management, and 
(v) responsibility & accountability differ between Case A and Case B, because Case A was 
conducted in a cohort format, whereas Case B was focused on a countrywide roll-out. 
Furthermore, for the components of awareness, education, and quality management, Case B 
additional intervention strategies were proposed using the CVSIT. The main reason for this is 
that Case B focuses more on creating a culture of reporting of ADRs.  
Based on this comparison, additional attributes of the CVSIT may thus be inferred. Firstly, it 




creates a customised implementation strategy best suited to the specific project. Secondly, it 
reaffirms that the CVSIT is robust enough to adapt to the specific environment with regard to 
the patients and the specific drug being considered. Thus, the comparison also reaffirms the 
need to readdress a PV system or Vigilance System when there are profile specific changes.  
Table 7.3: Comparison between CVSIT implementation strategies for Case A and Case B 
Comparison between CVSIT implementation strategies for Case A and Case B 



















The following were only advised for Case A: 





























The following were only advised for Case B: 













The following were only advised for Case B: 





The following were only advised for Case A: 



















 Summary of case study 
By conducting these two different case studies on the roll-out of Bedaquiline in South Africa, 
the following attributes of the CVSIT could be validated: 
i. The CVSIT is able to effectively identify intervention strategies for a Vigilance 
System that has been implemented in real world situations; 
ii. The CVSIT was able to identify additional components that were not implemented 
or considered in real world situations; 
iii. The CVSIT is able to develop a customised implementation strategy for a specific 
project and 
iv. The CVSIT is robust enough to adapt to changes in a project’s context. 
To further evaluate the CVSIT, semi-structured interviews with SMEs were conducted. This 




 VALIDATION PROCESS II: SEMI-STRUCTURED INTERVIEWS WITH 
SUBJECT MATTER EXPERTS 
In this section, the semi-structured interview process of the CVSIT validation is discussed. In 
these semi-structured interviews, six SMEs from various backgrounds relevant and/or related 
to PV, MPP and or pharmaceuticals, took part in validating the CVSIT. The aim was to 
evaluate the applicability and practicality of the tool to assist with effective and efficient 
reporting of ADRs within the environment of MPP drug provision systems, as well as to 
determine if the tool adds value to PV and drug safety monitoring. 
In this section, the semi-structured interview process, validation results and findings as well 
as possible refinements are discussed. 
 Semi-structured interview process 
The semi-structured interviews were conducted in two steps: firstly, the SMEs were given pre-
read documents, and secondly, the replied to the validation questions in Skype interviews (the 
pre-read document and validation questionnaire can be seen in Appendices I, Section I.1 and 
I.2 respectively). SMEs were contacted via email to determine their willingness to assist with 
validating the CVSIT and, on reply, they were sent the pre-read documents to work through. 
For an overview of the qualifications and background experiences of the different SMEs who 
assisted with the validation, refer to Table 7.4. 
Two sets of pre-read documents were provided to them: the first set of documents introduced 
the background of the research, a short overview of the different dimensions of the CVSIT, 
and instructions on the operation of the CVSIT. Accompanying this document was the Excel 
CVSIT document, which the SME could access and operate. The second set of documents 
provided information on the two case studies of the roll-out of Bedaquiline that had been 
conducted, as documented in Section 7.2, to illustrate the operations of the tool. These 
documents, with reference to the case studies, contained information on Bedaquiline and the 
actual PV plans executed during the roll-out of the drug for both the BCAP (Case A) and the 
countrywide roll-out (Case B). Furthermore, these documents also included the customised 
implementation strategy for a Vigilance System developed by using the CVSIT along with the 
Excel CVSIT documents for each of the respective cases, Case A and Case B.  
The SMEs were then contacted via Skype for a validating question-based interview to verify 
the operability and practicality of the CVSIT. During these interviews, a short presentation 
was given, summarising the content of the pre-read documents, to ensure that the SMEs 
understood the aim, dimensions and functions of the CVSIT. A demonstration on the 
operability of the CVSIT was then given, via Skype, using a presentation and the case study, 
as documented in Section 7.2, after which the case studies and findings were presented. The 
validation questionnaire, shown in Appendix E, was then completed. The questionnaire was 
aimed at evaluating the practicality of the CVSIT and the applicability of the tool in real world 
situations. A 5-point Likert scale was used to rate the responses to the questions. In the 
following section, the results from the validation process are presented, with an overview of 













MB, BS in 
Medicine 
Board member and treasurer of ISoP (from 2016 to the present) 
Principal consultant at the NDA Group AB, a drug development consultancy 
company (from 2007 to the present) 
The deputy qualified person of PV at Johnson & Johnson (2005 – 2007) 
The Senior Medical Assessor of the Medical and Healthcare products 
Regulatory Agency of the United Kingdom (1994 – 1999) 
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BSc (Hons) 
MPH Epidemiology  
PhD Clinical 
Pharmacology 
Head of clinical research at University of Cape (from 2002 to the present) 
Clinical operations manager at i3 Research, a global pharmaceutical services 
company (1998 – 2002)  
Clinical research Associate at Novo Nordisk, a global healthcare company 
focused on treatments related to chronic diabetes (1996 – 1998) 




Deputy Qualified Person for Pharmacovigilance at Salom Pharmacy Ltd 
Ghana (from 2017 to the present) 
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PhD research in Pharmacovigilance at the University of Sheffield, School of 
Health and Related Research (from 2014 to the present) 
Member of ISoP  
Member of the Clinical Human Factor Group, a charity aimed at improving 
the healthcare environment 
Member of the Pharmaceutical Information and Pharmacovigilance 
Association 
Member of Pharmaceutical and Human Factor Group an organisation 







Senior Manager at Guidehouse, a management consulting firm servicing the 
public and commercial sectors, within the department of Medicine Selection 
and Use (from March 2019 to the present) 
Senior Technical Advisor at Management Sciences for Health a global non-
profit organisation focused on developing sustainable health systems (2017 
– 2019) 
Pharmacy technical assistance manager for Right to Care, a non-profit 
organisation aimed at pioneering solutions related to treatments for HIV and 







Medical Specialist: Clinical Pharmacologist at Stellenbosch University 
(from 2013 to the present) 
Professor and coordinator of undergraduate clinical pharmacology at the 
Faculty of Medicine and Health Sciences of Stellenbosch University  
 
 Semi-structured interview validation results 
The results from the semi-structured interview process with the SME are provided in this 
section. Each of the questions, from the questionnaire found in Appendix I, are summarised 
and the main findings are discussed in more detail.  
The questionnaire contained eight questions, which evaluated the applicability and the 
practicality of the tool within the context of developing a context-specific PV system for use 
in MPP drug provision systems. Furthermore, the questionnaire was aimed at identifying 
possible weakness and/or strengths of the tool. The first five questions made use of a 5-point 




understand the concepts of the tool, and the targeted audience group. The subsequent two 
questions sought to identify any strengths or weaknesses of the tool, and the final question 
considered the value of the CVSIT with respect to drug safety monitoring in a real-world case. 
The results of the first five questions are summarised in Figure 7.3. From the results of 
Question 1, it can be seen that the SMEs were in agreement that the CVSIT provides a holistic 
approach for the implementation of a Vigilance System for a context-specific PV system, 
specifically for drug provision projects within the context of the MPP drug provision systems. 
Furthermore, it was found that, although the CVSIT is applicable to the environment of MPP 
drug provision systems, it could also be applied to other similar environments and other related 
diseases, if adaptions are made to it. 
With reference to Question 2, the SMEs also agreed that the CVSIT can provide a holistic 
overview not only of the direct components for ADR reporting but of accompanying and 
supporting components that are often disregarded in traditional PV systems. It was found that 
the CVSIT provides a novel approach to addressing PV systems that challenge the 
conventional drug safety monitoring systems.  
When considering the CVSIT in terms of ease of use and intuitiveness of understanding 
(Question 3), the SMEs were also in agreement. This confirmed the practicability of the tool 
in real world cases within the context of MPP drug provision systems. 
With regard to Question 4, the level of experience required to operate the tool, there was some 
disagreement. 40% of the SMEs had a neutral perspective of the fact that very limited 
knowledge with respect to PV and drug safety monitoring was required. However, subsequent 
discussions revealed that the SMEs agreed that a rudimentary knowledge of PV or the system 
components of drug safety monitoring would be required to ensure the most effective 
operation of the tool. It was also found that, because the vigilance components are context-
specific to PV systems, the user of the tool would need to understand the different components 
and processes related to PV.  
Question 5, the last one, focused on the types of drug projects, within the context of the MPP 
drug provision systems, that the CVSIT would be targeted at, i.e. drug roll-outs, pilot drug 
projects, existing or established etc. The SMEs were in agreement that the CVSIT could be 
applicable to different projects within the context of the MPP drug provision systems, which 
reaffirmed that the CVSIT serves as a very good blueprint for the development of a universal 





Figure 7.3: SME validation results for Questions 1 – 5 
As previously mentioned, Questions 6 and 7 focused on identifying the strengths and 
weaknesses of the CVSIT, and the results are summarised in Table 7.5. The strengths 
identified confirmed that the CVSIT is a tool that can encompass all the components called for 
in a drug safety monitoring system. Furthermore, it is found that the tool is robust and agile, 
as it considers the patient aspect and is applicable to different environments, i.e. countries, 
drugs and population groups. Another strength that was highlighted, was that the tool provides 
a novel, systematic thinking approach for the development of a context-specific PV system. 
Furthermore, it was also confirmed that, although the CVSIT is targeted at audiences that 
implement PV systems for specific drug projects, i.e. regulatory authorities or national PV 
systems, it is not limited in its use to those specific audience groups and would be applicable 
to various stakeholders for different reasons. For example, it could be used by pharmaceutical 
companies to identify gaps or challenges related to their industry within the context of drug 
safety monitoring.  
However, from the weaknesses identified, it can be deduced that, due to the broad applicability 
of the tool, there are country specific requirements that are lacking and that would have to be 
addressed when setting up a Vigilance System, such as incorporating a national PV regulation. 
Furthermore, it was also found that, as the CVSIT is developed for the specific context of the 
MPP drug provision systems, its use could be limited. However, it was also found that it could 





































Table 7.5: Strengths and weaknesses of CVSIT identified through SME validation 
What do you view as some of the key 
strengths of the CVSIT? 
What do you view as some of the key 
weaknesses of the CVSIT? 
i) Incorporating the patient aspect into the tool. The 
patient aspect is a key component in any PV 
system and incorporating it makes the system 
more robust.  
ii) The tool is also able to address specific patient and 
drug issues. 
iii) The tool is very easy to use and does not require a 
high level of experience or knowledge on 
pharmacovigilance or drug safety monitoring 
iv) The tool encompasses and captures all the 
components required for a PV system. This tool 
should be the first step to look at PV 
implementation strategies. 
v) The tool is broad enough to be applicable to 
different countries and stakeholders. For example, 
pharmaceutical companies, National Health 
Departments or medicine regulatory bodies can 
make use of the tool for various different reasons. 
vi)  It’s a comprehensive tool that is also context-
specific to different environments. 
vii) The tool leads you through a systematic process of 
addressing and thinking about the different 
components and processes of a PV system. 
viii) It challenges the conventional PV systems and 
provides a novel thinking process of addressing a 
PV system. 
 
i) As the tool is very broad (not only specific to one 
country) there is the downfall of not implementing 
a specific country’s national PV regulations. 
ii) Context-specific to niche factors. 
 
 
The final question addressed the unique contribution of the CVSIT in the field of PV and 
focused on the identification of additional tools that could be used to complement the CVSIT. 
The SMEs agreed that they were not aware of any form of system modelling that has been 
conducted to the same detailed extent as in this study. To their knowledge, there was no such 
a tool with which the CVSIT could be compared. However, there were tools and frameworks 
identified that could be used to complement the CVSIT and to further strengthen the 
implementation stare of a Vigilance System. These tools, similar to the CVSIT, provide 
guidelines and recommendations for the set-up of a PV system and can thus be used in 
alignment with the CVSIT to set up a Vigilance System for a specific drug project. The 
following tools were identified as possible complementary tools: (i) Indicator-Based 
Pharmacovigilance Assessment Tool (IPAT), (ii) the WHO PV Toolkit, and (iii) BioPhorum 
members-only organisation. A short description on each of these tools is provided.  
Indicator-Based Pharmacovigilance Assessment Tool (IPAT) 
The IPAT is a performance metric for PV systems that acts as a benchmark to identify gaps, 
diagnose strengths and weaknesses, and evaluate the different systems. The IPAT addresses 5 
components, namely: policy, system structures, signal generation and data management, risk 
assessment, and risk management and communication, by assessing 43 indicators. The IPAT 




diagnose and assess the performance of a PV and medicine safety system (Strengthening 
Pharmaceutical Systems (SPS) Program., 2009). The IPAT is thus a useful tool to use in 
conjunction with the CVSIT to assess an existing projects’ PV system and identify possible 
shortcomings, after which the CVSIT can be used to identify possible intervention strategies 
to address these shortcomings.  
WHO PV Toolkit 
The toolkit gives an overview of the different practices within PV with the aim of providing 
PV practitioners in developing countries with access to trusted resources on PV related 
activities. The resources provided include the minimum set of requirements for a functioning 
PV system, and basic instructions on how to set up a PV centre, and manage the data (WHO, 
2018a). However, the toolkit only provides an overview of these PV practices, and thus can 
be used mainly as an introductory tool to the implementation of a PV system, after which the 
CVSIT can be used to provide a more structured strategy for the implementation of such a 
system with customised intervention strategies.  
BioPhorum 
BioPhorum is an international members-only organisation that was established in 2014 with 
the aim of creating a communication forum for the global biopharmaceutical industry that 
fosters collaboration to accelerate progress within this industry (BioPhorum, 2014). To date, 
more than 82 member companies are part of this organisation, which connects industry leaders 
and delivers solutions by pooling knowledge, experiences and practices. BioPhorum has 
delivered solutions related to demand forecasting, quality improvement, and user 
implementation requirements for pharmaceutical manufacturing companies (BioPhorum, 
2014). It is envisaged that collaboration with BioPhorum could improve the roll-out of the 
CVSIT within the pharmaceutical industry. Furthermore, in collaborating with this 
organisation, alterations could be incorporated into the CVSIT, as BioPhorum has a vast 
experience and knowledge base for the roll-out of tools and frameworks within the healthcare 
landscape. 
In the following section, the refinements made by the SMEs during the validation process, as 
well as how such refinements were addressed, are discussed.  
 Refinements to the Customised Vigilance System Implementation Tool  
During the validation process, the SMEs made certain recommendations regarding the 
applicability of the CVSIT, which were taken into account. These recommendations were 
reviewed and addressed either by reining the tool or considering these recommendations as 
possible future work, when such recommendations fall outside of the scope of this research 
study.  
Suggested refinement 1: The inclusion of a pregnancy exposure registry as an intervention 
strategy  
During the validation process, it was brought to the researcher’s attention that a possible 
intervention strategy to include under the vigilant component of the reporting process, would 
be a pregnancy exposure registry. Pregnancy exposure registries are a cohort format study, 
where pregnant women who receive prescription biopharmaceutical products voluntarily 




with women who do not take the same medication. This method allows for the improvement 
of safety information of medications, as the risk involved with the drug can be monitored. 
Furthermore, this study also allows not only for the assessment of the risk involved with the 
drug but also of the effectiveness of the drug (Gliklich RE, Dreyer NA and Leavy MB, 2014). 
As the CVSIT does consider the specific patient group, pregnant women, the inclusion of this 
intervention strategy is seen to be of value to the tool and thus incorporated into the CVSIT. 
Suggested refinement 2: The component of education should be adapted to education & 
competency 
During the validation process, it was mentioned that the vigilance component of education 
also addresses competency in the field of PV and that this aspect should be highlighted and 
incorporated. Competency refers to the possession of a sufficient amount of knowledge on 
regarding a topic, which for this dissertation is aimed at PV related knowledge. Thus, it was 
decided to adapt the wording of the vigilant component to education & competency.  
Suggested refinement 3: Excluding text-based reporting as an intervention strategy 
During the validation process, the recommendation was made by an SME to exclude text-
based reporting as a possible intervention strategy as a mode of reporting due to the expert’s 
experience and knowledge in that particular field. Text-based reporting has been found to be 
challenging in certain areas due to the language barrier. However, during this dissertation, it 
was found that this form of reporting is favourable in RLS, as stated in Section 5.11. The 
research found related to this intervention strategy reaffirms the effectiveness thereof in 
developing countries, and thus this recommendation was not incorporated into the CVSIT. 
Suggested refinement 4: The inclusion of national PV guidelines 
With regard to the applicability of the CVSIT in real-world situations, a recommendation was 
made that the tool needs to be restructured by incorporating the national PV guidelines for a 
specific country as stated by the regulatory authorities. However, as the CVSIT was developed 
for the broader purpose of being adaptable to various environments related to MPP drug 
provision systems, i.e. any RLS environment, the inclusion of a specific country’s PV 
requirements would limit the operation of the tool. During the development of the tool the 
minimum set of PV requirements as stated by the WHO was taken into account. As this a valid 
recommendation to take into consideration when implementing the tool in a real-world 
situation, this recommendation should be considered as future work and will be discussed in 
the following chapter.  
 CONCLUDING REMARKS CONCERNING THE CUSTOMISED 
VIGILANCE SYSTEM IMPLEMENTATION TOOL 
From the validation process with the SMEs regarding the applicability, practicability, and the 
value of the CVSIT, it was reaffirmed that the CVSIT is indeed an effective tool for developing 
an implementation strategy for a Vigilance System that considerers direct, indirect and 
supporting components. Furthermore, due to the broad and robust nature of the tool, it could 
be implemented in various environments (i.e. countries, patients, drugs). However, this also 
limits the context specificity of the tool, as the CVSIT does not consider the different national 




used complimentary with the CVSIT to ensure that the implementation strategy developed by 
the tool considers the specific countries PV related. 
Furthermore, the CVSIT is aimed at developing a customised implementation strategy for a 
Vigilance System based on the profile of the relevant drug provision projects; moreover, the 
audience group could comprise various stakeholders, from pharmaceutical companies and 
National Health Departments to medicine regulatory bodies that are, for various reasons, 
considering the implementation of Vigilance System.  
It was also confirmed that the CVSIT does not require a high level of PV experience or 
knowledge; however, to ensure optimum use of the tool, the user would need a rudimentary 
understanding of PV or multiple users would need to be consulted.  
From the semi-structured interviews, it was established that the CVSIT should be used as one 
of the initial tools when considering the implementation strategy of a PV system within the 
context of MPP drug provision systems, as it addresses the different components that such a 
system requires, in order to develop a customised implementation strategy within the context 
of the projects’ unique requirements. However, as the tool is seen as an initial tool, 
complementary tools were identified that should ideally be used together with the CVSIT to 
ensure a more effective uptake of such a Vigilance System. These tools were identified as: 
(i) a country’s specific national PV guidelines, (ii) the WHO PV Toolkit, and (iii) the IPAT. 
 CHAPTER 7 CONCLUSION 
In this chapter, the developed tool, the CVSIT, was validated with the purpose of determining 
the applicability, practicability, and the value of the tool to assist drug provision projects with 
developing a customised implementation strategy for a Vigilance System. A two-step process 
was conducted that consisted, firstly, of a retrospective case study to illustrate the operation of 
the tool and determine the applicability and value of the CVSIT with respect to real-world 
situations, and secondly, semi-structured interviews were conducted with SMEs in the field of 
pharmaceuticals and PV. These validation processes reaffirmed the contributions of the 






Chapter 8: Conclusion and future work 
In this chapter, closing remarks are made in respect of the research and its contributions to the 
pharmacovigilance industry, as well as its limitations and scope for possible future work 
related to the research. 
8.1 OVERVIEW OF THE RESEARCH 
In this research study, a decision support tool, the Customised Vigilance System 
Implementation Tool (CVSIT), was developed that facilitates the development of context-
specific PV systems, a Vigilance System, within the context the MPP to subsequently 
contribute towards effective and efficient reporting and monitoring of ADRs.  
In order to develop the CVSIT in a meticulous manner, the systems engineering approach was 
used. This is a comprehensive, iterative problem solving technique that begins by identifying 
an environmental need and analytically transforming it into a system solution (United States 
Government, 2001). In this thesis, it comprised four phases: (i) input identification, (ii) 
requirement analysis, (iii) functional analysis, and (iv) design synthesis.  
In Chapter 1, the research study was introduced by discussing the background, the research 
rationale, the research aim and objectives, the scope, the research methodology, and finally 
the verification and validation process.  
The first phase of the systems engineering approach, the input identification phase, entailed 
identifying and contextualising the different factors that had to be considered in developing a 
context-specific PV system. It was decided that an in-depth input investigation was not 
necessary, as the particular environment, in which the PV system would have to function (i.e. 
the MPP drug provision system), included four niche factors: (i) traditional PV systems, (ii) 
the MPP, (iii) HIV, TB and Hepatitis C, and (iv) RLS.  
In Chapter 2, the first niche factor, traditional PV systems, was contextualised, and a 
systematic literature review identified the challenges associated with this factor and 
synthesised these into a challenges landscape within the context of PV systems. A similar 
approach was followed in Chapter 3, which focused on contextualising the other three niche 
factors, (i) the MPP, (ii) HIV, TB and Hepatitis C, and (iii) RLS. Challenges associated with 
these factors were identified and synthesised into a challenges landscape. The two landscapes 
of Chapter 2 and Chapter 3 were then integrated to develop an overarching challenges 
landscape in the context of MPP drug provision systems, referred to as the pharmaceutical 
value chain challenges landscape (PVCCL). 
In Chapter 4, the second phase of the systems engineering approach was executed, namely 
the requirement analysis, in order to develop a requirements specification that would guide the 
development of the decision support tool. A preliminary requirements specification was 
developed from systematic literature reviews pertaining to each of the niche factors and by 
consulting the PVCCL to identify possible additional requirements to consider when 




was followed to authenticate the preliminary requirement specification. This entailed 
interviews with SMEs, who completed questionnaires related to the requirement 
specifications, within the context of each specific niche factor. The results were captured and 
analysed, and the necessary changes were made to develop a final requirement specification. 
During the functional analysis, the third phase of the systems engineering approach, which is 
documented in Chapter 5, intervention strategies were identified by means of triangulation. 
Building on the findings from the intervention strategies, a Vigilance System was proposed as 
a context-specific PV system within the context of MPP. In order to guide the development of 
the decision support tool that facilitates the development of a Vigilance System, an index guide 
was synthesised, providing an overview of the various component and intervention strategies 
to consider when implementing a Vigilance System. This index guide is referred to as the 
Vigilance System Component – Intervention Index. 
The final phase of the systems engineering approach, the design synthesis phase, was 
subdivided into two sub-phases (A and B). The aim was to develop a decision support tool 
building on the foundational features of the Vigilance System Component – Intervention 
Index. In Chapter 6, therefore, sub-phase A of the design synthesis phase focused on 
developing the decision support tool – the CVSIT, to assist with the effective and efficient 
reporting of ADRs within the environment of MPP drug provision systems. In this chapter, 
the dimensions of the tool, its operations and the background logic are discussed.  
In sub-phase B, which was discussed in Chapter 7, a validation process evaluated the 
applicability and the practicability of the tool. Two methods were used: (i) a case study was 
applied, and (ii) semi-structured interviews with SMEs were conducted. The aim of the first 
method was to evaluate applicability of the CVSIT in real world situations, and furthermore 
to determine if the tool could assist practically with the effective and efficient reporting of 
ADRs within the environment of MPP drug provision systems. In this regard, two 
retrospective case studies looked at the roll-out of Bedaquiline, a drug used for MDR-TB 
treatments in South Africa. Case A investigated how Bedaquiline had been made available in 
a cohort format, while Case B focused on the country-wide roll-out of Bedaquiline in South 
Africa. The relevant background information related to these two cases was provided, and the 
findings with respect to the application of the CVSIT were discussed. The second method, 
conducting semi-structured interviews was aimed at evaluating the applicability, and 
practicability of the tool and to determine if the tool adds value to the effective and efficient 
reporting of ADRs. This process, the results of the interviews and the subsequent adaptations 
made to the CVSIT, were discussed in that chapter. It concluded by presenting some closing 
remarks about the CVSIT validation process. 
8.2 CONTRIBUTION TO THE PHARMACOVIGILANCE INDUSTRY  
During this research study, it was established that, in the current healthcare landscape more 
innovative forms of drug manufacturing and distribution, such as the MPP, are becoming 
prevalent. However, these are challenging the traditional methods of drug safety monitoring 
and PV. The environments defined as the MPP drug provision systems pose distinctive 
challenges that call for a more context-specific PV system. Thus, this research sought to 
address this by developing a decision support tool that facilitates the development of context-




In this research investigation, four niche factors, namely, (i) traditional PV systems, (ii) MPP, 
(iii) HIV, TB and Hepatitis C, and (iv) RLS were all taken into account when developing this 
decision support tool. Furthermore, in order for the Vigilance System to address the challenges 
posed by these factors, a so-called challenges landscape was developed to gain a systems level 
perspective and understanding of them. Known as the PVCCL, this landscape gives an 
overview of the different challenges faced throughout the entire pharmaceutical value chain, 
from drug manufacturing to ADR monitoring, that have to be taken into consideration when 
developing the proposed decision support tool. The PVCCL thus contributes to the field of 
pharmacovigilance, as it provides a synopsis of the challenges that are faced when considering 
these niche factors, and moreover indicates how these challenges influence the pharmaceutical 
value chain and subsequently the PV processes. The PVCCL further contributes to the 
pharmaceutical landscape as a whole, as it considers the entire pharmaceutical value chain and 
the unique challenges brought on by the niche factors within this context. Thus, the PVCCL 
can be seen as a foundational platform for research within the field of the pharmaceutical 
industry, specifically as it pertains to the niche factors. 
Using the developed PVCCL, systematic literature reviews and verification processes, a 
requirement specification was developed that would guide the development of the decision 
support tool. This requirement specification in itself contributes to the PV industry, as it does 
not only address the minimum requirements of a PV systems (WHO and The Global Fund, 
2010), but also the unique requirements of the niche factors within the context of the entire 
pharmaceutical value chain.  
The aim of this research inquiry was to develop a context-specific PV system within the 
environment of MPP drug provision systems. Thus, the Vigilance System was proposed 
through the development of the Vigilance System Component – Intervention Index, which 
aids as a guideline for the implementation of a Vigilance System. This index contributes to the 
field of PV by providing a structure for the implementation of a Vigilance System that 
considers direct, supporting and additional components with subsequent intervention 
strategies. Furthermore, this index proposes that attention should be paid to those supporting 
components in the PV industry, that do not directly relate to the ADR reporting process and 
that are often disregarded in traditional PV systems.  
The final outcome of the dissertation was to transform the Vigilance System 
Component – Intervention Index, an index that provides an overview of the various Vigilance 
System components and intervention strategies, into a decision support tool (the CVSIT) that 
would assist in the development/implementation of a Vigilance System. The CVSIT can be 
used to assess a specific drug provision project’s profile (with respect to the drug being 
considered, the target patient group, and the resources available to the project) and 
subsequently to create a customised implementation plan for a Vigilance System that identifies 
the intervention strategies applicable to the specific project. The following attributes of the 
CVSIT were reaffirmed: 
i. The CVSIT is an all-encompassing tool that considers both direct and supporting 
components within a Vigilance System and provides a holistic systematic approach 




i. The CVSIT should be used as an initial tool (or a first phase tool), when developing a 
Vigilance System, as it provides a guideline for an implementation strategy that could 
be investigated further; 
ii. The CVSIT can be used complementary with other PV related tools, such as a 
country’s specific national PV guidelines, the WHO PV toolkit, and the IPAT, thus 
reaffirming that the roll-out of this tool will be supported within the healthcare 
landscape; and 
iii. The CVSIT is both robust and agile, as it can be used by various RLS countries and 
stakeholders, such as medicine regulatory authorities, pharmaceutical companies, 
health and drug launching programs, and other stakeholders involved with PV to 
improve ADR reporting within the context of MPP drug provision systems. 
In conclusion, this research inquiry contributes to the pharmacovigilance industry and the 
pharmaceutical industry not only with the final research output, the CVSIT, but also by 
challenging the current traditional PV systems. The contribution of this research lies in 
providing systematic though processes for the development of a drug safety reporting system 
that considers innovative intervention strategies currently being overlooked.  
8.3 ADRESSING THE RESEARCH OBJECTIVES 
The aim and objectives as set out in Chapter 1 have been met by this research study. The aim 
was to develop a tool that would assist pilot drug roll-out projects with implementing a 
Vigilance System, and this was achieved by developing the CVSIT. Table 8.1 gives an 
overview of the objectives and in which chapters and sections they were achieved.  
Table 8.1: Research aim and objectives achieved  
Research objectives 
Chapter and section 
numbers 
RO1 Review the literature pertaining to the factors of (i) traditional PV systems, (ii) the 
MPP, (iii) the disease burden associated with the MPP (HIV, TB and Hepatitis C), and (iv) 
RL S, in order to contextualise the research problem under consideration, namely, the fact 
that traditional PV systems are inadequate in supporting the unique needs and challenges 
brought on by these factors. 
Chapter 2, Section 2.2 
& Chapter 3, Section 
3.1 
RO2 Develop a challenges landscape related to the factors of (i) traditional PV systems, (ii) the MPP, (iii) HIV, TB 
and Hepatitis C, and (iv) RLS in order to gain an understanding of what challenges a context-specific PV system 
will have to address. 
RO2.1 Conduct systematic literature reviews to identify the challenges associated with 
each of the factors as stated above. 
Chapter 2, Section 2.3 
& Chapter 3, Section 
3.2 
RO2.2 Identify and define possible relationships between the identified challenges and the 
pharmaceutical value chain. 
Chapter 2, Section 
2.4.2 & Chapter 3, 
Section 3.4.2 
RO2.3 Synthesise the challenges and the identified relationships to develop a challenges 
landscape that will support the development of a proposed context-specific PV system.  
 
Chapter 3, Section 3.5 






… continued from previous page. 
Research objectives 
Chapter and section 
numbers 
RO3 Develop a requirements specification that will guide the development of a decision support tool, drawing on 
the findings from RO1 and RO2. 
RO3.1 Conduct systematic literature reviews pertaining to (i) traditional PV systems, (ii) 
the MPP, (iii) HIV, TB and Hepatitis C, and (d) RLS, to identify any additional 
requirements that these factors would call for 
Chapter 4, Section 4.2 
RO3.2 Consider the developed challenges landscape as described in RO2, with respect to 
the identified requirements specification; as per RO3.1, to determine if additional 
requirements should be considered 
Chapter 4, Section 4.3 
RO3.3 Synthesise the requirements identified in RO3.1 and RO3.2 to develop a combined 
requirements specification that will guide the development of a decision support tool 
Chapter 4, Section 4.4  
RO3.4 Conduct a verification process to authenticate the developed requirements 
specification as stated in RO3.3.  
Chapter 4, Section 4.5 
RO4 Develop a decision support tool that facilitates the development of a context-specific PV systems within the 
context of the MPP. 
RO4.1 Identify possible intervention strategies that would address the requirements 
specification as discussed in RO3 
Chapter 5, Section 5.1  
RO4.2 Synthesise the intervention strategies identified in RO4.1 to develop the 
foundational features of the decision support tool 
Chapter 5, Section 5.2 
RO4.3 Develop the detailed decision support tool Chapter 6  
RO4.4 Validate the developed decision support tool to evaluate the applicability and 
practicability of the developed tool 
Chapter 7 
8.4 LIMITATIONS 
As this research inquiry investigated the niche setting of MPP drug provision systems, the 
outcomes are context-specific to these settings. Thus, the CVSIT was developed for the 
specific context of the niche factors, (i) traditional PV systems, (ii) MPP, (iii) HIV, TB and 
Hepatitis C, and (iv) RLS, which limits the operation of the tool.   
8.5 FUTURE WORK 
It is recommended that the following opportunities are explored as future research, as they 
build on the deliverables of this research investigation.  
The first recommendation is that the developed tool, the CVSIT, be amended with regard to 
the consideration of three different cases. Firstly, the tool could be adapted by including 
national PV requirements according to the specific country’s regulatory authority, i.e. the PV 
requirements mandated by SAPRHA for South Africa. During the CVSIT validation process, 
this recommendation was made, however it fell outside the scope of this study, as the aim was 




provision systems – and thus not limited by a specific country’s PV requirements. Thus, it is 
recommended that future investigations look at incorporating national PV guidelines, and how 
this would affect the operation and usability of the tool. 
During the CVSIT validation process, it was also established that the tool is not universal to 
all PV related project; however, it must be borne in mind that the tool was developed to assist 
specifically with the effective and efficient reporting of drug provision projects within the 
context of the MPP drug provision systems and that it is thus context-specific to these 
environments. However, it was also established that it can be applied to different environments 
if adaptations are made. Thus, it is recommended that future opportunities should explore the 
gaps in the tool when considering projects outside the present context, and identify 
opportunities to improve the CVSIT in these aspects. Furthermore, it is also proposed to follow 
a similar systematic thought process to investigate the development of an alternative, context-
specific PV system within the context of other environments, for instance by considering other 
disease burdens.  
Furthermore, the CVSIT offers a customised implementation strategy for a Vigilance System, 
with intervention strategies that are most appropriate and most suitable for a specific drug 
provision project. However, the CVSIT is only subsequent to the identification of such 
intervention strategies, and thus the financial, technical and operational feasibility of the 
intervention strategies should be pursued. This is an opportunity for future research to build 
on the CVSIT by identifying what further feasibility studies, i.e. financial, technical and 
operational, should be considered and conducted once a vigilance implementation plan has 
been developed for a specific project. 
During the validation process, a number of tools were identified that could be used to 
complement the CVSIT, such as the WHO PV toolkit, and the IPAT. To verify these findings, 
it is recommended that additional investigations should be conducted on the complementary 
use of these tools in real world situations by looking at additional case studies. Furthermore, 
it was confirmed during the validation process that a case study related to an existing drug 
project in the context of MPP drug provision systems should be looked at in order to truly 
validate the usability of the CVSIT in a real-world situation.  
In this research inquiry, a system engineering approach was used to develop a context-specific 
PV system, namely the Vigilance System, for the niche environment of MPP drug provision 
systems. This systematic approach addressed the needs of this specific environment and 
developed systems solution to address the challenges faced within these settings. The MPP 
drug provision systems represented an environment where factors such as the MPP, RLS and 
disease burden associated with the MPP (HIV, TB and Hepatitis C) had to be taken into 
consideration, and thus the tool is ideally developed for these environments; however, it is not 
exclusively applicable to these environments. Future investigations could thus verify the use 
of the CVSIT in other environments of different illnesses, patient groups and resources, for 
instance.  
8.6 CHAPTER 8 CONCLUSION  
This chapter concludes this research inquiry, which investigated the absence of adequate PV 




specific PV system – a Vigilance System that considers the relevant niche factors within this 
particular environment. In this chapter, an overview of the research was provided, and it 
discussed how the aim and objectives were achieved. The contributions made to the research 
were also included as well as suggestions for possible future work that could build on the 
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 Research outputs 
In this appendix the articles that have been written and published during the course of this 
research inquiry is included. The first document is titled “Developing a challenges landscape 
relating to drug safety, provision, and distribution in resource-limited settings for the case of 
HIV/AIDS” and is published in the South African Journal of Industrial Engineering Volume 
9, addition 3.  
The second document is titled “The case for a niche pharmacovigilance system relating to drug 
provision and distribution in resource limited settings “and can be found in the ICE conference 
proceedings in the IEEE Xplore Library. 
The following sections are included: 
A1: Article 1 - Developing a challenges landscape relating to drug safety, provision, and 
distribution in resource-limited settings for the case of HIV/AIDS 
A2: Article 2 - The case for a niche pharmacovigilance system relating to drug provision and 





 Article 1  -  Developing a challenges landscape relating to drug safety, 








HIV/AIDS, the majority of whom lived in low-middle income countries [2]. These factors, combined 
with strict drug patent laws, make the affordable supply of drugs in these countries problematic [3]. 
 
Thus in 2010 the UNITAID medicine patent pool (MPP)2 was established to improve access to the 
treatment of HIV, tuberculosis (TB), and hepatitis C by allowing access to specific drug patents [4], 
[5]. This innovation has played a significant role in addressing the HIV/AIDS epidemic from the 
perspective of access to medicine, as between 2005 and 2016 the proportion of patients receiving 
treatment increased from 6.9% to 53% globally [2]. However, the MPP has given rise to other 
challenges [6]. As multiple drug manufactures are allowed to access the drug patents, quality 
monitoring in these settings has to be very well-established. Such challenges are often attributed to 
inadequate local drug manufacturing and distribution systems [6]. 
 
However, when aiming to address specific challenges brought about by an intervention, as is the 
case with those arising from the MPP allowing any drug manufacturers access to patents, the context 
within which such a system exists has also to be considered. As mentioned earlier, the MPP only 
allows access to patents in low- and middle-income countries, which often have only limited 
resources. One example of limited resources in the sub-Saharan African region is the deficit of 24.8 
million doctors and nurses, resulting in 2.3 healthcare workers per 1000 people in Africa. This is 90% 
less than in the United States of America, where there are 24.8 healthcare workers per 1000 people 
[7]. In addition to the limited human resources in these countries, funding and opportunities for 
research and development are also limited [8]. Thus, when considering the challenges that arise 
through the implementation of the MPP, the context of limited resources should also be considered. 
 
These challenges in drug manufacturing and distribution in the context of resource-limited settings 
call for an effective, well-established drug monitoring and pharmacovigilance (PV)3 system to assist 
in improving patient safety. In order to develop such a PV system that will support, facilitate, and 
improve additional challenges brought on by inadequate drug manufacturing and distribution, the 
challenges need to be identified and understood to ensure that such a PV system overcomes them 
and does not give rise to any additional ones. It is also recognised that the current PV systems do 
not adequately support the unique MPP practices. This highlights the need for a PV system to support 
the unique needs of drug monitoring in such a setting, and to provide evidence that warrants the 
deployment of a PV system to support effective drug monitoring. In order to develop the 
characteristics of such a ‘niche PV system’4, a requirement specification will have to be developed. 
This requirement specification will be based partly on the insights gained from evaluating the 
challenges and incorporating best practices, current PV requirements, and the ability of the PV 
system to function in such a setting. A niche PV system can then be designed either by transforming 
the traditional PV system or by transitioning to a new PV system using the developed requirement 
specification. 
 
This paper, however, will focus on the challenges posed by drug manufacturing and distribution 
systems within resource-limited settings, which will be incorporated into the requirement 
specification for PV systems for such a setting. These challenges will be identified by conducting a 
systematic review, after which they will be arranged into a challenges landscape to understand the 
system perspective. Due to the high prevalence of HIV in South Africa, this research inquiry will 
consider challenges that arise with the roll-out of antiretrovirals (ARVs) [2].  
2 CONTEXTUALISATION: MPP DRUG SAFETY, MANUFACTURING, AND DISTRIBUTION IN 
RESOURCE-LIMITED SETTINGS 
Due to the growing number of HIV/AIDS patients without treatment in low- and middle-income 
countries, it was evident that an innovative way to provide antiretroviral treatment (ART) had to be 
                                                      
2  MPP is an initiative which allows any manufacturer to access the available patents and manufacture drugs; 
thereby aiming to decreasing lead time and costs associated with these drugs. 
3  ‘Pharmacovigilance’ is defined as the science and application of the detection, assessment, and monitoring 
of adverse drug reactions after drugs have been licensed for use.  
4  In this research inquiry, ‘niche PV system’ refers to a PV system that is designed for a specific population, 
implying a specific region and a specific drug. Such a PV system will most likely operate and be managed 





implemented [2], [3]. One of the reasons that very few HIV/AIDS patients did not receive treatment 
was the high prices for treatment caused by the patent system, in which a company had the 
monopoly over a particular drug. ARVs also have to be taken in combination with other drugs, each 
with their own patent; and this also resulted in very high prices [3].  
 
Thus, in 2010 the MPP was established by UNITAID to increase access to treatments for specific 
communicable diseases such as HIV, hepatitis C, and TB in low- and middle-income countries through 
sharing technologies and patents [4]. A patent pool is defined as a collaboration between patent 
holders and other third parties, where licences are offered for use in exchange for a fixed price or 
royalties. The implementation of a medicine patent pool makes the production and distribution of 
drugs accessible to a broader population at a faster rate and at more affordable prices [3]. The WHO 
assist the MPP by prioritising the medicines that were required, and patent holders voluntarily 
agreed to license their medicines to the MPP, which in turn issued generic pharmaceutical companies 
with licence rights to manufacture these medicines.  
 
The implementation of MPP has many advantages, such as facilitating competition, improving low-
cost manufacturing, and encouraging research and development (R&D) [3], [9]–[11]. Through the 
implementation of the MPP, competition is facilitated because multiple drug manufacturing 
companies can access the same patents. As competition between manufacturers increases, drug 
prices drop, making drugs more affordable [9]. Through the MPP, low-cost manufacturing companies 
are also able to approach the patent pool to negotiate licensing agreements to create generic 
versions of these drugs [3]. As mentioned earlier, antiretroviral drugs need to be taken in 
combination with other drugs in order to be effective [3]. However, the patent pool encourages R&D 
and innovation for the treatment of HIV/AIDS, as the patents for the drugs are accessible and can 
be used for new fixed-dosage combinations [3], [10]. The manufacturing companies are given the 
flexibility to develop new and appropriate formulations and fixed-dosage combinations to meet the 
specific needs of patients. Often the drugs are not adapted for use in developing countries — as in 
the case of paediatric treatments, as virtually no children are affected by HIV/AIDS in developed 
countries [9]–[11]. 
 
However, certain challenges arise when considering the provision of access to medicine through the 
MPP, such as local manufacturing, distribution, R&D, sub-standard medicines, and other regulatory 
issues [6]. The patents are available to any drug manufacturing companies in low- and middle-
income countries that wish to make use of them; and although the manufacturers need to meet 
certain quality standards, it is often difficult to monitor the quality process of these drugs. Research 
found that, although the MPP does not directly cause any difficulties, the drug manufacturing and 
distribution system in these settings, made possible through the MPP, produces numerous challenges 
[12], [8].  
 
In section 3, the different challenges that arise due to inadequate manufacturing and distribution 
systems in resource-limited settings will be identified through a systematic review, after which they 
will be discussed before developing a challenges landscape. 
3 CHALLENGES POSED BY DRUG MANUFACTURING, DELIVERY, AND RESOURCE-LIMITED 
SETTINGS 
As previously mentioned, the challenges that arise in the manufacturing and distribution of drugs 
for which patents are made available through the MPP can be attributed to inadequate drug 
manufacturing and distribution systems [6], [12]. These challenges affect patient safety, and so 
need to be addressed to ensure that the necessary monitoring systems are in place. The low- and 
middle-income countries that access the MPP also often have limited resources, which further 
complicates the challenges [7]. 
 
In this section, the aim is to identify the challenges arising from drug manufacturing and distribution 
systems in resource-limited settings in developing countries. Once these challenges have been 
identified through a systematic review, a challenges landscape can be developed to indicate the 
system perspective, which will contribute to the development of the requirement specification for 










Figure 1: Process of systematic review 
3.2 Results 
Once the systematic review had been completed, the different challenges posed by inadequate drug 
manufacturing and distribution systems, and the challenges posed by limited resources, could be 
identified and listed. From the literature the following 19 factors were identified: 
 
 Drug dosages 
 Labelling & packaging 
 Specialised drugs 
 Traditional medicines 
 Paediatric drugs 
 Drug resistance 
 Drug quality 
 Counterfeit drugs 
 Substandard drugs 
 Record-keeping 
 Adverse drug reactions (ADR) 
 Drug-drug interactions 
 Drug adherence  
 Drug supply 
 Drug shortages 
 Drug stock-outs 
 Late ART initiation 
 Lack of safety reporting 
 Integrity of system 
Table 2: Overview of occurrences in systematic review 
 
 
From the data provided in Table 2, a number of trends seem to emerge, as some challenges are only 
mentioned in more recent years. For example, labelling, specialised drugs, drug-to-drug 





































2010 X X X X X X X X X XX X X
2011 X X X X X X X X X X X X X X X X
2012 X X X X
2013 X X X X X X X X X X X X X 
2014 X X X X X X X X X X X X X X
2015 X X X X X X
2016 X X X X X X X X X X X X
2017 X X X X X X
Total 3 3 3 3 2 4 3 2 13 9 8 4 4 4 3 5 5 4 2
Each X represents a document 
Occurrences of challenges in systematic review
Date
RLSDrug Manufacturing Combination of manufacturing, distribution and RLS
Combination of 
distribution and RLS
1870 articles identified after duplicate 
articles removed. 
Exclude 
Articles before 2010 
Articles translated 
Articles not available as full text 
1187 articles for screening of titles and 
abstracts. 
Exclude articles that are not relevant to: 
 
Drug manufacturing OR 
Drug distribution OR 
Resource-limited setting OR 
Challenges in HIV settings  
80 articles: introduction, main points, and 
conclusion examined for relevance. 
41 relevant articles found. 
Exclude articles that are not relevant to: 
 
Drug manufacturing OR 
Drug distribution OR 
Resource-limited setting OR 
Challenges in HIV settings 
48 articles to be examined to determine 
challenges. 
Seven relevant articles retrieved from PubMed using informal 






such as drug shortages and drug resistance have not appeared in the literature in recent years. From 
Table 2 it can also be seen that certain challenges have occurred more constantly over the last eight 
years, such as ADR and quality challenges.  
3.3 Defining challenges 
The 19 factors that were identified in the systematic review have a specific impact on the 
pharmaceutical and healthcare systems. These challenges are defined and explained in the next 
sub-section. 
3.3.1 Adverse drug reactions  
According to the WHO, an ADR is defined as “any response to a drug which is noxious and unintended, 
and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease, or 
for the modification of physiological function” [13]. ADRs can affect the treatment process and have 
negative effects on patients’ quality of life, especially for HIV-infected patients on ART. Serious ADR 
often causes patients to stop taking drugs, leading to a lack of drug adherence or to treatment 
failure, which negatively impacts patients and society. ADRs are also often a cause of re-admission 
to a hospital, aggravating the health care burden in resource-limited settings [14]–[19]. It has also 
been shown that ADRs have been found to be preventable, justifying the need to improve 
pharmacovigilance. The early detection of ADRs is also pivotal when ensuring the sustainability and 
optimisation of a treatment process. However, it has been reported that detection, especially in 
paediatric treatments, is difficult [20]. Furthermore, through the MPP, multiple drug manufacturers 
are able to produce generic drugs and new fixed-dosage combinations, making it critical that ADRs 
in HIV patients are monitored carefully [14], [18], [19]. 
3.3.2 Drug adherence 
‘Drug adherence’ refers to patients keeping to the recommendations made for the dosage, timing, 
and frequency of taking their medication. With regard to ART, it is said that 95% drug adherence is 
required to ensure that patients do not develop resistance or suffer from treatment failure [21]. 
From the literature consulted, it has been determined that non-adherence in ART is caused by a 
range of different factors; but one of the main causes is ADR [17], [18], [22]. However, studies in 
developing countries have also indicated that other factors contribute to non-adherence, such as 
dissatisfaction with the healthcare system, perceived stigmas, distance to ART clinics, limited social 
support, poor record-keeping, the attitude of healthcare workers, and certain personal factors [23], 
[17], [21]. Studies do indicate, however, that adherence can be improved with peer counselling and 
education [24].  
3.3.3 Quality 
Ensuring that the drugs that patients take are safe and effective is one of the priorities of the 
pharmaceutical industry, and it needs to be continuously addressed throughout the process. Many 
different aspects, such as good manufacturing practices, quality monitoring, and drug plant 
characteristics contribute to low-quality drugs. It has been found that, in low income countries, the 
quality of drugs is often inconsistent; thus proper quality control should be assessed more often, 
especially when new drug manufacturers are used [25]–[27]. Another aspect to consider when 
addressing drug quality is the production of generic drugs, which is promoted through the MPP. 
Generic drug manufacturing and the production of fixed-dosage combinations challenge the existing 
system, as the different areas of responsibility are misunderstood [28], [23]. 
3.3.4 Lack of reporting 
Limited human resources in developing countries contribute to the lack of reporting of ADRs, 
especially in public HIV healthcare systems. Most low- and middle-income countries have inadequate 
legislation for mandatory reporting by health care professionals [29], [30], [31]. Furthermore, it has 
been found that the severity and preventability of ADRs are often under-reported in developing 
countries, possibly due to inadequate healthcare resources and knowledge among healthcare 
workers in these regions [14]. 
3.3.5 Record-keeping 
Medical health records are essential to health care providers, as they contain specific information 
about a patient, such as their unique patient identifiers and medical history. Medical health records 
contain vital information about a patient’s health, and are needed for their current and future 
treatment. Health care providers are required to write up health records so that the information is 






in developing countries that effective record-keeping is a challenge [31], [34]. Healthcare providers 
mention that patients’ records are often lost, resulting in the loss of all previous data, and 
sometimes even leading to certain medical procedures being repeated [21]. This therefore underpins 
the need for effective record-keeping systems, such as electronic health records.  
3.3.6 Counterfeit drugs 
The WHO describes counterfeit or falsified drugs as “medical products that deliberately/ 
fraudulently misrepresent their identity, composition or source” [35]. The WHO also states that 
counterfeit drugs can be branded or generic drugs that contain the incorrect ingredients, or none at 
all, or inadequate amounts of active ingredients, or that are falsely packaged [36]. The health of 
patients who receive counterfeit drugs is threatened, as they are at risk of developing ADR or drug 
resistance [23], [27], [28], [37]. Counterfeit drugs are often a concern in areas where there is a 
shortage of drugs, or drug manufacturing and distribution systems are not registered [23], [38].  
3.3.7 Drug-drug Interactions 
The interaction between ARVs and other drugs is often harmful to a patient’s treatment procedure. 
ARVs are often co-administered with antitubercular medication; however, this often leads to a 
higher frequency of drug-induced liver incidents and peripheral neuropathy. Thus TB/HIV co-
infected patients’ treatment should be managed more carefully. ‘Drug-drug interaction’ is defined 
as a change in the effect of the drug when it is taken together with another drug, and it can often 
lead to ADR [39]. The use of traditional medicines has also given rise to challenges in drug-drug 
interactions [23]. 
3.3.8 Drug supply 
In developing countries, drug supply has often been a concern, especially for illnesses such as TB 
and HIV/AIDS, whose treatment requires a strict regime to be effective. Furthermore, when limited 
amounts of ART are available, ethical issues often arise about how the medication should be 
prioritised for different patients [23]. Delays in drug delivery in resource-limited settings are often 
caused by poor infrastructure such as poor roads and by financial burdens such as a lack of funding 
for fuel [37], [40]. The challenges posed by poor drug supply involve all aspects of the supply chain, 
from ordering systems to the storage and distribution of drugs. Case studies on weak ARV supplies 
in South Africa found that they were often caused by poor communication between provincial 
districts and facilities or between the consumer and the facilities. Studies have shown that supply 
systems that rely on consumer ordering affect shortages [41].  
3.3.9 Late ART initiation 
From the literature it has become evident that the need to ensure that people start their treatment 
during the early phases of the disease is just as important as ensuring that patients receive treatment 
[42]. Although there is no clear definition of just when it is ‘late’ for a patient to start ART, it can 
be deduced that it is when a patient’s CD4 count is very low (CD4 <50 cells/μL). Patients who initiate 
late ART have a higher risk of opportunistic infections than patients who start treatment at a higher 
CD4 count, with TB being the most common illness [43], [44]. From previous studies, the causes of 
late ART initiation can be grouped into health system-related issues, socio-economic obstacles, or 
inappropriate treatment criteria [44].  
3.3.10 Substandard drugs 
The WHO defines substandard drugs as “authorized medical products that fail to meet either their 
quality standards or specifications, or both” [35]. A drug is thus regarded as a substandard drug if it 
contains too many or too few active ingredients in comparison with the formulation specifications. 
However, there have been substandard drugs that were toxic in nature or that contained fatal levels 
of toxic ingredients. Substandard drugs are often found in poorer settings with manufacturing and 
distribution systems that use unqualified personnel and inadequate control systems. Substandard 
drugs are more frequently found, and pose a greater threat to patients than counterfeit drugs [27], 
[36]. 
3.3.11 Dosages 
Taking the correct dosage when on ART is important, since taking an incorrect dosage leads to there 
being an inadequate amount of the drugs to fight the virus. Often, when tablets are split, asymmetry 
results in an unproportioned dosage of the ARV drugs. Furthermore, it cannot be assumed that the 






3.3.12 Drug resistance 
Drug resistance is when the response to a drug in a susceptible parasite population decreases 
significantly [46]. According to studies by the WHO, it was found that in 2010 the prevalence of HIV 
drug resistance for patients starting treatment was 6.8% for any drug, and that the treatment of 
these patients was more likely to fail [47], [48]. Drug resistance leads to further challenges relating 
not only to the patient’s own future treatment, but also to the whole community [25].  
3.3.13 Drug stock-outs 
The WHO defines a drug stock-out as the total absence of a medication that has been identified as 
essential at the point of service delivery [49]. Drug stock-outs are often the result of poor 
infrastructure and insufficient human resources [40], [50]. Although alternative ARTs are often 
provided in the case of a stock-out, it still poses the threat of drug resistance, as it might cause 
suboptimal drug levels [34]. It has been reported that one-third of countries worldwide struggle with 
drug stock-outs, thus increasing the risk of treatment failure and failed drug adherence [30], [34], 
[51]. To ensure that stock-outs do not occur, it is critical that ART programme planning and rational 
forecasting processes are in place [30]. 
3.3.14 Paediatric drugs 
The need for paediatric antiretroviral drugs is much higher in low- to middle-income countries, as 
developed countries have significantly reduced the mother-to-infant HIV rate. Furthermore, the use 
of adult ART for children is seen as ineffective, as children absorb and metabolise drugs differently 
than do adults. Through the MPP, drug manufacturers in developing countries can develop innovative 
fixed-dosage combinations specifically for paediatric use. However, when developing paediatric 
drugs, the palatability, taste, size, dosages, formulation, and ease of handling or administration of 
the drugs should be considered [45], [52].  
3.3.15 Specialised drugs 
In developing countries, certain specialised drugs are manufactured to specific contextual criteria. 
Two examples of such drugs that occur in the HIV treatment context are paediatric antiretrovirals 
and the use of traditional medicines. This is often the case in countries that are part of the MPP, as 
the patents often only cater for  a developed country’s needs [53], [45]. 
3.3.16 Traditional medicines 
Many cultural and social differences that further complicate HIV/AIDS treatment in developing 
countries need to be considered, one being the increasing production and use of traditional 
medicines [54]. The increased production of these medicines raises issues of quality control, 
although intercultural standards are being developed for traditional medicines. Aspects to consider 
in relation to quality control are the use of raw materials, the knowledge of the manufacturers, and 
the lack of general safety studies [55]–[57].  
3.3.17 Drug shortages 
A drug shortage is defined by the WHO as the insufficient supply of medication or health products 
to meet the public’s and patients’ needs [49]. The drugs that are often affected by shortages are 
produced by smaller generic companies with little redundant capacity, which complicates the 
situation with production problems [58]. Previous case studies showed that patients who were on a 
waiting list for ART often died due to drug shortages. However, drug shortages can be prevented if 
there are sufficient resources to inspect and approve new drugs and ensure the quality of drugs. It 
has also been predicted that reducing the number of reviews and speeding up inspections would 
help to avoid shortages [59].  
3.3.18 Integrity of system 
The support, integrity, and confidentiality of health care workers has been seen to have an impact 
on ART. From the literature it has been found that HIV patients’ distrust of and dissatisfaction with 
the healthcare system can lead to serious problems such as late treatment initiation or poor drug 
adherence, which often result in drug resistance or treatment failure. Healthcare workers who are 
supportive will motivate patients to take their ARVs, and educate them about the consequences and 
benefits of keeping to the treatment programme [21], [44],[60]. A case study [44] revealed that HIV 
patients often do not seek treatment, as they know that the healthcare staff often discuss their 
status — which is a very sensitive topic — in public. The compassion and support of healthcare 






Mislabelling drugs can have a severe impact on a patient’s safety, and can be more harmful for 
them. According to the WHO, labelling on drugs needs to contain the names and amount of the 
active ingredients, the batch number from the manufacturer, the expiry date, the name and address 
of the manufacturer, any storage instructions, and directions for use. It is particularly important 
that the directions and guidelines for use are clearly indicated [61].  
4 CHALLENGES LANDSCAPE 
As previously mentioned, the challenges that were identified in section 3 were found to relate to 
one another and to have an impact on one another. It was also established that challenges could 
have (possibly different) impacts on the various parts of the pharmaceutical value chain. Thus, an 
overview of the ‘challenges landscape’ is developed here to gain a holistic view of the challenges 
that face the drug manufacturing and distribution systems in relation to the provision of drug patents 
through the MPP. The challenges landscape will serve as a guide to determining any shortcomings in 
the traditional PV system by developing a requirement specification for a (niche) PV system that will 
support effective and efficient drug surveillance and monitoring. However, the development of the 
requirement specification falls outside of the scope of this paper; the key focus of this paper is, as 
mentioned earlier, to develop a challenges landscape to understand the system perspective in these 
settings.  
 
The pharmaceutical value chain framework used for the purpose of this study has four sections: 
supply, distribution, product, and health system [62]. The ‘supply’ section is then sub-divided into 
‘drug development’ and ‘manufacturing’, while the ‘health system’ section is split into ‘patient 
usage’ and ‘monitoring systems’ [62].  
 
The challenges landscape, as discussed in the sections that follow, is discussed from three 
perspectives: firstly, the relationships between the various challenges are considered and presented 
in a relationship diagram; secondly, the relationship diagram, the pharmaceutical value chain 
framework, and the various challenges are amalgamated and presented in a schematic 
representation of the challenges landscape; and thirdly, the linkages and groupings presented in the 
schematic representation of the challenges landscape are elaborated on. 
4.1 Relationship diagram & schematic representation of the challenges landscape 
In Figure 2 the respective relationships between the challenges are indicated. These relationships 
were not necessarily explicitly mentioned in the literature, but after synthesising the information 
gathered through the systematic literature review, certain correlations and relationships between 
the different challenges could be identified. The relationships indicated in Figure 2 are grouped so 
as to indicate the impact a relationship has on a specific section of the pharmaceutical value chain. 
These sections of the value chain are distinguished in the key provided in Figure 2. In the case where 
a relationship has an impact on more than one section, both are indicated. The relationship diagram 
was used as an aid to create the challenges landscape. Schematic representation of the challenges 
landscape 
 
Using the relationship diagram in section 4.1 and the information from section 3, a challenges 
landscape (Figure 3) was developed to indicate the inter-relationships and impacts between the 
different challenges, and their relationships with the different stages of the pharmaceutical value 
chain.  
 
As seen in the schematic representation, the pharmaceutical chain is subdivided into four sections: 
supply, distribution, product, and health system. The challenges are in three main groups, referred 
to as A1-A3. They are formed when considering the systematic review and the causes of the 
challenges — namely, drug manufacturing and distribution in resource-limited settings. A1 refers to 
challenges due to inadequate manufacturing and distribution systems; A2 to challenges due to 
quality issues in drug manufacturing and distribution; and A3 to challenges due to limited resources. 
These challenges are grouped in subsections within these main groups; these sub-groupings, C1–C8, 
































































































































































































































































































































































































































































































































































































































































































































































































































Table 3: Explanation of groupings of different challenges  










In low- and middle-income countries, the development and manufacturing 
of drugs often requires the creation of drugs for specific needs of patients, 
referred to as ‘specialised’ drugs. In the case of HIV, the two specialised 
drugs that are most often found are paediatric drugs and traditional 
medicines [53], [45]. These challenges mostly appear in the phases of drug 
development and manufacturing. Furthermore, it is seen that traditional 








The identified quality challenges have been shown to have an impact on 
the supply side of the value chain. Drug manufacturing companies have to 
have quality systems in place to ensure that the drugs they manufacture 
are safe and effective, and will not harm patients [26], [27]. Inadequate 
quality systems in drug manufacturing companies further complicate 
challenges such as drug dosage and labelling. If drug manufacturing 
companies do not have quality systems in place, the drugs dosages are 
often not adequate, as the ingredients are not distributed evenly [45]. The 
labels are often also incorrect. These challenges cause further problems 
with patient safety [61].  
C3 Distribution 
Drug supply, drug 
shortages, drug 
stock-outs 
In the drug distribution part of the value chain, drug supply in low- and 
middle-income countries is one of the major concerns that is further 
affected by limited resources in these settings. As mentioned, many 
factors affect drug supply, from poor infrastructure to factors in the supply 
chain such as ordering systems [41]. The problems in drug supply create 
difficulties such as drug shortages and drug stock-outs. These lead to 
problems with patient safety, since shortages and stock-outs often are the 







Of the challenges that were identified, drug-drug interaction is one that 
arises in the final product stage of the value chain. As mentioned, ARVs 
often have to be taken in combination with other drugs, which can lead to 
negative drug-drug interactions. It has also been found that traditional 
medicines, which are often used in low- and middle-income countries, 
have an effect on drug-drug interactions [23]. Drug-drug interactions often 
also cause serious side effects and ADRs [39]. As previously mentioned, 
ADRs often have an effect on a patient’s treatment process, as serious 
ADRs can impact a patient’s adherence to the treatment, since they often 
stop taking their medications due to ADRs [21]. This inevitably affects not 
just the patient but the community as a whole. Drug adherence implicates 







The quality of the final product is reduced by ineffective manufacturing 
and distributions systems [27], [28]. Drugs of inauspicious quality often 
lead to counterfeit drugs or sub-standard drugs. These challenges are 
mostly caused by a lack of quality in the drug supply process, and can 
seriously affects patient safety. Furthermore, counterfeit drugs often lead 
to serious ADR or drug resistance [23], [27], [28], [37].   
C6 Patient usage Drug resistance 
Drug resistance is one of the challenges in the HIV setting that is 
associated with patient usage. Although drug resistance is not grouped 
together with other challenges, many factors impact on and lead to drug 
resistance. From the identified challenges, the biggest contributors to drug 
resistance are drug delivery, shortages, stock-outs, and poor drug 
adherence [34], [42]. Furthermore, drug resistance is complicated by 
inadequate drug monitoring systems, such as the low integrity of a health 
system and poor record-keeping [21], [44].    
C7 Monitoring 
Integrity of the 
health system, 
record-keeping 
system, late ART 
initiation 
In monitoring — the final stage of the drug value chain — many challenges 
arise from limited resources. The poor integrity of the health care system 
and the lack of effective record-keeping are two of the contributing 
factors for late ART initiation. Late ART initiation can be very detrimental 
to patient care, and often leads to unnecessary deaths. Furthermore, the 
lack of effective record-keeping and dissatisfaction with the health care 
system affects drug adherence, which again leads to drug resistance [44].  
C8 Monitoring Lack of reporting 
The lack of reporting during ART is one of the major challenges in 
resource-limited settings during the monitoring stage of the value chain. As 
mentioned, preventable ADRs have often been found to be under-reported, 
leading to further complications such as poor drug adherence and drug 
resistance [14].  
4.3 The need to investigate the development of a niche PV system 
Given the challenges landscape discussed above, the three perspectives — the relationships between 
the various challenges, the schematic representation of the challenges landscape, and the discussion 
on the linkages and groupings — lead to a comprehensive understanding of and insight into the 





in settings with limited resources. From this challenges landscape, it is evident that there are 
shortcomings in the current (traditional) PV systems, as the challenges faced in these settings are 
not considered or incorporated when developing and designing the requirements and characteristics 
of a traditional PV system [63].  
 
Thus, the challenges landscape highlights the need for an innovative PV system, such as a niche PV 
system, not only to support, facilitate, and improve the manufacturing and distribution of drugs and 
to address the challenges faced in these settings, but also to ensure that such a PV system will not 
create any additional problems or reinforce existing ones. The insights gained from the challenges 
landscape will assist with the development of a requirement specification for such a niche PV system 
that will address the current shortcomings in drug surveillance and monitoring in these settings. 
5 CONCLUSION AND FURTHER RESEARCH 
The challenges that arise in the manufacturing and distribution systems of drugs whose patents are 
made available through the MPP were discussed in this article. The challenges specifically related 
to developing countries, and challenges faced within the HIV/AIDS setting, were considered. It was 
determined that these challenges complicate different stages of the pharmaceutical value chain, 
and thus an innovative PV system is required to address these challenges.  
 
The challenges landscape developed in this paper is a useful tool that indicates the relationships 
from a system perspective. Furthermore, the challenges landscape and the insights gained from it 
can be used in combination with other elements that relate to drug surveillance monitoring, such as 
best practices and current PV characteristics, to develop a requirement specification for an effective 
PV system in these settings.  
 
In conclusion, this paper highlights the need for an innovative PV system, such as a niche PV system 
for a specific region and specific drug, to address and possibly eliminate the challenges that are 
faced in these settings, and to increase the effectiveness and efficiencies of such systems, given 
their unique characteristics. The insights gained from this paper will be considered when designing 
a niche PV system by transforming or transitioning from the traditional PV system. 
REFERENCES 
[1] Rohrbach, M.. 2017. The decline of the traditional pharmaceutical business model - Expert blog. [Online]. 
Available: https://blog.kpmg.ch/decline-traditional-pharmaceutical-business-model/. [Accessed: 16-Apr-
2018]. 
[2] Sidibé, M. 2017. Global HIV and AIDS statistics. AVERT. [Online]. Available: https://www.avert.org/global-
hiv-and-aids-statistics. [Accessed: 16-Apr-2018]. 
[3] Modell, N. 2003. Swallow the pill and jump in the patent pool - A study into how an HIV/AIDS patent pool 
would result in cheaper drugs and increase. Intellectual property Dissertation. University of Kent. 
[4]  Medicines Patent Pool. n.d. Who we are - MPP  [Online]. Available: https://medicinespatentpool.org/. 
[Accessed: 21-May-2018]. 
[5] Medicine Patent Pool. n.d. What we do — MPP. [Online]. Available: 
https://medicinespatentpool.org/what-we-do/. [Accessed: 21-May-2018]. 
[6] Burrone, E. Global cooperation for IP and development - presentation. [Online]. Availiable: 
https://slideplayer.com/slide/10673957/. [Accessed: 17-Apr-2018]. 
[7] Naicker, S., Plange-Rhule, J., Tutt, R.C. and Eastwood, J.B. 2009. Shortage of healthcare workers in 
developing countries — Africa. Ethn Dis, vol. 19, pp. 160 - 164. 
[8] T’Hoen, E., Berger, J., Calmy, A. and Moon, S. 2011. Driving a decade of change: HIV/AIDS, patents and 
access to medicines for all. J. Int. AIDS Soc., vol. 14, no. 1, pp. 1–12. 
[9] Medicine Patent Pool. 2012. WHO submission to the UN SG High Level Panel on access to medicines. 
Geneva: World Health Organization. 
[10] UNITAID. 2010. UNITAID launches patent pool for HIV / AIDS drugs. Bridges, vol. 14, no. 21, pp. 2–3. 
[11] Medicines Patent Pool. 2012. The medicines patent pool - Stimulating Innovation, Improving Access. 
Geneva: World Health Organization. 
[12] Taylor, R.B. et al., 2011. The UNITAID patent pool initiative: Bringing patents together for the common 
good, Open AIDS J., vol. 2, no. 2, pp. 214–219.  
[13] World Health Organization (WHO). 2002. Safety of medicines, Br. Med. J., vol. 4, no. 5834, p. 192  
[14] Angamo, M.T., Chalmers, L., Curtain, C.M. and Bereznicki, L.R.E. 2016. Adverse-drug-reaction-related 
hospitalisations in developed and developing countries: A review of prevalence and contributing factors, 







[15] Mouton, J.P. et al., 2016. Adverse drug reactions causing admission to medical wards: A cross-sectional 
survey at 4 hospitals in South Africa, Med. (United States), vol. 95, no. 19, pp. 1–10.  
[16] Masenyetse, L.J., Manda, S.O.M. and Mwambi, H.G. 2015. An assessment of adverse drug reactions among 
HIV positive patients receiving antiretroviral treatment in South Africa, AIDS Res. Ther., vol. 12, no. 1, pp. 
1–8.  
[17] Syed, I.A., Sulaiman, S.A.S., Hassali, M.A. and Lee, C.K.C. 2014. Adverse drug reactions and quality of 
life in HIV/AIDS patients: Advocacy on valuation and role of pharmacovigilance in developing countries, 
HIV AIDS Rev., vol. 14, no. 1, pp. 28–30.  
[18] Tetteh, R.A. et al., 2016. Association between the occurrence of adverse drug events and modification of 
first-line highly active antiretroviral therapy in Ghanaian HIV patients, Drug Saf., vol. 39, no. 11, pp. 1139–
1149.  
[19] Manickum, V.K. and Suleman, F. 2012. Evaluating adverse drug reactions among HAART patients in a 
resource constrained province of South Africa, African J. AIDS Res., vol. 11, no. 2, pp. 75–81.  
[20] Impicciatore, P., Choonara, I., Clarkson, A., Provasi, D., Pandolfini, C. and Bonati, M. 2001. Incidence 
of adverse drug reactions in paediatric in/out-patients: A systematic review and meta-analysis of 
prospective studies., Br. J. Clin. Pharmacol., vol. 52, no. 1, pp. 77–83.  
[21] Bezabhe, W.M., Chalmers, L., Bereznicki, L.R., Peterson, G.M., Bimirew, M.A. and Kassie, D.M. 2014. 
Barriers and facilitators of adherence to antiretroviral drug therapy and retention in care among adult HIV-
positive patients: A qualitative study from Ethiopia, PLoS One, vol. 9, no. 5.  
[22] Oguntibeju, O.O. 2012. Quality of life of people living with HIV and AIDS and antiretroviral therapy, 
HIV/AIDS - Research and Palliative Care, vol.4, pp. 117–124.  
[23] Maponga, C.C., Ma, Q., Slish, J.C. and Morse, G.D. 2007. HIV pharmacotherapy issues , challenges , and 
priorities in sub-Saharan African countries, Top HIV Med., vol.15, no. 3, pp 104 -110. 
[24] Haberer, J.E. et al., 2017. Review article: Improving antiretroviral therapy adherence in resource-limited 
settings at scale : A discussion of interventions and recommendations, Journal of the International AIDS 
Society, vol. 20, pp. 1–15.  
[25] Houston, S. 2002. Justice and HIV care in Africa — Antiretrovirals in perspective, JIAPAC, vol. 1, no. 2, pp. 
46–50.  
[26] Stevens, W., Gous, N., Ford, N. and Scott, L.E. 2014. Feasibility of HIV point-of-care tests for resource-
limited settings: Challenges and solutions, BMC Med., vol. 12, no. 173, pp. 1–8.  
[27] Djobet, M.P.N., Singhe, D., Lohoue, J., Kuaban, C., Ngogang, J. and Tambo, E. 2017. Antiretroviral 
therapy supply chain quality control and assurance in improving people living with HIV therapeutic 
outcomes in Cameroon, AIDS Res. Ther., vol. 14, no.19  pp. 1–8.  
[28] Miller, V., Nwokike, J. and Stergachis, A. 2012. Pharmacovigilance and global HIV / AIDS, Curr. Opin. HIV 
AIDS, vol. 7, no. 4, pp. 299–304.  
[29] Ampadu, H.H. et al., 2016. Adverse drug reaction reporting in Africa and a comparison of individual case 
safety report characteristics between Africa and the rest of the world: Analyses of spontaneous reports in 
VigiBase®, Drug Saf., vol. 39, no. 4, pp. 335–345.  
[30] Tassie, J., Bertagnolio, S. and Souteyrand, Y. 2011. Integrated surveillance of HIV care in low-income 
and middle-income countries, Curr. Opin. HIV AIDS, vol. 6, pp. 233-238.   
[31] Olsson, S., Pal, S.N., Stergachis, A. and Couper, M. 2010. Pharmacovigilance activities in 55 low- and 
middle-income countries, Drug Saf, vol. 33, no. 8, pp. 689–703.  
[32] World Health Organization. 2006. Medical records manual : A guide for developing countries.Geneva: 
World Health Organization.  
[33] Rachlis, B. et al., 2016. Targeted spontaneous reporting: Assessing opportunities to conduct routine 
pharmacovigilance for antiretroviral treatment on an international scale, Drug Saf., vol. 39, no. 10, pp. 
959–976.  
[34] Fokam, J. et al., 2013. Declining trends in early warning indicators for HIV drug resistance in Cameroon 
from 2008 – 2010: Lessons and challenges for low-resource settings, BMC Public Health, vol.13, no. 308, 
pp. 1–10.  
[35] World Health Organization. 2017. Executive Summary: WHO Global Surveillance And monitoring system 
for Substandard and Falsified Medical Products. Switzerland: World Health Organization. 
[36] Johnston, A. and Holt, D.W. 2013. Substandard drugs: A potential crisis for public health. Br. J Clin. 
Pharmacol, vol. 78, no. 2, pp. 218-243. 
[37] Nsimba, S.E.D. 2009. Anti-retroviral (ARV) rationing schemes in developing countries: a review article on 
strategies and ethical issues related to the successes and failures of ARVprogrammes, East African journal 
of public health, vol. 6, no. 2, pp. 220–225.  
[38] Siva, N. Tackling the booming trade in counterfeit drugs, Lancet, vol. 376, no. 9754, pp. 1725–1726. 
[39] 12[Accessed: 25-Apr-2018]. 
[40] Nilseng, J., Gustafsson, L.L., Nungu, A., Bastholm-rahmner, P., Mazali, D. and Pehrson, B. 2014. A 
cross-sectional pilot study assessing needs and attitudes to implementation of Information and 
Communication Technology for rational use of medicines among healthcare staff in rural Tanzania, BMC 
Medical Informatics and Decision Making, vol.14, no. 78, pp. 1-12. 
[41] Steyn, F. et al., 2009. Scaling up access to antiretroviral drugs in a middle-income country: Public sector 
drug delivery in the Free State, South Africa, AIDS Care, vol. 21, no.1, pp. 1-6. 
[42] Ford, N., Calmy, A. and Mills, E.J. 2011. The first decade of antiretroviral therapy in Africa, Globalization 






[43] Lahuerta, M.M., Ue, F., Hoffman, S., Elul, B., Kulkarni, S.G., Wu, Y., Nuwagaba-Biribonwoha, H., 
Remien, R.H., El Sadr, W. and Nash, D. 2013. The problem of late ART initiation in sub-Saharan Africa: A 
transient aspect of scale-up or a long-term phenomenon?, J. Heal. Care Poor Underserved, vol. 24, no.1, 
pp. 359-383.  
[44] Muhamadi, L. et al., 2010. Inadequate pre-antiretroviral care, stock-out of antiretroviral drugs and stigma: 
Policy challenges / bottlenecks to the new WHO recommendations for earlier initiation of antiretroviral 
therapy ( CD < 350 cells /   L ) in Eastern Uganda, Health Policy, vol. 97, no. 2–3, pp. 187–194.  
[45] Phelps, B.R. and Rakhmanina, N. 2011. Antiretroviral drugs in paediatric HIV-infected patients: 
Pharmacokinetic and practical challenges, Pediatr. Drugs., vol. 13, no. 3, pp. 175–192.  
[46] Keiser, J. and Utzinger, J. 2010. The drugs we have and the drugs we need against major helminth 
infections, Adv. Parasitol., vol. 73, pp. 197–230.  
[47] Bertagnolio, S., Perno, C.F., Vella, S. and Pillay, D. 2013. The impact of HIV drug resistance on the 
selection of first- and second-line ART in resource-limited settings, Journal of Infectious Diseases, vol. 
207, no.SUPPL 2, pp. 45–48.  
[48] Wallis, C.L., Godfrey, C., Fitzgibbon, J.E. and Mellors, J.W. 2018. Key factors influencing the emergence 
of human immunodeficiency virus drug resistance in low- and middle-income countries, Journal of 
Infectious Diseases, vol. 216, no.SUPPL 9, pp. 851–856.  
[49] World Health Organization. 2016. Meeting report: Technical definitions of shortages and stockouts of 
medicines and vaccines, Geneva: World Health Organization. 
[50] Pasquet, A. et al., 2010. Impact of drug stock-outs on death and retention to care among HIV-infected 
patients on combination antiretroviral therapy in Abidjan, Côte d’Ivoire, PLoS One, vol. 5, no. 10, pp. 1- 
9.  
[51] Stop Stock Outs Projects. 2016. Stop Stockouts: SSP Stockouts National Survey. South Africa.  
[52] Dubrocq, G., Rakhmanina, N. and Phelps, B.R. 2017. Challenges and opportunities in the development of 
HIV medications in paediatric patients, Pediatr. Drugs., vol. 19, no. 2, pp. 91–98.  
[53] Dahinten, A.P., Dow, D.E., Cunningham, C.K. and Msuya, L.J., Mmbaga, B.T. and Malkin, R.A. 2016. 
Providing safe and effective preventative antiretroviral prophylaxis to HIV-exposed newborns via a novel 
drug delivery system in Tanzania, Pediatr. Infect. Dis. J., vol. 35, no. 9, pp. 987–991.  
[54] Kisangau, D.P., Lyaruu, H.V.M., Hosea, K.M. and Joseph, C.C. 2007. Use of traditional medicines in the 
management of HIV/AIDS opportunistic infections in Tanzania: A case in the Bukoba rural district, J. 
Ethnobiol. Ethnomed., vol. 3, no. 29, pp. 1–8.  
[55] Kloos, S. 2017. Rethinking Sowa Rigpa and the Herbal Pharmaceutical Industry in Asia, Current 
Anthropology,  vol. 58, no. 6, pp. 693–717.  
[56] Perampaladas, K., Masum, H., Kapoor, A., Shah, R., Daar, A.S. and Singer, P.A. 2010. The road to 
commercialization in Africa: Lessons from developing the sickle-cell drug Niprisan, BMC Int. Health Hum. 
Rights, vol. 10, no. SUPPL. 1, pp. 1–7.  
[57] Sahoo, N. and Manchikanti, P. 2013. Herbal drug regulation and commercialization : An Indian industry 
perspective, The Journal of Alternative and Complementary Medicine, vol. 19, no. 12, pp. 957–963.  
[58] Wechsler, J. 2016. Drug shortages raise economic and ethical challenges, Pharmaceutical Executive, vol. 
36, no. 8. 
[59] Jaskot, D. et al., 2011. Globalizing the FDA: Achieving safety, access, and transparency through a 
comprehensive Generic Drug User Fee Program, Journal of Generic Medicines, vol. 8, no. 4, pp. 198 - 203. 
[60] Busza, J. et al., 2018. The role of community health workers in improving HIV treatment outcomes in 
children: Lessons learned from the ZENITH trial in Zimbabwe, Health Policy and Planning, vol. 33, no. 3, 
pp. 328–334.  
[61] World Health Organization. 2007. Survey of the quality of antiretroviral medicines circulation in selected 
African countries. Geneva: World Health Organization 
[62] Kankhar, S. 2006. IT-based drug discovery: Future driver for the Australian Pharmaceutical IT Market, 
[Online]. Available: http://www.frost.com/prod/servlet/market-insight-print.pag?docid=68419421. 
[Accessed: 28-May-2018]. 
[63] Strengthing Pharmaceutical Systems SPS. 2009. Indicator-based pharmacovigilance assessment tool: 






 Article 2 - The case for a niche pharmacovigilance system relating to 
drug provision and distribution in resource limited settings
 
978-1-7281-3401-7/18/$31.00 ©2019 IEEE    2019 IEEE International Conference on Engineering, 
Technology and Innovation (ICE/ITMC) 
The case for a niche pharmacovigilance system 
relating to drug provision and distribution in 
resource limited settings 
Presented by the development of a requirement specification 
 
Biancé Huysamen  
Health Systems Engineering and 
Innovation Hub 
Department of Industrial Engineering, 
Faculty of Engineering 
Stellenbosch University, South Africa  
18200648@sun.ac.za 
 
Imke H. de Kock  
Health Systems Engineering and 
Innovation Hub 
Department of Industrial Engineering, 
Faculty of Engineering 
Stellenbosch University, South Africa  
imkedk@sun.ac.za 
 
Louzanne Bam  
Health Systems Engineering and 
Innovation Hub 
Department of Industrial Engineering, 
Faculty of Engineering 
Stellenbosch University, South Africa  
louzanne@sun.acza 
In the contemporary healthcare landscape, the 
implementation of innovative drug manufacturing and 
distribution systems is becoming increasingly prominent in 
developing countries. One such a platform is the Medicine Patent 
Pool (MPP) which grants multiple pharmaceutical manufacturers 
access to specific drug patents in order to manufacture these 
drugs. However, research suggests that these ‘niche drug 
provision systems’ often give rise to challenges which intensify the 
need for effective drug monitoring and pharmacovigilance (PV) 
systems that will support these practices of drug delivery. PV is 
defined as the practice of monitoring the effects of medical drugs 
after they have been licensed for use. This paper argues for the 
development and implementation of a ‘niche PV system’ that will 
support the unique needs presented by these practices; a 
requirement specification for such a PV system is thus presented.   
Keywords — pharmacovigilance; MPP; requirement 
specification; challenges landscape; resource limited settings 
I. INTRODUCTION 
In the modern-day healthcare landscape, there has been 
significant changes within the pharmaceutical industry with 
regards to innovative drug manufacturing and distribution 
systems in developing countries. The key drivers of these 
changes were the unavailability of drugs (i.e. drug shortages 
and stock-outs) and the inaccessibility of affordable drugs in 
developing countries, often due to the high drug prices which 
are governed by the strict drug patent laws [1].  
 
An innovation that aims to address the unavailability of, and 
inaccessibility to affordable drugs, is availing intellectual 
properties of drug patents made available through the 
Medicines Patent Pool (MPP) to pharmaceutical companies 
in developing countries [2]. The aim of the MPP is to increase 
the rate of manufacturing and decrease the prices of specific 
drugs, i.e. TB, HIV and Hepatitis C drugs, in an attempt to 
increase availability, and accessibility of affordable drugs to 
those who are affected [3]. The MPP allows for any 
pharmaceutical company to access these patents and develop 
generic versions of these drugs in an attempt to improve the 
availability, and access to affordable drugs [4]. 
 
                                                        
1 In this article, ‘niche PV system’ refers to a PV system that is designed 
for a specific population, implying a specific region and a specific drug. 
This innovation has given rise to ‘MPP drug provision 
systems’ which refers to drug systems that consist of different 
practices in a pharmaceutical value chain, such as drug 
manufacturing, distribution, and quality monitoring within 
the context of the MPP. Furthermore, the MPP is often 
implemented in resource limited settings which face the 
challenge of having a limited amount of resources and 
funding available [5], [6], and thus when considering the 
context of these MPP drug provision systems, such 
challenges should be taken into account. It is suspected that 
by proposing the development of a ‘niche PV system’1, the 
challenges faced in the MPP drug provision systems will also 
be eliminated.  
 
It is often the case that these MPP drug provision systems are 
deployed in areas that do not have effective drug monitoring 
systems, such as pharmacovigilance (PV), in place which 
creates additional challenges [7]. This – the drug provision 
system described above along with the related challenges – 
highlights the need to look at the incorporation of good 
manufacturing practice (GMP) and good distribution 
practices (GDP) when addressing these challenges. GMP is a 
quality system that aims to ensure that medical products are 
consistently produced to meet quality standards [8], whereas 
GDP is a quality assurance system that ensures the quality of 
medical products is maintained throughout all stages of the 
supply chain [9].  
 
The World Health Organization (WHO) defines PV as, “the 
science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other 
drug-related problem” [10]. The challenges that arise from 
the MPP drug provision systems highlight the need to have 
an effective, well-established pharmacovigilance (PV) 
system in place to adequately support drug safety monitoring. 
However, it is recognised that the current PV systems are not 
equipped to adequately support these unique requirements 
[7]. Furthermore, it has been noted that the current PV 
systems face challenges that compromise the effectiveness of 
these drug monitoring systems and should thus also be taken 
Such a PV system will most likely operate and be managed differently from 





978-1-7281-3401-7/18/$31.00 ©2019 IEEE                                                                            2019 IEEE International Conference on Engineering, 
  Technology and Innovation (ICE/ITMC) 
into consideration when aiming to develop a niche PV system 
[11] given the context of the MPP. 
 
In order to identify, define and ultimately develop such a 
niche PV system, a requirement specification that guides the 
development of the envisaged PV system has to be 
developed. However, before such a requirement specification 
can be developed it is important to understand the context of 
the environment that is being investigated, i.e. challenges 
associated with MPP and PV. This paper addresses the 
context of niche PV system by discussing the background and 
the challenges associated with the MPP drug provision 
systems and current PV systems. Subsequently, the process 
of developing the requirement specification as well as the 
core set of requirements for the niche PV system is discussed.  
II. EXISTING THEORIES & PREVIOUS WORK 
Before a requirement specification for the niche PV system 
can be developed, it is important to understand the context 
within which such a PV system will have to exist. In this 
section the focus is placed on providing background on the 
context of the pharmaceutical value chain which considers 
both the MPP drug provision systems and PV systems as well 
as the challenges that arise in these settings within the 
pharmaceutical value chain.  
A. Pharmaceutical value chain  
The pharmaceutical value chain has three main components, 
namely the manufacturing of the medicines, the final medical 
product and the distribution of the medicines [12]. However, 
it can be argued that drug safety monitoring, such as PV 
systems, should be included when considering the 
pharmaceutical value chain; as it has been found that these 
innovative modes of drug supply, such as the MPP, not only 
impact the manufacturing and distribution, but also the 
process of drug safety monitoring [9]. Thus, in the context of 
this paper, the pharmaceutical value chain is considered to 
have four key elements: supply, distribution, final product, 
and the health system which refers to the patient usage and 
drug safety monitoring [9], [12], [13]. 
B. The Medicine Patent Pool (MPP) 
The MPP is a public health organisation that was launched in 
2010 by UNITAID and aims to improve accessibility and 
development of life-saving drugs for HIV, TB, and Hepatitis 
C in developing countries through the sharing of technologies 
and patents [2]. The MPP collaborates closely with industry 
stakeholders and patent holders to develop licence 
agreements which allow pharmaceutical companies to 
manufacture generic versions of drugs, as well as with the 
WHO to prioritise these drugs for licensing [4]. Through this 
innovation, drugs are made available to a broader population 
at a faster rate [4]. 
 
In addition to having drugs provided to a broader population 
through the implementation of the MPP, there are additional 
advantages such as encouraging research and development 
(R&D), and facilitating competition [3], [14], [15]. 
Competition is assisted through the implementation of the 
                                                        
2 ADR is a response to a drug which is noxious and unintended, in a 
normal dosage for a specific treatment procedure [6]. 
MPP as multiple pharmaceutical companies are allowed to 
access the drug patents and manufacture the drugs, which 
often results in a decrease in prices [3]. The pharmaceutical 
companies are also provided the flexibility to develop and 
adapt the drug formulations to create new fixed-dosage 
combinations to meet the specific needs for the area’s 
population [9].  
 
However, there are certain challenges that arise when 
considering the implementation of the MPP to improve 
availability and access to treatments. The MPP allows any 
pharmaceutical company in developing countries access to 
the drug patents, and although they have to meet certain 
quality standards, research shows that this has been difficult 
to monitor [9]. Though the MPP does not directly give rise to 
specific challenges, MPP drug provision systems do 
indirectly contribute towards challenges that impact the drug 
safety monitoring systems [9], [16], [17]. Thus, in the context 
of the pharmaceutical value chain it is important to 
understand the relationships and impacts of these challenges.  
C. Pharmacovgilance (PV) 
According to the WHO, the effective functioning of a PV 
system relies on data collection from health practitioners, and 
the systematic monitoring and analysis of the input data, 
especially in the case of new drugs that are rolled out. PV is 
aimed at improving patient safety with regards to medication 
but also to contribute to monitoring and assessing different 
drug reactions as well as the quality of drugs [18]. 
Furthermore, to ensure effective monitoring, PV should be a 
continuous process throughout the pre- and post-marketing 
authorisation phase of a drug [18]. With the roll-out of a new 
drug, an effective PV system is of paramount importance as 
all possible adverse drug reactions (ADRs)2 should ideally be 
reported and investigated to ensure rapid detection and 
characterisation of drug risks. Additionally, PV systems 
continuously change and adapt to respond to certain 
requirements within a setting [18]. 
 
Numerous challenges exist with regards to drug safety 
monitoring, especially in developing countries [19]. From a 
study investigating the PV systems in South Africa, Uganda 
and India, it was found that barriers to effective drug 
monitoring include limited funding and a lack of training 
programmes [19]. With regards to the PV system in South 
Africa, research has established that, although legal 
requirements for drug safety monitoring are in place, 
challenges such as underreporting of ADRs, ineffective 
communication channels, and a culture of implementing PV 
tends to be lacking [18], [19].  
 
Thus, when considering the development of the niche PV 
system that will address the challenges that the MPP drug 
provision systems contribute towards, ‘traditional 3 ’ 
challenges faced in PV system should also be considered.  
 
3 Traditional challenges refer to the challenges that are faced in PV systems 
in the context of the pharmaceutical value chain, which are not directly 
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III. METHODS 
In this section the process, which was followed to determine 
the requirement specification, that outlines the foundational 
concepts from which the niche PV system can be developed, 
is described. 
 
To ensure that the requirement specification for the niche PV 
system address the challenges that arise from the MPP drug 
provision systems and PV in the context of the 
pharmaceutical value chain a challenges landscape, referred 
to as the pharmaceutical value chain challenges landscape, 
was firstly developed based on insights gained from 
literature. The process of developing this challenges 
landscape and the final outcome of the landscape is discussed 
in this section. 
 
The process of determining the requirements was threefold: 
the pharmaceutical value chain challenges landscape was 
consulted to determine what requirements these challenges 
call for in a PV system, a systematic review was conducted 
of literature pertaining to general requirements of a PV 
system; and the ability for such a PV system to work 
effectively in this environment of the MPP drug provision 
systems was considered. 
 
Given that this research focuses on resource-limited settings 
and the inclusion of drug manufacturing and distribution, the 
requirement specification was developed with this focus in 
mind, and thus GMP & GDP were also taken into 
consideration. These practices were reviewed, and concepts 
were identified that could be incorporated into the set of 
requirements to improve the system and strengthen the 
function of the niche PV system (especially given the 
presence of the MPP). Furthermore, the literature also shows 
that many of the challenges that arise due to the inadequate 
drug manufacturing and distribution systems can be elevated 
through the implementation of these practices [20]. 
A. Pharmaceutical value chain challenges landscape 
As mentioned, there are challenges that arise in the context of 
the pharmaceutical value chain due to flaws in the MPP drug 
provision system and current PV systems. It is thus important, 
when considering the development of the niche PV system, 
that such challenges are identified, understood and 
adequately addressed, to ensure that the proposed niche PV 
system can effectively support the unique requirements of 
these environments. In order to gain a holistic view of all 
these challenges, the pharmaceutical value chain challenges 
landscape was developed.  
 
The pharmaceutical value chain challenges landscape is an 
expansion of the challenges landscape developed by 
Huysamen et al [6] which identified challenges associated 
with MPP drug provision systems. However, to address the 
traditional challenges faced in PV system a systematic review 
was conducted to identify the challenges which could be 
included to develop a challenges landscape that would 
address both MPP drug provision systems and ‘traditional’ 
PV systems. All the challenges identified were then examined 
to determine whether they relate to one another, as well as to 
determine the potential impacts and effects the different 
challenges might have on one another, and on the 
pharmaceutical value chain. The challenges were grouped 
together based on their common characteristics and cause-
and-effect relationships [6]. Seven main groups of 
challenges, referred to as ‘challenges groups’, were 
identified. Also, the impact that the challenges groups have 
on the different stages of the pharmaceutical value chain were 
identified. Both a schematic representation and a relationship 
diagram were developed for the pharmaceutical value chain 
challenges landscape, which can be found in Addendum A, 
Fig. 1 and Fig. 2. 
 
The pharmaceutical value chain challenges landscape 
contains two dimensions. The first dimension is the 
pharmaceutical value chain with its’ four key elements as 
explained in Section II, Subsection A. The second dimension 
is the main body of the challenges landscape that contain all 
the challenges identified during the systematic reviews in 
their respective groups; namely supply and distribution, 
quality, drug monitoring, PV culture, education, PV 
stakeholders, and ADR reporting. The landscape is arranged 
in such a way to clearly show how the challenges groups 
impact the pharmaceutical value chain at the different 
respective stages.  
 
The understanding gained from the pharmaceutical value 
chain challenges landscape will contribute to the 
development of the requirement specification for the niche 
PV system.  
B. Systematic literature on PV requirements 
In order to gain a better view and understanding of the current 
PV system requirements that are documented, literature was 
consulted. The aim of this systematic literature review was to 
identify and gain a better understanding of the current PV 
requirements found in literature. Scopus and PubMed were 
used as the primary search databases. Using different 
keywords and phrases as indicated in Table I, relevant 
documents were identified. To ensure that only the most 
relevant documents were included, certain criteria points 
were used, such as only including documents that were 
published in English and from 2000 onwards. After these 
criteria were applied, the abstracts of the documents were 
screened for relevance, and then subsequently the whole 
article reviewed with regards to requirements of PV systems. 
It should be noted that duplicate documents found when 
conducting the search in PubMed were excluded as they had 
already been included when conducting the search in Scopus. 
Furthermore, Google Scholar was consulted for serendipitous 
findings and relevant articles were included in the study. A 
total of 15 documents were identified to use as a basis for 
identifying PV system requirements. The process is 
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TABLE II.  INFORMATION ON SYSTEMATIC REVIEW  
 
IV. FINDINGS 
In this section the requirements identified from consulting the 
pharmaceutical value chain challenges landscape, Section 
III, Subsection A and from conducting the systematic 
literature review, Section III, Subsection B, are given.  
A. Collected Data:Requirements identifed  
After consulting the relevant documents identified in the 
systematic literature review, Section III, Subsection B, a total 
of 30 requirements for an effective PV system were 
identified. Table II provides a summary of these PV 
requirements. Some of the requirements that were most 
prominent in the literature were; that PV education should 
form a more integral part of the healthcare system and that 
proper communication channels should exist between the 
different parties involved. 
 
Furthermore, the challenges landscape was also consulted to 
identify the unique requirements the pharmaceutical value 
chain challenges landscape call for in the niche PV system. 
Each of the 7 challenges groups, as shown in the challenges 
landscape in Addendum A, were investigated to identify the 
unique requirements that challenges group calls for. Once 
again PV education was one of the most demanding 
requirements identified as 6 out of the 7 challenges groups 
call for some form of PV education. Furthermore, there were 
also unique requirements identified from the challenges 
landscape such as that quality control checks in the niche PV 
system should incorporate traditional medicines, sub-
standard drugs and counterfeit drugs. All the requirements 
identified from the challenges landscape are shown in Table 
III. 
B. Analysis of data: Developing core set of requirements 
Drawing from the information gained in Section IV, 
Subsection A, it is clear that there is a broad spectrum of 
requirements when considering PV systems. Thus, to ensure 
that the niche PV system considers all the necessary 
requirements identified from both literature and from the 
challenges landscape, the requirements discussed above were 
reviewed and combined to ultimately propose one set of 
requirements for the niche PV system. However, reviewing 
the two sets of requirements, Table II and Table III, it was 
found that certain requirements consider the same concept. 
Similar and/or complementary requirements were thus 
grouped together in order to propose a core set of 
requirements for the niche PV system; these groups are: 
reporting system, PV education, quality, communication, 
stakeholders’ roles, consumer involvement, reporting forms, 
new-released drugs, and databases. 
 
However, to ensure that the requirement specification is 
relevant to this specific niche environment when considering 
the context of the challenges landscape, i.e. MPP drug 
provision systems, the core set of requirements were 
reviewed to ensure that the proposed final set of requirements 
accounts for the needs of this specific environment.  
 
The core set of niche PV requirements is provided in the 
following section. 
C. Core set of niche PV requirements 
After the screening process was conducted a total of 10 core 
requirements are identified that the niche PV system will 
have to satisfy to be able to perform effectively in the MPP 
drug provision systems. This core set includes requirements 
such as, having a national PV centre, PV education, quality 
control systems, clear communication channels, specific 
ADR reports, and clearly defined stakeholder roles in place 
for effective drug monitoring. The 10 core requirements are 
listed in detail below. 
 
1. An effective system for the reporting and managing 
of ADRs needs to exist with a national PV centre, designated 
staff and advisory committees and a well-defined structure.  
 
2. PV Education and ADR education must form an 
integral part of the healthcare system and all stakeholders 
must be educated on the importance of PV and their specific 
roles. PV education should include training programmes, PV 
subjects in the curriculum of healthcare students and 
workshop sessions. Furthermore, PV education must also 
address niche environment-specific conditions such 
counterfeit drugs, sub-standard drugs, traditional medications 
and drug-drug interactions. 
 
3. Effective quality control systems need to be in place 
throughout the entire PV system from ADR reporting to the 
storage and managing of the data and information. 
Furthermore, special attention needs to be paid to the quality 
control monitoring of counterfeit and sub-standard drugs, 
traditional medicines and consumer-specific drugs such as 
paediatric drugs.  
 
4. Clear communication channels need to exist 
between the different stakeholders involved in the PV system. 
These communication channels should include creating links 
between quality control labs and PV centres; government and 
PV centres; and healthcare professionals, pharmaceutical 
companies and consumers. Furthermore, it is important that 
during communication with consumers a professional, yet 
compassionate nature is exercised.  
Search 
base 





















86 17 7 




AND requirements - - 3 






978-1-7281-3401-7/18/$31.00 ©2019 IEEE                                                                            2019 IEEE International Conference on Engineering, 
  Technology and Innovation (ICE/ITMC) 
 


































PV Education needs to be incorporated into the health system (training, 
studies etc.).
X X X X X X X X 8
A reporting system with ADR reporting forms needs to exist. X X X X X x X 7
Clear lines of communication need to be implemented. X X X X X 5
Forms of public awareness on PV need to be incorporated into the system. X X X X 4
PV needs to be introduced in undergraduate and graduate levels of teaching. X X X X 4
There must be a clinical trial and post-marketing database for specific drug 
roll-outs.
X X X X 4
A national PV centre needs to exist with designated staff and roles and 
well-defined structure.
X X X 3
The PV plan should take into account risk identification during product 
development and risk management.
X X X 3
Regular audits and inspections of pharmaceutical companies by healthcare 
workers need to be implemented.
X X X 3
The roles of the stakeholders need to be clearly defined. X X X 3
Proper quality management and control systems need to be in place. X X X 3
All organisations involved with PV need to embrace the concept of quality 
control and have a collaborative, transparent proactive behaviour.
X X X 3
Qualified personal must be in charge of PV. X X X 3
Database for the collecting and managing of ADRs needs to exist. X X 2
A PV advisory committee needs to exist and assist on technical matters. X X 2
Additional monitoring is required for new released drugs. X X 2
Knowledge on the safety profile of medicines has to be in place. X X 2
Specific populations/ patients need to be considered when setting up a PV 
system.
X X 2
Reports need to contain all relevant information and if important info is 
omitted, a system must be in place to contact reporter/healthcare unit to 
verify the case.
X X 2
Special attention needs to be placed on drugs that are suspected for defects. X X 2
Certain drug safety aspects need to be incorporated, such as drug 
interactions and assessing the contribution of 'inactive' ingredients.
X X 2
During drug development, companies need to consider what type of safety 
information will be required during post-marketing phase, and plan PV 
activities accordingly.
X X 2
In clinical trials, improvements in the mode of safety data collection, 
timelines, duplication, harmonization, and coverage need to be explored. 
X X 2
A proactive approach with regards to reporting needs to be taken. X 1
ADR reporting must be compulsory to some extent for healthcare 
professionals.
X 1
Traditional medicines should be incorporated into national PV 
programmes.
X 1
Drug labels must be visible, readable and easy to identify by consumers 
and healthcare workers especially the section on ADRs.
X 1
Low-cost reporting solutions at international standards are required. X 1
Specific patient and drug information must be present in the ADR reports, 
such as medical history, age, etc.
X 1
Generic drugs must be treated as a new released drug and follow all the 
necessary safety reporting requirements.
X 1
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5. The different stakeholders’ roles and responsibilities 
need to be clearly defined within the PV system. This 
includes the aspect that pharmaceutical companies need to be 
more proactively involved with drug safety monitoring; 
government needs to be actively involved with the 
implementation of National PV systems; and that healthcare 
workers need to assist with the identification, monitoring and 
reporting of ADRs.  
 
6. The PV system needs to encourage patient 
involvement, by implementing and supporting consumer 
reporting. Thus, public awareness and consumer feedback 
sessions need to form an intricate part of the PV system. 
Furthermore, more care should be taken with specialised 
consumer groups such as pregnancies/ paediatrics.  
 
7. A niche environment specific ADR report needs to 
be designed that will not require previously captured 
information to be included but will still ensure that all 
PV SYSTEM REQUIREMENTS BASED ON CHALLENGES LANDSCAPE 
 
Proper good manufacturing practices (GMP) have to be in place.
PV education systems need to incorporate education on specialised drugs and the impacts they have on drug safety.
Communication between the drug manufactures (pharmaceutical companies) and the PV stakeholders have to be in place.
Quality control over ingredients used in traditional medicines have to be in place.
Education needs to incorporate knowledge on drug-drug interactions.
Proper good manufacturing practices (GMP) and good distribution practices (GDP) have to be in place.
Good quality management systems need to be in place for drug distribution systems.
There should be proper funding system in place to improve infrastructures. 
Knowledge on how certain drugs interact with other drugs and lead to serious ADRs have to be incorporated.
The PV system must be able to locate ADRs in a quick and easy manner and in the case that a dangerous drug is identified it should be removed as soon as 
possible. 
Healthcare workers must be able to identify an illness and initiate treatment as soon as possible. 
Generic drugs need to be seen as new role-out drugs and follow safety reporting requirements.
Healthcare workers need to have professional, yet caring nature when working with patients.
Patients need to be educated on the process of their treatment, as well as what ADRs are and how they implicate drug adherence.
Patients need to be educated on the process of their treatment and how ADRs impact drug adherence.
Patient drug adherence needs to be improved to ensure that drug resistance does not occur during the treatment process.
Proper quality monitoring systems have to be in place to monitor quality of drugs taken by patients and remove all sub-standard drugs and counterfeit drugs.
Proper good manufacturing practices (GMP) have to be in place.
Proper quality control checks during the labelling process must be incorporated.
The inclusion of additional safety information is required for certain drugs on the labels.
The label of drug medications must be easily visible, especially the section on ADRs. Patients and health care professionals must easily be able to identify this 
section.
Research and developmenet (R&D) must be improved to include quality checks.
Proper good manufacturing practices (GMP) have to be in place.
Generic drugs need to be seen as new role out drugs and follow safety reporting requirements.
Quality checks have to be in place to identify fraudulent drug products.
Links need to exist between quality control labs and PV centres.
Quality control over ingredients used in drug manufacturing have to be inplace.
PV analysts should have access to the drug manufacturing process (as well as have access to records that are made during manufacturing). 
Quality monitoring over patients taking drugs have 
Healthcare workers need to have professional, yet caring nature when working with patients.
ADR reporting must be compulsory to some exstent to all healthcare workers.
Education on ADRs, and how to properly report ADRs in the healthcare system must be in place.
Proper storage of patient healthcare records and reports are needed, includes ADR reports.
PV should involve all the stakeholders throughout the entire process.
PV education should be implemented for all students in healthcare and include aspects of the challenges that are faced within unique areas. 
PV culture should be improved in the healthcare system.
Knowledge, attitude and practices (KAP) of PV must be integrated throughout the whole system and involve all stakeholders.
Training programmes on how to report ADRs and monitor ADRs must be implemented in the healthcare system.
All stakeholders need to be educated on PV and the importance thereof. 
The curriculum for students in the healthcare system needs to incorporate the education of PV in some manner such as implementing a subject or training program.
Consumers/ patients need to be educated on issues such as drug adherence and drug resistance as well as the reporting of ADRs.
The training programmes and other forms of education need to incorporate the challenges identified by inadequate manufacturing.
The PV system needs to be able to operate and work effectively without having an extensive amount of resources or funds available.
There needs to be a clear line of communication between government and healthcare workers, when it comes to decision making and taking actions.
PV education and PV culture must be intergrated within the government or within a sector of the department.
Government needs to reprioritising funding and resources towards PV.
Stakeholders involvement should extend from PV system to manufacturing and distribution of pharmaceutical drugs.
All stakeholders need to gain some education and knowledge on PV and the importance thereof. 
There needs to be a clear line of communication between healthcare workers and the pharmaceutical companies when ADRs are detected.
Healthcare workers should be educated on how to professionally and compassionately work with their patients.
For specialised consumers (pediatric/ pregnant) more care should be taken with regards to monitoring of ADRs.
Consumers need to be informed and educated on ADRs and the dangers associated with them.
Education on PV, drug safety monitoring and ADR reporting needs to be implemented and integrated into the healthcare system.
Consumer feedback with regards to ADR reporting must be in place.
The communication between consumers and the healthcare workers needs to be professional yet compassionate.
Guidelines on ADR reports need tobe in place.
Proper quality control with regards to reporting of ADRs, and the monitoring process must be in place.l
The reporting forms (or other similar reporting method) must  incorporate specific condition/ criteria for the area/ region and drug that is launched. 
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relevant information is obtained. Furthermore, in the case 
where important information is omitted, a system must be in 
place to contact reporter/healthcare unit to verify the case. 
8. Additional monitoring is required for newly 
released drugs and generic versions of drugs. 
 
9. There must be a clinical trial and post-marketing 
database for specific drug roll-outs that can be accessed by 
PV centres so that previously captured patient information 
does not have to be captured again.  
 
10. The PV system must be able to work effectively by 
identifying, reporting and monitoring ADRs without 
requiring an extensive amount of financial or human 
resources. 
 
After identifying the ten core requirements it was found that 
there is not only one area, but a range of different aspects that 
have to be addressed when developing a niche PV system. 
These aspects include operational management, quality 
management, and educational practices. For the niche PV 
system to function and operate effectively all these different 
requirements have to be addressed.  
V. CONCLUSION AND FURTHER RESEARCH 
This article focused on addressing the challenges that arise 
due to the implementation of the MPP and those existing 
challenges found in traditional PV systems, by developing a 
requirement specification for a niche PV system that will 
address the unique needs called for by MPP drug provision 
systems.  
 
In this article, a number of approaches were used to 
ultimately develop a core set of niche PV system 
requirements. The requirement specification was based on 
insights gained from consulting literature on PV 
requirements, advising the pharmaceutical value chain 
challenges landscape and assessing the ability of such a PV 
system to operate in the environment of the MPP drug 
provision systems. 
 
However, it should be noted that there are context specific 
aspects that limit this study. This study investigates the 
development of a requirement specification for a niche PV 
system and it was designed for the environment of the MPP 
drug provision systems. It is thus specifically designed for 
developing countries that have inadequate drug 
manufacturing and – distribution systems in RLS. The MPP 
also only address specific drugs for HIV, TB, and Hepatitis 
C treatments, which further limit the developed niche PV 
system.  
 
In conclusion this article reaffirms that there is a need for an 
innovative, niche PV system that will meet the requirements 
set out in this article. At this stage it is envisioned that the 
most ideal solution would be to propose the development and 
implementation of a mobile application as the niche PV 
system solution, as this form of ICT would be able to fulfil 
most of the PV requirements; such as being a less time-
consuming, resource-limited solution that can include other 
operations such as PV education. However, it is also clear that 
there is a need to look at the entire pharmaceutical value 
chain, from R&D phase to drug monitoring phase, from a 
system perspective to identify other forms of ICT to address 
the challenges that arise in these MPP drug provision 
systems.   
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Specialized drugs X X
pediatric drugs X X X X X X
traditional 
medicines X X X X X X X
Supply X X X X X X X X X X
Shortages X X X X X X X X
Stock-outs X X X X X X X
Drug -drug 
interactions X X X X
ADRs X X X X X X X X X X X X X X X
Drug Adherence X X X X X X X X X X
Drug resistance X X X X
Quality X X X X X X X X
Dosages X
Labelling X
Counterfeit Drugs X X X
Sub-standard
Integrity of system X X X X X
Record Keeping X X X X
Late initiation X X X
Lack of reporting X X X X X X
X X X X X X X X
 Education X X X X X X X X X
KAP X X X X X X
Training X X X
Cirriculum X X X
Government X X X X
Limited resources X X X
Lack of funding X X X
Pharmaceutical 
companies X X X X
Doctors X X X X X X
Pharmacists X X X X X
Consumers X X X X X
Pediatric/ pregnant X
Tradional
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 Additional information for 
PVCCL 
In this appendix additional information regarding the systematic literature reviews conducted 
to develop the PVCCL is found.  
The following sections are included: 
B1: Challenges related to PV challenges landscape 





B.1. PV related Challenges  
Table B.1 provides an overview of the occurrence of the different challenges documented in each year. 
Table B.1: Overview of occurrences in PV challenges 
  Date 
Total 
































Stakeholders    2   1   7 1 1 4 5 2 2 3 26 
Education 1  1      4 1 1 1 3 1 1 2 16 
under reporting   2      3 1  2 3 1   12 
KAP      1   4 1   3 1  1 11 
quality of data 1  1    1  1  1 2   2  9 
Training         2 1  1 2 1  2 9 
consumer reporting   1   1      1 2  1 2 8 
pharma companies   1      2 1  2 1  1  8 
ADR reporting/id  1 1  1     1  1   1  6 
limited resources    1 1    1 1  1    1 6 
Doctors         2   1  1  1 5 
Herbal medicine      1       2  1  5 
communication 1        1   1 1    4 
finances     1    1 1   1    4 
government          3       1 4 
Pharmacists         2  1  1    4 
Specific groups      1      1 2    4 
ethical 1        1       1 3 
Insufficient  amount of data          1   1  1  3 
standardised reporting        1    1   1  3 
Pregnant women/ped         1 1   1    3 
Data process 1  1              2 
self-medication      1    1       2 
students             1 1   2 
Deduction and monitoring          1        1 
Media   1              1 
off label usage        1         1 





B.2. MPP, disease burden associated with MPP and RLS related challenges 
In Table B.2 an overview of the occurrence of the challenges found in literature is provided 
Table B.2: Overview of occurrences of challenges related to in MPP, disease burden associated with 
MPP and RLS  
    Date 
    























































Co-infections 1 1 1 1   1     5 
Paediatric drugs 1 1       1 1 1 5 
Dosages   1   1     1   3 
Specialised drugs   1       1 1   3 
Traditional 
medicine 
2             1 3 




























 Drug supply   2   1 2       5 
Drug stock-outs 1 1   1   1     4 



















































ADR   2 2 1 3 2 5   15 
Drug adherence 1 2 1 2 3 2 1   12 
Quality 3 1   1 2 2 1 2 12 
Drug-drug 
interactions 
      2   3 1   6 
Drug resistance 1 1   2    1 1   6 
Counterfeit  drugs     1 1 1     1 4 





Record-keeping  2       1 1 1 1 6 
Lack of safety 
reporting 
2 1     1   1   5 
Late ART Initiation 1 2     1       4 
Data         1 1 1   3 
















Diagnostics testing 1         3 1 2  7 
Laboratory 1       1 2   1 4 
Knowledge and 
awareness 
    1     1   1 3 
Poor healthcare 
infrastructure 






 Additional information on 
Requirement Analysis 
This appendix contains information regarding the three systematic literature reviews that were 
conducted in Chapter 4, with reference to the requirement analysis approach.  
The following sections are included: 
C1: Requirements related to traditional PV systems 
C2: Requirements related to HIV, TB and Hepatitis C 







C.1. Requirements related to traditional PV systems 
Table C.1 provides an overview of the different requirements identified related to PV systems and the occurrence of each of these requirements in the respective 
document. 






















































































PV Education needs to be incorporated into the health system (training, studies 
etc.). 
  X X   X   X     X   X     X X 8 
Effective 
system 
A reporting system with ADR reporting forms need to exist. X     X X   X     X       x X   7 
communication Clear lines of communication needs to be implemented. X                 X       X X X 5 
patient 
involvement 
Some form of public awareness on PV needs to be incorporated into the system.       X           X X       X   4 
database 
There must be a clinical trial and post-marketing database for specific drug roll-
outs. 
  X         X X           X     4 
Education PV needs to be introduced in undergraduate and graduate levels of teaching.     X       X     X X           4 
Quality 
Regular audits & inspections of pharmaceutical companies by healthcare 
workers need to be implemented. 
    X X           X             3 
Stakeholders Stakeholders roles need to be defined clearly.     X X     X                   3 
Effective 
system 
The PV plan should take into account risk identification during product 
development and risk management. 
  X     X                   X   3 
Quality Quality management and control systems need to be implemented.   X   X           X             3 
Stakeholders 
All organizations involved with PV needs to embrace the concept of quality 
control and have a collaborative, transparent proactive behaviour. 
X   X X                         3 
Education Qualified personal in charge of PV.     X   X         X             3 
Effective 
system 
A national PV centre needs to exist with designated staff and roles and well 
defined structure. 
X                 X         X   3 
Database 
Computer systems used for PV should be validated and included the use of 
safety information outside drug safety functions (call centres). 
      X X                       2 
Reports 
Reports need to contain all relevant information and if important info is omitted, 
a system must be in place to contact reporter/healthcare unite to verify the case. 
          X           X         2 
Specialised 
drugs 




































































Certain drug safety aspects need to be incorporated such as drug interactions 
and assessing the contribution of 'inactive' ingredients. 
  X                           X 2 
Effective 
system 
During drug development companies need to consider what type of safety 
information will be required during post marketing phase and plan PV activities 
accordingly.   
X 
          
X             
    
2 
Clinical trials 
In clinical trials, improvements in the mode of safety data collection, timelines, 
duplication, harmonization, and coverage need to be explored.    
X 
          
            X 
    
2 
Database Database for the collecting and managing of ADRs needs to exist. X                           X   2 
Effective 
system 
A PV advisory committee needs to exist and assist on technical matters. X X                             2 
Specialised 
drugs 
Additional monitoring is required for new released drugs.   X         X                   2 
Education Increase knowledge on the safety profile of medicines.   X               X             2 
Niche specific 
Specific populations/ patients need to be considered when setting up a PV 
system. 
  X                     X       2 
Stakeholders Pharmaceutical companies need to be involved in PV and ADR reporting.     X     X                     2 
Stakeholders Pharmaceutical companies need to have trained staff.     X               X           2 
Database Using literature to identify cases.         X                       1 
Reporting 
process 
A more proactive approach with regards to reporting needs to be taken.         X                       1 
Patient 
involvement 
Pharmaceutical companies should have someone in charge for handling of PV.     X                           1 
Reporting 
process 
ADR reporting must be compulsory for healthcare professionals.             X                   1 
Niche specific 
Creating a single country-specific adverse event reporting form to be used by 
all. 
            X                   1 
Specialised 
drugs 
Necessary that traditional medicines incorporated into national PV programmes.                               X 1 
Labels 
Drug labels must be visible, readable and easy to identify by consumers and 
health care workers especially the section on ADRs. 
              
  X           




Low cost reporting solutions at international standards are required. 
              
    X         





































































Generic drugs must be treated as a new released drug and follow all the 
necessary safety reporting requirements.               
          X   
    
1 






C.2. Requirements related to HIV, TB and Hepatitis C 
Table C.2 provides additional information related to the requirements identified associated with the disease burden of HIV, TB and Hepatitis C. 






































PV Education should form an integral part of the system. 
PV education should also be standardised. 
X   X       X X   x     X     X   X   8 
Reporting process 
More active monitoring systems are required. Additional 
or other PV methods/ technique to be incorporated. 
X X       X X X             X         6 
Education 
PV education should be target at specific groups of 
people. Patients should be educated on their specific 
ADRs 
X X               X     X X           5 
Community 
Community involvement should form an integral part of 
the system.  
    X       X   X     X               4 
Database 
All data collected to be entered into some form of a 
database  
X           X               X     X   4 
Report Standardised ADR reporting should be used     X                       X     X   3 
Niche 
environment 
The system should take the environment into account 
(for example lack of computers, internet etc.) 
X                           X X       3 
Vulnerable 
patients 
Special care should be taken for specific patients such as 
patients who are on first line regime 
X X   
                    
X           3 
Reporting process 
ADR reporting should be made compulsory to some 
extent or healthcare workers should receive rewards for 
reporting 
    X X                             X 3 
Education 
Improved adherence of illness (HIV treatment) - provide 
basic education and counselling on treatment 
      X             X     X           3 
Education Training regarding countries specific PV guidelines              X X               X       3 
Quality control  Regular quality control checks to be performed           X X               X         3 
Communication Communication & harmonisation between facilities               X   X                   2 
Education 
Insure there are not incorrect believes - like that TB can 
be cured using herbal medicines 


















 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19  
Stakeholders' 
roles 
Patients should be treated professional but 
compassionate (not discriminated against patients with 
certain illness) 
                  X X                 2 
Report 
Reports need to be patient and illness (treatment) 
specific. 
X X                                   2 
Database 
The specific drugs and treatments need to be listed on 
PV databases 
X           X                         2 
Patient 
involvement 
Patient involvement should form part of the system.             X             X           2 
Vulnerable 
patients 
More care should be taken when considering ADR 
reporting of older patients 
  X                             X     2 
specialised drugs 
Special focus should be taken with regards to traditional 
monitoring 
        X         X                   2 
Stakeholders' 
roles 
Designated person in charge of PV activities               X                       1 
Education PV culture should form an integral part of the system           X                           1 
Quality control  
The system should focus on reporting quality of drugs to 
report suspectable counterfeit & sub-standard drugs 
          X                           1 
Vulnerable 
patients 
Monitor patients who are on their first line of treatment 
(ensure they do not stop the treatment) 
                          X           1 
Report 
Terms/ words in reports should be consistent. For 
example adverse reaction vs adverse event. 
                            X         1 
Report Ensure viability of ADR reports                               X       1 
Public awareness 
Targeted interventions should be aimed at colleague 
students  








C.3. Requirements related to RLS 
In this section additional information regarding the requirements identified related to RLS is provided in Table C.3. 
Table C.3: Occurrence of requirements related to RLS 
 
Requirement group Specific requirement 



































PV education in academia 
PV Education should form an integral part of the system. PV 
education should also be standardised. 
X X   X   X   X   X   X 7 
Environment specific system  
The PV system needs to be region specific and take the specific 
environments' needs into account 
  X         X   X   X   4 
Reporting process and 
reporting forms 
Standard procedures X   X X         X       4 
PV education in academia Capacity building should be integrated in the PV system X           X     X     3 
Environment specific system  
Specific populations/ patients need to be considered when setting 
up a PV system. 
      X     X       X   3 
Reporting process and 
reporting forms 
The ADR reporting forms should be easy to complete, non-time 
consuming and resource limited friendly 
        X     X X       3 
Additional reporting 
More active monitoring systems are required. Additional or other 
PV methods/ techniques to be incorporated. 
  X   X                 2 
Link to clinical trials  
The database for the PV system should be linked to clinical trial 
databases 
    X       X           2 
Link to clinical trials  
The PV system should be linked to clinical trials and PV training 
should be introduced during the clinical trial phase. 
X           X           2 
Communication & Feedback Clear lines of communication needs to be implemented.   X           X         2 
Communication & Feedback 
Feedback processes  need to be incorporated to keep patients 
informed about the process.  
              X   X     2 
PV education in academia 
PV education should be implemented in the academia. This 
entails the inclusion of PV subjects into undergraduate 
programmes.  






Requirement group Specific requirement 










33 37 41 35 40 32 36 6 38 34 39 31 
Additional reporting 
Cohort Event Monitoring (CEM) and Targeted Spontaneous 
Reporting should be investigated as possible additional methods  
      X                 1 
Communication & Feedback 
Communication channels with the MRA (Medicine Regulatory 
Authorities) 
      X                 1 
Consumer involvement Consumer in reporting of ADRs is required.               X         1 
Environment specific system  System must be able to identify ARS as soon as possible                 X       1 
Reporting process and 
reporting forms 
Innovative ways of capturing data in RLS is required               X         1 
Reporting process and 
reporting forms 
Standard terminology should be used in the reports etc.       X                 1 
Reporting process and 
reporting forms 
The reports should be available in the region/ countries' local 
languages. 
              X         1 
Remuneration 
Reporting should be made compulsory or some form of 
remuneration should be granted 
              X         1 
National strategy  
The Government should form an integral part of the system and 
some form of a national strategy should be implemented 






 Preliminary requirement 
specification 
This appendix contains the preliminary requirement specification that considers the 
environment of the MPP drug provision systems and accounts for the requirements the niche 
factors call. 
The following sections are included: 
D1: Requirements related to traditional PV systems 
D2: Requirements related to MPP 
D3: Requirements related to HIV, TB and Hepatitis C 





D.1. Requirements related to traditional PV systems 
36Figure D.1 provides an overview of the preliminary requiremnts related to PV systems. 
 
                                                 
 
36 These challenges refer to all the challenges identified through systematic literature reviews that the factors (MPP, specific illnesses, RLS and traditional PV systems) attribute to 
and that the niche PV system needs to address. A total of 8 challenges groups were identified, listed A-H and a total of 43 challenges were identified. A shorted list is provided 
below. 
 
A – Supply & distribution: Specialized drugs, paediatric drugs, traditional medicines, supply, shortages, stock-outs, drug-drug interactions (as a change in the effect of the drug 
when it is taken together with another drug and it can often lead to ADR), adverse drug reactions (any response to a drug which is noxious and unintended), drug adherence (the act 
where patients abide to the recommendations made regarding the dosage, timing and frequency of medication taken), drug resistance (the response to a drug in a susceptible parasite 
population decreases significantly) 
B – Quality: Quality, dosages, labelling, counterfeit drugs (medical products that deliberately/fraudulently misrepresent their identity, composition or source), sub-standard drugs 
(authorized medical products that fail to meet either their quality standards or specifications, or both) 
C – Monitoring: Integrity of the system (the support, integrity and confidentiality of the health care workers has seen to have an impact on treatment), record keeping, late initiation, 
lack of reporting, poor health system, awareness (lack of awareness and knowledge regarding the illness and treatment procedures) 
D – Testing: Laboratory (the poor and limited amount if laboratories and testing infrastructures), diagnostics (diagnostic testing is required to predict the correct treatment 
procedure)  
E – PV Culture 
F – Lack of education: KAP (knowledge, attitude and Practices associated with PV), training (lack of effective PV training programs for healthcare professions), curriculum 
(incorporate PV subjects into the curriculum of healthcare students) 
G – Stakeholder involvement: Government, lack of resources (people, time and money) lack of finances, pharmaceutical companies, pharmacists, doctors, consumers, 
paediatric/pregnant, traditional medicine users 
H – Reporting & process: Adverse drug reaction detection (identification of ADRs together with the detection of the connection between the ADRs and the drug exposure), 
confidentiality & ethics (trusting the healthcare workers), under reporting of ADRs, quality of data (the data gathered from reporting should be of a high quality), communication 
(communication platforms between the different stakeholders have to exist) 
 




Pharmacovigilance education needs to be incorporated into the health 
care system.
Pharmacovigilance needs to be introduced in undergraduate and 
graduate levels of teaching.
Qualified personal have to be in charge of pharmacovigilance within the 
different sectors.
Knowledge on the safety profile of medicines have to be increased 
within the healthcare system.
Pharmaceutical companies need to have trained staff.
A reporting system with ADR reporting forms need to exist.
The PV plan should take into account risk identification during product 
development and risk management.
A national PV centre needs to exist with designated staff and roles and 
well defined structure.
A PV advisory committee needs to exist and assist on technical matters.
Regular audits & inspections of pharmaceutical companies by 
healthcare workers need to be implemented.
Quality management and control systems need to be implemented.
PV 4 Communication
Clear lines of communication have to exist between the different 










Quality of data, 
confindence & ethics, 
communication 
Stakeholders roles need to be defined clearly.
All organizations involved with PV needs to embrace the concept of 
quality control and have a collaborative, transparent proactive 
behaviour.
Pharmaceutical companies need to be involved in PV and ADR 
reporting.
Pharmaceutical companies need to have trained staff.
Some form of public awareness on PV needs to be incorporated into the 
system.
Patients need to receive feedback after reporting an ADR
There must be a clinical trial and post-marketing database for specific 
drug roll-outs.
Computer systems used for PV should be validated and included the use 
of safety information outside drug safety functions (call centres).
Database for the collecting and managing of ADRs needs to exist.
Using literature to identify cases.
Specific populations/ patients need to be considered when setting up a 
PV system.
Creating a single country-specific adverse event reporting form to be 
used by all.
PV 9 ADR reports
Reports need to contain all relevant information and if important info is 
omitted, a system must be in place to contact reporter/healthcare unite 
to verify the case.
Specialised drugs, 
pediatrics, traditional 






Awareness, lack of 









Special attention needs to be placed on drugs that are suspected for 
defects.
Certain drug safety aspects need to be incorporated such as drug 
interactions and assessing the contribution of 'inactive' ingredients.
Additional monitoring is required for new released drugs.
Necessary that traditional medicines incorporated into national PV 
programmes.
Generic drugs must be treated as a new released drug and follow all the 
necessary safety reporting requirements.
A more proactive approach with regards to reporting needs to be taken.
Low cost reporting solutions at international standards are required.
ADR reporting must be compulsory for healthcare professionals.
PV 12
Link to clinical 
trials
In clinical trials, improvements in the mode of safety data collection, 
timelines, duplication, harmonization, and coverage need to be 
explored. 
- -
record keeping, lack of 
reporting
- - - limited resources communication
PV 13 Drug labels
Drug labels must be visible, readable and easy to identify by consumers 
and health care workers especially the section on ADRs.































resources, lack of 
finances






Reporting process ADR, drug adhernece -
Late initiation, lack of 
reporting, awareness, 
poor healthcare system
















Awareness, lack of 
reporting
laboratory, diagnostcs PV culture














ADR, drug adherence, 
drug resistance
quality 
Intergity of the system, 









Lack of KAP 
(Knowledge, Attitude 
and Practices), lack of 





Adverse drug reactions 
detection, under 
reporting, quality of 
data
Effective system - -
record keeping, poor 
healthcare system
laboratory, diagnostcs PV culture



























form an integral 




drug reactions, drug 
adherence
-
Lack of reporting, late 
initiation, awareness
Databases - quality 
record keeping, poor 






























D.2. Requirements related to MPP 










PV Education should include education on specialised drugs (such 
as traditional medicines).
PV Education should include education on drug-drug interactions
Drug manufacturing companies should be informed and educated 
on the importance of PV
Patients need to be educated on what ADRs are and how to report 
ADRs.
Communication channels betweeb quality control labs and PV 
centres





Proper funding systems should be in place to improve 





late initiation, poor 
healthcare system
- -
Lack of KAP, lack 





ADR reproting should be made compulsory to some extent for all 
health care workers
The system must ensure the effective capturing and storgae of the 
ADR reports .
A drug monitroing system must be able to locate ADRs in a quick, 
easy manner.
Healthcare workers must be able to identify an illness and or 
ADRs and report them as soon as possible. 
Pharmaceutical companies need to play a vital role in the system. 
Healthcare workers need to have professional, yet caring nature 
when working with patients.
Special attention needs to be paid to quality control monitoring of 
counterfeit and sub-standard drugs.
Special attention needs to be paid to quality control monitoring of 
specialised drugs such as traditinal medicine and pediatric drugs.
Proper quality control checks during the labelling process must be 
incorporated.
Quality monitroing pver patients taking drugs have to exist 
Proper quality control over ingredients used in traditional 
medicines.
Proper good manufacturing practices (GMP) and good distribution 
practices (GDP) have to be in place 
The label of drug medications must be easily visible, especially 
the section on ADRs.
 Patients and health care professionals must easily be able to 
identify this section.
Specific populations/ patients need to be considered when setting 
up a PV system.
The system should be designed  specifically for pediatri and 
traditional medicine users
Generic drugs must be treated as a new released drug and follow 
all the necessary safety reporting requirements.
The system needs to take the environments' unique challenges into 
account such as shortaed amd stock-outs.














































Intergity of the 


















- - Consumers Quality of data























































Lack of KAP, lack 
of training , 
cirriculum
Challenges 






D.3. Requirements related to HIV, TB and Hepatitis C 






















PV Education should form an intergral part of the system. PV 
education should also be standardised.
Pv Education should be target at specific groups of people. Patients 
hould be educated on their specific ADRs
Improved adherence of illness (HIV treatmnet) - provide basic 
education and counsilling on treatment
Training regarding countries specific PV guidelines 
Insure there are not inccorect believes - like that TB can be cured 
using herbal medicines
PV culture should form an integral part of the system
SI 2 Reporting process
More active monitoring systems are required. Additional or other PV 
methods/ tecniques to be incorporated.
ADR, drug adhernce, 
drug resistance
- - - PV culture - doctors, pharmacists
ADR detection, under 
reporting,
Reports need to be patient and illness (treatment) specific.
Standardised ADR reporting should be used
Terms/ words in reports should be consistant. For exsmple adverse 
reaction vs adeverse event.
Ensure availibity of ADR reports
The system should take the environment into account (for example 
lack of computers, internet ect)
Reports need to be patient and illness (treatment) specific.
Special care should be taken for specific patients such as patients 
who are on first line regime
More care should be taken when considering ADR reporting of older 
patients
Monitor patients who are on their first line of treatment (ensure they 
do not stop the treatment)
ADR reporting should be made compulsory to some extent or 
healthcare workers should receive rewards for reporting
Patients should be treated professional but compasionate (not 
discrimianted against patients with certain illness)
Designated person in charge of PV activities
The specific drugs and treatments need to be listed on PV databases
Special focus should be taken with regards to traditional monitoring
Regular quality control checks to be performed
The system should focus on reporting quality of drugs to report 
suspectible counterfeit & sub-standard drugs
Targeted interventions should be amined at collegue students 
Patient involvement should form part of the system.




























late initiation, lack 






Lack of KAP, lack 
of training , 
cirriculum





ADR detection, under 












Quality of data, 
confidentiality & ethics
stakeholders - -
lack of reporting, 
poor health 
system, awarness
- PV culture KAP, training













- PV culture -
consumers, pediatric, 
traditional medicines


























ADR detection, quality 




































- - - consumers





D.4. Requirements related to RLS 













Pharmacovigilance education should form an 
intergral part of the system. Pharmacovigilance 
education should also be standardised.
Pharmacovigilance education should be implemented 
in the academia. This entails the inclusion of 
pharmacovigilance subjects into undergarduare 
programmes. 
Capcity buidling should be integrated in the 
pharmacovigilance system.
Cohort Event Monitoring (CEM) and targeted 
spontaneous reporting should be investigated as 
possible additional methods 
More active monitoring systems are required. 
Additional or other PV methods/ tecniques to be 
incorporated.
The database for the pharmacovigilance system 
should be linked to clinical trial databases
The pharmacovigilance system should be linked to 
clinical trials and pharmacovigilance training should 
be introduced during the clinical trial phase.
Clear lines of communication needs to be 
implemented.
Communication channels with the MRA (Medicine 
Regulatory Authorities)
Feedback processes  need to be incorporated to keep 
























System must be able to identify adverse drug 
reactions as soon as possible.
The system needs to be region specific and take the 
specific environments' needs into account.
Specific populations/ patients need to be considered 
when setting up a pharmacovigilance system.
The process needs to be standardised.
Innovative ways of capturing data in resource limited 
settings are required
Standard termininogy should be used in the reports.
The reports should be available in the region/ 
countries' local languages.
The adverse drug reaction reporting forms should be 
easy to complete, non-time consuming and resource 
lminited friendly.
RLS 8 Remuneration
Reporting should be made compulsory or some form 
of remunisation should be granted to healthcare 
workers when they report adverse drug reactions
- -
Poor health 















RLS 9 National strategy
The Government should play an integral part of the 
pharmacovigilance system and some form of a 






system, lack of 
reporting, 



































































Integrity of the 









































































 Requirement specification 
verification information 
In this appendix additional information regarding the validation process of the vigilance 
system requirement specification is provided. This information includes the pre-read 
documents and questionnaires used during the validation. 
The following sections are included: 
E1: PV requirement validation documents  
E2: MPP requirement validation documents 
E3: RLS requirement validation documents 
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In the modern-day health landscape, there has been a significant change within the 
pharmaceutical industry with regards to innovative drug manufacturing and distribution 
systems which calls for improved surveillance and monitoring systems that can support such 
systems. One such an innovation is the Medicine Patent Pool (MPP)1 which aims to improve 
access to affordable drugs for TB, HIV and Hepatitis C in low- and middle-income countries 
[1].  
However it is often the case that these provision systems are deployed in areas that do not have 
effective PV systems 2 for the reporting of adverse drug reactions (ADRs) and face the 
challenge of being implemented in resource limited settings (RLS) [2]. The fact that numerous 
manufacturers could be utilised through the MPP to generate drugs, intensifies the need to 
monitor drug quality and once again highlights the need for effective drug safety monitoring 
and PV systems within this context.  
 
All these factors reaffirm the need for more innovative PV systems to be implemented that will 
address these niche specific factors. Thus, the aim of this research investigation is to propose 
a iche PV e , h gh he de e e  f a c ce a  f a e k, ha  will support 
he effec i e a d efficie  e i g f ADR  for pilot drug roll-out projects in RLS.  
                                                 
1 The MPP is a public health organisation that was launched in 2010 by UNITAID and aims to improve 
accessibility and development of life-saving drugs for HIV, TB, and hepatitis C in developing countries through 
the sharing of technologies and patents [1]. The MPP collaborates closely with industry stakeholders and patent 
holders to develop licence agreements which allow pharmaceutical companies to manufacture generic versions of 
drugs, as well as with the World Health Organisation to prioritise these drugs for licensing [21]. Through this 
innovative drugs are made available to a broader population at a faster rate [21]. In addition to having drugs 
provided to a broader population through the implementation of the MPP, there are additional advantages such as 
encouraging research and development and facilitating competition [3], [22], [23]. 
 
2The World Health Organisation defines pharmacovigilance (PV) as, the science and activities relating to the 
detection, assessment, understanding and prevention of adverse effects or any other drug-related problem [24]. 
The key objective of an effective PV system is to report and monitor adverse drug reactions (ADRs) in an attempt 
to minimise risks [25]. In addition, the identifying and evaluating of previously un- or underreported ADRs is also 
a vital part of such a PV system. According to the WHO for a PV system to work effectively, data collection from 
health practitioners, systematic monitoring and analysis of input data is required especially in the case of new 
drugs that are rolled out [26]. There are still however many challenges to be faced with regards to drug monitoring 










It was decided that a system engineering approach would be used to develop the conceptual 
framework of the niche PV system, as this approach transforms an operational need into a 
system solution by breaking down the need into smaller comprehendible parts to address [3]. 
Refer to figure 1 for a representation of the approach. In conducting this approach the first step 
was to identify the different factors that would impact the niche PV system. The four factors 
identified were the MPP, the specific illnesses the MPP address (HIV, TB and Hepatitis C), 
RLS, and traditional PV systems. Furthermore, to gain a better understanding of these factors, 
the challenges these factors face when considering drug monitoring (PV systems) where 
identified through conducting in-depth systematic literature reviews. A brief description of 
these challenges are provided in Table 1. The next step was to conduct a requirement analysis 
to identify what unique requirements each of the factors would call for in the niche PV system.  
The final step of the process would be to conduct a functional analysis that would entail 
identifying possible solutions to address the requirements of each factor. 
 
 
Table 1: Overview of challenges identified 
Challenges Group Challenges identified 
Supply & distribution 
Specialized drugs, pediatric drugs, traditional medicines, supply, shortages, stock-
outs, drug-drug interactions ( a change in the effect of the drug when it is taken 
together with another drug and it can often lead to ADR), adverse drug reactions 
(any response to a drug which is noxious and unintended), drug adherence (the act 
where patients abide to the recommendations made regarding the dosage, timing 
and frequency of medication taken), drug resistance (the response to a drug in a 
susceptible parasite population decreases significantly) 
 
Quality 
Quality, dosages, labelling, counterfeit drugs (medical products that 
deliberately/fraudulently misrepresent their identity, composition or source), sub-
standard drugs (authorized medical products that fail to meet either their quality 







Identify different factors and their needs.
MPP RLS Specific illnessPV 
Pharmaceutical value chain challenges
landscape (PVCCL)
Identify the requirement specification 
for each of the factors.
Systematic literature 
reviews
Identify intervention strategies to 
address the different identified 
requirements.
Validate framework











Integrity of the system (the support, integrity and confidentiality of the health care 
workers has seen to have an impact on treatment), record keeping, late initiation, 
lack of reporting, poor health system, awareness (lack of awareness and knowledge 
regarding the illness and treatment procedures) 
 
Testing 
Laboratory (the poor and limited amount if laboratories and testing infrastructures), 
diagnostics (diagnostic 
 
PV Culture - 
Lack of education 
KAP (knowledge, attitude and Practices associated with PV), training (lack of 
effective PV training programs for healthcare professions), curriculum (incorporate 




Government, lack of resources (people, time and money) lack of finances, 
pharmaceutical companies, pharmacists, doctors, consumers, pediatric/pregnant, 
traditional medicine users 
 
Reporting & process 
Adverse drug reaction detection (identification of ADRs together with the detection 
of the connection between the ADRs and the drug exposure), confidentiality & ethics 
(trusting the healthcare workers), under reporting of ADRs, quality of data (the data 
gathered from reporting should be of a high quality), communication 
(communication platforms between the different stakeholders have to exist) 
 
 
However the purpose of this validation is to address and reaffirm the validity of the 
requirements identified, focusing specifically on the requirements that a PV system calls for.  
2. Requirement specification related to PV 
A total of 13 unique requirements were identified related to PV systems, refer to Appendix A. 
An individual description of each of the 13 requirements listed PV 1 ± PV 13, are given in this 
section.  
PV 1.  Pharmacovigilance education needs to form an integral part 
of the system. 
 





Pharmacovigilance education needs to be incorporated 
into the health care system.
Pharmacovigilance needs to be introduced in 
undergraduate and graduate levels of teaching.
Qualified personal have to be in charge of 
pharmacovigilance within the different sectors.
Knowledge on the safety profile of medicines have to 
be increased within the healthcare system.
















































One of the most identified needs and requirements when looking at developing a 
pharmacovigilance system is the aspect of PV education. Literature calls for PV education to 
form a more vital part within the whole health system  [4]–[11]. In a study done by the WHO 
and the Upsala Monitoring Centre the importance of having drug safety and PV integrated in 
the medical health curricula is highlighted as well as the lack of research and postgraduate 
training in this field. The research argues that if healthcare practitioners are confident in their 
ability to correctly diagnose, manage and prevent ADRs, they would be more likely to report 
ADRs. Furthermore, when looking at PV education all stakeholders should be actively 
involved, however the national PV centres and other similar establishments should be seen as 
the primary teaching bases. Furthermore, PV education should not just be limited to training 
sessions but should include a variety of different methods, such as conferences, educational 
programmes and scientific publications [11]. 
Thus, when looking at the establishing of a PV system proper PV education is one of the 
main requirements for the system to work and function effectively. 
 
PV 2.  Clear lines of communication have to exist within the 
system. 
For a system to work and function effectively clear lines of communications between 
different stakeholders are vital. Thus, for the niche PV system to operate effectively clear 
channels of communication need to be formed between quality control labs and PV centres; 
government and PV centres; healthcare professionals and consumers and pharmaceutical 
companies [8], [10], [11].  Communication and collaboration is also one of the minimum 
requirements the WHO states a PV system requires 






Clear lines of communication have to exist 






























PV 3. The system requires public/consumer involvement. 
The proposed niche PV system will require consumer involvement to play a more vital 
part of the system. This entails involving the consumers more directly with the PV system and 
improving public awareness with regards to ADR reporting and PV systems [12]. The aspect 
of including consumer feedback sessions should also be taken into consideration [10].  
 
PV 4.  The system requires an effective database for the collecting 
and managing of reports. 
The WHO states that one of the minimum requirements needed for a PV system is that a 
database for the collecting and the managing of ADRs needs to exist {min requirements}. 
Although the success of a PV system requires the reporting of ADRs, the managing of the data 
gathered and the databases that contain the data plays a vital role in the effectiveness of the PV 
system. The National PV centre is the stakeholder responsible for the managing of the data 
bases, the collecting of the reports, evaluating of the reports, the identifying of suspicious 
reactions, and the recommendation of regulatory actions that should be taken [10]. 
Furthermore, with the growing use of technology in the health system the databases and process 
of identifying ADRs are more computerised which call for more effective quality control and 
validation systems to be in place [6], [12]. 
Thus, the niche PV system will also require the existence of an effective database that 
will assist the National PV Centres with the managing of the data in the specific environments 
that face challenges such as limited human resources and lack of funding.  





There must be a clinical trial and post-marketing 
database for specific drug roll-outs.
Computer systems used for PV should be 
validated and included the use of safety 
information outside drug safety functions (call 
centres).
Database for the collecting and managing of 
adverse drug reactions needs to exist.
































Some form of public awareness on pharmacovigilance needs to be 
incorporated into the healthcare system.























Lack of KAP 
(Knowledge, 
Attitude and 



















PV 5.  A pharmacovigilance centre or reporting system needs to 
exist. 
Having a well-structured PV system that entails all aspects from collecting and managing 
ADR e , cli icall  e al a i g he ADR e , di i g i h ADR  f m i e , aki g 
regulatory action, and alerting prescribers, manufacturers and the public [7], [8], [10], [12]. 
Furthermore, the system needs to have designated staff with qualified people in charge as well 
as an advisory committee to assist with technical matters [4], [8], [10]. Literature has also 
shown that the PV system should also be integrated in the product development phase with 
regards to risk identification [6].  
 
PV 6.  The system requires effective quality management and 
quality control systems. 
Quality management and control systems need to be integrated within in different sectors 
and areas of the PV system. Good Pharmacovigilance Practices state that this entails that 
quality management systems should include clear policies, standard operating procedures, 
working instructions and job descriptions with regards to drug safety [12]. Furthermore, quality 
management also entails ensuring that the system is regular reviewed and audited, and that the 
computers (or other equipment used) are validated and have change control processes in place 
[12]. All organizations involved with PV needs to embrace the concept of quality control and 
have a collaborative, transparent proactive behaviour to implementing quality control [4], [8], 
[12].  Thus  for the niche PV system to function effectively it is required that there are effective 





A reporting system with adverse drug reaction 
reporting forms need to exist.
The pharmacovigilance plan should take into 
account risk identification during product 
development and risk management.
A national pharmacovigilance centre needs to 
exist with designated staff, roles and well defined 
structure.
A pharmacovigilance advisory committee needs 
to exist and assist on technical matters.
Lack of KAP 
(Knowledge, 
Attitude and 


































Regular audits & inspections of pharmaceutical 
companies by healthcare workers need to be 
implemented.
Quality management and control systems need to 
be implemented.



















quality control systems in place with regular audits and inspections and the different 
stakeholders involved are all actively involved to ensure quality control is incorporated.  
PV 7.  St The akeholder  role  need o be clearl  defined. 
For the niche PV system to work effectively it is required that all the different 
akeholde  (Government, national PV Centres, healthcare practitioner pharmaceutical 
companie  and c ome ) ole  and e pon ibili ie  a e clea l  defined [4], [6], [7].  It has 
been seen in literature that pharmaceutical companies need to be more actively involved with 
the PV process and reporting of ADRs [4], [13], [14]. Furthermore, as stated in stakeholders 
need to embrace the concept of quality control and training in the PV system In defining the 
akeholde  ole  i  i  al o nece a  o ake he pecific en i onmen  in o acco n  fo  he 
niche PV system. 
 
PV 8.  ADR reporting forms need to contain all relevant 
information. 
For a PV system to operate successfully and effectively it is vital that ADRs are reported, and 
thus the ADR reporting forms are a vital part of the system [10]. The ADR reporting forms 
need to contain all the relevant information and some form of standardisation is required for 
the system to function more effectively. Furthermore, in the case that relevant information is 
omitted or questioned, the system must be able to verify the report through contacting the 
necessary parties [9], [13], [15].   





All organizations involved with PV needs to 
embrace the concept of quality control and have a 
collaborative, transparent proactive behaviour.
Pharmaceutical companies need to be involved in 
adverse drug reaction reporting.
Pharmaceutical companies need to have trained 
staff.
Lack of KAP 
(Knowledge, 
Attitude and 











































PV 8 Adverse drug 
reaction reports
Reports need to contain all relevant information 
and if important information is omitted, a system 
must be in place to contact the 




































PV 9.  More care needs to be taken with special drugs. 
In the case for the niche PV system their requirements that have to be taken into account when 
looking at the environments where the system will be used, low- and middle-income countries. 
One such a requirement is to pay more attention to specialised drugs such as traditional 
medicines which are more prone to be used in these areas. The reactions that inactive 
ingredients, used in traditional medicines, can cause should be taken into account when 
developing the niche PV system [4], [11]. Furthermore, this also entails paying more attention 
to drugs that are suspect of defects as low and middle income countries do have more cases of 
counterfeit and sub-standard drugs [4], [11].  
 
PV 10.  A link needs to exist between pharmacovigilance systems 
and clinical trials. 
The WHO defines clinical trials as any research study that evaluates the health effects by 
prospectively assigning humans to health-related studies [16]. However it has been found that 
there should be a stronger link between the clinical trial phase of a drug and the PV monitoring 
system [5], [17]. In order to ensure that the niche PV system will allow for the most effective 
collection and evaluation of safety information, it is imperative that during the clinical trial 
phase the planning and operation of the PV system is taking into account. This entails 
considering if additional or more strenuous PV activities would need to be included [18]. 
Furthermore for the clinical trial and PV databases  certain improvements are needed when 
addressing the timeliness, duplication, coverage and harmonization of the data collection [17]. 





Special attention needs to be placed on drugs that 
are suspected for defects.
Certain drug safety aspects need to be 
incorporated such as drug interactions and 
assessing the contribution of 'inactive' ingredients.
Additional monitoring is required for new 
released drugs.
Necessary that traditional medicines incorporated 
into national pharmacovigilance programmes.
Generic drugs must be treated as a new released 
































PV 10 Link to clinical 
trials
In clinical trials, improvements in the mode of 
safety data collection, timelines, duplication, 













PV 11.  The system must be designed for niche specific conditions. 
Although a PV system requires some form of standardisation in the reports it has come 
clear that the niche PV system still requires taking into account environment specific criteria 
[5]. When developing the niche PV system, it is necessary to take specific populations/ patients 
(such as paediatric patients, pregnant patients, elderly patients, and traditional medicine users) 
into account through the entire process i.e. the reporting phase, evaluation, and taking action 
and informing the customers [5].  
As previously mentioned the use of traditional medicines are growing and thus it is 
imperative that these traditional medicines are incorporated into the PV system and other 
regulatory frameworks as there are certain safety concerns [11], [19].   
Furthermore although there should be standardisation in developing an ADR report, the 
niche PV system also requires to create a single country-specific ADR report [7]. 
 
PV 12.  A more proactive reporting process is required. 
Spontaneous reporting methods are the most common method used with regards to ADR 
reporting, however from literature it has been gathered that a more proactive approach needs 
to be taken. This entails modernising the system and starting the process earlier. The main 
focus is to create a philosophy that is driven by improving safety rather than looking for harm 
[6]. Furthermore in order to improve the issue of under reporting it has been found that 
implementing compulsory reporting or providing some form of compensation is needed with 
in the healthcare system [7]. 
Thus, for the niche PV system to be effective the PV system/ reporting process needs to 
be more proactive and healthcare workers need to play a more active role.  





Specific populations/ patients need to be 
considered when setting up a pharmacovigilance 
system.
Creating a single country-specific adverse event 


























A more proactive approach with regards to 
reporting needs to be taken.
Low cost reporting solutions at international 
standards are required.




































PV 13.  Drug labels must be clear, readable, unambiguous and 
contain all the necessary information. 
Drug labels should be clear, readable, unambiguous and contain all the necessary 
information regarding the drugs and the ingrediencies [20]. According to the standards of GMP 
the drug labels need to contain the name of the medicine, list of active ingredients3, expire date, 
storages and usages directions, and the name of the manufactures (pharmaceutical company) 
[20].  
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4. Addendum A 
4  
  
                                                 
4 These challenges refer to all the challenges identified through systematic literature reviews that the factors (MPP, specific illnesses, RLS and traditional PV systems) attribute to and that the 
niche PV system needs to address. A total of 8 challenges groups were identified, listed A-H and a total of 43 challenges were identified. A shorted list is provided below. 
 
A – Supply & distribution: Specialized drugs, pediatric drugs, traditional medicines, supply, shortages, stock-outs, drug-drug interactions (as a change in the effect of the drug when it is taken 
together with another drug and it can often lead to ADR), adverse drug reactions (any response to a drug which is noxious and unintended), drug adherence (the act where patients abide to the 
recommendations made regarding the dosage, timing and frequency of medication taken), drug resistance (the response to a drug in a susceptible parasite population decreases significantly) 
B – Quality: Quality, dosages, labelling, counterfeit drugs (medical products that deliberately/fraudulently misrepresent their identity, composition or source), sub-standard drugs (authorized 
medical products that fail to meet either their quality standards or specifications, or both) 
C – Monitoring: Integrity of the system (the support, integrity and confidentiality of the health care workers has seen to have an impact on treatment), record keeping, late initiation, lack of 
reporting, poor health system, awareness (lack of awareness and knowledge regarding the illness and treatment procedures) 
D – Testing: Laboratory (the poor and limited amount if laboratories and testing infrastructures), diagnostics (diagnostic testing is required to predict the correct treatment procedure)  
E – PV Culture 
F – Lack of education: KAP (knowledge, attitude and Practices associated with PV), training (lack of effective PV training programs for healthcare professions), curriculum (incorporate PV 
subjects into the curriculum of healthcare students) 
G – Stakeholder involvement: Government, lack of resources (people, time and money) lack of finances, pharmaceutical companies, pharmacists, doctors, consumers, pediatric/pregnant, 
traditional medicine users 
H – Reporting & process: Adverse drug reaction detection (identification of ADRs together with the detection of the connection between the ADRs and the drug exposure), confidentiality & 
ethics (trusting the healthcare workers), under reporting of ADRs, quality of data (the data gathered from reporting should be of a high quality), communication (communication platforms 
between the different stakeholders have to exist) 
 
Requirement group Defined Supply & Distribution Quality Monitoring Testing PV Culture PV Education Stakeholder Involvement Reporting & Process
Pharmacovigilance education needs to be incorporated into the health 
care system.
Pharmacovigilance needs to be introduced in undergraduate and 
graduate levels of teaching.
Qualified personal have to be in charge of pharmacovigilance within the 
different sectors.
Knowledge on the safety profile of medicines have to be increased 
within the healthcare system.
Pharmaceutical companies need to have trained staff.
A reporting system with ADR reporting forms need to exist.
The PV plan should take into account risk identification during product 
development and risk management.
A national PV centre needs to exist with designated staff and roles and 
well defined structure.
A PV advisory committee needs to exist and assist on technical matters.
Regular audits & inspections of pharmaceutical companies by 
healthcare workers need to be implemented.
Quality management and control systems need to be implemented.
PV 4 Communication
Clear lines of communication have to exist between the different 










Quality of data, 
confindence & ethics, 
communication 
Stakeholders roles need to be defined clearly.
All organizations involved with PV needs to embrace the concept of 
quality control and have a collaborative, transparent proactive 
behaviour.
Pharmaceutical companies need to be involved in PV and ADR 
reporting.
Pharmaceutical companies need to have trained staff.
Some form of public awareness on PV needs to be incorporated into the 
system.
Patients need to receive feedback after reporting an ADR
There must be a clinical trial and post-marketing database for specific 
drug roll-outs.
Computer systems used for PV should be validated and included the use 
of safety information outside drug safety functions (call centres).
Database for the collecting and managing of ADRs needs to exist.
Using literature to identify cases.
Specific populations/ patients need to be considered when setting up a 
PV system.
Creating a single country-specific adverse event reporting form to be 
used by all.
PV 9 ADR reports
Reports need to contain all relevant information and if important info is 
omitted, a system must be in place to contact reporter/healthcare unite 
to verify the case.
Specialised drugs, 
pediatrics, traditional 






Awareness, lack of 









Special attention needs to be placed on drugs that are suspected for 
defects.
Certain drug safety aspects need to be incorporated such as drug 
interactions and assessing the contribution of 'inactive' ingredients.
Additional monitoring is required for new released drugs.
Necessary that traditional medicines incorporated into national PV 
programmes.
Generic drugs must be treated as a new released drug and follow all the 
necessary safety reporting requirements.
A more proactive approach with regards to reporting needs to be taken.
Low cost reporting solutions at international standards are required.
ADR reporting must be compulsory for healthcare professionals.
PV 12
Link to clinical 
trials
In clinical trials, improvements in the mode of safety data collection, 
timelines, duplication, harmonization, and coverage need to be 
explored. 
- - record keeping, lack of reporting - - - limited resources communication
PV 13 Drug labels
Drug labels must be visible, readable and easy to identify by consumers 
and health care workers especially the section on ADRs.
- Quality, labelling - - - - Doctors, -


























resources, lack of 
finances
Under reporting, ADR 
detection
- consumers, pediatric, traditional quality of data
Reporting process ADR, drug adhernece -
Late initiation, lack of 
reporting, awareness, 
poor healthcare system












medicnes, ADRs, drug 
adherence, drug 
resistance
- Awareness, lack of reporting laboratory, diagnostcs PV culture














ADR, drug adherence, 
drug resistance
quality 
Intergity of the system, 









Lack of KAP 
(Knowledge, Attitude 
and Practices), lack of 





Adverse drug reactions 
detection, under 
reporting, quality of 
data
Effective system - -
record keeping, poor 
healthcare system laboratory, diagnostcs PV culture



























form an integral 




drug reactions, drug 
adherence
- Lack of reporting, late initiation, awareness
Databases - quality 
record keeping, poor 










pediatrics - awareness, integrity of system
qaulity, sub-standard, 
counterfeit
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As mentioned in the pre-read document the 'Niche Pharmacovigilance System' addresses 4 
factors namely current pharmacovigilance systems, the Medicine Patent Pool, resource limited 
settings, and specific illnesses (HIV, TB and Hepatitis C). However for the purpose of this 
questionnaire focus was placed on the unique requirements that the current pharmacovigilance 
system factor would call for in the Niche Pharmacovigilance Systems. This questionnaire is 
aimed at improving, adjusting and establishing the importance of the requirements called for 
by current pharmacovigilance systems.  
 
Please complete the following personal  details 
*Kindly note that the participant's personal information is required only for reference purposes and will not 
appear in the thesis document or in any published work. 
 
Na :  
 
Email address: .. 
 
P a  Ba :  
 
O a a :  
 
Experience in this field: 
 
      Highly experienced 
 
       Moderately experienced 
 
        Some experience 
 
 
2. Pharmacovigilance related requirement specification 
In the pre-read document the 13 requirements identified related to pharmacovigilance are 
provided along with a description and a breakdown of how these requirements address 
challenges identified in the pharmaceutical value chain.  
 
2.1.  Rating the relevance of the requirements 
Rate the 13 requirements (numbered PV1 - PV13) need to be rated with regards to the relevance 
to the contribution of the Niche Pharmacovigilance System using the following Likert scale. 
 
1 - Strongly disagree 





3 - More or less disagree 
4 - Neutral 
5 - More or less agree 
6 - Agree 




1 2 3 4 5 6 7 
PV1 
Pharmacovigilance education needs to form an integral part 
of the system. 
       
Additional comments related to PV1 
PV2 
Clear lines of communication have to exist within the system.        
Additional comments related to PV2 
PV3 
The system requires public/consumer involvement.        
Additional comments related to PV3 
PV4 
The system requires an effective database for the collecting 
and managing of reports. 
       
Additional comments related to PV4 
PV5 
A pharmacovigilance centre or reporting system needs to 
exist. 
       
Additional comments related to PV5 
PV6 
The system requires effective quality management and 
quality control systems. 
       
Additional comments related to PV6 
PV7 
T e a e de  e  eed  be c ea  de ed.        
Additional comments related to PV7 
PV8 
ADR reporting forms need to contain all relevant 
information. 
       
Additional comments related to PV8 
PV9 
More care should be taken with specialized drugs.        






A link needs to exist between pharmacovigilance systems 
and clinical trials. 
       
Additional comments related to PV10 
PV11 
The system must be designed for niche specific conditions.        
Additional comments related to PV11 
PV12 
A more proactive reporting process is required.        
Additional comments related to PV12 
PV13 
Drug labels must be clear, readable, unambiguous and 
contain all the necessary information. 
       
Additional comments related to PV13 
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As mentioned in the pre-read document the 'Niche Pharmacovigilance System' addresses 4 
factors namely current pharmacovigilance systems, the Medicine Patent Pool, resource limited 
settings, and specific illnesses (HIV, TB and Hepatitis C). However, for the purpose of this 
questionnaire focus was placed on the unique requirements that the Medicine Patent Pool factor 
would call for in the Niche Pharmacovigilance Systems. This questionnaire is aimed at 
improving, adjusting and establishing the importance of the requirements called for by current 
pharmacovigilance systems. 
 
Please complete the following personal details 
*Kindly note that the participant's personal information is required only  for reference  purposes  and will not 
appear in the thesis document or in any published work. 
 
 
Na :  
E a  a : .. 
P a  Ba :  
Organization:  






2. Medicine Patent Pool related requirement 
specification 
 
In the pre-read document, the 8 requirements identified related to the Medicine Patent Pool are 
provided along with a description and a breakdown of how these requirements address 
challenges identified in the pharmaceutical value chain.  
 
 
2.1.     Rating the relevance of the requirements 
 
Using a Likert scale each of the 8 requirements (numbered MPP1 - MPP8) need to be rated 
with regards to the relevance to the contribution of the Niche Pharmacovigilance System. 
 







3 - More or less disagree 
4 - Neutral 
5 - More or less agree 
6 - Agree 





1 2 3 4 5 6 7 
MPP1 
Pharmacovigilance education needs to form an integral part of the system. 
This entails educating pharmaceutical companies on pharmacovigilance. 
       
Additional comments related to MPP1        
MPP2 
Clear lines of communication have to exist within the system.        
Additional comments related to MPP2        
MPP3 
Proper funding systems should be in place to improve infrastructures for 
drug monitoring systems. 
       
Additional comments related to MPP3        
MPP4 
The reporting system must be able to locate adverse drug reactions 
promptly and ensure effective storage of the reports. 
       
Additional comments related to MPP4        
MPP5 
T e a e de  e  eed  be c ea  de ed.        
Additional comments related to MPP5        
MPP6 
Effective quality control systems have to be in place in the different areas 
of the pharmacovigilance system.   
       
Additional comments related to MPP6        
MPP7 
Drug labels must be clear, readable, unambiguous especially the section on 
adverse drug reactions. 
       
Additional comments related to MPP7        
MPP8 
The system must be designed for niche specific conditions.        
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As mentioned in the pre-read document the 'Niche Pharmacovigilance System' addresses 4 
factors namely current pharmacovigilance systems, the Medicine Patent Pool, resource limited 
settings, and specific illnesses (HIV, TB and Hepatitis C). However, for the purpose of this 
questionnaire focus was placed on the unique requirements that resource limited settings factor 
would call for in the Niche Pharmacovigilance Systems. This questionnaire is aimed at 
improving, adjusting and establishing the importance of the requirements called for by current 
pharmacovigilance systems.  
 
Kindly note that the participants personal information is required only for reference purposes 
and will not appear in the thesis document or in any published work. 
 
Please complete the following personal details 
*Kindly  note  that the participant's  personal information is required only  for  reference  purposes  and will not 




Email add e : .. 
P fe i al Backg d:  
Organization:  





2. Resource limited settings related requirement 
specification 
 
In the pre-read document the 9 requirements identified related to resource limited settings are 
provided along with a description and a breakdown of how these requirements address 
challenges identified in the pharmaceutical value chain.  
 
2.1.     Rating the relevance of the requirements 
 
Using a Likert scale each of the 9 requirements (numbered RLS1 - RLS9) need to be rated with 
regards to the relevance to the contribution of the Niche Pharmacovigilance System. 
 
1 - Strongly disagree 








3 - More or less disagree 
4 - Neutral 
5 - More or less agree 
6 - Agree 




1 2 3 4 5 6 7 
RLS1 
Pharmacovigilance education and capacity building need to form an 
integral part of the system. 
       
Additional comments related to RLS1        
RLS2 
Additional and more active reporting methods are required.        
Additional comments related to RLS2        
RLS3 
A link needs to exist between pharmacovigilance systems and clinical 
trials. 
       
Additional comments related to RLS3        
RLS4 
Clear lines of communication have to exist within the system.        
Additional comments related to RLS4        
RLS5 
The system requires public/consumer involvement.        
Additional comments related to RLS5        
RLS6 
The system needs to be region specific and take the specific environments' 
needs into account. 
       
Additional comments related to RLS6        
RLS7 
The reporting process must be able to operate with limited resources        
Additional comments related to RLS7        
RLS8 
Reporting should be made compulsory or some form of remuneration 
should be granted to healthcare workers when they report adverse drug 
reactions 
       
Additional comments related to RLS8        
RLS9 
The Government should play an integral part of the pharmacovigilance 
system and some form of a national strategy should be implemented. 
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As mentioned in the pre-read document the 'Niche Pharmacovigilance System' addresses 4 factors 
namely current pharmacovigilance systems, the Medicine Patent Pool, resource limited settings, 
and specific illnesses (HIV, TB and Hepatitis C). However for the purpose of this questionnaire 
focus was placed on the unique requirements that the specific illness factor would call for in the 
Niche Pharmacovigilance Systems. This questionnaire is aimed at improving, adjusting and 
establishing the importance of the requirements called for by specific illnesses 
Kindly note that the participants personal information is required only for reference purposes and 
will not appear in the thesis document or in any published work. 
 
Please complete the following personal details 
*Kindly  note  that the participant's  personal information is required only  for  reference  purposes  and will not 




Email add e : .. 
P fe i al Backg d:  
Organization:  





2. Resource limited settings related requirement 
specification 
 
In the pre-read document, the 9 requirements identified related to pharmacovigilance are 
provided along with a description and a breakdown of how these requirements address 
challenges identified in the pharmaceutical value chain 
 
2.1.     Rating the relevance of the requirements 
 
Using a Likert scale each of the 9 requirements (numbered SI1 - SI9) need to be rated with 
regards to the relevance to the contribution of the Niche Pharmacovigilance System. 
 
1 - Strongly disagree 








3 - More or less disagree 
4 - Neutral 
5 - More or less agree 
6 - Agree 




1 2 3 4 5 6 7 
SI1 
Pharmacovigilance education needs to form an integral part of the system 
and should incorporate knowledge on specific illnesses. 
       
Additional comments related to SI1        
SI2 
More active monitoring systems and additional methods and techniques 
have to be incorporated. 
       
Additional comments related to SI2        
SI3 
Reports need to be standardized but should still be illness specific.        
Additional comments related to SI3        
SI4 
The system needs to take the environment' conditions into account.        
Additional comments related to SI4        
SI5 
More care needs to be taken with vulnerable patients.        
Additional comments related to SI5        
SI6 
Stakeholders' roles need to be clearly defined.        
Additional comments related to SI6        
SI7 
The system should be designed to take into account specialized drugs.        
Additional comments related to SI7        
SI8 
The system requires proper quality management and control systems to be 
in place. 
       
Additional comments related to SI8        
SI9 
Public awareness should form an integral part of the system and should be 
targeted at specific patient populations. 
       























 Additional information 
related to the CVSIT 
Appendix F provides additional information regarding the developed tool, the CVSIT. 
The following sections are included: 
F1: Inclusion/ exclusion criteria of the intervention strategies 
F2: Dimensions of the CVSIT in excel-base 
F2.1. Dimension 1 
F2.2. Dimension 2 
F2.3. Dimension 3 
F2.4. Dimension 4 






F.1. Inclusion/ exclusion criteria of intervention strategies 
In this section the inclusion/ exclusion criteria for the intervention strategies, as depicted in 
the Vigilance system implementation landscape, is provided. The criteria sets are used during 
the development of the CVSIT, in order to establish what project related information, within 
the context of the environment, i.e. the infrastructure, resources etc., would be required in 
order to determine which of the intervention strategies are applicable to a project. This criteria 
set is based of the Vigilance system implementation landscape and relevant literature and is 
summarised in Table F.1. 
Table F.1: Inclusion/exclusion criteria of intervention strategies for CVSIT development 
Intervention strategy 
Inclusion/exclusion criteria with respect to environment (i.e. the infrastructure and 
resources) 
Domain 
Component 1: Mode of reporting 
Mobile application 
Resources assisting with reporting or operating of the drug safety system i.e. HCP such as 
doctors, pharmacists, nurses and/or other PV experts, need to have a low/rudimental level 
of experience with regards to drug safety systems and identifying of ADRs (Aranda-Jan, 
Mohutsiwa-Dibe and Loukanova, 2014). 
Human 
resources 
Requires  access to a cellular network  (Politi, 2001; Bradshaw, 2013) 
Requires the reporting facility to have access to handheld devices for the function of 
reporting (Politi, 2001; Mechael, 2009; Aranda-Jan, Mohutsiwa-Dibe and Loukanova, 
2014; Kuchya et al., 2016) 
Technology 
resource 
Paper-based No specific requirement with respect to infrastructure is required (Almenoff, 2007) _ 
Text-based 
Requires that patient have knowledge on identification of ADRs and the reporting process 
(Baron et al., 2013). 
Patient 
information 
Resources operating drug safety system i.e. doctors, pharmacists, nurses and/or other PV 
experts need to have a low/ rudimental level of experience with regards to drug safety 
systems (Aranda-Jan, Mohutsiwa-Dibe and Loukanova, 2014). 
Human 
resources 
Requires  access to a cellular network  (Politi, 2001; Bradshaw, 2013) 
Requires the reporting facility to have access to handheld devices for the function of 
reporting (Politi, 2001; Mechael, 2009; Aranda-Jan, Mohutsiwa-Dibe and Loukanova, 




Requires that resources i.e. doctors, pharmacists, nurses and/or other PV experts, that assist 
with ADR reporting have a rudimental level of experience with regards to drug safety 




This intervention strategy requires the reporting facility to have access to the Internet, 
network connection (Gibb, 2016; Summerfield, 2019) 
This intervention strategy requires the reporting facility to have access to a desktop or 
handheld devices for the function of reporting (Politi, 2001; Medicines & Healthcare 
Agency Regulatory (MHRA), 2019) 
Technology 
resources 
Component 2: Reporting process 
3-step approach 
The patient(s) must visit a healthcare facility/ health care practitioner for the reporting of 







Requires a moderate availability of nurses or/and interns to assist with the reporting 
process (if other HCP are not available) (Mudzviti et al., 2013) 
Resources operating drug safety system, i.e. nurses and/or other interns, need to have a low 





This intervention requires the project to focus on one specific drug (Martin et al., 1998; 
European Medicines Agency, 2013) 
Requires to be implemented for the reporting and monitoring of newly released drug(s)/ or 




Resources operating drug safety system i.e. doctors, pharmacists, and/or other PV experts 





Requires the project to focus on one specific drug (Wallberg, 2009; Pal et al., 2013) 
Project 
information 
This intervention strategy requires the project to focus on a finite, pre-defined patient group 
(Wallberg, 2009; Pal et al., 2013; Dodoo et al., 2014) 
Requires that the patients visit a healthcare facility/ health care practitioner for 




This intervention strategy requires moderate availability of human resources, i.e. doctors, 
pharmacists, nurses, or other PV experts, to operate the reporting system (Wallberg, 2009; 
Pal et al., 2013; Dodoo et al., 2014)(Kunak et al., 2015) 
Requires that resources assisting with the identification and reporting of ADRs during the 




Designated PV person 




Requires high level of availability of human resources, i.e. doctors, pharmacists, nurses, 
or other PV experts, to operate the reporting system (Rachlis et al., 2016; Edwards, 2019). 
Resources operating drug safety and reporting system need to have a high level of 




The patient would require to have knowledge on identification of ADRs and the reporting 
process (Anderson et al., 2011; Delaney, 2017). 
Patient 
information 
Patients are required to have access to a cellular network or the Internet (Anderson et al., 
2011; Delaney, 2017) 
The patients are required to have access to mobile devices or desktops (Anderson et al., 





Requires that the project to focus on one specific drug/ disease (Management Sciences for 
Health (MSH), 2010; Olsson et al., 2010; Miller, Nwokike and Stergachis, 2012). 
The project should be targeted at a specific set of healthcare facilities (Management 
Sciences for Health (MSH), 2010; Olsson et al., 2010). 
Project 
information 
Requires that the project to focus on a finite, pre-defined patient group (Management 
Sciences for Health (MSH), 2010). 
The patient(s) would be required to visit a healthcare facility/ health care practitioner for 
continuous evaluation and reporting of ADRs (Management Sciences for Health (MSH), 
2010; Olsson et al., 2010). 
Patient 
information 
Requires moderate availability of resources, i.e. doctors, pharmacists, nurses, or other PV 
experts, to assist with the reporting and monitoring process (Miller, Nwokike and 
Stergachis, 2012 
Resources required to have a high level of experience with regards to drug safety systems 




Requires limited availability of HCP, i.e. doctors, pharmacists, nurses, interns or other PV 





The patient(s) would be required to visit a healthcare facility/ health care practitioner for 







Requires a moderate availability of nurses or/and interns to assist with the reporting 
process if doctors, pharmacists and/or other HCP have limited availability (WHO, 2007b; 
Olsson, Pal and Dodoo, 2015a; Prasad et al., 2018) 
Resources i.e. nurses and/or other interns, required to have a low level of experience with 





Requires the project to focus on one specific drug/ disease (Pal et al., 2013; Ndagije, 
Nambasa and Namagala, 2015). 
Project 
information 
Requires the project to focus on a finite, pre-defined patient group (Pal et al., 2013; 
Ndagije, Nambasa and Namagala, 2015).. 
The patient(s) would be required to visit a healthcare facility/ health care practitioner for 
continuous evaluation and reporting of ADRs (Pal et al., 2013; Prasad et al., 2018) 
Patient 
information 
Requires moderate availability of resources, i.e. doctors, pharmacists, nurses, or other PV 
experts, to assist with monitoring and reporting of ADRs (Pal et al., 2013; Prasad et al., 
2018). 
Resources operating drug safety system i.e. doctors, pharmacists, nurses and/or other PV 
experts need to have a high level of experience with regards to drug safety systems (Pal et 
al., 2013; Prasad et al., 2018). 
Human 
resources 
Component 3: Database 
Individual databases 
This intervention strategy should be considered if the project requires a dedicated database 
(a database for their own use) gathered (WHO and The Global Fund, 2010; Chakrabarty 
and Thawani, 2011) 
Project 
information 
Requires moderate availability of human resources, i.e. doctors, pharmacists, or other PV 
experts, to operate the database (WHO and The Global Fund, 2010; Chakrabarty and 
Thawani, 2011).. 
Resources operating drug safety system required to have a limited level of experience with 




Requires  the reporting facility to have access to a desktop for the purpose of data-capturing 
requires access to data processing software (WHO and The Global Fund, 2010; 




Resources assisting with the database quires a limited level of experience and availability 
with regards to drug safety data monitoring as the operations of the data process is 
outsourced  (Edwards, 2008; Arora, 2012) 
Human 
resources 
This intervention requires access to the Internet in order to gain access to the real-time data 




Requires that the reporting forms need to be stored in a safe space once they have been 




Resources, HCP, required need to have a limited level of experience with regards to drug 




This intervention strategy requires the reporting facility to have access to the Internet for 
the purpose of entering the data in VigiBase (Lindquist, 2008; Gibb, 2016; Summerfield, 
2019; UMC, 2019b) 
This intervention strategy requires the reporting facility to have access to a device for the 
purpose of data-capturing and entering of the data into VigiBase(Politi, 2001; Lindquist, 
2008; UMC, 2019b) 
Technology 
resources 
Component 4: Response strategy 
App Alerts 
This intervention strategy requires the reporting facility to have access to a cellular network 
or to the Internet (Politi, 2001; Bradshaw, 2013; Edwards, 2019; Walker, 2019) 
This intervention strategy requires the reporting facility to have access to handheld devices 












Requires the reporting facility to have access to a cellular network (Politi, 2001; Bradshaw, 
2013) 
Requires the reporting facility to have access to handheld devices for the purpose of 




Requires the reporting facility to have access to a cellular network or the Internet (Politi, 
2001; Bradshaw, 2013; Gibb, 2016; Summerfield, 2019) 
Requires the reporting facility to have access to handheld devices or desktop for the 








Requires the reporting facility to have access to a cellular network or the Internet (Politi, 
2001; Bradshaw, 2013) (Gibb, 2016; Summerfield, 2019) 
Requires the reporting facility to have access to handheld devices or desktop for the 




No specific requirement with respect to infrastructure or resources is required (Almenoff, 
2007; Vermeir et al., 2015) 
- 
Policy & guidelines 
No specific requirement with respect to infrastructure or resources is required (WHO, 
2002c; Mehta, Allen, et al., 2014) 
- 
Component 5: Awareness 
Campaigns 
For this intervention strategy to be effective the project should focus on creating a culture 
of drug safety reporting in addition to reporting of ADRs.(Lamprecht, Bam and De Kock, 





For this intervention strategy to be effective  the project should focus on creating a culture 
of drug safety reporting in addition to reporting of ADRs (Lamprecht, Bam and De Kock, 





No specific requirement with respect to infrastructure or resources is required (Dennison, 
Wu and Ickes, 2014). 
- 
Paper-based 
No specific requirement with respect to infrastructure or resources is required (Almenoff 
et al., 2007; Ilic and Rowe, 2013) 
- 
Social media 
This intervention strategy requires the reporting facility to have access to a cellular network 
or the Internet (Politi, 2001; Bradshaw, 2013; Sloane, Osanlou and Lewis, 2015; Gibb, 
2016; Summerfield, 2019) 
This intervention strategy requires the reporting facility to have access to a desktop or 
handheld devices (Politi, 2001; Bradshaw, 2013; Gibb, 2016; Summerfield, 2019). 
The patient(s) are required to have access to a cellular network or the Internet (Sloane, 
Osanlou and Lewis, 2015). 
The patient(s) are required to have access to mobile devices or desktops (Politi, 2001; 
Bradshaw, 2013) (Gibb, 2016; Summerfield, 2019) 
Technology 
resources 
Component 6: Communication 
Communication plans 




Requires limited availability of resources, i.e. HCP doctors, pharmacists, nurses, interns or 
other PV experts, to assist with the communication of ADR reports, actions to take with 
respect to the ADR etc (Lu, 2009). 
Human 
resources 
Requires the reporting facility to have access to a cellular network or the Internet for 
communication purposes (Politi, 2001; Gichoya, 2005; Bradshaw, 2013; Aranda-Jan, 
Mohutsiwa-Dibe and Loukanova, 2014) 
 
Requires the reporting facility to have access to a desktop or handheld devices for 
communication purposes (Politi, 2001; Gichoya, 2005; Bradshaw, 2013; Aranda-Jan, 




Requires limited availability of resources, i.e. HCP doctors, pharmacists, nurses, interns or 
other PV experts, to assist with the communication of ADR reports, actions to take with 




No specific requirement with respect to infrastructure or resources is required (WHO, 
2004; Bahri, 2010). 
 
Component 7: Educational 
Learning centres 
The project should focus on creating a culture of drug safety reporting in addition to 








Requires there to be a facility for educational response and other activities in addition to 
the reporting of ADRs (WHO, 2012). 
Resources 
Paper-based 
No specific requirement with respect to infrastructure or resources is required (Ilic and 
Rowe, 2013). 
- 
Patient information cards 
No specific requirement with respect to infrastructure or resources is required, however 




The project should focus on creating a culture of drug safety reporting in addition to 
reporting of ADRs, aimed at addressing the entire healthcare facility (Hagemann et al., 
2014; Hartman, Härmark and van Puijenbroek, 2017; Edwards, 2019). 
Project 
information 
Requires limited/ moderate availability of resources, i.e. interns or students, to partake in 
the intervention by completing the curriculum (Hagemann et al., 2014; Hartman, Härmark 




The project should focus on creating a culture of drug safety reporting in addition to 
reporting of ADRs, as resources would have to complete the course (Lamprecht, Bam and 
De Kock, 2017) 
Project 
information 
Requires limited availability of human resources, i.e. doctors, pharmacists, nurses, interns 
or other PV experts, to be educated on the operations of drug safety monitoring by 
completing the course (Dunn and Thorogood, 2002). 
Human 
resources 
Requires the reporting facility to have access to the Internet, in the case of e-learning (Dunn 
and Thorogood, 2002; Gibb, 2016; Summerfield, 2019; The Global Health Network, 
2019a) 
Requires the reporting facility to have access to a desktop or handheld devices for 
educational purposes in the case of e-learning (Politi, 2001; Dunn and Thorogood, 2002; 




The project should focus on creating a culture of drug safety reporting in addition to 
reporting of ADRs (Edwards, 2019). 
Project 
information 
Requires the reporting facility to have access to a cellular network or the Internet for 
educational purposes (Politi, 2001; Edwards and Lindquist, 2011; Bradshaw, 2013; Sloane, 
Osanlou and Lewis, 2015; Gibb, 2016; Summerfield, 2019) 
Requires the reporting facility to have access to a desktop or handheld devices for 
educational purposes (Politi, 2001; Edwards and Lindquist, 2011; Bradshaw, 2013; Gibb, 




Requires the reporting facility to have access to the Internet (Politi, 2001; Bradshaw, 2013; 
Gibb, 2016; Summerfield, 2019; The Global Health Network, 2019b; Walker, 2019) 
Requires the reporting facility to have access to a desktop for educational purposes (Politi, 
2001; Bradshaw, 2013; The Global Health Network, 2019b; Walker, 2019) 
Technology 
resources 
Component 8: Quality management 
Addressing GMP & 
GDP 
Requires limited availability of human resources, i.e. HCP, such as doctors, pharmacists, 
nurses, interns or other PV experts, to address the guidelines  as stipulated in GMP & GDP 




No specific requirement with respect to infrastructure or resources is required (Pietrek, 
Coulson and Czarnecki, 2009; Nwaiwu, Oyelade and Eze, 2016) 
- 
GVP 
Requires limited availability of human resources, i.e. HCP, such as doctors, pharmacists, 
nurses, interns or other PV experts, to address the guidelines  as stipulated in GVP (Pietrek, 
Coulson and Czarnecki, 2009; Pan American Health Organization, 2011; European 
Medicines Agency, 2017) 
Human 
resources 
Policy and guidelines 
No specific requirement with respect to infrastructure or resources is required (WHO, 
2002b, 2004; European Medicines Agency, 2017) 
- 
Component 9: Responsibility and accountability 
Career development 
The project should focus on creating a culture of drug safety reporting in addition to 




Requires moderate availability of human resources, i.e. doctors, pharmacists, nurses, 
interns or other PV experts, to partake in career development practices, i.e. education 







Designated PV person 




Requires high level of availability of human resources, i.e. doctors, pharmacists, nurses, 
or other PV experts, to operate the reporting system (Rachlis et al., 2016; Edwards, 2019). 
Resources operating drug safety system i.e. doctors, pharmacists, nurses and/or other PV 
experts need to have a high level of experience with regards to drug safety systems (Rachlis 
et al., 2016; Edwards, 2019). 
This intervention requires a dedicated person for the purpose of drug safety monitoring 




The project should focus on creating a culture of drug safety reporting in addition to 







The project should focus on creating a culture of drug safety reporting in addition to 





No specific requirement with respect to infrastructure or resources is required (Mehta, 
Allen, et al., 2014) 
- 
Workload management 
This intervention strategy requires high availability of human resources, i.e.  nurses or 
interns or other PV experts to assist doctors and other healthcare practitioners with ADR 
reporting (Weller, 2008; Elovainio, 2010). 
Human 
resources 
Component 10: Novel technologies 
Blockchain 
Resources assisting with drug safety system within the context of blockchain need to have 
a rudimental - high level of experience based on specified roles (Price, 2018). 
Human 
resources 
Requires the access to the Internet (or network for storage purposes) (Rosic, 2016; Elliot, 
2018; Liang et al., 2018; Price, 2018) 
Requires access to a desktop (or other hardware) for data capturing and data processing. 
Rosic, 2016; Elliot, 2018; Liang et al., 2018; Price, 2018) 
Requires the project to have access to data processing software/ and data storage. Rosic, 
2016; Elliot, 2018; Liang et al., 2018; Price, 2018) 
The project should have the capability to invest into R&D with respect to novel 




Resources assisting with the operating of the drug safety system have to have a rudimental 
level of experience with regards to drug safety systems. Also they would have to have a 




Requires access to the Internet, or other network services (Wilson, Thabane and Holbrook, 
2004; Cleland-Huang, 2015; Engels et al., 2016; Shukla, 2017; Wu et al., 2017) 
Requires access to a hardware, such as desktop or laptop, for data capturing and data 
processing. Furthermore also requires access to data processing software, data storage and 
other related infrastructures, such as data operating systems(Wilson, Thabane and 
Holbrook, 2004; Cleland-Huang, 2015; Engels et al., 2016; Shukla, 2017; Wu et al., 2017) 
The project should have the capability to invest into R&D with respect to novel 




Resources assisting with the operating of the drug safety system, within the context of 
machine learning have a rudimental level of experience with regards to drug safety 
systems. Also they would have to have a high level of experience with machine learning 
(Lee and Chen, 2019). 
Human 
resources 
Requires the reporting facility to have access to the Internet or network for cloud storage 
purposes (Russom, 2018; Wiens and Shenoy, 2018; Lee and Chen, 2019; Singh, 2019) 
Access to a Hardware, such as desktop or laptop, for data capturing and data processing 
within the context of Machine learning. Furthermore it also requires access infrastructure 
for data management (i.e. data systems, processing software etc.)  (Russom, 2018; Wiens 
and Shenoy, 2018; Lee and Chen, 2019; Singh, 2019) 
Access to large volumes of data, in order to develop the learning algorithms(Russom, 
2018) 
The project should have the capability to invest into R&D with respect to novel 








Resources assisting with the operating of the drug safety system, within the context of 
social media have a rudimental level of experience with regards to drug safety systems. 
Also they would have to have a high level of experience with respect to data science 
(Nikfarjam et al., 2015; Sloane, Osanlou and Lewis, 2015). 
Human 
resources 
Requires the reporting facility to have access to a cellular network, the Internet or other 
networking system (Cleland-Huang, 2015; Nikfarjam et al., 2015; Sloane, Osanlou and 
Lewis, 2015) 
Requires access to hardware and , such as desktop or laptop, for data capturing and data 
processing. Requires the project to have access to infrastructure for data management, i.e. 
data processing software, data system) (Cleland-Huang, 2015; Nikfarjam et al., 2015; 
Sloane, Osanlou and Lewis, 2015) 
The project should have the capability to invest into R&D with respect to novel 







F.2. CVSIT Dimensions 
In this section the different dimensions of the CVSIT in the excel based format is provided. 
There are four subsections related to the four different dimensions, dimension1 - vigilance 
profile assessment, dimension 2 – Vigilance System Component-Intervention Index, 
dimension 3- profile-interventions mapping, and dimension 4 - vigilance implementation 
strategy. 
F2.1. Dimension 1 
In this section the four domains, depicted in the excel based form, related to the Vigilance 
profile assessment is provided. Figure F.1 – F.4 are the four domains of the vigilance profile 
assessment that are found at the user interface.  
 
Figure F.1: Vigilance profile assessment: Project information 
 
Introduction Next 
1. Adverse drug reactions (ADRs) are unintended or noxious responses to a drug which is 
taken at a normal dosage.
  
2. Newly released drugs refer to drugs that have till date not yet been released to the specific 
market.
3. Traditional medicines are skills and practices based on indigenous cultural believes and 
theories used to prevent, diagnose, improve or treat health related illnesses. 
Project Information
1. Is this project primarily focused on the capturing of ADRs
1
 or 
are you trying to build a culture of drug safety reporting?
2. Is the project aimed at reporting of one specific drug or any 
drugs?
3. Is this project considering newly released
2 
drug(s)?
4. Is the project aimed at only reporting and capturing of specific 
ADRs?
7. Is this project aimed at only targeting a specific set of 
healthcare provision facilities?
5. Does this project consider drugs not licensed by the regulatory 
authority? 










Figure F.2: Vigilance profile assessment: Patient information 
 
Figure F.3:Vigilance profile assessment: Human resource availability 
Back NextPatient Information
Please answer the following questions to the best of your 
ability 
1. Is this project targeted at a well defined, controlled patient 
group?
2. Would it be required that your patients visit a healthcare facility 
or healthcare practitioner to report ADRs?
3.Will your patient have some knowledge on their specific 
treatment (drug), ADRs and/or the reporting process?
4. Will the project cater for any of the following patient groups: 
pregant patients, pediatrics, eldery patients and/or first regime 
patients?










Other experts in drug safety 
monitoring
4. Does the project have the ability to facilitate a sole person/ 
department for ADR reporting and drug safety monitoring?
2. What is the availability of these resources to report ADRs?
Resource availability
Please answer the following questions to the best of your 
ability 
1. Is there access to a facility for the reporting of ADRs? Can this 
facility be used for educational and response purposes?
3. What level of experience on ADR identification and reporting 










For the purpose of  ADRs reporting and data 
capturing.
For the process of data analysis.
For other purposes such as communication, 
providing feedback etc.
Technology readiness & 
maturity 
1. Is there access to cellular network at the reporting facility?
6. Is there room for expanding technology or conducting 
research and development with regards to new technologies 
within drug safety monitoring?
2. Is there access to the internet at the reporting facility?
7. Would your patients be likely to have access to a mobile 
device?
3. Is there access to a suitable device (e.g. desktops, tablets 
etc.):
5. Do you have access to data processing software for ADR 
reporting?
4. Is there access to mobile  devices at the facility for the 
purpose of ADR reporting?
8. Would  your patients be likely to have access to the 
Internet?






F2.2. Dimension 2 
In this section the second dimension – the Vigiance System Componet- Intervention Index is 
depicted in the excel based form in Figure F.5.  
 
 
Figure F.5: Dimension 2: Vigilance System Component-Intervention Index 
 




Vigilance System Implementation Landscape
In order to have a functioning drug sfatey monitoring system it has been established that the entire pharmaceutical value chain needs to be 
considered. Thus, the concept of a vigilance system was introduced that considers aspects over the entire healthcare landscape. The vigilance 
system has 10 componets that have to be addressed to ensure effective functioning. These 10 components are grouped into three categories 
namely: structural components, supporting componets, and additional factors. The Vigilance system framework was created to provide an 
overview of the these components and possible intervention strategies that can be implemnted to address these components. The vigilance System 
framework is displayed in the figure belowe.
However to ensure the effetive implementation of the vigilance system this tool provides the user with a personalised system.Using the data 
captured from the Vigilance Profile assessment, the applicable intervention strategies for the specific project under consideration is provided on 





F2.3. Dimension 3 




























Email Web-based Paper-based App alerts
Policy & 
guidelines
NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED Building a culture of drug safety reporting NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED Building a culture of drug safety reporting NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED
NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED A specific drug A specific drug A specific drug NOT REQUIRED NOT REQUIRED NOT REQUIRED A specific drug NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED
NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED
NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED
NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED
REQUIRED NOT REQUIRED REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED



















































































































































































































NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED REQUIRED REQUIRED REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED
Patients Patients
NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED REQUIRED REQUIRED REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED
If not patient card
NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED Knowledge on both NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED Knowledge on both NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED










































































































































































































NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED
Access only to a facility 
for reporting
Access only to a facility 
for reporting
Access only to a facility for reporting
Access only to a facility 
for reporting
Access only to a facility 
for reporting
NOT REQUIRED NOT REQUIRED Access only to a facility for reporting NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED
Doctors High level of availability 
Moderate level of 
availability
Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Limited availability
Moderate level of 
availability
Moderate level of 
availability
Moderate level of availability Limited availability Limited availability Not applicable
Moderate level of 
availability
High level of availability Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable
Nurses Limited availability Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Limited availability
moderate level of 
availability
Moderate level of 
availability
Moderate level of availability
Moderate level of 
availability
Moderate level of 
availability
Not applicable Not applicable High level of availability Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable
Student interns Moderate level of availability Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Limited availability Not applicable Not applicable Not applicable
Moderate level of 
availability
Moderate level of 
availability
Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable
Other experts in drug safety monitoring Moderate level of availability
Moderate level of 
availability
Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Limited availability
Moderate level of 
availability
Moderate level of 
availability
Moderate level of availability Limited availability Limited availability Not applicable
Moderate level of 
availability
High level of availability Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable
5. Does the project have the ability to 
facilitate a sole person/ department for 
ADR reporting and drug safety monitoring?

























































































































































































































































NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED REQUIRED REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED REQUIRED NOT REQUIRED NOT REQUIRED REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED REQUIRED NOT REQUIRED
NOT REQUIRED REQUIRED REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED REQUIRED REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED
*** Need to do an or for 
app**** **** Add or****
3.1.The purpose of reporting ADRs Yes NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED
3.2. For the process of data-capturing & 
processing
Yes REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED
3.3. For additional other purposeses Yes REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED REQUIRED REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED
NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED REQUIRED REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED REQUIRED NOT REQUIRED
REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED
NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED
NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED NOT REQUIRED











































































































































































































7. Does/ Will  your patients have access to internet?
No
No
2. Is there access to internet at your facility?
Yes
3. Will you have access to computer/ laptop/ Ipad for:
4. Will there be access to mobile devices at the facility for the purpose of ADR reporting?
Yes
Yes
Technology readiness & maturity 
1. Is there access to cellular network at your facility?
8. Does/ Will  your patients have access to a mobile device?
No
Viable Options for technology readiness & maturity
Viable Options for resource availability
Viable options after analysis
5. Do/ Will you be able to gain access to dataprocessing software for ADR reporting?
Yes
6. Is there room for expanding technology or conducting R&D with regards to new 
technologies within drug safety monitoring?
3. What is the availibility of these resources to report ADRs?
Yes
3.Will you patient have knowledge on their specific treatment (drug), ADRs & the 
reporting process?
Knowledge on none
4. Will the project cater for any specialised patient groups such as  pregant patients, 
pediatrics, eldery patients and/or  first regime patients?
Yes
Viable Options for patient information
Resource availibility
1. Is there acess to a facility for the reporting of ADRs? Can this facility be used for 
educational and response purposes?
Access to a facility for reporting, and educational/ response 
2. Who would be able to report ADRs. Which of the following HCP will be "available" at 
the facility?
2. Would it be required that your patients visit a healthcare facility or healthcare 
practitioner to report ADRs?
No
5. Is this project considering "traditional medicines"?
No
6. For this project do you need a unique/ sole databse?
Yes
7. Is this project aimed at only targetting specific and limited facilities?
Yes
Viable Options for project information
Patient Information
1. Is this project targeted at a well defined, controlled patient group?
No
4. Is the project aimed at only reporting & capturing of specific ADRs?
ICT Feedback
Project Information
1. Is this project soley focused on the capturing of ADRs or are you trying to build a 
culture of drug safety reporting 
Building a culture of drug safety reporting
2. Is the project aimed at reporting for one specific drug or any drugs?
Any drug
3. Is this project considering "new released"drugs?
Yes






Figure F.7: Background logic related to supporting components and intervention strategies
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Figure F.8: Background logic related to additional factors and intervention strategies
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F2.4. Dimension 4 
In this section the customised vigilance implementation strategy is provided in the excel based 
form. This implementation strategy is subdivided into the categories (i) direct components (see 
Figure F.9) , (ii) supporting components (see Figure F. 10) and (iii) additional factors (see 
Figure F.11). 
 




This method is a paperless, quick method using text-messages to report ADRs. Patients receive a text-message inquiring if any reactions have be 
noticed and are prompt to reply to using a text-message. Simple technologies such as FrontlineSMS can be used to create a text-message database.
-
The Uppsala Monitoring centre has guideline on how to set up an ADR 
reporting form.
No
This method is a paperless, quick and simple way of reporting and managing ADR reports. An app can be created that uses simple techniques to 
prompt the user to enter information (reporter information and information on the suspected adverse event) and once the data is captured it gets send 
through the required monitoring centre. 
-
ADR reports need to contain the following information:
* Patient information ( age, sex )
* Description of ADR 
* Suspected product information (brand name, active ingredient, batch 
number)
Yes
Electronic ADR reporting forms or online platforms used to submit ADRs are most commonly used mode of reporting in developing and developed 
countries. Using an online platform is efficient and cost-effective mode of reporting, that does not require an extensive amount of resources.
-
Additionaly include a section on specialised patients (pregnat, peaditric 
or elderly)
Yes
The mode requires the patient or HCP to complete a  hard copy form and sent it to the corresponding authority via post or facsimile. The paper-
based reports are the simplest form and are fairly easy to develop and complete. 
- -
Yes
Spontaneous reporting provides early signal detection of a medication which leads to further investigation, regulatory warnings or product changes 
to be made. Spontaneous reporting is a passive form of reporting and thus relies on the initiative of the patient to report an ADR. Furthermore, as 
there is no systematic patient follow-up, clear protocols or PV mandate, it is challenging to determine the accurate rates and frequencies of ADRs 
experienced. 
No
Sentinel surveillance operates by selecting specific reporting units that have a higher probability with addressing cases about the illness under 
consideration and that have a high qualified and experienced staff. Sentinel site deliberately only involves a limited, specific network. More feedback 
and supervisor can be provided, as sentinel sites are located in fewer facilities which again leads to higher quality data being obtained.
Yes
This approach looks at utilising different stakeholders for the different practises of the reporting process. The first step refers to using any available 
individuals, no qualification needed, to capture the data by filling out a form with the patient. The second step requires a clinical minded HCP, such 
as a pharmacist or nurse, to collect the data from the various treatment centres and the third step is to then submit the data to the necessary central 
body, such as the National PV centre or WHO.
Yes
This process entails having tasks such as completing ADR reports and collecting data to be ‘task-shifted’ to HCP with a lower level PV knowledge, 
such as nurses or student interns.
No
Patient direct reporting (PDR) entails having the patients directly report the suspected ADRs to the National PV centres. To date the most commonly 
used forms of PDR is through using mobile applications, such as the UK’s Yellow Card Scheme which is a paper-based scheme that was has been 
changed to an online platform, that are directly linked to the databases.
No
Black triangle monitoring was introduced for medicines that are under additional monitoring, and being monitored more closely by regulatory 
authorities. The reason for the more intensive monitoring is because there is generally less safety information available on that medicine, it contains 
a new active substance, the medication has only been approved under exceptional circumstances, it is a ‘biological medicine’ , or the manufacturing 
company is required to perform additional monitoring for example based on a rare side effect that was identified during the clinical trial phase. 
Drugs under black triangle monitoring are denoted with a black inverted triangle (▼ ) often with a short sentence explaining the meaning of it.
Yes
This initiative is aimed at introducing a dedicated department to the reporting and other PV related processes. A dedicated PV person/ department 
can be introduced into the healthcare facilities that have the sole responsibility of addressing all PV related areas, from reporting of ADRs, to the 
proving feedback and follow-up with patients. This department can also be more actively involved with providing PV education. 
Yes
A database can be created to capture this projects specific ADR data and information. The database developed should be classified, safely stored and 
managed, retrievable and retain some degree of confidentiality. The WHO and UMC provide guidelines on how to set up commercialised data 
programme that can be customised to specific usage.
No
VigiBase (https://www.who-umc.org/vigibase/vigibase/) is a database system used for data management and processing which is operated by the 
UMC on behalf of the WHO. The main aim of VigiBase is to collect and analyse the ADR reports of all members of the ‘WHO Drug Monitoring 
Program’ . 
Yes
There are a variety businesses, like Primevigilance or Oracle,  that maintain global adverse drug reporting databases. These compromise provide 
solutions for the processing, analysing and reporting of ADRs and enable clients to view their data in real time. 
Yes
For the case of paper-based reporting the reporting forms need to be stored in a safe space once they have been uploaded to the specific database, as 
the reports could contain confidential medical information. The reports need to be disposed of in such as manner that the information is completed 
distracted, i.e. burning or shredding the documents. 
Mobile applications No
Mobile applications can be created with the purpose of reporting and providing the reported with feedback. The mobile application can also provide 
links to additional information that the user would want to have.
Email Yes
An email response and feedback system can be created to immediately inform the reporter about receiving the report. The email can also provide 
additional information to the reporter about the process that will follow after the report has been received and actions that might be taken.
Web-based Yes
Web-based platforms, such as VigiAccess (http://www.vigiaccess.org/), which allows members of the public information about the amount or reports 
received and the list of ADRs reported for every drug.
Paper-based Yes
Paper-based resources, such as formal letters or newsletters, can be distributed using postal services to the different reporters. Newsletters, that 
provide information about the reported ADRs, can also be distributed to healthcare facilities.
No
This intervention is aimed at informing HCP, pharmacist and doctors, about drugs that are suspected to cause severe drug reactions or be of sub-
standard quality. The focus of the alert is only to inform HCP if immediate action needs to be taken. The app alerts should work on a severity scale, 
i.e. only provide an alert if a drug has had a high volume of reports in a specific time frame. 
Yes
Guidelines need to be created to ensure that there is an effective, achievable response strategy in place for when a suspect drugs has been identified 
and needs to undergo further monitoring or further action needs to be taken such as removing the drug from the market. The guidelines need to be 
clear about the exact steps that need to be taken by each of the stakeholders’ during the response strategy. These guidelines should stipulate the 
actions that pharmaceutical manufacturing companies need to take when a drug needs to be monitored more carefully or be taken of the market.






Important additional information to consider
Response strategy 
Response strategies should be implemented 
to ensure that the stakeholders are 
communicated about the report that has been 
received, the process to follow and in the 
case of severe/ dangerous case the 
























For the specific project under consideration, the following intervention strategies were identified as the most applicable to consider. However the full list of the different intervention strategies are provided if you would wish to consider these strategies.
Feedback
One of the minimum requirements for a PV 
system, as stated by the WHO, is that the 
system has a functioning reporting system 
with a national ADR reporting form. This 
component refers to the different possible 
methods that can be used to report ADRs.
The WHO states that one of the minimum 
requirements for a functional PV system is to 
have a functioning national reporting system. 
Thus, one of the basic fundamentals for a 
working PV system is to have a effective 
system for the reporting of ADRs. The 
reporting process component refers to the 
possible different reporting process that can 
be implemented.
One of the fundamental properties for a 
functioning PV system is to have a national 
database for the collating and managing of 










Targeted spontaneous reporting (TSR) builds on the principals of spontaneous reporting but applied more actively and within a defined setting. This 
method requires HCP to manage a well-defined patient group and report specific medicine related safety concerns. TSR can be customised to either 
report all suspects ADRs experienced by the group or focus on specific reactions that are of particular concern, in order to limit the ADRs to those 
who are of more significance. This method is a particularly significant method to use for targeted follow-up of patients. 
Cohort Event Monitoring (CEM) is an active form of PV which used to monitor ADRs in patients who are receiving a specific treatment regime in a 
method to assess causality. CEM involves actively following up with a cohort of patients to register all ADRs that occur during and for a short 
period after the patients’ treatment. CEM also captures all other medicine-related events, from medication errors, issues brought on by poor storage 
conditions, poor quality drugs, counterfeit drugs, and drug interactions and it records all events regardless of the severity of the event. This PV 






In any reporting system it is essential that the participants receive feedback. The feedback should entail providing confirmation of that the report has been received and in if needed the necessary actions to be taken. In a PV system it is crucial that the reporter is provided 
with feedback, as underreporting of ADRs is often associated with a lack of feedback. The content and the mode used to provide the feedback can vary. As mentioned, a confirmation of receiving the ADR report is required, however a study done with regards to patient 
direct reporting found that often patients have a need for more information regarding their reported ADR [20]. For example, patients would like to be informed if the report has contributed, if more reports were received and if necessary, action has been taken. 
-
Patient does not have access to mobile device or internet, thus provide paper-feedback for patient










Figure F.10: Vigilance implementation strategy related to supporting components 
Name Definition Definition
Yes
A campaign consists out of a series of planned events and activities aimed at achieving a specific objective. Campaigns share a single message and 
aim to convey the message to a target audience group. In 2015 the UMC initiated a campaign, Take & Tell, with the focus of making 
pharmacovigilance a household word. The Take & Tell campaign was aimed at improving the publics knowledge about what PV entails through 
informing patients about how to report a possible side-effect. The objectives of the campaign are to create awareness about PV, create open 
communication between patients and HCP, and support active reporting of ADRs. Through the campaign a toolkit M4ID is provided that assists 
patients to monitor and report ADRs 
No
Social media can thus be a vital instrument for improving awareness on PV in the healthcare and public environments. Platforms such as YouTube, 
Twitter, Facebook, and LinkedIn can be used as a platform to create awareness on the importance of ADR reporting. A profiles for the specific 
project can be created on these platforms that can be used to inform the public about the importance and process of reporting.
Yes
 Using paper-based resources, such as posters or pamphlets, to create a culture of PV and ADR reporting can be very effective especially in RLS. 
The most effective campaigns are aimed at evoking emotions with the readers, and thus using tactics such as statists, images and slogans would 
improve the impact of the campaign. These resource can be distributed at healthcare facilities, such as clinics and hospitals, or at other public 
environments such as schools, libraries etc.
Yes
Improving the awareness and PV culture within the public, focusing on patients, can be achieved through community involvement projects. This can 
be done through including patients/ members of the public into the planning phase of the project  to ensure the patients’ needs can be addressed. 
Through involving the different stakeholders in the planning phases of the project's drug safety can assist with gaining knowledge on the aspects to 
consider when addressing communication and education interventions.
Yes
Collaborating and partnering with existing PV bodies, healthcare facilities and pharmaceutical companies can be an effective strategy to engage with 
people and create awareness about PV with different stakeholders. Advocating about the importance of PV can be conducted by creating and 
fostering partnerships with different stakeholders. 
Yes
Ensuring that there is a proper communication network plan, that indicates the flow of information between the different stakeholders is vital. The 
communication network plan should provide an overview of the different communication channels that have to exist between the different 
stakeholders. Furthermore, the communication network plan should specify the flow of information and communication tool used. This 
communication network needs to be designed specifically taking the projects' needs into consideration. 
Email Yes
As most people have access to email accounts, email communication is a very effective and commonly used form. Email groups can also be created 
between the different stakeholders to ensure transparency. 
Text-messages No
Text-message applications, like WhatsApp, are widely used in developing and developed countries for the purpose of communicating. Groups can be 
formed with the people of interest to ensure that the necessary information is provided to all parties a and that there is transparency when 
communicating about important information.
Video-conferences Yes
Video conferencing, such as Skype, is a preferred form of communicating with different parties, often when a formal meeting or discussion is 
required. 
Yes
In the environments where electronic forms of communication are not a viable option, paper-based communication settings need to be in place to 
ensure the information flow between the different stakeholders. Formal letters, newsletters and paper-based resources can be distributed using postal 
services. 
Yes
Guidelines and policies can be used to improve communication between the different stakeholders. The guidelines should stipulate the different 
communication channels that have to exist between the different stakeholders. These guidelines should include a detailed description of the 
information flow that should exist within these communication lines. 
Yes
Web-based learning and PV websites can be used to improved PV education for different audience groups, from HCP, to patients. These websites 
can serve as a platform that can link the user to  e-learning services, articles and reading materials, and training or workshops being held. 
Furthermore a website can be used as a platform to provide current news and information about pharmacovigilance and drug safety monitoring. 
Websites, such as Global Pharmacovigilance (https://globalpharmacovigilance.tghn.org/) have proven to be a great success for not only educational 
purposes but also for networking, creating awareness and providing information about careers, conferences and events. 
Yes
The focus of learning centres are to create an open environment for collaboration, discussion and teaching opportunities on a more permanent basis. 
The learning centres can serve as an environment for PV education through providing and facilitating workshops, training courses and collaborations 
with other PV bodies. Furthermore, these learning centres can be aimed at different target audience groups within the healthcare setting and different 
levels of PV experience. The training centres can host workshops aimed at students in the pharmaceutical and medical fields; conferences for experts 
in the field of PV or events for all audience groups. 
Yes
The WHO in collaboration with International Society of Pharmacovigilance (ISoP) and its’ Education and Training Project (ETP) group developed 
the Pharmacovigilance Curriculum. The focus of this curriculum is to provide an overview of PV, provide information and teachings on new topics 
in PV and propose a range of tasks for practical training.  The PV curriculum consist out of 15 different theoretical chapters that look at the 
background and history of PV, clinical aspects of ADRs, risks of serious ADRs, quality defects, reporting methods, regulatory bodies, and 
communication. This PV curriculum that has been developed in such a way that it can be adapted to the specific audience, environment and 
availability of time. 
Yes
Short courses are excessive method of education that does not require an extensive amount of time and resources that can be used to acquire, update 
or enhance skills in PV. Short courses are aimed at teaching skills at a high level in a short amount of time. The short courses can be provided on an 
online platform or in a physical space such as at university or PV centres. 
No
When considering the different social media platforms and the focus of PV education, the main platforms to consider would be YouTube, using 
video education, and Twitter and LinkedIn for creating academic networks. Currently there are a vast number of videos available on YouTube that 
provide an overview of what PV is and how it can be used to improve patient safety. These videos are aimed at rudimental level of PV knowledge is 
thus a great intervention for educating patients. When considering the networking platforms, Twitter and LinkedIn, these platforms can be used to 
share and distribute articles that are being published related to PV or news about situations in the PV environment. 
Yes
Paper-based resources, such as pamphlets and posters, can be a very effective way of improving education on PV, ADRs and drug safety monitoring 
in RLS. Pamphlets and posters can be used to provide necessary and important information about what PV is, the need thereof and how to go about 
reporting ADRs. These paper-based educational resources can be aimed at different audience groups, however, would probably be the most effective 
educational resource for educating patients on PV. 
Yes
The guidelines for GVP were published in 2010 by the EU and are divided into two main chapters: pharmacovigilance processes and population- and 
product specific considerations. The guidelines provide an extensive overview of all the relevant aspects with regards to PV and drug safety in 
general. The guidelines provide best practice information about collection of the different reports, the validation and follow-up of the reports, and 
the data management process. Information of the use of medications during pregnancy and for paediatric and elderly also included. 
Yes
Audits play a vital role to ensure the quality standards are met and as with any system PV system requires regular audits to be conducted. During a 
PV audit a number of investigations are conducted to ensure that each proses meets the required quality standards. The aim is to use evidence to 
evaluate the pharmacovigilance system and the effectiveness of the system. The audit entails a review of the quality management of the collection, 
processing and management of the data systems and assessing if the database meets the current regulations. The qualification, and roles and 
responsibilities of the personnel are also assessed. 
Yes
To ensure that effective quality management is executed within the system a document plan which outlines the standard operating procedures should 
be developed. The document plan, policy, should ensure that the different stakeholders are clear about the different roles, responsibilities, and 
required task and that provision for proper control and if need be changes are included 
Yes
Throughout the different stages and processes of the PV system quality management should be executed. The necessary authorities need to ensure 
that quality standards are met during the documenting, data collection, data transfer, management, evaluation and validation, and follow-up. Quality 
control procedures need to be in place to assess the data entry and the appropriate use of terminology. Furthermore, the stored data needs to be 
compared to the initial and follow-up data to confirm the originality of the data. These different quality control checks need to be performed at a 
regular random evaluation or systematically. These monitoring systems and sites should also be introduced to pharmaceutical manufacturing 
companies where the drugs are manufactured. 
Yes
As with GVP, guidelines for good manufacturing practices (GMP) and good distribution practices (GDP) have been developed by the WHO to 
ensure consistent quality standards are met in all aspects of drug manufacturing from material sourcing to the final product. These guidelines do also 
consider drug safety monitoring aspects. The WHO guidelines do include guidelines related to complaints, product recalls, quality audits, materials, 
and training; which can be improved to incorporate PV specific aspects 
Yes
For a system to be effective it is necessary that there is a policy that stipulates a high-level statement that provides information about the overarching 
aim of the system. Furthermore, this policy needs to clearly define the roles, responsibilities and accountability of the different stakeholders 
involved. The policy needs to state the required actions called for by the stakeholders and be linked to the different standards, procedures and 
guidelines. Standards define the mandatory actions needed, procedures define the operational processes to achieve the policy and guidelines provide 
general recommendations needed. The PV stakeholder policy refers to the development of a policy for a specific  PV system that will define the 
roles and responsibilities of the stakeholders within that specific system. The WHO has set up a PV policy that can be used as guidelines on how to 
set a policy related to the stakeholder’s roles for a  PV system. 
Yes
Having a designated member of staff that specifically takes on the role of accountability of ADR reporting within the healthcare facility would not 
only elevate the workload of the HCP but will also address the concept of accountability as there would be a specific group/ individual that takes on 
all aspects of PV. Depending on the availability of resources and the size of the healthcare facility the size of the designated PV department can be 
determined. The departments’ main focus as mentioned would be to report ADRs to the National PV centre and provide necessary feedback where 
needed. As this department would be responsible for all PV related aspects, the margin of error in the reporting process will be reduced and the 
process of follow-up would be easier. Furthermore, this concept of designated PV departments can also be introduced to pharmaceutical 
manufacturing companies to improve the relationships, communication, and responsibility of pharmaceutical manufacturing companies with the PV 
canters and healthcare facilities. 
Financial incentives Yes
There are three main financial incentives categories namely basic wages and conditions, performance-linked payments, and then additional financial 
services. The first category, basic wages and conditions, refer to ensuring the level of wages paid are satisfactory and fair when compared to other 
colleagues. Offering a basic level of remuneration is a key element in ensuring a satisfied workforce. The second category, performance-linked 
payments refer to additional payments or bonusses. These forms of incentives are aimed to promote a culture of continuousness of care and to retain 
more experienced workforce. Bonusses paid will vary according to the duties of the individual and are linked to the individual’s work performance 
or professional development. The last category, additional financial services, can refer to fellowships or subsides for housing, transport and other 
expenses.
Career & performance 
development
Yes
Incentives such as access to education programs and training, effective monitoring and supervision can contribute to a supportive approach to 
continuous development. Through providing educational and development opportunities individuals improve their professional development which 
enhances their ability to financial and other benefits.
Workload management No
In the healthcare landscape, heavy workloads are a major concern that contribute to low motivation, poor performance or ultimately leaving the 
healthcare profession. Many of these factors that contribute to heavy workloads are the shortage of workers, uneducated staff, or even just an 
increased demand. However, there are possible methods that can be implemented to address heavy workloads. Firstly, incorporating overtime 
payments for staff as a compensation for working overtime and a motivation for employers to improve workload management. Secondly introducing 
additional leave or time-in-lieu to avoid burn outs. Another possible method is to revise existing roles and responsibilities to improve workload 





Ensuring a positive working environment through creating a positive organisational culture and safe working environment are crucial factors for 
retaining staff members and improving job satisfaction. Factors to consider incorporating are decentralised organisational structures, flexible 
working hours, and systematic communication between management and staff. Incorporating these factors enhance the working environment by 
improve moral of staff members.
Benefits & support Yes
Although financial incentives are not always a possibility there are other support incentives that can be offered and provided. Such as providing 
housing, transport and food. Also proving centres for childcare or employee support
-
In the healthcare landscape incentive schemes have become an emerging strategy in various fields and targeted at a range of HCP. Incentives strategies that are designed for the specific context and environment in which they will be implemented are found to be more 
successful. Incentives are a strategy to assist governments and healthcare bodies to develop and sustain a skilled workforce.
Patient information cards need to be paper-based
Patient information cards need to be prioritised as the patient has no knowledge on ADRs or the process of reporting. 
Communication networks
In any system ensuring that proper quality 
management is integrated within the different 
sectors are of the utmost importance. This is 
true for the development of a PV system as 
well. The concept of quality management 
should not only be addressed within the 
process of reporting and assessing ADRs but 
should also look at integration with the drug 
manufacturing and -distribution systems. 
Responsibility and accountability are a key 
factor that relates to stakeholder involvement 
within a PV system. As there are multiple 
stakeholders involved within the PV system it 
is vital that each stakeholder understands their 
specific role. Responsibility refers to an 
individual conducting and taking ownership 
of a specific task, whereas accountability 
refers to the taking on of a liability and 
answerability of a task. Thus, within a system 
one individual may be responsible for 
conducting a task, however the accountability 
lies with a different individual. 
GVP
Audits
Policy & guidelines 
Monitoring sectors


















Creating a culture of PV and drug safety 
monitoring is of the utmost importance as it 
will improve the challenges recognised in the 
reporting process with regards to ADR 
detection, underreporting, and the quality of 
data. It is thus important to consider different 
interventions that can assist with create 
awareness about the importance of PV and 
drug safety monitoring. 
In a PV system there are various stakeholders 
that play a vital role in the system. . Thus, 
interventions are needed to create, improve, 
enhance and maintain communication 
channels between the different stakeholders. 
Information about ADRs received and  
actions taken or considering to be 
implemented should be communicated to the 
different stakeholders to ensure transparency.
The education component address the 
different interventions that can be 
implemented to improve  capacity building 
on PV and ADR reporting. The educational 
interventions can be targeted at the different 
stakeholders or audience groups and focus 
not only on educating on the process of 











Important additional information to consider
Patient information cards are a paper-based method aimed at providing the patient with information regarding their specific treatment and possible 
ADRs. The card contains information on the symptoms of the known ADRs related to the specific illness, and how and where to report the ADRs. 
These information cards can be paper-based or electronic deepening on the patients. 
Patient does not have access to mobile device or internet, thus use paper-based communication for patient
-
Patient does not have access to mobile device or internet, thus use paper-based communication for patient
Information and Communication Technologies are technologies, primarily communication technologies such as internet, wireless- and cellular networks, that use telecommunication to provide access to information. ICT can be an effective intervention and communication 
tool used by different stakeholders for different means, from reporting, proving feedback and information flow between the different stakeholders
Communication
Information communication technologies (ICT)
Patient information cards Yes









Figure F.11: Vigilance implementation strategy related to additional factor
Name Definition Definition
No
Blockchain is a form of distributing data allowing users to process data through nodes on a network instead of through a central authority. 
Blockchain can be a valuable source when ensuring data is not falsified or manipulated. Blockchain also provides reliable flow of data between the 
different stakeholders, allowing patients direct information on the reported ADRs. Blockchain can also assist with aligning international standards of 
drug safety monitoring due to it's distributed nature allowing a more systematic approach to data maintained. 
No
Due to the growing development of large electronic health data storage system and advances in technology the demand for datamining within the 
healthcare environment has significantly increased. Datamining, for the purpose of this study, will refer to the utilisation of statistical techniques 
within the knowledge discovery process, which refers to the extraction process of valid, previously unknown information from large databases. 
Using datamining techniques data related to ADRs can be identified from massive medical databases that can be used to build a big-data platform. 
Then using this platform and different intelligent data processing techniques an ADR monitoring and filtering model can be built op to fins 
suspected ADRs. The system will still require experts to confirm and check the identified suspected ADRs 
No
Machine learning is an application that offers a system the ability to automatically deduce and learn from its past experiences to improve without 
being explicitly programmed. Conventional machine learning methods have been used to for post-marketing drug side effects, however the complex 
biological and chemical structures of drugs often make it more difficult to be detected and thus deep learning methods are often preferred for 
prediction tasks. In a study done by Chun Yen Lee et. al. in 2019, a two-stage framework was developed based on using deep learning methods to 
predict the association between ADRs and drugs; and integrating individual’s biological data into a system. This framework can be used to determine 
the likelihood of an ADR occurring in a patient before a new medication is prescribed [35]. There are countless opportunities to utilise these 
machine learning techniques in pharmacovigilance. 
No
Social media generates large volumes of data that can be utilised for signal and ADR detection, advancing PV systems. The use of social media sites 
as platforms to facilitate discussions of ADRs between patients and HCP have become increasingly predominant and suspected ADRs from social 
media should also be recorded for data gathering. There are however still challenges, technical and ethical, that have to be addressed for this to 
become a viable intervention. Algorithms still need to be adjusted to interpret layperson technology, identifying ADRs through postings with 
certainty, and unambiguous regulations still have to be put in place. However, the use of social media brings with it the opportunity for early 
detection and enhancement of patient safety 
Novel Technologies
In the modern-day landscape with the 
approach of a 4th industrial revolution, 
artificial intelligence (AI) is becoming part of 
everyday systems and operations. Thus, for 
the PV system to stay agile, continuing and 
permanent - novel technologies should be 
investigated and incorporated. 
Blockchain
Datamining





Additional factors do not directly impact the reporting process, neither does it support the effectiveness of the system, but it rather provides the system with an agile component that focuses on the future of PV systems.
Important additional information to consider










F.3. Detailed level map for CVSIT 
 Figure 54 is a detailed representation of how the data gathered during the profile vigilance 
assessment is mapped against the criteria of a Vigilance System implementation landscape and 
how each of the different intervention strategies are analysed to determine if it is applicable to 
the specific project under consideration. In order to gain a better view of the Figure it has been 
subdivide into three sections, Figure F.12 – Figure F.15. 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 Additional documents related 
to Case A 
Appendix G provides additional information regarding the application of Case A. 
The following sections are included: 
G1: Information related to Vigilance profiles assessment  





G.1. Information related to Vigilance profiles assessment 
In this section the resources used to complete the vigilance profile assessment for Case A is 
provided in Table G.1. 




Explanation References used 
Project information  
Information related to the 
specific drug being 
considered, the required 
databases and the targeted 
facilities 
(Conradie et al., 2014) 
(Clayden, 2014).. 
Patient information 
Information related to target 
audience group, 
consideration of specialised 
patients and PV related 
knowledge of patients 
(Clayden, 2014; Ndjeka 
et al., 2015) 
Human resources 
availability 
Information related to 
resources, HCP, availability 
and PV experiences 
(TBFacts, no date; HR 




Information related to 
technology resources 
availability  
(TBFacts, no date; HR 









G.2. Case A Customised vigilance implementation strategy  









The Uppsala Monitoring centre has guideline on how to set up an ADR 
reporting form.
No
This method is a paperless, quick and simple way of reporting and managing ADR reports. An app can be created that uses simple techniques to 
prompt the user to enter information (reporter information and information on the suspected adverse event) and once the data is captured it gets send 
through the required monitoring centre. 
-
ADR reports need to contain the following information:
* Patient information ( age, sex )
* Description of ADR 
* Suspected product information (brand name, active ingredient, batch 
number)
Yes
Electronic ADR reporting forms or online platforms used to submit ADRs are most commonly used mode of reporting in developing and developed 
countries. Using an online platform is efficient and cost-effective mode of reporting, that does not require an extensive amount of resources.
- -
Yes
The mode requires the patient or HCP to complete a  hard copy form and sent it to the corresponding authority via post or facsimile. The paper-
based reports are the simplest form and are fairly easy to develop and complete. 
- -
Yes
Spontaneous reporting provides early signal detection of a medication which leads to further investigation, regulatory warnings or product changes 
to be made. Spontaneous reporting is a passive form of reporting and thus relies on the initiative of the patient to report an ADR. Furthermore, as 
there is no systematic patient follow-up, clear protocols or PV mandate, it is challenging to determine the accurate rates and frequencies of ADRs 
experienced. 
No
Sentinel surveillance operates by selecting specific reporting units that have a higher probability with addressing cases about the illness under 
consideration and that have a high qualified and experienced staff. Sentinel site deliberately only involves a limited, specific network. More feedback 
and supervisor can be provided, as sentinel sites are located in fewer facilities which again leads to higher quality data being obtained.
Yes
This approach looks at utilising different stakeholders for the different practises of the reporting process. The first step refers to using any available 
individuals, no qualification needed, to capture the data by filling out a form with the patient. The second step requires a clinical minded HCP, such 
as a pharmacist or nurse, to collect the data from the various treatment centres and the third step is to then submit the data to the necessary central 
body, such as the National PV centre or WHO.
Yes
This process entails having tasks such as completing ADR reports and collecting data to be ‘task-shifted’ to HCP with a lower level PV knowledge, 
such as nurses or student interns.
No
Patient direct reporting (PDR) entails having the patients directly report the suspected ADRs to the National PV centres. To date the most commonly 
used forms of PDR is through using mobile applications, such as the UK’s Yellow Card Scheme which is a paper-based scheme that was has been 
changed to an online platform, that are directly linked to the databases.
Yes
Black triangle monitoring was introduced for medicines that are under additional monitoring, and being monitored more closely by regulatory 
authorities. The reason for the more intensive monitoring is because there is generally less safety information available on that medicine, it contains 
a new active substance, the medication has only been approved under exceptional circumstances, it is a ‘biological medicine’ , or the manufacturing 
company is required to perform additional monitoring for example based on a rare side effect that was identified during the clinical trial phase. 
Drugs under black triangle monitoring are denoted with a black inverted triangle (▼ ) often with a short sentence explaining the meaning of it.
No
This initiative is aimed at introducing a dedicated department to the reporting and other PV related processes. A dedicated PV person/ department 
can be introduced into the healthcare facilities that have the sole responsibility of addressing all PV related areas, from reporting of ADRs, to the 
proving feedback and follow-up with patients. This department can also be more actively involved with providing PV education. 
No
A database can be created to capture this projects specific ADR data and information. The database developed should be classified, safely stored and 
managed, retrievable and retain some degree of confidentiality. The WHO and UMC provide guidelines on how to set up commercialised data 
programme that can be customised to specific usage.
Yes
VigiBase (https://www.who-umc.org/vigibase/vigibase/) is a database system used for data management and processing which is operated by the 
UMC on behalf of the WHO. The main aim of VigiBase is to collect and analyse the ADR reports of all members of the ‘WHO Drug Monitoring 
Program’ . 
No
There are a variety businesses, like Primevigilance or Oracle,  that maintain global adverse drug reporting databases. These compromise provide 
solutions for the processing, analysing and reporting of ADRs and enable clients to view their data in real time. 
Yes
For the case of paper-based reporting the reporting forms need to be stored in a safe space once they have been uploaded to the specific database, as 
the reports could contain confidential medical information. The reports need to be disposed of in such as manner that the information is completed 
distracted, i.e. burning or shredding the documents. 
Mobile applications No
Mobile applications can be created with the purpose of reporting and providing the reported with feedback. The mobile application can also provide 
links to additional information that the user would want to have.
Email Yes
An email response and feedback system can be created to immediately inform the reporter about receiving the report. The email can also provide 
additional information to the reporter about the process that will follow after the report has been received and actions that might be taken.
Web-based Yes
Web-based platforms, such as VigiAccess (http://www.vigiaccess.org/), which allows members of the public information about the amount or reports 
received and the list of ADRs reported for every drug.
Paper-based Yes
Paper-based resources, such as formal letters or newsletters, can be distributed using postal services to the different reporters. Newsletters, that 
provide information about the reported ADRs, can also be distributed to healthcare facilities.
No
This intervention is aimed at informing HCP, pharmacist and doctors, about drugs that are suspected to cause severe drug reactions or be of sub-
standard quality. The focus of the alert is only to inform HCP if immediate action needs to be taken. The app alerts should work on a severity scale, 
i.e. only provide an alert if a drug has had a high volume of reports in a specific time frame. 
Yes
Guidelines need to be created to ensure that there is an effective, achievable response strategy in place for when a suspect drugs has been identified 
and needs to undergo further monitoring or further action needs to be taken such as removing the drug from the market. The guidelines need to be 
clear about the exact steps that need to be taken by each of the stakeholders’ during the response strategy. These guidelines should stipulate the 
actions that pharmaceutical manufacturing companies need to take when a drug needs to be monitored more carefully or be taken of the market.


















One of the minimum requirements for a PV 
system, as stated by the WHO, is that the 
system has a functioning reporting system 
with a national ADR reporting form. This 
component refers to the different possible 
methods that can be used to report ADRs.
The WHO states that one of the minimum 
requirements for a functional PV system is to 
have a functioning national reporting system. 
Thus, one of the basic fundamentals for a 
working PV system is to have a effective 
system for the reporting of ADRs. The 
reporting process component refers to the 
possible different reporting process that can 
be implemented.
One of the fundamental properties for a 
functioning PV system is to have a national 
database for the collating and managing of 
the ADR reports. 
CEM
Cohort Event Monitoring (CEM) is an active form of PV which used to monitor ADRs in patients who are receiving a specific treatment regime in a 
method to assess causality. CEM involves actively following up with a cohort of patients to register all ADRs that occur during and for a short 
period after the patients’ treatment. CEM also captures all other medicine-related events, from medication errors, issues brought on by poor storage 
conditions, poor quality drugs, counterfeit drugs, and drug interactions and it records all events regardless of the severity of the event. This PV 




Targeted spontaneous reporting (TSR) builds on the principals of spontaneous reporting but applied more actively and within a defined setting. This 
method requires HCP to manage a well-defined patient group and report specific medicine related safety concerns. TSR can be customised to either 
report all suspects ADRs experienced by the group or focus on specific reactions that are of particular concern, in order to limit the ADRs to those 









Important additional information to consider
Response strategy 
Response strategies should be implemented 
to ensure that the stakeholders are 
communicated about the report that has been 
received, the process to follow and in the 
case of severe/ dangerous case the 






The resources required training/ education on ADR identification and reporting before this intervention can be 
implemented
-







In any reporting system it is essential that the participants receive feedback. The feedback should entail providing confirmation of that the report has been received and in if needed the necessary actions to be taken. In a PV system it is crucial that the reporter is provided 
with feedback, as underreporting of ADRs is often associated with a lack of feedback. The content and the mode used to provide the feedback can vary. As mentioned, a confirmation of receiving the ADR report is required, however a study done with regards to patient 
direct reporting found that often patients have a need for more information regarding their reported ADR [20]. For example, patients would like to be informed if the report has contributed, if more reports were received and if necessary, action has been taken. 
-
Patient does not have access to mobile device or internet, thus provide paper-feedback for patient







Blockchain is a form of distributing data allowing users to process data through nodes on a network instead of through a central authority. 
Blockchain can be a valuable source when ensuring data is not falsified or manipulated. Blockchain also provides reliable flow of data between the 
different stakeholders, allowing patients direct information on the reported ADRs. Blockchain can also assist with aligning international standards of 
drug safety monitoring due to it's distributed nature allowing a more systematic approach to data maintained. 
No
Due to the growing development of large electronic health data storage system and advances in technology the demand for datamining within the 
healthcare environment has significantly increased. Datamining, for the purpose of this study, will refer to the utilisation of statistical techniques 
within the knowledge discovery process, which refers to the extraction process of valid, previously unknown information from large databases. 
Using datamining techniques data related to ADRs can be identified from massive medical databases that can be used to build a big-data platform. 
Then using this platform and different intelligent data processing techniques an ADR monitoring and filtering model can be built op to fins 
suspected ADRs. The system will still require experts to confirm and check the identified suspected ADRs 
No
Machine learning is an application that offers a system the ability to automatically deduce and learn from its past experiences to improve without 
being explicitly programmed. Conventional machine learning methods have been used to for post-marketing drug side effects, however the complex 
biological and chemical structures of drugs often make it more difficult to be detected and thus deep learning methods are often preferred for 
prediction tasks. In a study done by Chun Yen Lee et. al. in 2019, a two-stage framework was developed based on using deep learning methods to 
predict the association between ADRs and drugs; and integrating individual’s biological data into a system. This framework can be used to determine 
the likelihood of an ADR occurring in a patient before a new medication is prescribed [35]. There are countless opportunities to utilise these 
machine learning techniques in pharmacovigilance. 
No
Social media generates large volumes of data that can be utilised for signal and ADR detection, advancing PV systems. The use of social media sites 
as platforms to facilitate discussions of ADRs between patients and HCP have become increasingly predominant and suspected ADRs from social 
media should also be recorded for data gathering. There are however still challenges, technical and ethical, that have to be addressed for this to 
become a viable intervention. Algorithms still need to be adjusted to interpret layperson technology, identifying ADRs through postings with 
certainty, and unambiguous regulations still have to be put in place. However, the use of social media brings with it the opportunity for early 
detection and enhancement of patient safety 
Additional factors
Novel Technologies
In the modern-day landscape with the 
approach of a 4th industrial revolution, 
artificial intelligence (AI) is becoming part of 
everyday systems and operations. Thus, for 
the PV system to stay agile, continuing and 
permanent - novel technologies should be 
investigated and incorporated. 
Blockchain
Datamining





Additional factors do not directly impact the reporting process, neither does it support the effectiveness of the system, but it rather provides the system with an agile component that focuses on the future of PV systems.
Important additional information to consider










Figure G.2: Case A customised vigilance implementation strategy 
Name Definition Definition
No
A campaign consists out of a series of planned events and activities aimed at achieving a specific objective. Campaigns share a single message and 
aim to convey the message to a target audience group. In 2015 the UMC initiated a campaign, Take & Tell, with the focus of making 
pharmacovigilance a household word. The Take & Tell campaign was aimed at improving the publics knowledge about what PV entails through 
informing patients about how to report a possible side-effect. The objectives of the campaign are to create awareness about PV, create open 
communication between patients and HCP, and support active reporting of ADRs. Through the campaign a toolkit M4ID is provided that assists 
patients to monitor and report ADRs 
No
Social media can thus be a vital instrument for improving awareness on PV in the healthcare and public environments. Platforms such as YouTube, 
Twitter, Facebook, and LinkedIn can be used as a platform to create awareness on the importance of ADR reporting. A profiles for the specific 
project can be created on these platforms that can be used to inform the public about the importance and process of reporting.
Yes
 Using paper-based resources, such as posters or pamphlets, to create a culture of PV and ADR reporting can be very effective especially in RLS. 
The most effective campaigns are aimed at evoking emotions with the readers, and thus using tactics such as statists, images and slogans would 
improve the impact of the campaign. These resource can be distributed at healthcare facilities, such as clinics and hospitals, or at other public 
environments such as schools, libraries etc.
Yes
Improving the awareness and PV culture within the public, focusing on patients, can be achieved through community involvement projects. This can 
be done through including patients/ members of the public into the planning phase of the project  to ensure the patients’ needs can be addressed. 
Through involving the different stakeholders in the planning phases of the project's drug safety can assist with gaining knowledge on the aspects to 
consider when addressing communication and education interventions.
No
Collaborating and partnering with existing PV bodies, healthcare facilities and pharmaceutical companies can be an effective strategy to engage with 
people and create awareness about PV with different stakeholders. Advocating about the importance of PV can be conducted by creating and 
fostering partnerships with different stakeholders. 
No
Providing feedback on the receiving of reports are important, however to create a culture of PV, more detailed feedback should be provided to the 
reporter. Thus feedback systems should be created that provide the reporter with additional information of the process to follow once a report has 
been received. The feedback system should also consider proving some form of a "tracking" system of the report, to keep the reporter up to date, if 
they would wish to know more. 
No Education of PV can improve the culture of reporting through capacity building.
Yes
Ensuring that there is a proper communication network plan, that indicates the flow of information between the different stakeholders is vital. The 
communication network plan should provide an overview of the different communication channels that have to exist between the different 
stakeholders. Furthermore, the communication network plan should specify the flow of information and communication tool used. This 
communication network needs to be designed specifically taking the projects' needs into consideration. 
Email Yes
As most people have access to email accounts, email communication is a very effective and commonly used form. Email groups can also be created 
between the different stakeholders to ensure transparency. 
Text-messages No
Text-message applications, like WhatsApp, are widely used in developing and developed countries for the purpose of communicating. Groups can be 
formed with the people of interest to ensure that the necessary information is provided to all parties a and that there is transparency when 
communicating about important information.
Video-conferences Yes
Video conferencing, such as Skype, is a preferred form of communicating with different parties, often when a formal meeting or discussion is 
required. 
Yes
In the environments where electronic forms of communication are not a viable option, paper-based communication settings need to be in place to 
ensure the information flow between the different stakeholders. Formal letters, newsletters and paper-based resources can be distributed using postal 
services. 
Yes
Guidelines and policies can be used to improve communication between the different stakeholders. The guidelines should stipulate the different 
communication channels that have to exist between the different stakeholders. These guidelines should include a detailed description of the 
information flow that should exist within these communication lines. 
Yes
Web-based learning and PV websites can be used to improved PV education for different audience groups, from HCP, to patients. These websites 
can serve as a platform that can link the user to  e-learning services, articles and reading materials, and training or workshops being held. 
Furthermore a website can be used as a platform to provide current news and information about pharmacovigilance and drug safety monitoring. 
Websites, such as Global Pharmacovigilance (https://globalpharmacovigilance.tghn.org/) have proven to be a great success for not only educational 
purposes but also for networking, creating awareness and providing information about careers, conferences and events. 
No
The focus of learning centres are to create an open environment for collaboration, discussion and teaching opportunities on a more permanent basis. 
The learning centres can serve as an environment for PV education through providing and facilitating workshops, training courses and collaborations 
with other PV bodies. Furthermore, these learning centres can be aimed at different target audience groups within the healthcare setting and different 
levels of PV experience. The training centres can host workshops aimed at students in the pharmaceutical and medical fields; conferences for experts 
in the field of PV or events for all audience groups. 
No
The WHO in collaboration with International Society of Pharmacovigilance (ISoP) and its’ Education and Training Project (ETP) group developed 
the Pharmacovigilance Curriculum. The focus of this curriculum is to provide an overview of PV, provide information and teachings on new topics 
in PV and propose a range of tasks for practical training.  The PV curriculum consist out of 15 different theoretical chapters that look at the 
background and history of PV, clinical aspects of ADRs, risks of serious ADRs, quality defects, reporting methods, regulatory bodies, and 
communication. This PV curriculum that has been developed in such a way that it can be adapted to the specific audience, environment and 
availability of time. 
No
The workshops are aimed at engaging different people in activities and discussions on PV and ADRs, much similar to learning centres. However, the 
workshops are seen as a more  intermediate solution that will occur on a need basis. As the workshops will be organised on a need’s basis, the 
specific PV topic, audience, and area will be determined on where the need is. Current PV workshops have been active in different areas around the 
world and online platforms. Materials/ resources can be found through using the ISoP PV curriculum and can be tailored to address the 
environments, audience specific needs.
Yes
Short courses are excessive method of education that does not require an extensive amount of time and resources that can be used to acquire, update 
or enhance skills in PV. Short courses are aimed at teaching skills at a high level in a short amount of time. The short courses can be provided on an 
online platform or in a physical space such as at university or PV centres. 
No
When considering the different social media platforms and the focus of PV education, the main platforms to consider would be YouTube, using 
video education, and Twitter and LinkedIn for creating academic networks. Currently there are a vast number of videos available on YouTube that 
provide an overview of what PV is and how it can be used to improve patient safety. These videos are aimed at rudimental level of PV knowledge is 
thus a great intervention for educating patients. When considering the networking platforms, Twitter and LinkedIn, these platforms can be used to 
share and distribute articles that are being published related to PV or news about situations in the PV environment. 
Yes
Paper-based resources, such as pamphlets and posters, can be a very effective way of improving education on PV, ADRs and drug safety monitoring 
in RLS. Pamphlets and posters can be used to provide necessary and important information about what PV is, the need thereof and how to go about 
reporting ADRs. These paper-based educational resources can be aimed at different audience groups, however, would probably be the most effective 
educational resource for educating patients on PV. 
No
The guidelines for GVP were published in 2010 by the EU and are divided into two main chapters: pharmacovigilance processes and population- and 
product specific considerations. The guidelines provide an extensive overview of all the relevant aspects with regards to PV and drug safety in 
general. The guidelines provide best practice information about collection of the different reports, the validation and follow-up of the reports, and 
the data management process. Information of the use of medications during pregnancy and for paediatric and elderly also included. 
Yes
Audits play a vital role to ensure the quality standards are met and as with any system PV system requires regular audits to be conducted. During a 
PV audit a number of investigations are conducted to ensure that each proses meets the required quality standards. The aim is to use evidence to 
evaluate the pharmacovigilance system and the effectiveness of the system. The audit entails a review of the quality management of the collection, 
processing and management of the data systems and assessing if the database meets the current regulations. The qualification, and roles and 
responsibilities of the personnel are also assessed. 
Yes
To ensure that effective quality management is executed within the system a document plan which outlines the standard operating procedures should 
be developed. The document plan, policy, should ensure that the different stakeholders are clear about the different roles, responsibilities, and 
required task and that provision for proper control and if need be changes are included 
Yes
Throughout the different stages and processes of the PV system quality management should be executed. The necessary authorities need to ensure 
that quality standards are met during the documenting, data collection, data transfer, management, evaluation and validation, and follow-up. Quality 
control procedures need to be in place to assess the data entry and the appropriate use of terminology. Furthermore, the stored data needs to be 
compared to the initial and follow-up data to confirm the originality of the data. These different quality control checks need to be performed at a 
regular random evaluation or systematically. These monitoring systems and sites should also be introduced to pharmaceutical manufacturing 
companies where the drugs are manufactured. 
No
As with GVP, guidelines for good manufacturing practices (GMP) and good distribution practices (GDP) have been developed by the WHO to 
ensure consistent quality standards are met in all aspects of drug manufacturing from material sourcing to the final product. These guidelines do also 
consider drug safety monitoring aspects. The WHO guidelines do include guidelines related to complaints, product recalls, quality audits, materials, 
and training; which can be improved to incorporate PV specific aspects 
Yes
For a system to be effective it is necessary that there is a policy that stipulates a high-level statement that provides information about the overarching 
aim of the system. Furthermore, this policy needs to clearly define the roles, responsibilities and accountability of the different stakeholders 
involved. The policy needs to state the required actions called for by the stakeholders and be linked to the different standards, procedures and 
guidelines. Standards define the mandatory actions needed, procedures define the operational processes to achieve the policy and guidelines provide 
general recommendations needed. The PV stakeholder policy refers to the development of a policy for a specific  PV system that will define the 
roles and responsibilities of the stakeholders within that specific system. The WHO has set up a PV policy that can be used as guidelines on how to 
set a policy related to the stakeholder’s roles for a  PV system. 
No
Having a designated member of staff that specifically takes on the role of accountability of ADR reporting within the healthcare facility would not 
only elevate the workload of the HCP but will also address the concept of accountability as there would be a specific group/ individual that takes on 
all aspects of PV. Depending on the availability of resources and the size of the healthcare facility the size of the designated PV department can be 
determined. The departments’ main focus as mentioned would be to report ADRs to the National PV centre and provide necessary feedback where 
needed. As this department would be responsible for all PV related aspects, the margin of error in the reporting process will be reduced and the 
process of follow-up would be easier. Furthermore, this concept of designated PV departments can also be introduced to pharmaceutical 
manufacturing companies to improve the relationships, communication, and responsibility of pharmaceutical manufacturing companies with the PV 
canters and healthcare facilities. 
Financial incentives Yes
There are three main financial incentives categories namely basic wages and conditions, performance-linked payments, and then additional financial 
services. The first category, basic wages and conditions, refer to ensuring the level of wages paid are satisfactory and fair when compared to other 
colleagues. Offering a basic level of remuneration is a key element in ensuring a satisfied workforce. The second category, performance-linked 
payments refer to additional payments or bonusses. These forms of incentives are aimed to promote a culture of continuousness of care and to retain 
more experienced workforce. Bonusses paid will vary according to the duties of the individual and are linked to the individual’s work performance 
or professional development. The last category, additional financial services, can refer to fellowships or subsides for housing, transport and other 
expenses.
Career & performance 
development
Yes
Incentives such as access to education programs and training, effective monitoring and supervision can contribute to a supportive approach to 
continuous development. Through providing educational and development opportunities individuals improve their professional development which 
enhances their ability to financial and other benefits.
Workload management Yes
In the healthcare landscape, heavy workloads are a major concern that contribute to low motivation, poor performance or ultimately leaving the 
healthcare profession. Many of these factors that contribute to heavy workloads are the shortage of workers, uneducated staff, or even just an 
increased demand. However, there are possible methods that can be implemented to address heavy workloads. Firstly, incorporating overtime 
payments for staff as a compensation for working overtime and a motivation for employers to improve workload management. Secondly introducing 
additional leave or time-in-lieu to avoid burn outs. Another possible method is to revise existing roles and responsibilities to improve workload 





These initiative looks at accommodating workers to encourage effective working moods. These incentives include providing arrangements to allow 
flexible hours of work, extended leave arrangements or arrangements for staff members that are balancing their work with their other commitments 
like family life. Furthermore, these initiatives should also include introducing arrangements that allow older staff to stay employed but with less 




Ensuring a positive working environment through creating a positive organisational culture and safe working environment are crucial factors for 
retaining staff members and improving job satisfaction. Factors to consider incorporating are decentralised organisational structures, flexible 
working hours, and systematic communication between management and staff. Incorporating these factors enhance the working environment by 
improve moral of staff members.
Benefits & support Yes
Although financial incentives are not always a possibility there are other support incentives that can be offered and provided. Such as providing 
housing, transport and food. Also proving centres for childcare or employee support
Patient information cards need to be paper-based
Patient information cards need to be prioritised as the patient has no knowledge on ADRs or the process of reporting. 
-
In the healthcare landscape incentive schemes have become an emerging strategy in various fields and targeted at a range of HCP. Incentives strategies that are designed for the specific context and environment in which they will be implemented are found to be more 
successful. Incentives are a strategy to assist governments and healthcare bodies to develop and sustain a skilled workforce.
-
Patient does not have access to mobile device or internet, thus use paper-based communication for patient
Information and Communication Technologies are technologies, primarily communication technologies such as internet, wireless- and cellular networks, that use telecommunication to provide access to information. ICT can be an effective intervention and communication 
tool used by different stakeholders for different means, from reporting, proving feedback and information flow between the different stakeholders
Communication networks
-
In any system ensuring that proper quality 
management is integrated within the different 
sectors are of the utmost importance. This is 
true for the development of a PV system as 
well. The concept of quality management 
should not only be addressed within the 
process of reporting and assessing ADRs but 
should also look at integration with the drug 
manufacturing and -distribution systems. 
Responsibility and accountability are a key 
factor that relates to stakeholder involvement 
within a PV system. As there are multiple 
stakeholders involved within the PV system it 
is vital that each stakeholder understands their 
specific role. Responsibility refers to an 
individual conducting and taking ownership 
of a specific task, whereas accountability 
refers to the taking on of a liability and 
answerability of a task. Thus, within a system 
one individual may be responsible for 
conducting a task, however the accountability 
lies with a different individual. 
GVP
Audits
Policy & guidelines 
Monitoring sectors

















Patient does not have access to mobile device or internet, thus use paper-based communication for patient
-






Creating a culture of PV and drug safety 
monitoring is of the utmost importance as it 
will improve the challenges recognised in the 
reporting process with regards to ADR 
detection, underreporting, and the quality of 
data. It is thus important to consider different 
interventions that can assist with create 
awareness about the importance of PV and 
drug safety monitoring. 
In a PV system there are various stakeholders 
that play a vital role in the system. . Thus, 
interventions are needed to create, improve, 
enhance and maintain communication 
channels between the different stakeholders. 
Information about ADRs received and  
actions taken or considering to be 
implemented should be communicated to the 
different stakeholders to ensure transparency.
The education component address the 
different interventions that can be 
implemented to improve  capacity building 
on PV and ADR reporting. The educational 
interventions can be targeted at the different 
stakeholders or audience groups and focus 
not only on educating on the process of 











Information communication technologies (ICT)
Patient information cards Yes
The supporting components refer to the components and intervention strategies that assist with the effectiveness and abiding of the system.
Supporting components
Intervention strategies
Patient information cards are a paper-based method aimed at providing the patient with information regarding their specific treatment and possible 
ADRs. The card contains information on the symptoms of the known ADRs related to the specific illness, and how and where to report the ADRs. 





 Additional documents related 
to Case B 
Appendix H provides additional information regarding the application of Case B. 
The following sections are included: 
H1: Information related to Vigilance profiles assessment  





H.1. Information related to Vigilance profiles assessment 
In this section the resources used to complete the vigilance profile assessment for Case B is 
provided in Table H.1. 




Explanation References used 
Project information  
Information related to the 
specific drug being 
considered, the required 
databases and the targeted 
facilities 
(Global TB Community 
Advisory Board, 2018), 
(SAnews, 2018) 
Patient information 
Information related to target 
audience group, 
consideration of specialised 
patients and PV related 
knowledge of patients 
(Clayden, 2014; Ndjeka 
et al., 2015; Global TB 
Community Advisory 




Information related to 
resources, HCP, availability 
and PV experiences 
(TBFacts, no date; 
Mathlathi et al., 2015; 
HR Pulse News Desk, 
2019; Tshehle, 2019) 
Technology resources 
availability  
Information related to 
technology resources 
availability  
(TBFacts, no date; 
Mathlathi et al., 2015; 
HR Pulse News Desk, 





H.2. Case B Customised vigilance implementation strategy  








This method is a paperless, quick method using text-messages to report ADRs. Patients receive a text-message inquirimg if any reactions have be 
noticed and are promt to reply to using a text-message. Simple technologies such as FrontlineSMS can be used to create a text-message database.
-
The Uppsala Monitoring centre has guideline on how to set up an ADR 
reporting form.
No
This method is a paperless, quick and simple way of reporting and managing ADR reports. An app can be created that uses simple techniques to 
prompt the user to enter information (reporter information and information on the suspected adverse event) and once the data is captured it gets send 
through the required monitoring centre. 
-
ADR reports need to contain the following information:
* Patient information ( age, sex )
* Description of ADR 
* Suspected product information (brand name, active ingredient, batch 
number)
Yes
Electronic ADR reporting forms or online platforms used to submit ADRs are most commonly used mode of reporting in developing and developed 
countries. Using an online platform is efficient and cost-effective mode of reporting, that does not require an extensive amount of resources.
- -
Yes
The mode requires the patient or HCP to complete a  hard copy form and sent it to the corresponding authority via post or facsimile. The paper-
based reports are the simplest form and are fairly easy to develop and complete. 
- -
Yes
Spontaneous reporting provides early signal detection of a medication which leads to further investigation, regulatory warnings or product changes 
to be made. Spontaneous reporting is a passive form of reporting and thus relies on the initiative of the patient to report an ADR. Furthermore, as 
there is no systematic patient follow-up, clear protocols or PV mandate, it is challenging to determine the accurate rates and frequencies of ADRs 
experienced. 
No
Sentinel surveillance operates by selecting specific reporting units that have a higher probability with addressing cases about the illness under 
consideration and that have a high qualified and experienced staff. Sentinel site deliberately only involves a limited, specific network. More feedback 
and supervisor can be provided, as sentinel sites are located in fewer facilities which again leads to higher quality data being obtained.
Yes
This approach looks at utilising different stakeholders for the different practises of the reporting process. The first step refers to using any available 
individuals, no qualification needed, to capture the data by filling out a form with the patient. The second step requires a clinical minded HCP, such 
as a pharmacist or nurse, to collect the data from the various treatment centres and the third step is to then submit the data to the necessary central 
body, such as the National PV centre or WHO.
Yes
This process entails having tasks such as completing ADR reports and collecting data to be ‘task-shifted’ to HCP with a lower level PV knowledge, 
such as nurses or student interns.
No
Patient direct reporting (PDR) entails having the patients directly report the suspected ADRs to the National PV centres. To date the most commonly 
used forms of PDR is through using mobile applications, such as the UK’s Yellow Card Scheme which is a paper-based scheme that was has been 
changed to an online platform, that are directly linked to the databases.
Yes
Black triangle monitoring was introduced for medicines that are under additional monitoring, and being monitored more closely by regulatory 
authorities. The reason for the more intensive monitoring is because there is generally less safety information available on that medicine, it contains 
a new active substance, the medication has only been approved under exceptional circumstances, it is a ‘biological medicine’ , or the manufacturing 
company is required to perform additional monitoring for example based on a rare side effect that was identified during the clinical trial phase. 
Drugs under black triangle monitoring are denoted with a black inverted triangle (▼ ) often with a short sentence explaining the meaning of it.
No
This initiative is aimed at introducing a dedicated department to the reporting and other PV related processes. A dedicated PV person/ department 
can be introduced into the healthcare facilities that have the sole responsibility of addressing all PV related areas, from reporting of ADRs, to the 
proving feedback and follow-up with patients. This department can also be more actively involved with providing PV education. 
No
A database can be created to capture this projects specific ADR data and information. The database developed should be classified, safely stored and 
managed, retrievable and retain some degree of confidentiality. The WHO and UMC provide guidelines on how to set up commercialised data 
programme that can be customised to specific usage.
Yes
VigiBase (https://www.who-umc.org/vigibase/vigibase/) is a database system used for data management and processing which is operated by the 
UMC on behalf of the WHO. The main aim of VigiBase is to collect and analyse the ADR reports of all members of the ‘WHO Drug Monitoring 
Program’ . 
No
There are a variety businesses, like Primevigilance or Oracle,  that maintain global adverse drug reporting databases. These compromise provide 
solutions for the processing, analysing and reporting of ADRs and enable clients to view their data in real time. 
Yes
For the case of paper-based reporting the reporting forms need to be stored in a safe space once they have been uploaded to the specific database, as 
the reports could contain confidential medical information. The reports need to be disposed of in such as manner that the information is completed 
distracted, i.e. burning or shredding the documents. 
Mobile applications No
Mobile applications can be created with the purpose of reporting and providing the reported with feedback. The mobile application can also provide 
links to additional information that the user would want to have.
Email Yes
An email response and feedback system can be created to immediately inform the reporter about receiving the report. The email can also provide 
additional information to the reporter about the process that will follow after the report has been received and actions that might be taken.
Web-based Yes
Web-based platforms, such as VigiAccess (http://www.vigiaccess.org/), which allows members of the public information about the amount or reports 
received and the list of ADRs reported for every drug.
Paper-based Yes
Paper-based resources, such as formal letters or newsletters, can be distributed using postal services to the different reporters. Newsletters, that 
provide information about the reported ADRs, can also be distributed to healthcare facilities.
No
This intervention is aimed at informing HCP, pharmacist and doctors, about drugs that are suspected to cause severe drug reactions or be of sub-
standard quality. The focus of the alert is only to inform HCP if immediate action needs to be taken. The app alerts should work on a severity scale, 
i.e. only provide an alert if a drug has had a high volume of reports in a specific time frame. 
Yes
Guidelines need to be created to ensure that there is an effective, achievable response strategy in place for when a suspect drugs has been identified 
and needs to undergo further monitoring or further action needs to be taken such as removing the drug from the market. The guidelines need to be 
clear about the exact steps that need to be taken by each of the stakeholders’ during the response strategy. These guidelines should stipulate the 
actions that pharmaceutical manufacturing companies need to take when a drug needs to be monitored more carefully or be taken of the market.


















One of the minimum requirements for a PV 
system, as stated by the WHO, is that the 
system has a functioning reporting system 
with a national ADR reporting form. This 
component refers to the different possible 
methods that can be used to report ADRs.
The WHO states that one of the minimum 
requirements for a functional PV system is to 
have a functioning national reporting system. 
Thus, one of the basic fundamentals for a 
working PV system is to have a effective 
system for the reporting of ADRs. The 
reporting process component refers to the 
possible different reporting process that can 
be implemented.
One of the fundamental properties for a 
functioning PV system is to have a national 
database for the collating and managing of 
the ADR reports. 
CEM
Cohort Event Monitoring (CEM) is an active form of PV which used to monitor ADRs in patients who are receiving a specific treatment regime in a 
method to assess causality. CEM involves actively following up with a cohort of patients to register all ADRs that occur during and for a short 
period after the patients’ treatment. CEM also captures all other medicine-related events, from medication errors, issues brought on by poor storage 
conditions, poor quality drugs, counterfeit drugs, and drug interactions and it records all events regardless of the severity of the event. This PV 




Targeted spontaneous reporting (TSR) builds on the principals of spontaneous reporting but applied more actively and within a defined setting. This 
method requires HCP to manage a well-defined patient group and report specific medicine related safety concerns. TSR can be customised to either 
report all suspects ADRs experienced by the group or focus on specific reactions that are of particular concern, in order to limit the ADRs to those 









Important additional information to consider
Response strategy 
Response strategies should be implemented 
to ensure that the stakeholders are 
communicated about the report that has been 
received, the process to follow and in the 
case of severe/ dangerous case the 






The resources required training/ education on ADR identification and reporting before this intervention can be 
implemented
-







In any reporting system it is essential that the participants receive feedback. The feedback should entail providing confirmation of that the report has been received and in if needed the necessary actions to be taken. In a PV system it is crucial that the reporter is provided 
with feedback, as underreporting of ADRs is often associated with a lack of feedback. The content and the mode used to provide the feedback can vary. As mentioned, a confirmation of receiving the ADR report is required, however a study done with regards to patient 
direct reporting found that often patients have a need for more information regarding their reported ADR [20]. For example, patients would like to be informed if the report has contributed, if more reports were received and if necessary, action has been taken. 
-
Patient does not have access to mobile device or internet, thus provide paper-feedback for patient







Blockchain is a form of distributing data allowing users to process data through nodes on a network instead of through a central authority. 
Blockchain can be a valuable source when ensuring data is not falsified or manipulated. Blockchain also provides reliable flow of data between the 
different stakeholders, allowing patients direct information on the reported ADRs. Blockchain can also assist with aligning international standards of 
drug safety monitoring due to it's distributed nature allowing a more systematic approach to data maintained. 
No
Due to the growing development of large electronic health data storage system and advances in technology the demand for datamining within the 
healthcare environment has significantly increased. Datamining, for the purpose of this study, will refer to the utilisation of statistical techniques 
within the knowledge discovery process, which refers to the extraction process of valid, previously unknown information from large databases. 
Using datamining techniques data related to ADRs can be identified from massive medical databases that can be used to build a big-data platform. 
Then using this platform and different intelligent data processing techniques an ADR monitoring and filtering model can be built op to fins 
suspected ADRs. The system will still require experts to confirm and check the identified suspected ADRs 
No
Machine learning is an application that offers a system the ability to automatically deduce and learn from its past experiences to improve without 
being explicitly programmed. Conventional machine learning methods have been used to for post-marketing drug side effects, however the complex 
biological and chemical structures of drugs often make it more difficult to be detected and thus deep learning methods are often preferred for 
prediction tasks. In a study done by Chun Yen Lee et. al. in 2019, a two-stage framework was developed based on using deep learning methods to 
predict the association between ADRs and drugs; and integrating individual’s biological data into a system. This framework can be used to determine 
the likelihood of an ADR occurring in a patient before a new medication is prescribed [35]. There are countless opportunities to utilise these 
machine learning techniques in pharmacovigilance. 
No
Social media generates large volumes of data that can be utilised for signal and ADR detection, advancing PV systems. The use of social media sites 
as platforms to facilitate discussions of ADRs between patients and HCP have become increasingly predominant and suspected ADRs from social 
media should also be recorded for data gathering. There are however still challenges, technical and ethical, that have to be addressed for this to 
become a viable intervention. Algorithms still need to be adjusted to interpret layperson technology, identifying ADRs through postings with 
certainty, and unambiguous regulations still have to be put in place. However, the use of social media brings with it the opportunity for early 
detection and enhancement of patient safety 
Additional factors
Novel Technologies
In the modern-day landscape with the 
approach of a 4th industrial revolution, 
artificial intelligence (AI) is becoming part of 
everyday systems and operations. Thus, for 
the PV system to stay agile, continuing and 
permanent - novel technologies should be 
investigated and incorporated. 
Blockchain
Datamining





Additional factors do not directly impact the reporting process, neither does it support the effectiveness of the system, but it rather provides the system with an agile component that focuses on the future of PV systems.
Important additional information to consider









Figure H.1: Case B customised vigilance implementation strategy 
Name Definition Definition
No
A campaign consists out of a series of planned events and activities aimed at achieving a specific objective. Campaigns share a single message and 
aim to convey the message to a target audience group. In 2015 the UMC initiated a campaign, Take & Tell, with the focus of making 
pharmacovigilance a household word. The Take & Tell campaign was aimed at improving the publics knowledge about what PV entails through 
informing patients about how to report a possible side-effect. The objectives of the campaign are to create awareness about PV, create open 
communication between patients and HCP, and support active reporting of ADRs. Through the campaign a toolkit M4ID is provided that assists 
patients to monitor and report ADRs 
No
Social media can thus be a vital instrument for improving awareness on PV in the healthcare and public environments. Platforms such as YouTube, 
Twitter, Facebook, and LinkedIn can be used as a platform to create awareness on the importance of ADR reporting. A profiles for the specific 
project can be created on these platforms that can be used to inform the public about the importance and process of reporting.
Yes
 Using paper-based resources, such as posters or pamphlets, to create a culture of PV and ADR reporting can be very effective especially in RLS. 
The most effective campaigns are aimed at evoking emotions with the readers, and thus using tactics such as statists, images and slogans would 
improve the impact of the campaign. These resource can be distributed at healthcare facilities, such as clinics and hospitals, or at other public 
environments such as schools, libraries etc.
Yes
Improving the awareness and PV culture within the public, focusing on patients, can be achieved through community involvement projects. This can 
be done through including patients/ members of the public into the planning phase of the project  to ensure the patients’ needs can be addressed. 
Through involving the different stakeholders in the planning phases of the project's drug safety can assist with gaining knowledge on the aspects to 
consider when addressing communication and education interventions.
No
Collaborating and partnering with existing PV bodies, healthcare facilities and pharmaceutical companies can be an effective strategy to engage with 
people and create awareness about PV with different stakeholders. Advocating about the importance of PV can be conducted by creating and 
fostering partnerships with different stakeholders. 
No
Providing feedback on the receiving of reports are important, however to create a culture of PV, more detailed feedback should be provided to the 
reporter. Thus feedback systems should be created that provide the reporter with additional information of the process to follow once a report has 
been received. The feedback system should also consider proving some form of a "tracking" system of the report, to keep the reporter up to date, if 
they would wish to know more. 
No Education of PV can improve the culture of reporting through capacity building.
Yes
Ensuring that there is a proper communication network plan, that indicates the flow of information between the different stakeholders is vital. The 
communication network plan should provide an overview of the different communication channels that have to exist between the different 
stakeholders. Furthermore, the communication network plan should specify the flow of information and communication tool used. This 
communication network needs to be designed specifically taking the projects' needs into consideration. 
Email Yes
As most people have access to email accounts, email communication is a very effective and commonly used form. Email groups can also be created 
between the different stakeholders to ensure transparency. 
Text-messages No
Text-message applications, like WhatsApp, are widely used in developing and developed countries for the purpose of communicating. Groups can be 
formed with the people of interest to ensure that the necessary information is provided to all parties a and that there is transparency when 
communicating about important information.
Video-conferences Yes
Video conferencing, such as Skype, is a preferred form of communicating with different parties, often when a formal meeting or discussion is 
required. 
Yes
In the environments where electronic forms of communication are not a viable option, paper-based communication settings need to be in place to 
ensure the information flow between the different stakeholders. Formal letters, newsletters and paper-based resources can be distributed using postal 
services. 
Yes
Guidelines and policies can be used to improve communication between the different stakeholders. The guidelines should stipulate the different 
communication channels that have to exist between the different stakeholders. These guidelines should include a detailed description of the 
information flow that should exist within these communication lines. 
Yes
Web-based learning and PV websites can be used to improved PV education for different audience groups, from HCP, to patients. These websites 
can serve as a platform that can link the user to  e-learning services, articles and reading materials, and training or workshops being held. 
Furthermore a website can be used as a platform to provide current news and information about pharmacovigilance and drug safety monitoring. 
Websites, such as Global Pharmacovigilance (https://globalpharmacovigilance.tghn.org/) have proven to be a great success for not only educational 
purposes but also for networking, creating awareness and providing information about careers, conferences and events. 
No
The focus of learning centres are to create an open environment for collaboration, discussion and teaching opportunities on a more permanent basis. 
The learning centres can serve as an environment for PV education through providing and facilitating workshops, training courses and collaborations 
with other PV bodies. Furthermore, these learning centres can be aimed at different target audience groups within the healthcare setting and different 
levels of PV experience. The training centres can host workshops aimed at students in the pharmaceutical and medical fields; conferences for experts 
in the field of PV or events for all audience groups. 
No
The WHO in collaboration with International Society of Pharmacovigilance (ISoP) and its’ Education and Training Project (ETP) group developed 
the Pharmacovigilance Curriculum. The focus of this curriculum is to provide an overview of PV, provide information and teachings on new topics 
in PV and propose a range of tasks for practical training.  The PV curriculum consist out of 15 different theoretical chapters that look at the 
background and history of PV, clinical aspects of ADRs, risks of serious ADRs, quality defects, reporting methods, regulatory bodies, and 
communication. This PV curriculum that has been developed in such a way that it can be adapted to the specific audience, environment and 
availability of time. 
No
The workshops are aimed at engaging different people in activities and discussions on PV and ADRs, much similar to learning centres. However, the 
workshops are seen as a more  intermediate solution that will occur on a need basis. As the workshops will be organised on a need’s basis, the 
specific PV topic, audience, and area will be determined on where the need is. Current PV workshops have been active in different areas around the 
world and online platforms. Materials/ resources can be found through using the ISoP PV curriculum and can be tailored to address the 
environments, audience specific needs.
Yes
Short courses are excessive method of education that does not require an extensive amount of time and resources that can be used to acquire, update 
or enhance skills in PV. Short courses are aimed at teaching skills at a high level in a short amount of time. The short courses can be provided on an 
online platform or in a physical space such as at university or PV centres. 
No
When considering the different social media platforms and the focus of PV education, the main platforms to consider would be YouTube, using 
video education, and Twitter and LinkedIn for creating academic networks. Currently there are a vast number of videos available on YouTube that 
provide an overview of what PV is and how it can be used to improve patient safety. These videos are aimed at rudimental level of PV knowledge is 
thus a great intervention for educating patients. When considering the networking platforms, Twitter and LinkedIn, these platforms can be used to 
share and distribute articles that are being published related to PV or news about situations in the PV environment. 
Yes
Paper-based resources, such as pamphlets and posters, can be a very effective way of improving education on PV, ADRs and drug safety monitoring 
in RLS. Pamphlets and posters can be used to provide necessary and important information about what PV is, the need thereof and how to go about 
reporting ADRs. These paper-based educational resources can be aimed at different audience groups, however, would probably be the most effective 
educational resource for educating patients on PV. 
No
The guidelines for GVP were published in 2010 by the EU and are divided into two main chapters: pharmacovigilance processes and population- and 
product specific considerations. The guidelines provide an extensive overview of all the relevant aspects with regards to PV and drug safety in 
general. The guidelines provide best practice information about collection of the different reports, the validation and follow-up of the reports, and 
the data management process. Information of the use of medications during pregnancy and for paediatric and elderly also included. 
Yes
Audits play a vital role to ensure the quality standards are met and as with any system PV system requires regular audits to be conducted. During a 
PV audit a number of investigations are conducted to ensure that each proses meets the required quality standards. The aim is to use evidence to 
evaluate the pharmacovigilance system and the effectiveness of the system. The audit entails a review of the quality management of the collection, 
processing and management of the data systems and assessing if the database meets the current regulations. The qualification, and roles and 
responsibilities of the personnel are also assessed. 
Yes
To ensure that effective quality management is executed within the system a document plan which outlines the standard operating procedures should 
be developed. The document plan, policy, should ensure that the different stakeholders are clear about the different roles, responsibilities, and 
required task and that provision for proper control and if need be changes are included 
Yes
Throughout the different stages and processes of the PV system quality management should be executed. The necessary authorities need to ensure 
that quality standards are met during the documenting, data collection, data transfer, management, evaluation and validation, and follow-up. Quality 
control procedures need to be in place to assess the data entry and the appropriate use of terminology. Furthermore, the stored data needs to be 
compared to the initial and follow-up data to confirm the originality of the data. These different quality control checks need to be performed at a 
regular random evaluation or systematically. These monitoring systems and sites should also be introduced to pharmaceutical manufacturing 
companies where the drugs are manufactured. 
No
As with GVP, guidelines for good manufacturing practices (GMP) and good distribution practices (GDP) have been developed by the WHO to 
ensure consistent quality standards are met in all aspects of drug manufacturing from material sourcing to the final product. These guidelines do also 
consider drug safety monitoring aspects. The WHO guidelines do include guidelines related to complaints, product recalls, quality audits, materials, 
and training; which can be improved to incorporate PV specific aspects 
Yes
For a system to be effective it is necessary that there is a policy that stipulates a high-level statement that provides information about the overarching 
aim of the system. Furthermore, this policy needs to clearly define the roles, responsibilities and accountability of the different stakeholders 
involved. The policy needs to state the required actions called for by the stakeholders and be linked to the different standards, procedures and 
guidelines. Standards define the mandatory actions needed, procedures define the operational processes to achieve the policy and guidelines provide 
general recommendations needed. The PV stakeholder policy refers to the development of a policy for a specific  PV system that will define the 
roles and responsibilities of the stakeholders within that specific system. The WHO has set up a PV policy that can be used as guidelines on how to 
set a policy related to the stakeholder’s roles for a  PV system. 
No
Having a designated member of staff that specifically takes on the role of accountability of ADR reporting within the healthcare facility would not 
only elevate the workload of the HCP but will also address the concept of accountability as there would be a specific group/ individual that takes on 
all aspects of PV. Depending on the availability of resources and the size of the healthcare facility the size of the designated PV department can be 
determined. The departments’ main focus as mentioned would be to report ADRs to the National PV centre and provide necessary feedback where 
needed. As this department would be responsible for all PV related aspects, the margin of error in the reporting process will be reduced and the 
process of follow-up would be easier. Furthermore, this concept of designated PV departments can also be introduced to pharmaceutical 
manufacturing companies to improve the relationships, communication, and responsibility of pharmaceutical manufacturing companies with the PV 
canters and healthcare facilities. 
Financial incentives Yes
There are three main financial incentives categories namely basic wages and conditions, performance-linked payments, and then additional financial 
services. The first category, basic wages and conditions, refer to ensuring the level of wages paid are satisfactory and fair when compared to other 
colleagues. Offering a basic level of remuneration is a key element in ensuring a satisfied workforce. The second category, performance-linked 
payments refer to additional payments or bonusses. These forms of incentives are aimed to promote a culture of continuousness of care and to retain 
more experienced workforce. Bonusses paid will vary according to the duties of the individual and are linked to the individual’s work performance 
or professional development. The last category, additional financial services, can refer to fellowships or subsides for housing, transport and other 
expenses.
Career & performance 
development
Yes
Incentives such as access to education programs and training, effective monitoring and supervision can contribute to a supportive approach to 
continuous development. Through providing educational and development opportunities individuals improve their professional development which 
enhances their ability to financial and other benefits.
Workload management Yes
In the healthcare landscape, heavy workloads are a major concern that contribute to low motivation, poor performance or ultimately leaving the 
healthcare profession. Many of these factors that contribute to heavy workloads are the shortage of workers, uneducated staff, or even just an 
increased demand. However, there are possible methods that can be implemented to address heavy workloads. Firstly, incorporating overtime 
payments for staff as a compensation for working overtime and a motivation for employers to improve workload management. Secondly introducing 
additional leave or time-in-lieu to avoid burn outs. Another possible method is to revise existing roles and responsibilities to improve workload 





These initiative looks at accommodating workers to encourage effective working moods. These incentives include providing arrangements to allow 
flexible hours of work, extended leave arrangements or arrangements for staff members that are balancing their work with their other commitments 
like family life. Furthermore, these initiatives should also include introducing arrangements that allow older staff to stay employed but with less 




Ensuring a positive working environment through creating a positive organisational culture and safe working environment are crucial factors for 
retaining staff members and improving job satisfaction. Factors to consider incorporating are decentralised organisational structures, flexible 
working hours, and systematic communication between management and staff. Incorporating these factors enhance the working environment by 
improve moral of staff members.
Benefits & support Yes
Although financial incentives are not always a possibility there are other support incentives that can be offered and provided. Such as providing 
housing, transport and food. Also proving centres for childcare or employee support
Patient information cards need to be paper-based
Patient information cards need to be prioritised as the patient has no knowledge on ADRs or the process of reporting. 
-
In the healthcare landscape incentive schemes have become an emerging strategy in various fields and targeted at a range of HCP. Incentives strategies that are designed for the specific context and environment in which they will be implemented are found to be more 
successful. Incentives are a strategy to assist governments and healthcare bodies to develop and sustain a skilled workforce.
-
Patient does not have access to mobile device or internet, thus use paper-based communication for patient
Information and Communication Technologies are technologies, primarily communication technologies such as internet, wireless- and cellular networks, that use telecommunication to provide access to information. ICT can be an effective intervention and communication 
tool used by different stakeholders for different means, from reporting, proving feedback and information flow between the different stakeholders
Communication networks
-
In any system ensuring that proper quality 
management is integrated within the different 
sectors are of the utmost importance. This is 
true for the development of a PV system as 
well. The concept of quality management 
should not only be addressed within the 
process of reporting and assessing ADRs but 
should also look at integration with the drug 
manufacturing and -distribution systems. 
Responsibility and accountability are a key 
factor that relates to stakeholder involvement 
within a PV system. As there are multiple 
stakeholders involved within the PV system it 
is vital that each stakeholder understands their 
specific role. Responsibility refers to an 
individual conducting and taking ownership 
of a specific task, whereas accountability 
refers to the taking on of a liability and 
answerability of a task. Thus, within a system 
one individual may be responsible for 
conducting a task, however the accountability 
lies with a different individual. 
GVP
Audits
Policy & guidelines 
Monitoring sectors
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Creating a culture of PV and drug safety 
monitoring is of the utmost importance as it 
will improve the challenges recognised in the 
reporting process with regards to ADR 
detection, underreporting, and the quality of 
data. It is thus important to consider different 
interventions that can assist with create 
awareness about the importance of PV and 
drug safety monitoring. 
In a PV system there are various stakeholders 
that play a vital role in the system. . Thus, 
interventions are needed to create, improve, 
enhance and maintain communication 
channels between the different stakeholders. 
Information about ADRs received and  
actions taken or considering to be 
implemented should be communicated to the 
different stakeholders to ensure transparency.
The education component address the 
different interventions that can be 
implemented to improve  capacity building 
on PV and ADR reporting. The educational 
interventions can be targeted at the different 
stakeholders or audience groups and focus 
not only on educating on the process of 











Information communication technologies (ICT)
Patient information cards Yes
The supporting components refer to the components and intervention strategies that assist with the effectiveness and abiding of the system.
Supporting components
Intervention strategies
Patient information cards are a paper-based method aimed at providing the patient with information regarding their specific treatment and possible 
ADRs. The card contains information on the symptoms of the known ADRs related to the specific illness, and how and where to report the ADRs. 




 Validation questionnaires 
In this appendix additional information regarding the verification process of the tool is 
provided. This information includes the pre-read documents and questionnaires used during 
the validation. 
I1 Pre read documen t 
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strategy provides the user with an overview of the different vigilance components that need to 
be implemented for an effective vigilance system as well as the different intervention strategies 
that address each of these vigilance components. The second section, the customised vigilance 
implementation strategy builds on the previous section as it provides the user with the 


















Determine the project's profile with regards to drug safety monitoring.
Vigilance components
with accompanying  intervention
strategies to be implemented for a
functioning vigilance system. 
The Project's vigilance profile gets
mapped against the Vigilance
system framework and the criteria
set of each of the intervention
strategies, to identify those best
for for the specific project. 
Provides the user with information about the implementation of the vigilance
system. This dimension is subdivided into two sections.
Project's vigilance profile
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